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ABSTRACT 
Throughout the development of corporate R&D, there has been a search for the `one best 
way' to manage the processes involved. Although perceptions of what constitutes the `one 
best way' have changed over time, the quest for reliable pointers continues. This thesis 
develops the author's personal interest in how things `ought to be' in order to secure 
success within corporate R&D. Marrying ideas from the fields of R&D Management and 
Knowledge Management, and using the results from an empirical study into 
pharmaceutical R&D in the United Kingdom, the thesis shows the distinct differences 
between knowledge creation in research and knowledge creation in development and 
concludes that these two activities should be carried out separately, but not separate from 
each other. 
In arriving at this conclusion, the thesis upholds the criticisms of the knowledge creation 
model advocated by Nonaka and Takeuchi (1995); and points to the failings of the pluralist 
framework proposed by Cook and Brown (1999); arguing, after Polanyi (1966), that 
knowledge creation in any context is better modelled with reference to the individual acts 
of tacit knowing of the particular people involved, acts of tacit knowing which lead to the 
subsidiary conclusion that research should remain a scientific endeavour, whereas 
development should be a transdisciplinary, trans functional, and perhaps a trans- 
organizational activity. Hence, the thesis rejects the trends in R&D generations reported in 
the R&D Management literature; and the corresponding move from a Mode 1 to a Mode 2 
approach predicted by Gibbons and co-workers in the Knowledge Management literature. 
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1 INTRODUCTION 
1.1 Background to the Research and the Research Question 
Throughout the development of corporate R&D, there has been a search for the `one best 
way' to manage the processes involved. Although perceptions of what constitutes the `one 
best way' have changed over time, the quest for reliable pointers continues. This thesis 
develops the author's personal interest in how things `ought to be' in order to secure 
success within corporate R&D. ' It presents the progression from a comparatively simple 
research question to more complex conceptual issues, together with the design and 
implementation of original empirical work. 
Over the years, success in corporate R&D has been associated with a number of factors: 
the right organizational configuration (Mintzberg, 1979, p. 217); the right people (Roberts 
and Fusfeld, 1981, p. 19); the right vision or strategy (Quinn, 1985, p. 266); the right climate 
(Ekvall, 1991, p. 73) or culture (Kanter et al, 1997, p. 4; Tang, 1998, p. 304); a fit between 
managerial approach and the stability of the technical and market environments (Burns and 
Stalker, 1961, p. 96); a fit between process and corporate strategy (Maidique and Patch, 
1978, p. 248); or a fit between market and technology (Abernathy and Clark, 1985, p. 5). 
More recently, success in corporate R&D has been linked to a fit between R&D approach 
and the prevailing commercial environment (Utterback, 1994, p. viii; Kumpe and Bolwijn, 
' It should perhaps be noted here that the present author hails from a corporate R&D background in 
the chemical industry. Hence, the references made within this thesis to 'experience'. However, it 
should also be noted that it was the intention that any discussion or theories expressed within this 
thesis would be grounded in the findings of this current study, and would not be assumed from this 
past experience. 
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1994; Varma, 1995; Rogers, 1996; Ahmed, 1998; Liyanage et al, 1999), a commercial 
environment that is currently treating `knowledge' as a source of advantage (see, for 
example, Jordan and Jones, 1997, p. 392; Brown and Duguid, 1998, p. 91; Coles, 1999, 
p. 61; McAdam and McCreedy, 1999, p. 91; Smart et al, 1999, p. 110; McElroy, 2000, 
p. 199) and the management of that knowledge as the competence of interest (for example, 
Stewart, 1997, p. xii; Quintas et al, 1997, p. 385; Davenport, 1997, p. 178; Inkpen and Dinur, 
1998, p. 454; Madhaven and Grover, 1998, p. 1; Ruggles, 1998, p. 80; Despres and Chauvel, 
1999, p. 110; Rickards and Moger, 1999, p. 67; Smith, 2000, p. 305; Armbrecht et al, 2001, 
p. 28; Coates, 2001, p. 9; Hansen and von Oetinger, 2001, p. 106;. Parikh, 2001, p. 27). 
The importance of knowledge, particularly scientific and technical knowledge, to effective 
human activity, and, indeed to the good of society in general, has been recognized for 
many years. For example, whether fact or fiction, and whatever the moral lessons that may 
or may not have been intended, Plato's Timaeus and Critias (circa 348 BC) both tell the 
story of the ultimate defeat of the invading armies from `Atlantis' by the more skilful and 
technologically advanced army of ancient Athens (Lee, 1965, p. 36; Galanopoulos and 
Bacon, 1969, p. 175). Over one and a half millennia later in 1605, in The Advancement of 
Learning, Francis Bacon also advocated the importance of scientific knowledge to human 
progression (Bacon, World Classics Edition, 1906, p. 39), a theme that he developed in 
New Atlantis in 1623, in his description of a society which is ruled by a knowledge elite 
that drives civilization forward through the pursuit and application of scientific knowledge 
(ibid, p. 296). More recently, scientific and technical knowledge has been seen, more 
specifically, as the harbinger of not only economic wealth but also the very survival of 
nations. For example, in 1935, Joseph Schumpeter advanced the opinion that scientific and 
technological innovations (or the effective application of new scientific and technical 
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knowledge) were important factors in determining the economic changes associated with 
the `business-cycle' (Schumpeter, 1935, p. 7). Later, in the Age of Discontinuity, Peter 
Drucker stressed the importance of theoretical and systemic knowledge (that is, scientific 
knowledge) as the crucial resource of the economy (Drucker, 1969, p. ix). And, in Science 
Since Babylon, Derek de Solla Price suggested that the prosperity and survival of nations 
in the modern world depended on their prowess in science and technology (de Solla Price, 
1975, p. 118). 
Since the mid 1970s business organizations in general have seriously begun to take 
account of the knowledge available to them, producing supplementary annual reports 
reflecting the intellectual capital that they own, employing balanced scorecard performance 
plans to try and capture and expand upon the value of their intangible assets, and 
employing chief knowledge officers to improve their processes for knowledge generation 
and application (Ruggles, 1997, p. 1). To some extent, organizations have therefore 
adopted the view that their economic and producing power lies as much in their intellectual 
capabilities as in their hard assets such as land, plant, and equipment (Quinn, 1992, p. 241). 
One notable account of how these intellectual capabilities might be managed in order to 
gain a competitive edge in the twenty-first century is Thomas Stewart's book: The Wealth 
of Knowledge (Stewart, 2002, p. 123). 
With the recognition that knowledge, and particularly scientific and technical knowledge is 
important to the economic welfare of organizations, we might perhaps question why the 
benefits expected from this `knowledge environment' have not, in general, materialized 
within corporate R&D in the United Kingdom (UK). Based on the assumption made by 
many organizations and some academics that knowledge would flow freely across 
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cyberspace, these benefits included the reduction of internal costs by the removal of 
duplicate and non-core activities, and the acquisition of new knowledge as and when 
required. However, rather than the efficient and effective use of knowledge expected from 
these approaches, companies have found that many of the skills and much of the 
knowledge upon which their organizations were and are based are no longer available to 
them or are no longer accessible by them. What was not realized, and what will be shown 
later in this thesis, is that knowledge is not a `commodity' that can be bought and sold or 
an `asset' that can be managed in the traditional sense, but is something that is inherently 
personal and context dependent (Winter, 1987, p. 160). As a consequence, the effective 
application of knowledge relies on the active participation of the people holding that 
knowledge in the particular activities being undertaken. As will also be shown later, 
success in contemporary corporate R&D then ultimately becomes dependent upon the 
interaction between approaches to R&D and evolving `needs' associated with the activity 
being pursued. 
Adopting a knowledge perspective, this thesis makes the assumption that the underlying 
purpose of corporate R&D is the creation of organizational knowledge that enables the 
development of a new or improved product, a new or improved product production process 
or an inter-related product-process innovation. Specifically, this thesis sets out to 
investigate the knowledge-creation process within an industry that has excelled in the 
`knowledge era'. It is hoped that the findings will prove useful in better understanding 
how relevant knowledge is created, and, in turn, how corporate R&D in general might be 
more effectively managed. The research question that forms the point of departure may be 
stated as: In what way should knowledge be created in corporate R&D? The investigation 
uses findings from the R&D and Knowledge Management literature. It also uses new 
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findings from an empirical study into corporate R&D in the UK pharmaceutical industry 
between the years 2000 and 2003, since there appeared to be a significant consensus at the 
time that UK pharmaceutical R&D compared favourably with the R&D of other industries. 
Despite a widespread acceptance of the `knowledge economy' within academic circles, it 
was the present author's experience that the importance of knowledge working had not 
generally been accepted within R&D circles. In order to understand how knowledge is 
created within corporate R&D, the research upon which this thesis is based therefore 
focused on those areas deemed most important in determining how knowledge is created in 
an R&D context, namely: the strategic approaches, the daily practices, and the knowledge 
processes employed in corporate R&D. This focus led to four specific aims of the 
research. These aims are outlined in Section 1.2 of this chapter. The themes that emerged 
as the work progressed are described in Section 1.3. And, an overview of the remaining 
chapters of this thesis is provided in Section 1.4. 
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1.2 The Specific Aims of the Research 
The first aim of the research was to identify the approaches and practices employed within 
corporate R&D, and the possible influences these approaches and practices might have 
upon the knowledge creation process, in order to provide the background for the empirical 
study into knowledge creation in corporate pharmaceutical R&D. The R&D Management 
literature provides descriptions of how R&D functions have been organized over the past 
decades and the changes that have occurred. This literature is reviewed and the typical 
approaches and practices are described in Chapter 2 of this thesis. 
The organizational changes reported in the R&D Management literature are reflected in the 
Knowledge Management literature's `Mode 1-Mode 2 knowledge production' debate 
instigated in 1994 by Michael Gibbons and his co-workers. Despite these authors' claims 
that knowledge production within the context of application (Mode 2) would come to 
predominate over knowledge production within a disciplinary context (Mode 1), there was 
some doubt in the present author's mind that such would or should be the case. The 
second aim of the research was to determine the extent to which these two forms of 
knowledge production are important in contemporary corporate R&D. It was the hope 
that, by adding to the Mode 1 /Mode 2 debate, the research would make sense of and 
provide a richer interpretation of how organizational knowledge is actually produced. This 
is not to say that the debate was without value. On the contrary, it provided a useful 
vocabulary for interpreting changes in the R&D climate. For example, it could be related 
to the shift in British science policy away from the linear (Mode 1) model where science 
invented and industry developed, towards the joint development of science for a particular 
commercial purpose (Mode 2) pioneered by countries such as Japan and Australia. As will 
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be shown later, it is not, however, the whole story. Gibbons and co-workers' proposals are 
described in Chapter 3; their importance is discussed in Chapter 6. 
Other workers have looked more closely at the actual knowledge creation process. The 
knowledge conversion cycle of Ikujiro Nonaka and Hirotaka Takeuchi is considered 
particularly important because of its reference to tacit knowledge (Nonaka and Takeuchi, 
1995). It has, however, been criticized because of its very reliance on conversions between 
four distinctly different forms of knowledge - tacit knowledge and explicit knowledge, of 
the individual and group varieties - which by definition defy the possibility of conversion. 
In consequence, Scott Cook and John Seely Brown proposed several shifts that they 
believed built upon Nonaka and Takeuchi's work and also answered this particular 
criticism. The result is a pluralist framework which differentiates between different 
categories of `knowledge tools'- Nonaka and Takeuchi's four forms of knowledge - that 
are possessed, which are used in the `active process of knowing' (Cook and Brown, 1999). 
Yet, since the earlier work of Michael Polanyi has shown us that all knowledge contains a 
tacit dimension (Polanyi, 1966), we might question both the categories of `knowledge 
tools' proposed by Cook and Brown, and the distinct `forms of knowledge' suggested by 
Nonaka and Takeuchi. The third aim of the research was to examine the extent to which 
these models might be useful in describing knowledge creation within an R&D context. 
These models are also described in Chapter 3, and discussed in Chapter 6. 
Finally, it was hoped that an investigation into the way in which knowledge is created 
within UK-based pharmaceutical R&D would serve as a basis for the identification of 
more general insights into the practice of corporate R&D. The practice of corporate R&D 
is discussed in Chapter 6, Sections 6.5 and 6.6. 
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1.3 The Themes in the Thesis 
One theme that emerged from the empirical study upon which this thesis is based is that 
the work of R&D is not the work of a single entity but is that of two distinctly different 
collectives, one associated with research and one associated with development. And, 
importantly, although these collectives overlap, the approaches, the practices, the 
knowledge, and the knowledge processes used within and necessary for knowledge 
creation in research differ significantly from those suitable for and prevailing in 
development. In essence, these differences may be explained by the fact that research is 
about the exploration for new knowledge, whilst development is about the exploitation of 
existing knowledge. It is a suggestion of this thesis that these fundamentally different 
knowledge purposes impose specific requirements upon how research and development are 
managed to the extent that, to a degree, research should be the master of the organization 
whilst the organization should definitely be the master of development. 
A second theme that emerged as the research progressed was that, as in much of life, the 
assumptions made and the perspectives adopted can significantly affect the way in which 
we view things. This was particularly so in relation to the models of organizational 
knowledge creation outlined in Chapter 3 of this thesis. For example, if we accept that the 
terms `tacit' and `explicit' refer to two distinctly different forms of knowledge, then we 
might accept the pluralist framework of Cook and Brown. In so doing, we can show quite 
clearly the distinctly different knowledge requirements of corporate research and 
development (Chapter 6, Section 6.4.2). If we cannot accept these two forms of 
knowledge, a view that would appear to agree with Polanyi's work, then these differences 
are either meaningless or require significant adjustment. 
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Finally, it is interesting that many of the participants of the empirical study upon which this 
thesis is based mentioned `communication' as being perhaps the one most important factor 
in ensuring success within R&D. Whilst this finding has no doubt been influenced by the 
topic of interest and by the way in which this study was conducted, it will be shown later 
that, despite the distinctly different approaches adopted in pharmaceutical research and 
pharmaceutical development, knowledge acquisition and knowledge sharing, as defined in 
the next section of this chapter, are essential requirements of both these activities. Without 
the opportunities that arise from the instinctive practices that develop between lifetime 
colleagues within tightly bound organizations such as exist in Japan (Ray et al, 2000, p. 3), 
it is hardly surprising that communication is important. The problem is that there is more 
that needs to be acquired, shared and then applied than the `knowledge' that is normally 
associated with the spoken word. 
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1.4 An Overview of the Chapters 
In addition to the present chapter, this thesis contains a further six chapters covering, in 
turn: a literature survey of the approaches and practices of corporate R&D; a literature 
survey on knowledge creation; the research methodology; the findings of the empirical 
research; the discussion of these findings; and a conclusion. The subject matter of these 
chapters is briefly outlined below. 
There has been much written about the management of corporate R&D, yet there have 
been few reports that have adopted a knowledge perspective. 2 So, although, it has 
generally been recognized that there is probably `no one best way' to manage the practices 
of R&D, Chapter 2 (Corporate R&D: A Literature Review) attempts to make sense of the 
approaches and practices observed by others in order to outline the general context within 
which knowledge is being created within this area of corporate activity. Five broadly 
defined approaches, often referred to as the `R&D Generations', are described. And, 
whilst the progress from one approach to the next has been attributed to changes in market 
forces and advances in technology, this progress would appear to be far from complete and 
far from being a certainty. At the same time, the daily practice of professional R&D 
workers would seem to be remarkably consistent; they want to generate the appropriate 
knowledge. The question of what constitutes 'appropriate' is, however, shown to vary 
enormously according to the approaches adopted and the particular stage of the R&D 
process. The chapter highlights the types of knowledge that are appropriate in typical 
instances. 
2 Notable exceptions are: Faulkner, 1994: Gibbons et al, 1994; Leonard-Barton, 1995; Liyanage et 
al, 1999; Nonaka and Takeuchi, 1995; and Madhavan and Grover, 1998. 
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Chapter 3 (Knowledge Creation: A Literature Review) begins with a brief discursion into 
the views of some 20th century philosophers regarding the growth of knowledge in the 
scientific community at large. It then looks into the complex and inherently personal 
nature of what is generally referred to by the term `knowledge', and draws the conclusion 
that it is information, not knowledge, that can exist independently, and which can thus be 
directly acquired or shared. Knowledge acquisition and knowledge sharing - or, in 
general, the flow of knowledge - is dependent upon the providers and receivers of 
information accepting and understanding the same `interpretation code' for that 
information -a far from guaranteed reality. Processes such as knowledge acquisition, 
knowledge sharing, and knowledge transfer within this thesis are then defined accordingly. 
The chapter then moves on to review the Mode 1 and Mode 2 approaches to knowledge 
production defined by Michael Gibbons and his co-workers (1994); the organizational 
knowledge creation and conversion cycle suggested by Ikujiro Nonaka and Hirotaka 
Takeuchi (1995); and the pluralist framework of knowledge and knowing described by 
Scott Cook and John Seely Brown (1999). Finally, the chapter revisits Michael Polanyi's 
earlier work on the `tacit dimension' (Polanyi, 1966) to outline how we may each create 
our own personal knowledge, an acceptance of which has serious implications for the 
models of Nonaka and Takeuchi and Cook and Brown mentioned above. 
Chapter 4 (The Research Methodology) notes the major assumptions made, and makes the 
case for the use of more explorative techniques to uncover and understand current practices 
in corporate R&D. In particular, the chapter refers to the still emergent state of theorizing 
and research into the importance of knowledge-based approaches to firm performance, 
which render quantitative techniques inappropriate. And, it describes the need for an 
adaptable but indirect observational technique, which led to the decision to employ a semi- 
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structured interview method for the collection of empirical data, interviewees being 
managers responsible for the research and/or development functions of their respective 
organizations. The chapter describes in detail the procedures employed in selecting the 
`more successful' R&D organizations for sampling, the actual interview (data collection) 
process, and the subsequent manual method of data analysis. 
Chapter 5 (The Findings of the Empirical Research) summarizes the findings from the 
empirical study. In contrast to the earlier literature, much of the more recent management 
literature appears to have treated the R&D process as if it was a single activity (albeit 
involving several iterative stages). 3 For most companies in most industries this may be 
perfectly adequate, since much corporate R&D is perhaps closer to D (development) than 
R (research). However, the pharmaceutical industry is one industry in which both research 
and development activities are carried out. Perhaps the strength of this present study is that 
it has, for this reason, been able to highlight the differences between corporate research and 
corporate development. Specifically the chapter shows how the approaches, the practices, 
the knowledge, and the fundamental knowledge processes used within and necessary for 
knowledge creation in research differ significantly from those suitable for and prevailing in 
development. 
Chapter 6 (Discussion) revisits the literature reviewed in Chapters 2 and 3 and discusses its 
relevance in the light of the findings reported in Chapter 5. First, the positions of 
pharmaceutical research and pharmaceutical development are pinpointed on the `R&D 
Generations' scale: research is related to first generation R&D, and development to third 
and fourth generation R&D. Second, the importance of both Mode 1 and Mode 2 
3 More recent exceptions are: Kumpe and Bolwijn (1994) and Becerra-Fernandez and 
Sabherwal (2001). 
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knowledge production is determined in relation to pharmaceutical research and 
pharmaceutical development: research is described as a transdisciplinary Mode 1 type 
activity, and development as a coordinated Mode 2 type activity. Third, the relevance of 
each of the three `models' of organizational knowledge creation is discussed in relation to 
pharmaceutical research and pharmaceutical development: whilst Nonaka and Takeuchi's 
model points us towards the types of knowledge processes important for knowledge 
creation in each of these contexts; and whilst Cook and Brown's model emphasizes the fact 
that we use the knowledge available to us at the time to pursue our various activities; it is 
Polanyi's proposal that knowledge creation is the result of purposeful (if sometimes 
indeterminate) acts of tacit knowing that provides the predictions that accord with the 
findings of this present study. Fourth, the chapter looks at the different knowledge creation 
processes in research and in development and makes some suggestions as to `why things 
are as they are'. In so doing, it suggests that it is the `needs of research' that determine 
how research is managed, but is the `needs of the organization' that determine how 
development is managed. The chapter concludes with a review of the various factors 
deemed to be the most important in achieving success in corporate `R&D', factors which 
relate to the need for commercial viability in development, whilst ensuring a degree of 
exploration in research. 
Chapter 7 (Conclusion) summarizes the major conclusions, highlights the major 
contributions made, and outlines the principal limitations of, and some possible extensions 
to, the work reported herein. 
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2 CORPORATE R&D: A LITERATURE REVIEW 
2.1 Introduction 
From a strategic perspective, corporate R&D might be viewed as `investment in invention', 
the generation of new knowledge that, given an appropriate combination of resources and 
circumstances, could result in an innovation that enhances or redirects the firm's capacity 
to compete. Yet, the potential costs and benefits of investing in invention are shrouded in 
uncertainty. Significant resources might be consumed by activities that do not unfold in 
the way that was initially expected, while the opportunity-cost of pursuing, what are 
subsequently judged to be, unsuitable R&D trajectories can have serious implications. 
Yet, knowledge created during apparent failure might also be a stepping-stone to 
tomorrow's success. Clearly, there is a high premium on generating insightful judgments 
about R&D policies that take suitable account of evolving patterns of constraints and 
opportunities. However, there would appear to be considerable disagreement about what 
constitutes `best practice' in any given circumstance. Nevertheless, this chapter attempts 
to make some sense of the approaches and practices described in the R&D Management 
literature, in order to outline the context within which knowledge is being created in this 
study. Chapter 3 then uses the Knowledge Management literature to identify specific 
approaches to the production or creation of knowledge. 
Building on the benefit of hindsight, five broadly defined basic approaches to R&D have 
been recognized or advocated in the literature. Often referred to as the `R&D 
Generations', these different approaches have, in the main, been attributed to changes in 
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market forces and advances in technology, particularly information and communications 
technologies (ICTs), which have required or enabled companies to alter their strategic 
stances and adopt different organizational forms and management procedures (Kumpe and 
Bolwijn, 1994; Varma, 1995; Rogers, 1996; Ahmed, 1998; Liyanage et al, 1999). 
Certainly, the present author's personal experience, generated during two decades as an 
R&D practitioner, supports the view that different organizations have adopted these 
approaches to varying degrees, and, indeed, that influences associated with several or all of 
these approaches may be evident in the same organization at the same time (Pearson, 1991, 
p. 21). The advent of a new generation does not necessarily erase the legacy of what went 
before and the progression from first to fifth generation approaches is not necessarily 
unidirectional in sequence. As Rothwell and Zegveld point out, `the linkages between 
science, technology and the market place are complex, iterative and multidirectional' and 
`within particular branches of industry causality can switch from being mainly in one 
direction to being mainly in the other' (Rothwell and Zegveld, 1985, p. 65). 
At the same time, the daily practice of professional R&D workers is in many ways 
remarkably consistent: they want to generate appropriate knowledge. Thereafter, the 
picture becomes more complicated: the question of what constitutes `appropriate' can vary 
enormously according to the perspective and interests of the observer. R&D is only one 
part of the firm's activities, and the extent to which different people feel that it should lead, 
or be guided by, corporate strategy is shaped by personal perspective and prevailing 
circumstances: it depends on whom you ask within the firm and the nature of the firm's 
business. As the empirical work presented in Chapter 5 will illustrate, corporate R&D 
simultaneously shapes the generation of knowledge and is shaped by a shifting 
constellation of influences which operate across the firm and its wider environment. 
Chapter 2: Corporate R&D 15 Section 2.1 
Briefly, the five generations of R&D covered in Section 2.2 of this chapter comprise: 
science/technology-push; market-pull; integration of activities within the firm; external 
collaborative working with wider communities; and virtual networking. Although the 
latter three generations might be associated directly with recent Knowledge Management 
and related discourses, a knowledge-based approach can also be used to deconstruct the 
more historical science/technology-push and market-pull debates. Indeed, as the next 
chapter will suggest, the science/technology-push model may be seen as the precursor to 
what Gibbons and his colleagues have called Mode I knowledge production, whilst the 
later R&D generations increasingly embody practices that fall within the general scope of 
what these authors refer to as Mode 2 knowledge production (Gibbons and Johnston, 1974; 
Gibbons et al, 1994; Gibbons, 2001; Gibbons, 2003; Nowotny et al, 2001; Nowotny et al, 
2003). 
Although successive generations of corporate R&D have moved the focus of management 
attention from exogenous knowledge generation to endogenous invention and then back to 
the exogenous influences associated with wider networks and cyberspace, paying undue 
attention to either the macro or micro level is simplistic and can be misleading: the 
innovating firm plays a vital role in brokering complex connections between the detail of 
corporate R&D and the bigger picture. Accordingly, Section 2.3 looks at the practice of 
R&D, specifically at the R&D process. 
Section 2.4 summarizes the main points of the chapter. 
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2.2 R&D Approaches 
Arguably, the first and second R&D generations are essentially two sides of the same coin, 
which is a point that is recognized in the third R&D generation where the emphasis on 
science/technology-push that characterized the first generation was complemented by 
attention to market-pull influences that framed second generation approaches. These early 
models placed the focus of attention on intra-firm activities. However, no firm can ignore 
the context in which it operates. Subsequent R&D generations embraced exogenous 
influences on the nature of the firm's daily business and direction of corporate strategy. 
2.2.1 First Generation R&D: Science/Technology-Push 
Many of the great technological innovations associated with the birth of the industrial era 
were undoubtedly based on the entrepreneurial exploitation of practical insights and 
learning that took place in the course of seeking more rapid (Hobsbawm, 1968, p. 34) and 
more advantageous ways of doing things (ibid, p. 43). Spurred on by the growth and 
acceleration of overseas trade (ibid, p. 34), the process of competitive innovation which 
propelled Britain into the industrial era and paved the way for many of the great 
engineering achievements of the Victorian period typically owed more to practical 
experience and know-how (ibid, p. 44) than to the formal learning associated with 
embryonic university disciplines (ibid, p. 45) - which was to become the foundation of 
Mode I knowledge production. Rather than science paving the way for technology, it 
would appear that it was technology that led to further technology (de Solla Price, 1975, 
p. 50). And, academic science generally took more from industry than it could offer in 
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return. Nevertheless, whilst formal scientific training was often absent, it has been 
suggested that informal scientific learning through personal efforts and contacts played a 
part in these major advances of the nineteenth century (Jewkes et al, 1958, p. 66; 
Hobsbawm, 1968, p. 43). By the end of the nineteenth century, progress in physics and 
chemistry had, however, started to inform the development of new trajectories of 
technological innovation, notably in the US electrical and the German chemical industries 
(Hobsbawm, 1968, p. 146; Graham, 1985, p. 49; Rothwell and Zegveld, 1985, p. 32). 
Science had reached the point where it could offer discoveries that had commercial 
implications, some of which were coupled to user needs by insightful entrepreneurs 
(Schumpeter, 1912, in Hobsbawm, 1968, p. 145; in Rothwell and Zegveld, 1985, p. 28; and 
in Utterback, 1994, p. 192). 
By the early 1900s, a number of R&D laboratories had been established within some of the 
larger Western organizations in order to exploit the opportunities that science offered. 
Initially, the focus of attention was directed towards the processes by which things were 
made, but later the focus turned to the internal development of production products. 
Instead of merely scanning the external environment for inventions in which to invest 
(exogenous invention), corporations started to invest in the production of invention 
(endogenous invention), and, in science-related industries, the R&D department became 
established as an important internal source of innovation (Varma, 1995, p. 232). 
The view that science-discovered and technology-applied became an embedded part of 
government policy for science in countries such as the US and UK. Science seems to have 
played a major role in the period after the Second World War, with science-related 
technologies - nuclear weapons, nuclear power, rockets, radar, thermoplastics, 
jet engines, 
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and so on - achieving a high profile. The policy lesson seemed to be simple: invest in 
publicly funded basic research and economic growth would take care of itself (Rothwell 
and Zegveld, 1985, p. 50) - although the `miracle' growth of economies such as Japan, 
which spent a comparatively low proportion of GDP on basic research, eventually 
prompted some fresh thinking. 
Up to the 1960s, corporate laboratories tended to operate in isolation from the rest of the 
organization. They often occupied sites that were separate from the main business 
functions: a semi-autonomous `Ivory Tower' that was protected by the corporate umbrella. 
In line with US and UK government policies, the assumption was that economic gain 
would inevitably flow from the work undertaken. There was an emphasis on long-term 
research, with scientists generating projects on the basis of a company's portfolio of 
research interests: 
`Corporate R&D was assumed to be a valuable and cost effective investment for 
the company's growth ... Industrial scientists saw their primary objective as being one of discovering and inventing, albeit within a corporate context. Many 
technical managers supported basic and long-term research of science, without 
much regard to development. They believed that the cumulative benefits of 
research would automatically produce products and processes of great value to 
the company. ' (Varma, 1995, p. 235) 
R&D was managed as part of a traditional, hierarchical, functionally driven organization 
(Rogers, 1996, p. 36). The R&D `team' consisted of an individual or a small group of 
scientists, who knew each other well, who all `spoke the same language', and who were led 
by a technical `manager'. Great emphasis was placed on individual creativity and the 
undertaking of scientific discovery with minimal bureaucratic controls (Bums and Stalker, 
1961, p. 159) and there were few formal techniques for the selection and evaluation of 
projects. 
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The discovery-push approach to corporate R&D knowledge creation was thus functionally 
split, with the various activities - research, development, production, marketing - taking 
place serially (Rothwell, 1992, p. 236). This `stage-gate' process was likened to a `relay 
race' where the process `baton' passes from one team to another as each stage is completed 
and the next begins, although as most authors emphasize there may be many iterations and 
feedback loops between the various stages before completion (Rothwell and Zegveld, 
1985, p. 48; Kumpe and Bolwijn, 1994, p. 38). As the principal supplier in a `sellers' 
market for new ideas, research could `take its time' in creating, analysing and perfecting 
scientific knowledge, whereas development concentrated on reducing costs (Kumpe and 
Bolwijn, 1994, p. 38). However, this task-separation meant that R&D workers had little 
appreciation of the overall business activities of the organization and business functions 
similarly had little understanding of the problems that were endemic to R&D. 
2.2.2 Second Generation R&D: Market Pull 
By the 1960s, it became apparent that simply waiting for the R&D department to come up 
with an invention that was ripe for innovation was not necessarily a recipe for commercial 
success (Kumpe and Bolwijn, 1994, p. 3). Although competition from countries such as 
Japan was initially dismissed as being limited to low-technology, low-quality and often 
unreliable products, continuous improvement innovations by Japanese manufacturers 
progressively paved the way to new standards for high-technology, high-performance 
products that redefined global expectations about reliability. Despite spending a 
comparatively low proportion of GDP on basic research, Japanese producers improved 
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market share and conquered new markets by aligning their trajectories of improvement 
innovations with the evolution of market needs. 
Meanwhile, it was recognized that although many Western corporate laboratories had 
produced promising research results, these results were not always translated into viable 
products or production processes (Varma, 1995, p. 235). Perhaps in an attempt to emulate 
their Japanese counterparts, Western organizations focused their efforts on customers' 
needs (Rothwell and Zegveld, 1985, p. 49). The process of R&D adopted a reactive role 
(Rothwell, 1992, p. 236). Cooperation between R&D and marketing and between R&D 
and manufacturing increased, and many companies established local technical units to 
support local sales and marketing operations (Kumpe and Bolwijn, 1994, p. 40). The 
knowledge creation process remained essentially linear (Ahmed, 1998, p. 47), but close 
attention was now paid to design aspects such as `producibility and serviceability' 
(Kumpe and Bolwijn, 1994, p. 40), and projects were selected on the basis that they would 
deliver tangible results within a specified time period (Liyanage et al, 1999, p. 376). 
Although scientific and technical knowledge creation remained largely the province of the 
central R&D department, marketing, design, and operations knowledge became important 
inputs into the process (Kumpe and Bolwijn, 1994, p. 40). 
By the end of the 1970s, a wide array of new technologies had led to the introduction of a 
diverse variety of products and processes into many markets. Local technical units were 
also increasingly developing additional products to meet their particular local 
requirements. As a consequence, companies began to experience difficulties in developing 
and supporting an ever-widening product range (Kumpe and Bolwijn, 1994, p. 40). There 
was an increasing emphasis on process improvements (Rothwell and Zegveld, 1985, p. 33) 
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in order to compress development times (Rothwell and Zegweld, 1985, p. 51). These 
improvements included concurrent engineering, simplification of designs, optimal use 
of proven technologies, standardization of components, the use of CAD-CAM 
technologies, and the outsourcing of some non-strategic technologies (Kumpe and Bolwijn, 
1994, p. 41). Products were designed with the objective of being produced efficiently and 
effectively using existing manufacturing capabilities (ibid, p. 41). 
By the middle of the 1980s, the centralized corporate R&D laboratories of many 
international companies had been physically restructured around their various business 
units (Varma, 1995, p. 232), and the availability of business money directed research: 
`Now, managers and scientists have to work with one of the business divisions 
to encourage joint projects between scientists and business divisions' people. 
The cooperation between research and business divisions is enforced by 
changing the funding scheme. Scientists have to obtain contracts from business 
divisions for their research efforts. ' (Varma, 1995, p. 236) 
Yet, these new power structures could be a source of tension: business divisions with their 
need to maintain short-term profit for shareholder return were not necessarily geared 
towards long-term scientific research, even if ultimately that research could bring them 
considerable competitive advantage. There were consequently problems in gaining funds 
for science/technology led projects. Business divisions were not willing to take the risks 
involved and were perhaps not, singly, able to provide the larger sums of money required. 
The power to select promising projects had moved from those favouring an emphasis on 
technical viability towards those whose principal concern was with commercial viability. 
Rather than rewarding scientific excellence, the model encouraged scientists to generate 
research and development (typically with an increased emphasis on development) towards 
the solution of specific problems of the business divisions. 
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Specific problem solving broadened the knowledge horizons of individual R&D (and 
other) workers, but meant that there was little focus to the functional knowledge created. 
The result was that exploitation of existing knowledge often prevailed at the expense of 
basic scientific knowledge creation. And, with the new focus on specific market needs, 
certain parts of the broad spectrum of technical opportunities were sometimes overlooked 
(Weick, 1979, p. 69). As recognized by Varma, this blurred the goals of R&D: 
`Under the autonomous [first generation R&D] model, goals for R&D were well 
established. Managers clearly stated what business the company was in; what 
business the company was going to be in ... scientists were able to 
link their 
research agendas to the broad goals and objectives of the company ... 
Since the 
mid-1980s, goals for corporate R&D have become rather vague ... corporate leaders are supporting corporate R&D as a discretionary item rather than 
providing a steady support ... Managers are ... 
directing research to solve 
specific problems. Both scientists and managers reported that their companies 
did not have plans for what their products would be in 3-4 years, or what 
businesses they would be in 5-10 years later' (Varma, 1995, p. 240). 
To the extent that the R&D and managerial interests represented had evolved 
independently, communication between the different interest groups could be awkward; 
neither side quite spoke the other's language - and there were often diverging expectations 
about what constituted `best practice' and `progress'. 
2.2.3 Third Generation R&D: Business Integration 
Third generation R&D arose from a need to consolidate the link between R&D and 
business strategies, particularly marketing strategy (Roussel et al, 1991, p. 2; Rothwell, 
1992, p. 236). Research planning became a corporate function and specific R&D 
programmes were formulated jointly between business and R&D managers so that both 
technical and market needs and strengths could be adequately engaged. Projects were 
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treated as a group of important investment portfolios that should be managed like any 
other production input such as labour or capital (Kumpe and Bolwijn, 1994, p. 41; 
Rogers, 1996, p. 36) and quantitative methods were employed to ascertain the likely 
contribution of individual projects. 
Project managers were put in charge of significant programs and multifunctional matrix 
coordinated R&D teams became common (Liyanage et al, 1999, p. 376). Scientists and 
technologists became more intimately aware of business needs, and the business division 
people became familiar with the scientific and technical expertise available to them. There 
was increased intermingling across the boundaries of previously separate spheres of 
responsibility as technical, production and business staff worked and learnt together as part 
of an `ongoing social process in which problems were solved and new problems were 
identified (Best, 1990, p. 12; Rothwell, 1992, p. 236). In essence, knowledge creation 
became transdisciplinary (see Gibbons et al, Chapter 3, Section 3.4.1, page 103). 
During the late 1980s and early 1990s, it was thought that geographic proximity to external 
researchers might be conducive to successful R&D, since `technological spillovers' could 
occur (Crane, 1972, p. 63; Kuemmerle, 1998, p. 113; Gassmann and von Zedtwitz, 1999, 
p. 241; Meyer-Krahmer and Reger, 1999, p. 757). Companies therefore began to locate 
some of their R&D units close to relevant centres of scientific excellence. However, the 
possible benefits of networking across organizational boundaries had to be offset against 
the costs of relocation. Since the mid 1990s, many companies have therefore rationalized 
their R&D units by locating them either (a) close to large markets (demand led units) to 
provide local and regional development and technical support, and exploit existing 
knowledge in an incremental way; and/or (b) close to external centres of excellence 
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(supply led units) in an attempt to gain expert knowledge, and create radically different 
products and processes (Chiesa, 1996, p. 12). 
Arguably, third generation R&D exhibits the problems of trying to reconcile factors that 
stretch far beyond the firm with a view of the organization as a self-contained entity. The 
idea that business integration is merely a matter of identifying and consolidating market 
and technical needs and trying to ensure that employees march in-step towards meeting 
those needs overlooks the fact that the firm is part of the wider knowledge-creating 
ecology and that its capacity to exploit boundary-spanning interconnections can play a vital 
role in the pursuit of competitive advantage. Subsequent R&D generations have 
acknowledged this and allow scope for modification through formal and informal 
collaboration. 
2.2.4 Fourth Generation R&D: External Collaboration 
Traditionally, corporate R&D was carried out in-house, the expectation being that the 
organization would hold or create all of the knowledge that it needed to carry out its 
particular pursuits. However, more recently, there has been a major shift to acquiring 
technology from sources external to the firm (Freeman, 1992, p. 95; Quintas and Brauner, 
1999, p. 49; Roberts, 2001, p. 3 1). Many organizations now engage in technology in- 
licensing (and out-licensing); outsource some (and in some cases all) of their R&D to 
others; participate in research collaborations or joint ventures; and are involved in 
knowledge networking activities with universities, customers, suppliers, companies in 
related fields, and even, on occasions, with direct competitors (Freeman, 1992, p. 99; 
Chapter 2: Corporate R&D 25 Section 2.2.4 
Rothwell, 1992, p. 236). Four factors are frequently mentioned in the literature as being 
important in motivating the change towards external R&D collaboration. 
First, R&D has become an increasingly complex and expensive exercise for all 
organizations. This is because (i) the necessary scientific and technological knowledge has 
become increasingly differentiated and specialized (de Solla Price, 1975, p. 139), and 
(ii) increasingly knowledgeable customers have expected more from new products and 
services (Kumpe and Bolwijn, 1994, p. 44). The result is that several scientific or 
technological knowledge sources are now often required to produce the most acceptable 
goods and services, increasing the costs of R&D (Leonard-Barton, 1992, p. 33; Powell et 
all 1996, p. 118; Bowonder and Miyake, 1999, p. 85; Kodama, 1999, p. 186; Niosi, 1999, 
p. 110; Roberts, 2001, p. 30). Increasing R&D costs have, in turn, led companies to 
rationalize their areas of scientific expertise around their core competencies, the 
assumption being that, when necessary, they could `buy-in' the latest technologies required 
to support these competencies (Powell et al, 1996, p. 118; Niosi, 1999, p. 110; Pyka, 2000, 
p. 28). 
Second, R&D is an uncertain business, and costs arise whether or not events unfold in an 
advantageous manner. Collaborating with other organizations is one way of reducing the 
firm's exposure to the costs of undesirable events. It reduces the stake by spreading the 
costs between participants and thus effectively reduces any losses that might occur, albeit 
at the cost of sharing the outcomes with others (Powell et al, 1996, p. 116; Niosi, 1999, 
p. I 10; Beeby and Booth, 2000, p. 76). Collaboration with companies in related fields that 
are not direct competitors, and that are not likely to become so, offers scope for each party 
to gain without eroding their respective positions. For example, collaboration between a 
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supplier and a customer is often of mutual benefit to both parties: the customer benefits 
from the additional ideas advanced by the supplier; the supplier benefits from 
understanding and better providing for the customer needs (Best, 1990, p. 15). 
Third, by applying the skills of more than one organization, collaborative problem solving 
may reduce the time to market and thus increase the producing organization's lead over its 
competitors; a state that may be particularly important at a time of rapid technological 
change (ibid, p. 15). 
Fourth, a common interest can be a powerful motivator for collaboration (ibid, p. 18). 
Consider, for example, the use of PVC (polyvinyl chloride) in window frames and other 
applications involving direct human contact. In the 1990s, PVC was considered to be a 
health hazard: it contains trace amounts of vinyl chloride monomer (a carcinogen). 
Environmental groups lobbied for a total ban on the use of PVC. Collaborative research by 
the PVC suppliers and users showed that, once processed, not only was PVC as safe as the 
then commercially available alternatives, but also that it was more environmentally 
friendly in that PVC products can be recycled whilst many of the alternatives of the time 
could not. 
Along with the four traditional motivations for collaboration, the Knowledge Management 
literature has underscored the importance of `path dependency'. Path dependency arises 
because existing knowledge often determines the way that new knowledge is interpreted 
and the way that existing and new knowledge is applied (Brook, 1973, p. 30; Weick, 1979, 
p. 46). The argument is that as well as bringing in new knowledge, collaboration also 
decreases the path dependency by bringing in new perspectives based upon the 
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collaborating partners' different knowledge sets. This increases the chance of creating 
something uniquely different to what might have been possible by in-house development 
alone (Bowonder and Miyake, 1999, p. 85). That is, collaboration increases the chance of 
radical innovation. 
In Kumpe and Bolwijn's interpretation of fourth generation R&D, external collaboration is 
seen as just one organizational form that companies adopt in order to compete on the basis 
of `uniqueness' (product differentiation) as well as price, quality and performance 
(Kumpe and Bolwijn, 1994, p. 42). Writing in 1994, these authors suggested that, within 
the company, various organizational forms would coexist alongside one another depending 
upon the requirements of the specific activities being undertaken. There would be 
considerable use of multidisciplinary ad hoc teams, and integrating managers would direct 
and coordinate the various activities from research to production and from components to 
products. They predicted that organizations would need to strike the right balance between 
`renewal and stability' and between `entrepreneurship and the tight, hands-on management 
of innovation'. In their view, external collaborations offered the flexibility of working 
with ideas new to the firm, and at the same time allowed a degree of stability as regards 
internal technology development (ibid, p. 43). 
The importance of customers as sources of knowledge, ideas, and expertise in the R&D 
process has been emphasized by several authors (see for example, Langrish et al, 1972, 
p. 74; von Hippel, 1976, p. 212; Best, 1990, p. 15). And, both Miller and Rogers saw fourth 
generation R&D as the process of concurrent learning with these customers (Miller, 1995, 
p. 30; Rogers, 1996, p. 37). In particular, collaborating with customers in cross-functional, 
cross-disciplinary teams was said to be essential for understanding future business 
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opportunities, and thus for the development of valuable new products and services (Miller, 
1995, p. 31). Ahmed noted that it might also be advantageous to involve suppliers in the 
process (Ahmed, 1998, p. 48). However, Teresko's research questions whether such 
relationships are sufficient for continued success in R&D: 
`A [US] presidential advisory committee questions whether [customer-supplier 
collaborations are] enough to seed the growth of technology-based business over 
the next 10 to 15 years ... 
[It] points to the economic and social benefits that 
have come from federal funding of research into computers and 
telecommunications. ' (Teresko, 1999, p. 30) 
Liyanage et al come to a similar conclusion and suggest that fourth generation R&D is not 
simply about the management of customer or supplier linkages, but about the management 
and integration of the appropriate external knowledge with the internal knowledge of the 
organization. In particular, it is about renewing outdated concepts with current or `state- 
of-the-art' knowledge acquired through rational enquiry and observation from whatever 
source (Liyanage et al, 1999, p. 373). 
2.2.5 Fifth Generation R&D: Virtual Learning Networks 
Several management researchers have remarked that economic, behavioural and 
technological forces are prompting organizations to explore virtual networked structures 
that transcend conventional organizational boundaries. Such structures have been defined 
as opportunistic alliances of core competencies distributed among a number of distinct 
operating entities within a single large company or group of companies (Goldman et al, 
1994, in Rogers, 1996, p. 39). They offer the possibility of combining expertise from a 
range of sources both within the firm and across its wider operating environment. 
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Rothwell (1992), Rogers (1996) and Ahmed (1998) appear to be the most prominent in 
charting the dimensions of fifth generation issues. 
Rothwell suggests a systems integration and networking (SIN) approach based upon the 
third generation business integration and fourth generation collaborative approaches 
outlined above, but specifically involving strong linkages with leading-edge customers and 
strategic integration with primary suppliers. The emphasis is on corporate flexibility, 
speed of development, and quality, through the `electronification of innovation'. That is, 
expert systems, such as simulated modelling of prototypes and integrated electronic design/ 
manufacturing systems, are employed within a multi-institutional networking environment 
in which conceptualization leads practice (Rothwell, 1992, p. 237). 
Rogers identifies five major shifts that are driving the move towards such organizations. 
These shifts comprise moves from: tangible assets (information) to intangible intellectual 
assets (knowledge) as the sources of wealth that need to be managed; formal bureaucracies 
to networks that afford the flexibility needed to harness the maximum potential of 
available intellectual capabilities; passive training and development with a focus on the 
trainer and the curriculum to active learning that places the learner at the heart of the 
activity; a focus on the local or national level to transnational foci; and competitive (win- 
lose) strategies to collaborative (symbiotic) strategies that allow more wealth creation than 
would be possible by operating alone. She proposes that the way in which organizations 
use their human resources to optimize their organizational learning capacity will be crucial 
in enabling a more optimal creation and application of new knowledge (Rogers, 1996, 
p. 33). Importantly, she suggests that all participants in the virtual network must be willing 
and able to continuously learn from each other to create new knowledge as a way of adding 
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value to the entire system. She offers several predictions, namely: that performance will be 
assessed in terms of the intellectual assets produced and the capacity to create and apply 
new ideas in the market place; management practices will be fluid and flexible and will be 
knowledge-based; management systems will be collaborative, not competitive or 
cooperative; and internal R&D, as just one part of the collaborative learning system, will 
focus on designing its innovation system in collaboration with its network affiliates. As a 
consequence, she suggests that knowledge flows will need to be optimized throughout the 
network and managers will need to monitor knowledge flow rigorously with an attention to 
detail that reflects the way in which they previously managed the monetary flow of capital 
and the flow of parts and materials into products and services (Rogers, 1996, p. 37). 
Rogers' report suggests that the exploitation of external knowledge and skills first becomes 
important through outsourcing and licensing agreements. Later, and more importantly, 
trans organizational knowledge is created as people from different organizations work 
together to create new products and processes; in so doing, they contribute to the overall 
progress in science and technology by `bidding-up' the currency of `best practice'. Such 
joint working is not necessarily restricted to collaboration between a university and an 
industrial concern but might involve a number of organizational entities such as 
commercial research institutes, organizations in related industries, and even organizations 
that would normally be thought of as competitors. Although the knowledge created by 
such collaborations may be exploited differently, it is available to everyone who 
participates - participation being essential to make sense of the outputs. Formal and 
informal knowledge sharing networks abound, leading to a complexity of interactions - 
scientific, technical and business - within and without the organization (ibid, p. 37). 
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In agreement with Rothwell, Ahmed sees fifth generation R&D emerging as a consequence 
of the increased utilization of electronic technology as a tool for facilitating the creation of 
a variety of internal and external linkages. However, in contrast to Rothwell's more 
managed approach (page 30 above), Ahmed implies a more informal arrangement. 
Linkages that are mutually beneficial to participating parties tend to become self- 
sustaining: people perceive that the time and effort needed to take part is of net-positive- 
benefit. Ahmed suggests that there are a number of factors that are important for 
successful fifth generation R&D. These include a focus on innovation and discovery; a 
culture of `equals'; effective sharing and processing of ideas; process distinctions between 
radical long-term innovation and incremental short-term business; and keeping and 
building knowledge, particularly embedded skills and memory. That is, `soft' issues, such 
as creating a climate for innovation, are just as important as if not more important than 
`hard' issues, such as organizational procedures and infrastructure, to successful R&D 
(Ahmed, 1998, p. 50). Referring to Cooper and Kleinschmidt (1987) and Zirger and 
Maidique (1990), Ahmed adds that it is in the `balance between the hard and soft factors 
that innovation success appears to be founded' (Ahmed, 1998, p. 57). 
In summary, it would appear that the distinguishing features of fifth generation R&D turn 
on the capacity of the innovating firm to exploit technological opportunities for working 
across boundaries. Advances in transport and communication technologies have made it 
increasingly easy to take advantage of expertise from a diversity of sources. Global virtual 
teams, which were almost unheard of a decade or so ago, have become an established part 
of business life. Modern communications technologies make it relatively easy to work 
across time zones and ensure that the sun never sets on current activity. Virtual 
networking has complemented the fourth generation notion of face-to-face collaborative 
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working. As a result, experts are now more aware of the wider communities of practice 
that are relevant to their respective areas of expertise, thereby providing their employers 
with greater opportunities to learn, albeit at the risk of allowing outsiders to acquire 
sensitive information and learn at the organization's expense (Mansfield, 1985, p. 222). 
Alternatively, it is possible that employees with specialist skills will become better able to 
position themselves as `free agents' who are able to eclipse traditional bureaucratic 
constraints by shaping their own work practices and networks of connections and, in so 
doing, promote their own economic or political agendas (Hayes and Walsham, 2000, p. 72). 
2.2.6 The R&D Generations: Some Trends Summarized 
The previous sections of this chapter have hinted at how the types of knowledge and the 
knowledge processes employed within corporate R&D vary between the R&D generations. 
These variations are summarized in Table 2.2.1 (next page). 
Broadly speaking, it would seem that two prominent overarching forces have driven the 
strategic approaches to corporate R&D, and, in turn, the types of knowledge employed in 
this activity. First, the influence of market forces, which began with the onset of second 
generation R&D in the 1960s, has elevated the importance of commercial knowledge to 
corporate R&D operations. Second, this more commercial approach has been 
complemented by an increasing recognition of the idea that sources outside the firm might 
provide the key to more effective R&D. This latter force became particularly evident with 
the rise of fourth generation R&D in the early 1990s. 
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TABLE 2.2.1: THE R&D GENERATIONS: KNOWLEDGE TYPES AND KNOWLEDGE 
PROCESSES 
Generation Knowledge Types Knowledge Processes 
Prior to 1900 Product and process Scientific and technical knowledge acquisition 
knowledge and skills and internal application. 
First Basic scientific and Internal scientific and technical knowledge 
Generation: technical knowledge. creation mainly through exploration and 
Science/ experimentation. 
Technology 4 Informal Community of Practice' knowledge Push (1900-60) 
acquisition and sharing. 
Second Product and process Internal knowledge creation mainly through 
Generation: knowledge. exploitation and adaptation. 
Market Pull Design skills. Formal and informal knowledge sharing (1960-early Business (particularly 
between R&D and commercial units 1980s) marketing) knowledge. (particularly marketing, production, 
manufacturing). 
Third Scientific, technical and Fundamental scientific and technical 
Generation: commercial knowledge knowledge creation through exploration by 
Business and skills. supply-led units. Commercial knowledge 
Integration Project planning and creation by knowledge application and 
(mid 1980s- evaluation skills. adaptation by demand-led units. 
early 1990s) Formal and informal knowledge sharing 
between R&D, business, and technical support 
units. 
Fourth Basic and applied Knowledge creation mainly through 
Generation: scientific, technical, knowledge application and adaptation. 
External and commercial Internal and external knowledge sharing Collaboration knowledge. 
through formal collaboration and informal 
knowledge networking. `Management' of 
internal and external knowledge and skills. 
Fifth Basic and applied Knowledge creation, sharing, processing and 
Generation: scientific, technical, exploitation through `opportunism' and as part 
Virtual and commercial of a collaborative learning system. 
Learning knowledge. 
Systems 
" Community of Practice: A group of people who have worked together over a period of time and 
through extensive communication have developed a common sense of purpose and a desire to share 
work-related [or specialty] knowledge and experience. They set their own goals, membership 
boundaries, personal relationships, generalized reciprocity, and production and collection of goods 
(Sharp, 1997, www, in Quintas et al, 1999, p. 46). 
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At the operational level, it becomes difficult to deconstruct the respective influences of the 
overarching forces identified above. Micro-level corporate R&D processes are complex. 
Nevertheless, two trends seem evident. First, formal processes of knowledge sharing 
through collaborative working have been added to and intertwined with the informal 
processes such as personal networking that have always existed. Second, the importance 
of sustaining radical new avenues of knowledge creation through exploration and 
experimentation oriented towards scientific breakthroughs (first generation R&D) has 
been, largely, replaced by an emphasis on knowledge creation through the application and 
adaptation of existing knowledge (second to fifth generation R&D). Discovery has 
become increasing overshadowed by recipes and strategies for producing more effective 
combinations of existing knowledge. At the same time, different types of people have 
come to shape the evolution of corporate R&D. Whereas the process of shaping R&D 
strategy was once dominated by individuals or teams of scientists and technologists 
(first and second generation R&D), it has more recently been influenced by 
multidisciplinary and transdisciplinary perspectives, reflecting a wide variety of specialist 
skills within and outside the organization (third, fourth and fifth generation R&D). 
Yet, although each successive generation reflects a shift in the principal focus of attention, 
it would appear that the influence of earlier generations can still represent an important part 
of the picture (Pearson, 1991, p. 21; Boghani et al, 1999, p. 696; Gassmann and von 
Zedtwitz, 1999, p. 231. Complex organizations create knowledge in a variety of ways and 
there are inevitably competing views about what counts as the perspective that matters. 
Technical experts, R&D leaders and others who enjoyed particular influence during earlier 
generations of R&D do not necessarily adopt new `mental models' simply because a new 
generation of strategic thinking has become popular in the management and business 
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literature. Similarly, those who are schooled in the market-rational disciplines associated 
with need-pull models are not necessarily equipped to appreciate the technical risks and 
opportunities associated with networking in the fourth and fifth generation approaches. 
Many different `nested' and `overlapping' interest groups might jostle to exert their 
respective influence over the evolution of corporate R&D strategy. 
Whilst the differing market and technological factors that exist between industries and 
indeed between companies within the same industry may thus explain some of the 
variations observed in corporate R&D strategy (see, for example, the work of Maidique 
and Patch, 1978, and Abernathy and Clark, 1985), these business level generalizations 
mask the complexities of micro-level R&D processes. As the issues addressed in the 
empirical part of this thesis focus on the micro-level, it is important to be clear about the 
types of issues that might be involved. With this objective in mind, the discussion now 
turns to the practice of R&D at the level of the innovating firm. The conceptual 
framework presented in Chapter 6 will draw on principal points arising from this 
discussion. 
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2.3 R&D Practice: The R&D Process 
The proceeding section has suggested that R&D might be organized in a number of ways: 
from individualist-centred autonomous units far removed from the other parts of the 
organization (first and second generation R&D) to cross-functional, cross-organizational, 
and even virtual team-based units (respectively, third, fourth and fifth generation R&D). 
At the same time, using corporate R&D as a proxy for corporate innovation, the 
management of innovation has been viewed as being anything between systematic to 
chaotic. For example, Drucker proposed that innovation could be systematically managed 
if one knows where and how to look (Drucker, 1985, p. 67). And, based upon his findings 
that most innovations result from a conscious, purposeful search for opportunities, he 
proposed several guiding principles: be context relevant - meet user expectations, values 
and needs; be simple and be focused; start small; aim to be the standard setter; and, most 
importantly, innovation is hard purposeful work rather than genius (ibid, p. 72). On the 
other hand, Quinn sees the management of innovation as `managed chaos': 
`Top managements ... tend to administer primarily 
by helping establish goals, 
selecting key people, and defining certain critical limits or decision points at 
which they will intervene. As technology leads or market needs emerge, they set 
a few - most crucial - performance targets or concept limits ... These management 
then allow their technical units to decide how to achieve these [goals], subject to 
defined constraints and program reviews at crucial junctures. ' (Quinn, 1985, 
p. 275) 
The definitive answer to how R&D should best be managed is perhaps still open to debate. 
Indeed, there probably is no one best way (Walker, 1994, p. 6). Nevertheless, it would 
seem evident that corporate innovation is assisted by individual empowerment, and 
organizational flexibility, combined with an integrative approach which focuses on the 
future rather than the past. For example, Kanter writes of the importance of the 
Chapter 2: Corporate R&D 37 Section 2.3 
empowerment of people; the need to see problems integratively `as wholes, related to 
larger wholes'; and of focusing on what is not yet known rather than controlling what is 
already known (Kanter, 1983, p. 27). She suggests that such approaches are more likely in 
organizations whose cultures and structures are also integrative; that is organizations which 
whilst allowing multiple perspective approaches also provide overall coherence and 
guidance (ibid, p. 28). She, furthermore, suggests that, in such organizations, 
experimentation is encouraged (ibid, p. 30); the search for solutions is broadened beyond 
departmental boundaries (ibid, p. 29); and specialist biases and political conflicts are 
resolved through a shared philosophy (ibid, p. 32) and pride in the organization (ibid, p. 34). 
Leonard-Barton similarly sees experimentation and integrated problem-solving across 
different cognitive and functional boundaries as key activities that enable organizations to 
innovate continuously and consistently (Leonard-Barton, 1995, p. xiv). To these she adds 
two further activities: importing know-how from outside the organization, and effective 
implementation of new methodologies and process tools (ibid, p. xv). She also sees 
innovative organizations as organic learning systems (ibid, p. 7) which emphasize long- 
term thinking (ibid, p. 265), and which depend on the sense of ownership derived from 
suitable incentive systems and the pride of accomplishments gained from shared problem- 
solving (ibid, p. 16). In essence, Kanter's and Leonard-Barton's reports agree with Burns 
and Stalker's findings that the uncertainty associated with innovation is best enabled by 
flat, interactive, consultative, organic organizational forms (Burns and Stalker, 1961, 
p. 121) operating from a basis of shared values and beliefs (ibid, p. 119), where the power to 
make decisions is given to those with the relevant ability and expertise (ibid, p. 122); rather 
than hierarchical, bureaucratic, rule-based, mechanistic structures (ibid, p. 120), where 
decisions are made by those holding the power associated with position and specialist 
function (ibid, p. 104). 
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Empowering individuals might seem to fit with the suggestion normally attributed to 
Francis Bacon (1561-1626) that `knowledge is power' (Mintzberg, 1979, p. 351). And if 
knowledge is power, then the owners of knowledge have power that may dissipate if others 
come to know what they know (Chumer et al, 2000, p. xviii). We might then question how 
empowered organizations do in fact function, since they undoubtedly rely on the sharing of 
knowledge between their employees. Burns and Stalker offer us an explanation by 
suggesting that commitment to the organization is far more extensive in organic than 
mechanistic systems, a fact that is perhaps due to the development of shared beliefs about 
the values and goals that are to be achieved (Burns and Stalker, 1961, p. 122). Whilst this 
is no doubt true, the present author prefers the view that `knowledge is potential's. As 
such, knowledge is there to be used for the good of all. As we shall see in Chapter 5 below 
(Section 5.4.1, page 176), this would also seem to be the view adopted by the participants 
of this current study, at least as regards their research activities. The problem, of course, 
arises when one's contribution to the organization goes unrecognized or, worse, is usurped 
by others for personal gain. 
Most organizations, whether they are innovative or not, will need to carry out a range of 
routine operations, for example, billing and fulfilling customers' orders, carrying out 
financial and other audits. For such stable operations, mechanistic approaches offer greater 
efficiencies (Burns and Stalker, 1961, p. 119). Most organizations might therefore be 
expected to, and in fact do, operate with a management system which includes both 
organic and mechanistic forms (ibid, p. 122). At the same time, organizations are formed 
5 An alternative translation to the normally stated quotation from Francis Bacon's Meditationes 
Sacrae (1597) is that `knowledge is itself potential' rather than `knowledge is itself power. ' 
(Conversation with John de la Mothe, March 3,2006) 
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by and with people. And people are social and political creatures. As we shall see in the 
pages that follow, individual politics and group power may each play a part in the decisions 
that are made concerning products, processes, enabling technologies, and, although related 
to but not strictly the subject of this thesis, organizational change. As we saw above 
(Section, 2.2.4, page 27), when people or groups feel threatened, they may take action to 
reduce or remove that threat. Within organizations, such actions are ostensibly pursued 
(and mostly believed to be pursued) in the interests of efficiency or as contributions to the 
firm's tasks and its future prosperity (Burns and Stalker, 1961, p. 145). With these thoughts 
in mind, it is now possible to turn to the specific activities involved in the R&D process, 
the focus of this section. 
There is a burgeoning literature on R&D processes. However, as Tang (1998) has 
suggested, the practice of R&D would appear to include some or all of the following 
activities: 
1. Scanning the environment for opportunities to be exploited or problems to be solved 
2. Generating ideas to satisfy those opportunities or problems 
3. Strategically screening ideas to select those meeting corporate goals and fitting with 
internally or externally available technical and market competences 
4. Preliminary investigation or concept testing to determine technical viability and to 
develop technical and marketing specifications 
5. Product development to meet as far as possible the specified requirements 
6. Product testing to determine the final product specification 
7. Test marketing to determine the appropriate market and entry method 
8. Product launch 
(Source: Tang, 1998, p. 298) 
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Whilst it is tempting to relate Tang's activities to the traditional stages in the innovation 
process - invention6 (Activities 1-4), followed by innovation? (Activities 1-5), followed by 
widespread use (Myers and Marquis, 1969, p. 4; Utterback, 1994, p. 193) - these activities 
may be, but do not necessarily need to be, undertaken strictly in the order listed. Many of 
them can be, and often are, carried out in parallel. As mentioned above (Section 2.2.1, 
page 20) it is also not uncommon for many iterations of these activities to occur throughout 
the course of an R&D project. As pointed out by Langrish et al, many of the inventive 
steps are embedded within the innovation process, not made prior to it or at its beginning 
(Langrish et al, 1972, p. 7). Nevertheless, in order to make the discussion in the pages that 
follow more manageable, this section does separate the R&D process into three distinct 
segments: project initiation (activities 1-4), project management (activities 5-7), and 
project termination (Activity 8). Thus, although it might appear that these three stages are 
being presented as if they were the beginning (invention), middle (innovation) and end 
(widespread use) of a traditional fairy story of successful innovation, it is important to 
stress that R&D is a complex web of many stories: apparent ends are often the beginning 
of another story, while other stories never seem to have an end. In short, the three phases 
can come in any order, and judgements about where one phase stops and another starts can 
vary considerably according to the perspective of the observer. At the same time, the way 
in which these activities are implemented may vary depending upon the strategic R&D 
approach adopted. For example, idea generation (activity 2) may still be seen as largely 
the function of the technical department (cf. first generation R&D), largely the function of 
6 The creation of an idea and its reduction to practice to prove the principle involved (Rothwell and 
Zegveld, 1985, p. 47) 
The commercialization of technological change (Rothwell and Zegveld, 1985, p. 47) 
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the commercial departments (cf. second generation R&D) or a joint operation between 
technical and commercial departments (cf. third generation R&D). Product development 
(activity 5) may similarly be a single function operation, a multifunction operation or a 
transfunctional operation. 
Whilst the literature usually links the practice of R&D to the exploration for new 
knowledge, the sections above have shown us that the exploitation of existing knowledge 
is also important in modern-day corporate R&D. And, increasingly, it is the exploitation 
of knowledge held external to the organization that is the focus of attention. As will be 
shown in the paragraphs that follow, knowledge acquisition and knowledge sharing are 
now viewed as important processes in the practice of corporate R&D, and the application 
of that acquired or shared knowledge is of fundamental importance throughout the task in 
hand, whether that be during project initiation, project management or project termination. 
That is, rather than the acquisition, transfer, and utilization of information (Burns and 
Stalker, 1961, p. 153) it is the acquisition, sharing (transfer) and application (utilization) of 
knowledge that is now seen to be important in the effective practice of corporate R&D. 
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2.3.1 Project Initiation 
Idea Generation (Activities 1- 2) 
Project initiation begins with an idea to be used or a problem to be solved. Whilst not 
always acknowledged previously, companies now do generally accept that ideas may come 
from anyone and anywhere (Leonard-Barton, 1995, p. 10), from both within or without the 
organization. They may come from workers, staff, and managers, and from consumers and 
suppliers (Best, 1990, p. 13). They may come from universities, research organizations, 
and government laboratories (Jewkes et al, 1958, p. 127; Gibbons and Johnston, 1974, 
p. 233). That is, it is not necessarily the institution which guides research to defined ends 
that provides the inventions upon which the eventual innovation is based (Jewkes et al, 
1958, p. 89). For example, in considering the R&D processes employed in companies 
gaining the UK Queen's Awards for technological innovation during the years 1966-67, 
Langrish and his co-workers came to the conclusion that, more often than not, technical 
novelty came from outside the organization (Langrish et al, 1972, p. 8). 
Many projects are the result of motivated staff producing and championing ideas in 
response to a perceived stimulus for change. That is, it is the `exceptional and largely 
intuitive powers of individuals to identify unexpected variations' that appear to have been 
the source of much invention (Jewkes et al, 1958, p. 120). Nevertheless, Quinn notes that 
the most innovative organizations' typically take a more proactive route to idea 
generation. Observing that scientific knowledge and technological advances from 
seemingly unrelated fields frequently interact to create totally new concepts or 
opportunities of importance to the enterprise (Jewkes et al, 1958, p. 118; de Solla Price, 
Chapter 2: Corporate R&D 43 Section 2.3.1 
1975, p. 22), he points out that these organizations often have active strategies to develop 
information for trading with a variety of external research or technology groups (Quinn, 
1985, p. 272). 
From the perspective of the producing company, projects may be initiated in order to solve 
a particular problem (Tang, 1998, p. 300), which may be customer, supplier or company 
related (Leonard-Barton, 1995, p. 184). For example, projects may be initiated to meet 
unusual customer requirements, to replace raw materials no longer available on health or 
safety grounds or in general decline, or to fill a gap in the company's product or process 
portfolio. They may be initiated in response to an emerging market, a segmenting market, 
or a change in consumer requirements in a previously stable market (Best, 1990, p. 14). Or 
they may be initiated specifically to combat competitor actions. Developing superior 
production-chain or distribution links are typical examples designed to meet this latter 
need. 
According to Langrish et al, the most frequent single method of transfer of external ideas 
into organizations is via a person joining the firm (Langrish et al, 1972, p. 9). Other 
common methods include previous or concurrent industrial or educational experience; 
commercial agreements (including take-overs and sale of know-how); literature searches; 
personal contact; collaboration with suppliers and customers; and information passed on by 
government agencies and consultants (ibid, p. 79). Corporate innovations (as opposed to 
inventions) are then, in most cases, the result of the convergence of multiple ideas resulting 
from many strands of events (ibid, p. 7). 
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Whilst noting that the relatively small numbers of innovations involving large changes in 
technology could be ascribed to the realization of the potential usefulness of a discovery 
(science-push, first generation R&D), Langrish et al observed that the clear identification 
of a need that could be met by the available technology (market pull, second generation 
R&D) was the highest common factor for successful corporate R&D (Langrish et al, 1972, 
p. 8). They did, however, also note that it was not unusual for the eventual need to differ 
from the initial one, and that some innovations proceed, in the early stages, in a market 
environment which is indifferent at best, only coming to fruition by some combination of 
personal enthusiasm, organizational pressure, and sheer historical accident (ibid, p. 50). 
Langrish et al's work is essentially confirmed by the findings of Project SAPPHO 
(Scientific Activity Predictor from Patterns with Heuristic Origins) (Rothwell et al, 1974). 
Defining `success' as a composite measure based upon (a) net monetary gain, (b) market 
share, and (c) alignment with company strategy, Rothwell and his co-workers compared 
paired `successful' and `unsuccessful' technological innovations in the chemical process 
and scientific instruments industries and showed that successful innovators out-performed 
their unsuccessful counterparts in respect of five competences: they had a much better 
understanding of continuing and changing user needs; made more use of outside 
technology and scientific advice; performed their development work more effectively, but 
not necessarily more quickly; gave the responsibility for project completion to more senior 
individuals with greater authority; and paid more attention to marketing and publicity (ibid, 
p. 259). Although some inter-industry differences were commented upon - most notably 
the degree of risk-taking: successful instrument makers operated with technologies and in 
markets with which they were more familiar; whereas the most successful companies in 
the chemical industry were first to market, and employed more radical technology - similar 
Chapter 2: Corporate R&D 45 Section 2.3.1 
results were found in both industries. In respect of the R&D approach adopted, in 21 % of 
the pairs studied market-pull was found to differentiate in favour of success, whereas in the 
remaining 79% of pairs there was no correlation between success and failure. In no case 
was technology-push found to differentiate in favour of success, or market-pull in favour 
of failure (Rothwell et al, 1974, p. 277). It should, however, be pointed out that these 
authors were writing at a time when second generation, market-pull R&D was the 
corporate norm in the UK (Section 2.2.6, page 34 above). In contrast, an earlier study in 
the USA had noted that for a range of successful innovations 45% were primarily 
marketing-led, 30% were production-led, and 21% were technology-led (Myers and 
Marquis, 1969, p. 39). 
Rather than customers, suppliers, and other organizations merely supplying ideas for 
development, or, perhaps, participating in the innovation process of the producer of an 
innovation, von Hippel noted that, not infrequently, organizations other than the producer 
had first developed and actually applied an invention upon which the producer's 
`innovation' was eventually based (von Hippel, 1988, p. 4). By studying innovations in the 
scientific instrument, engineering plastics, and process equipment industries, he observed 
that these first innovators - his `functional sources of innovation' - varied between 
industries. And, he advanced the proposition that the temporary profit or `economic rent' 
that might be reasonably expected by these innovators in being `first to market' could, by 
itself, explain these variations (ibid, p. 5). More importantly, he suggested that by 
understanding how the expected innovation profits are distributed amongst the various 
functional sources of innovation, and how the distribution of these profit expectations 
might be shifted, it should be possible to understand how the distributed innovation process 
might best be managed (ibid, 1988, p. 7). For example, if 'users' are more typically the 
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functional sources of innovation for a particular field of activity, an alternative proactive 
route for idea generation for the ultimate producer might be to look to the activities of 
those users known for their innovative capabilities. Such an approach is developed by von 
Nippel and his co-workers in the `Lead User8 Process' (von Hippel, 1978, p. 39; von 
Hippel, 1988, p. 106; von Hippel et al, 1999, p. 47). This process involves the systematic 
task of identifying a target market and the type and level of innovations required by 
stakeholders within the company; learning about the relevant emerging technologies and 
leading-edge applications by networking with experts in the fields of interest; selecting 
promising innovations and ideas; and working with several lead users to design concepts 
that fit the company's needs (von Hippel et al, 1999, p. 52). 
From a technical point of view, learning from lead users gives the supplier a view of what 
is possible rather than what might be possible. From a marketing perspective, learning 
from lead users gives the supplier a better idea of what other customers may need in the 
future. More importantly, however, involving lead users in the idea generation stage 
reduces the path dependency of innovation (Section 2.2.4, page 27, above). Interestingly, 
lead users' rewards for participating in the process may be purely intellectual, since sharing 
the resulting intellectual property rights is not necessarily part of the commitment 
(von Hippel et al, 1999, p. 54). What lead users do perhaps gain is additional knowledge 
and understanding of what the future might hold for each of them. 
In general, product, process, and organizational forms are all areas ripe for innovations 
(Best, 1990, p. 11; Utterback, 1994, p. vii), and, as shown by Utterback, often occur in that 
order (ibid, p. 90). Modelling the dynamics of American industrial innovation, Utterback 
8 Lead users are defined as `those organizations or individuals that are many years ahead of market 
trends and have needs that go far beyond those of the average user. ' (von Hippel et al, 1999, p. 48) 
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describes three phases of innovation. In the first phase - the fluid phase - the introduction 
of an innovative product gives rise to a variety of similar products, since unencumbered by 
universal standards or by uniform product expectations in the market place, competitors 
experiment freely with new forms and materials. The rate of product innovation is high 
(Utterback, 1994, p. 86). However, as the expectations of the market become more clearly 
defined, the bases on which product innovations can take place become fewer (ibid, p. 82). 
Expected requirements tend to promote a predominant product design and, in consequence, 
the rate of product innovation decreases (ibid, p. 83). In the second phase of innovation - 
the transitional phase - competition becomes based upon price, reliability and service (ibid, 
p. 86). This spurs the move towards process innovations. Since process innovations are 
generally less easily copied, the market eventually tends to be dominated by those 
organizations having the most effective and efficient production facilities. The rate of 
process innovations decreases (ibid, p. 88). The third innovation phase - the specific phase 
- commences when the industry reaches a point of stability in which there are only a few 
firms producing standardized or slightly differentiated products with stable sales and 
market shares (ibid, p. 96). Utterback sees the move from product innovation to process 
innovation to standardization being, of necessity, accompanied by changes in the firm's 
organizational form: from entrepreneurial organic forms during the fluid phase designed 
for uncertainties in the market and technology (ibid, p. 93); to intermediate forms in the 
transitional phase as the predominant design emerges and dictates operational rigidities 
(Utterback, 1994, p. 96), to hierarchical mechanistic forms in the specific phase designed 
for the production of specific products at high levels of efficiency (ibid, p. 91). In 
consequence, the sources of innovation change from industry pioneers and product users in 
the fluid phase, to manufacturers and users during the transitional phase, and often to 
suppliers in the specific phase (ibid, p. 94). 
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Idea Screening (Activity 3) 
It is not, of course, possible for an organization to act upon all of the ideas that might be 
advanced (Myers and Marquis, 1969, p. 30). At some stage it becomes necessary for those 
deemed worthy to be progressed further, and those deemed less important to be abandoned. 
To this end, a number of companies operate a form of idea evaluation funnel whereby 
ideas are explicitly screened, first, against strategic and business objectives and, second, 
against technical feasibility and financial objectives (Walker, 1994, p. 19). For example, 
will the product or process fit with or complement the existing business portfolio? Will the 
product or process deliver the required return on investment? Will the science or 
technology employed do what is expected of it within the time frame required? We should 
not, however, forget that there may be a third screening, a political or interest-based 
screening that encompasses the range of interests of importance to the actual decision 
makers. These interests include views concerning the `proper way' in which the task 
should be carried out, the implications of the decision on the decision makers' roles or 
careers within the organization, and perceptions about what the decision might say to 
others (Thomas, 1994, p. 83). Thus, both technological determinism and social choice 
issues may play a part in moving ideas forwards (ibid, p. 3). And, when group-based rather 
than position-based decisions are made, negotiation and persuasion between conflicting 
viewpoints may be the order of the day (Kanter, 1983, p. 48). 
Concept Testing (Activity 4) 
Following the idea generation and initial evaluation stages, concept testing and detailed 
feasibility studies are commonly undertaken in order to validate the choice between 
Chapter 2: Corporate R&D 49 Section 2.3.1 
various options, or even to determine if one option alone is appropriate. For instance, 
might the new product, process, or service be developed using an extension of an existing 
technique; a conjunction of existing techniques, products and processes; or techniques 
employed in related or unrelated fields of activity (Langrish et al, 1972, p. 43); or is an 
entirely new approach required? Testing of these concepts is usually carried out by a small 
technical team but with some marketing involvement. Evaluation of the commercial 
feasibility of the options is essentially a marketing activity but with some technical input. 
Resources permitting, the preferred choice of most companies is to develop several options 
in parallel until the `means' have been proven and the `ends' are fairly clear (Allen, 1977, 
p. 63; Pearson, 1991, p. 21). Subsequent decisions can then be made on the basis of 
informed cross-functional understanding as the project progresses (Leonard-Barton, 1995, 
p. 84). 
Whilst such concept testing might be assumed free from partisan influence, the way in 
which individuals or groups interpret what is required, or implement what is thought to be 
required, may be open to a degree of political or social manoeuvring as proposals are, 
perhaps only subconsciously, evaluated in the light of individual and group, in addition to 
organizational requirements (Thomas, 1994, p. 25). Whilst choices between sciences and 
technologies may originate with higher management, it is the lower echelons of the 
organization - whether organized by hierarchy or knowledge expertise - that are 
responsible for implementing those choices, and implementation choices may determine 
which science or technology is ultimately employed (ibid, p. 214), and, indeed, in what way 
that science or technology is employed (ibid, p. 218). At the same time, existing scientific 
and technological capabilities and competences may move the decision towards, for 
example, employing existing plant and machinery, especially if the organization has 
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invested considerable sums of money and training into the use of that equipment (Thomas, 
1994, p. 204). 
Knowledge Processes 
The acquisition of strategic knowledge is particularly important during the project 
initiation stage: there is the need to know what prior knowledge already exists regarding 
the subject of interest; what the likely advantages and difficulties might be in exploiting 
that knowledge; what expertise is needed for the evaluation of options; and what expertise 
might be needed to complete the chosen task. Sharing knowledge with others is also 
particularly important at this stage: both strategic and project-related ideas need to be 
shared so that the various options can be assessed by all of the parties involved; and the 
results of any feasibility studies need to be shared so that these ideas can then be promoted 
or terminated. The literature suggests a number of ways by which information, and the 
knowledge behind that information, might be acquired or shared. The sources typically 
used at this early stage of the R&D process include written communications such as 
patents, conference reports, reports in trade and academic journals and on the Internet; 
discussions with supply-chain contacts; technology in-licensing and outsourcing 
agreements; and community of practice networks (Mansfield, 1985, p. 221). As will be 
shown in Chapter 3, whilst published sources might more strictly be said to yield 
information, personal communication is expected to enhance knowledge acquisition and 
sharing, since it offers the advantage of a two-way conversation, and thus allows context 
and understanding to be explored and shared. Again, it cannot be assumed that such 
knowledge and such information is free from personal or group bias. And, where 
knowledge acquisition is the purpose, it perhaps goes without saying that, whatever the 
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method employed, the estimated worth of any knowledge to be acquired needs to be 
assessed against the cost of acquiring that knowledge and the risks of inadvertently sharing 
competitive knowledge with the provider (Mansfield, 1985, p. 221; Smart et al, 1999, 
p. 109). 
Technology in-licensing agreements are often viewed as offering a quick way of acquiring 
knowledge for upgrading products and processes. However, as Dickson and Hadjimanolis 
have pointed out, the exclusive use of licensors appears to have a negative effect on the 
wider learning and the accumulation of expertise of the firm (Dickson and Hadjimanolis, 
1998, p. 15). A major problem is that whilst in-licensing agreements transfer the 
information of how to do something, they do not necessarily transfer the knowledge behind 
what is to be done. Without the capacity to interpret information in a meaningful manner, 
the scope to learn is reduced. 
Outsourcing has been encouraged to decrease the path dependency (Section 2.2.4, page 27) 
of innovation (Bowonder and Miyake, 1999, p. 85). However, too much outsourcing can 
lead to the loss of key internal workers, together with their existing knowledge. This can 
lead to a company becoming ever more reliant on external R&D sources for its continued 
success. As a deliberate strategy, this might work well for the company (although not so 
well for its R&D employees). However, relationships with partners then become crucial. 
According to Quintal and Brauner, a key question for firms outsourcing their R&D is 
whether they retain the capability to understand and assimilate or absorb knowledge 
created externally, and also retain the ability to combine this with internal resources and 
capabilities (Quintas and Brauner, 1999, p. 50). 
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Customer links are the backbone of sales and marketing operations. As noted above 
(Section 2.2.4, page 28), they are also important to R&D personnel as they can often 
highlight new (technical) ideas and possibilities. Whether these ideas are strategically 
important is another matter. What is important is that it is known that such possibilities 
exist. Major suppliers can also provide ideas for development. The problem in both cases 
is that this knowledge will undoubtedly be provided to competitors (Mansfield, 1985, 
p. 221). Links with Standards and Trade Associations are useful for keeping up-to-date 
with current and possible future legislation that may impinge on the viability of current and 
possible future products and processes. 
Whilst community of practice networks do aid in the acquisition and sharing of knowledge 
(Bowonder and Miyake, 1999, p. 85), their purpose goes deeper than this. They enhance 
learning and build competencies (Powell et al, 1996, p. 119; Echeverri-Carroll, 1999, 
p. 298) and enable the search for new opportunities (Coulson-Thomas, 1997, p. 207). Their 
importance is indicated by Huber's observation that people who are well networked in the 
technical communities (both within the firm and within the industry) can often provide the 
`newly-seen-to-be-needed' technical knowledge more effectively than can a highly 
qualified technical expert who is not well networked (Huber, 1999, p. 72). These informal 
networks, thus, represent an important intangible resource to the organization, a resource 
which is difficult for competitors to replicate (Hall, 1992, p. 135; Conway, 1995, p. 338). 
However, because they show no respect for organizational boundaries, they are seen by 
some to be contrary to the interests of the organization (Mansfield, 1985, p. 223). They are 
also seen as inefficient since they do not necessarily relate directly to company strategy 
(Thomson et al, 1999, p. 11). For these reasons, some organizations attempt to limit the 
external links of their R&D workers by, for example, limiting access to customers, and 
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removing support for attendance at seminars and conferences. However, companies that 
seek to control these informal knowledge networks may well be losing access to the latest 
ideas, thoughts and understandings of areas of technology that could be vital to their future. 
As Brown and Duguid point out: 
`Cutting off the outflow can also cut off the inflow of knowledge. Living in a 
knowledge ecology is a reciprocal process, with organisations feeding into each 
other. ' (Brown and Duguid, 1998, p. 103) 
Informal communication networks extend well beyond the realms of the organization to 
which a particular scientist or technologist may belong. What is interesting is that, 
although there is a degree of overlap, distinct differences have been observed between the 
social organization of the networks that occur in science and those that occur in 
technology. 
Crane describes the social organization of specific research areas in science as `social 
circles' which encompass `invisible colleges' (de Solla Price, 1975, p. 101). It is the 
invisible colleges that help to unify the areas and provide coherence and direction to their 
fields (Crane, 1972, p. 138). 
Invisible colleges in the UK have their roots in the informal `club' that the London-based 
artisans and practitioners of science formed in the 17th century in order to promote and 
discuss their ideas, their problems, and their experimental findings. Initially, these 
amateurs, in modern terms both scientists and technologists, met informally within the 
chambers of the chief participants, within the shops of the instrument makers, and within 
the taverns (later coffee houses) that they frequented and used as a general post office. 
Eventually, meetings became more regular, and, with the granting of a Royal Charter, the 
`Royal Society' was formed (de Solla Price, 1975, p. 102). Today, the term `invisible 
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college' would appear to be restricted to the open social group that forms between an `elite 
of mutually interacting and productive scientists within a specific research area' (Crane, 
1969, p. 348). 
Social circles form on the basis of members' interests rather than propinquity or ascribed 
status (ibid, p. 348). There is no formal leadership (Crane, 1972, p. 14). Each member is 
usually aware of some but not all other members. It is not necessary to know a particular 
member of the group in order to be influenced by him/her (Crane, 1969, p. 348). And the 
exact boundaries of the circle are difficult to locate (Crane, 1969, p. 348; Crane, 1972, 
p. 13). 
Crane suggests that the presence of scientists whose productivity in a particular field is 
sufficient to make them visible to most of those who enter the same field, even briefly, 
produces a social circle (Crane, 1969, p. 349). And, in turn, the circle plays an important 
role in the normal growth of a research area and, ultimately, in the growth of scientific 
knowledge in general. First, interesting discoveries that provide models for future work 
attract scientists to a particular research area (Crane, 1972, p. 40). Initially there is little or 
no social organization (ibid, p. 172). Next, a few individuals of high potential develop a 
high degree of commitment to the area, and, as a result, are able both to direct the activities 
of others in the field, and to make it visible as a research area. This may be directly 
through their ability to set priorities for research, recruitment, or training; or indirectly 
through the influence of their research publications or presentations (Crane, 1969, p. 341; 
Crane, 1972, p. 40). The ties between high producing individuals and between these 
individuals and others in the circle are stronger than the ties between other members. 
Thus, social circles become orientated around these high producing individuals. The 
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central figures in these circles and some of their associates develop a kind of solidarity that 
is useful in building morale and motivation among all members of the circle, and an 
invisible college is formed (Crane, 1969, p. 345; Crane, 1972, p. 139). A period of normal 
science follows (Crane, 1972, p. 172), and a degree of conformity may set in around the 
norms set by the invisible college (ibid, p. 83). As the seminal ideas that form the bases of 
the research area become exhausted or become increasingly difficult to test due to the 
presence of anomalies that cannot be explained by the original model, new scientists are 
less likely to enter the area, old members are more likely to drop out (ibid, p. 40), or 
researchers become more specialized and split from each other (ibid, p. 83). Controversy 
may result between groups, or groups may become increasingly isolated from each other. 
The result is a gradual decline in membership in the original area (ibid, p. 40). Thus, 
growth in scientific knowledge is cumulative - at least until the presence of anomalies - 
and follows a logistic curve in which scientific advance begins slowly, accelerates 
exponentially, and then declines (ibid, p. 172). 
At the same time, no research area is completely isolated from other areas (ibid, p. 13). 
Members of a circle may be influenced by defectors - those who have left the area of 
interest - and by the publications of outsiders in general (Crane, 1969, p. 341). Whilst ties 
between members of the circle and outsiders are generally weaker than those between 
members, they are numerous. Whilst most circles tend to be linked only to those to which 
they are most related, all fields are interlocked in a `kind of honeycomb structure' (Crane, 
1972, p. 103). Thus, social and ideational links hold the various segments of scientific 
knowledge together and permit the diffusion of ideas from one area to another (Crane, 
1969, p. 349; Crane, 1972, p. 13). 
Chapter 2: Corporate R&D 56 Section 2.3.1 
Crane suggests that the links with outsiders can be best understood with reference to the 
phenomenon of `reference scattering' (Crane, 1969, p. 349). And, she adds that both 'core' 
and `scatter' are necessary for scientific advance: `the former to permit scientific 
knowledge to cumulate and grow, the latter to prevent it from becoming a completely 
subjective, sect-like phenomenon' (Crane, 1969, p. 350; Crane, 1972, p. 1 14). If there were 
no core, scientific knowledge would be so scattered that it would be virtually impossible 
for one scientist to build upon the work of others (ibid, p. 349). If there were no scatter, 
scientists would be divided into small groups, sharing the same interests, speaking only to 
each other, reading and citing only each other's work, and increasingly working in 
isolation from others. 
Crane does not specifically talk about the role of industrial scientists. Although it is 
conceivable that some industrial scientists may form the nuclei around which scientific 
advance occurs, the main purpose of these scientists' working lives is to provide and apply 
scientific knowledge in response to the needs of their organizations, not necessarily to 
publish papers or bulletins for the benefit of the scientific community in general. In 
consequence, although some industrial scientists may be classed as `high producers' in 
Crane's terms, the likelihood is that most, if included at all, will be amongst the `lower 
producers'. It is also more likely that industrial scientists will enter a particular social 
circle later rather than earlier (Rappa and Debackere, 1992, p. 214), either in response to a 
particular need of their organization, or because the developing field of science offers 
possibilities for organizational advancement. At the same time, the fact that industrial 
scientists are responsible, ultimately, for the production of some physical change in the 
world -a new product, a new production process, or a new method - means that their 
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networking actions may perhaps be closer to those of the technologists (or engineers) that 
Allen has studied (Allen, 1977, p. 3). 
Allen notes that the goals of technologists are very much in line with the goals of the 
organization - baring industrial espionage, both wish to develop products and processes 
that bring organizational success in the market place (ibid, p. 38). At the same time, the 
career aspirations of technologist are very much tied to their activities within the 
organization (ibid, p. 39). These facts, he suggests, work in two ways to inhibit the 
technologist from participating in informal technical communication channels outside the 
organization (ibid, p. 40). First, the technologist is inhibited by the requirement that he 
work only on problems that are of interest to his/her employer, and, second, he/she must 
refrain from early disclosure of the results of his/her research in order to maintain his/her 
employer's advantage over competition. As Allen points out, both these constraints violate 
the scientific norms that underlie and form the basis of the invisible college - the 
requirements that science be free to choose its own problems; that the community of 
colleagues be the only judges of the relative importance of possible areas of investigation; 
and that the substantive findings of research should be fully assigned and communicated to 
the entire research community (Allen, 1977, p. 41). The free and open communication that 
occurs between scientists is thus less likely between technologists (Rappa and Debackere, 
1992, p. 220). 
The effect of this `enforced localism' is to focus the technologist's attention inwards 
towards the technical information and knowledge that is held within the organization rather 
than outwards to the information and knowledge that is held by the external technical 
community (Allen, 1977, p. 41). As such, internal communication is particularly important 
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between technologists (Allen, 1977, p. 122). It was recognized that frequent links with 
more colleagues was more beneficial to performance than frequent contacts with just a few 
colleagues. And, for complex projects, links with colleagues outside of the project team 
were particularly important, since the inner team is unlikely to hold all of the information 
required to sustain itself and continue to work effectively (ibid, p. 123). 
Nevertheless, information from outside the organization is essential for keeping current 
with state-of-the-art ideas, products and practices (Allen, 1977, p. 126; Rappa and 
Debackere, 1992, p. 209). Normal staff turnover can help to transfer some information 
because a new employee can often bring in a new or different technology. But such a 
mechanism is perhaps not to be relied upon. As well as importing information with the 
new employee, the organization may also incur the export of some proprietary information 
with the loss of the old employee (Allen, 1977, p. 142). Long-term consultants who 
understand the needs of the organization can provide some relevant information but are 
unlikely to be able to meet fully the organization's needs for communication with the 
outside world. Instead, technology-based organizations tend to rely on `technological 
gatekeepers' to ensure that their personnel are kept aware of the results of research done 
elsewhere (ibid, p. 141). 
Technological gatekeepers are those individuals within the organization who make it their 
purpose to keep in touch with sources of technical information outside the organization. 
They understand at least a proportion of the more sophisticated technical journals, and can 
translate the information contained within these journals into terms that the average 
technologist can use (ibid, p. 145). In addition to their many internal contacts, they also 
have a broad range of external contacts that they can turn to for help on an informal basis. 
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In turn, they tend to be those individuals to whom others frequently turn for advice. They 
are usually high technical performers (Allen, 1977, p. 163) with high professional status 
(ibid, p. 168), and they frequently occupy first-line supervisor roles (ibid, p. 171). They 
generally attend and produce more papers for presentation at technical conferences (ibid, 
p. 163). 
Rather than the social circles of scientists with no particular organizational affiliation, 
technologists thus tend to form internal organizational networks, which are then connected 
to the outside world through these key individuals. Rather than information passing 
directly between the individual technologists of different organizations, external 
information passes to them indirectly through the technological gatekeeper (ibid, p. 148). 
In larger organizations, information networks can become complicated, but frequently a 
gatekeeper network may form which assists information diffusion throughout the entire 
organization (ibid, p. 162). These networks sometimes are, but may not necessarily be, 
aligned with the formal organizational groupings (ibid, p. 155). 
Rather than the social circles that develop purely between scientists, technologists may, as 
noted above (page 51), in addition to links with their technologist colleagues, also form 
links with customers; the sales representatives of other companies who would like to sell 
them components, subsystems, or instrumentation of use to their current project; and 
experienced consultants. They also typically contact government, non-profit, or university 
laboratories on an informal basis for ideas regarding solutions to specific problems (Allen, 
1977, p. 127). A technological community is thus more truly interdisciplinary in nature. 
whereas a scientific community is demarcated by its particular scientific boundary (Rappa 
and Debackere, 1992, p. 211). 
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Finally, Debackere and his colleagues point out that the continuous quest for individual 
credibility in scientific networks leads to a constant battle over the ideas that should be 
seen as important to scientific debate (Debackere et al, 1994, p. 23). In contrast, networks 
between technologists are designed to unite actors behind a particular problem. Whilst 
conflict may occur over the best way forwards, individuals are united in the end that they 
wish to achieve. 
Debackere and his colleagues argue that different types of network evolve in a scientific 
community as a technology matures (ibid, p. 23). Initially, a few researchers dedicate 
themselves to furthering a particular field of enquiry. Whether, or not, these pioneers are 
employed in academia or industry they start working on similar problems with similar 
ideas. They may do this with little support from their organizations or from their peers 
(ibid, p. 27). By `bootlegging' they proceed to the point where the promise of the idea 
becomes clear. Throughout this first phase, the community of scientists is concentrated 
among a small number of organizations, and the yearly increase in number of researchers 
into the field is fairly moderate. However, as the number of individuals working on the 
same problem area increases, a communication network emerges with ties that are much 
stronger than the ties binding the individuals to the organizations to which they formally 
belong. The norms of the scientific paradigm predominate. Information and knowledge is 
passed freely between participants (ibid, p. 28) and the producers of science are also its 
judges and consumers (ibid, p. 27). 
Spurred on by the advances made by the initial workers, a very rapid increase occurs in the 
number of scientists active in the field. A second phase begins. The new community of 
scientists becomes more widely distributed across organizations, sectors, and countries. 
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Congresses are organized and journals are founded in order to steer the efforts being made. 
If the work of the new field of enquiry attracts commercial interest, some scientists may be 
recruited by industrial concerns, while those already working within industry may be 
allowed to devote their efforts openly to the new field. Other scientists may decide to 
become entrepreneurs and start their own organizations. As the community expands and 
spreads, it develops a powerful momentum derived from the force of its numbers and the 
ingenuity of its researchers working independently in laboratories world-wide. However, 
with this expansion comes the diminishing ability of researchers to communicate easily 
with one another. Whilst some information can be passed through the published literature, 
the constant flow of new and complex ideas calls for something more. The informal 
communication network or grapevine is born (Debackere et al, 1994, p. 28). It is during 
this phase that a new industry may come into being or an old industry may restart its life 
cycle. In any case, a new technological paradigm is created. Usually, consumer 
preferences in the market are not sufficiently clear to allow organizations to give strict 
guidelines to their workers. As a consequence, the network of scientists remains intact and 
transcends academic and organizational boundaries. Open and speedy communication 
remains the norm, even though academic institutions and industrial organizations may seek 
to obtain property rights to their ideas. 
However, as the industry grows further, consumer preferences become stabilized, and 
product requirements become clarified. As Debackere et al point out this is the stage 
where the selection processes for industrial and non-industrial research start to divide (ibid, 
p. 29). Whilst academic researchers continue to work within the scientific paradigm, 
industrial scientists are bound by the technological paradigm (ibid, p. 30). This requires an 
adherence to the norms of commercial exploitation, and specifically to rules that seek to 
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safeguard proprietary knowledge, wherever possible, from rapid diffusion (Debackere et 
al, 1994, p. 24). Industrial scientists collectively stop forming an integral part of the 
scientific network. Some do, however, remain within that network on an individual basis 
(ibid, p. 30). From these individuals, come the technological gatekeepers who continue to 
keep their organizations abreast of the latest ideas and views within the relevant sciences 
(ibid, p. 34). 
As the second phase progresses further, one of two paths may emerge. Scientists continue 
to make progress in solving the problems confronting them, allowing the community to 
institutionalize itself, or progress begins to slow down, forcing the community to contract 
and perhaps even return to the conditions prevailing in the first place. If the new scientific 
paradigm becomes legitimized and sustained, it will attract many more researchers. As 
some researchers begin to concentrate on particular areas within the original field of 
enquiry, strategic groups may form. Over time, this leads to further specialization, 
increasing isolation, and ultimately sterility as the linkages that encourage innovation 
eventually fade. It is Debackere et al's suggestion that such sterility may be prevented, or 
at least postponed, by new stimuli coming from the industry which is in a phase of 
maturity and which is increasingly dominated by demand-pull innovation. Although the 
R&D community of all scientists in a field may have long split up, the long-term vitality of 
both successor parts is thus very much linked (ibid, p. 30). 
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2.3.2 Project Management 
`Product' Development (Activities 5- 7) 
Development is about applying existing knowledge to exploit a new idea (Jewkes et al, 
1958, p. 204). It is the stage at which known methods are applied to that idea. It is the stage 
at which the task to be performed is more precisely defined, the aim more exactly set, the 
chances of final success more susceptible to measurement. And, it is the stage at which 
commercial considerations are more systematically examined; where the limits of 
feasibility imposed by the markets are narrowed down (ibid, p. 18). Indeed, knowledge of 
markets, customers and suppliers, together with government legislation and regulation, is 
crucial throughout this part of the R&D process, and this is perhaps one reason why many 
Western companies have introduced `matrix' management approaches, the expectation 
being that such approaches would more actively encourage the dissemination and 
integration of the knowledge necessary for successful project completion (Kanter, 1983, 
p. 341; Best, 1990, p. 259; Leonard-Barton, 1995, p. xv). As a consequence, where project 
teams formerly involved only members from the technical departments they now often 
involve people from across the organization's different functional groups. These teams are 
essentially non-hierarchical. They may include members from within the organization or 
from other organizations, the requirement being that these individuals have the relevant (or 
best possible) knowledge and experience for the job in hand. For example, user 
involvement may be useful in gaining insights into the application environment of the 
product or service (Leonard-Barton, 1995, p. 94). 
Chapter 2: Corporate R&D 64 Section 2.3.2 
In the past, development teams have been organized either by product group or by 
functional group. As pointed out by Henderson, organization by product group focuses the 
energies of the organization on the customer and encourages rich communication across 
functions, but it often does so at the cost of a steadily eroding base of functional 
knowledge. Organization by function, on the other hand, ensures that the in-depth, 
specialized knowledge fundamental to long-term innovation is preserved and enhanced, 
but at the cost of a reduced focus on business priorities. By adopting matrix management 
and essentially organizing by both product and function, development teams are able to 
keep abreast of both the commercial and the scientific and technical advances of 
importance to the particular project (or projects) with which they are involved (Henderson, 
1994, p. 105). This does, however, mean that project teams now consist of people who are 
often not known to each other and who, both literally and figuratively, speak `different 
languages'. In addition, many team members join and leave the team as their part in the 
project is being progressed. As well as managing the project from a `technical' point of 
view - that is, designing and evaluating approaches, ensuring that adequate resources are 
made available, monitoring progress, redirecting resources, etc. - project leaders need also 
to manage people from a variety of backgrounds with many motives, interests, and world 
views (Thomas, 1994, p. 236). Success perhaps comes to those who are able to encompass 
these views and use the conflicts that undoubtedly will occur to move the project forwards 
in interesting and radically different ways (ibid, p. 238), to use conflict as a stimulus to 
innovation (ibid, p. 241). 
`Project Management' packages are often used in the West to aid resource allocation and 
task scheduling, for project monitoring and rescheduling of tasks when appropriate, and for 
calculating the various costs involved. Project management packages have also been used 
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by some Western organizations in an attempt to `control' the R&D process. However, as 
Burton and co-workers point out, such `control' is based on the assumption that the 
environment is predictable (Burton et al, 1988, p. 113) and, even at the development stage, 
R&D is still an inherently uncertain process. 
There have similarly been questions concerning the applicability of `project management' 
approaches to more innovative or radical R&D, and even to the more basic needs of R&D 
such as the freedom to experiment. For this reason, some companies also implement or 
allow additional approaches outside their normal R&D practices. For example, many 
radically new products have been said to result from work carried out within 
`skunkworks': small, flexible teams of scientists, technicians, and designers who work 
together to develop new products or processes from concept to commercial prototype stage 
`with no intervening organizational barriers' (Peters, 1983, p. 138; Quinn, 1985, p. 271). 
Other companies implement `professional venture teams': they assign particular 
innovations to `new venture teams' and give them `the professional (engineering, 
marketing and financial) skills to see them through'. The thinking behind the process is 
that an innovation is like a baby: it needs a `mother (champion) who loves it emotionally 
and will stay with it when others would give up; a father (authority figure with resources) 
who can support it; and pediatricians (experts) who can see it through technical 
difficulties' (Quinn, 1985, p. 273). Skunkworks and professional venture teams are perhaps 
two examples of Kumpe and Bolwijn's fourth generation R&D practices (Section 2.2.4, 
page 28). A number of companies also allow their R&D staff to undertake `work on the 
side' as long as this does not interfere with defined project targets. 3M's `15 percent rule' 
is a more formal approach, whereby R&D workers are expected to spend roughly fifteen 
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percent of their time dreaming up new products, new ways of lowering costs, or new ways 
of increasing productivity (McElroy, 2000, p. 199). 
Knowledge Processes 
The acquisition of knowledge is an on-going part of this stage in the R&D process. 
However, whilst the techniques employed are the same as those used during the project 
initiation stage (Myers and Marquis, 1969, p. 45), the emphasis is now upon the acquisition 
of project related knowledge. The sharing of this acquired knowledge within the project 
team is then crucial in order that everyone has an understanding of the wider picture, 
knows what is required of each and every one of them, knows what problems might and do 
occur, and knows the progress todate. Although such knowledge sharing is an integral part 
of team working, formal reporting procedures highlight major issues, such as changes in 
the overall goals of the project. Personal networks remain important to the individual 
R&D workers, but at this stage they are used for the exchange of general scientific rather 
than project-related knowledge (Myers and Marquis, 1969, p. 45; Oliver and Liebeskind, 
1997/98, p. 77). 
External knowledge sharing may result from team working when the team is formed as the 
result of a collaborative venture (Ray, 1998, p. 163). Although collaborations have usually 
been observed to simply support transfers of `commoditized knowledge' in the form of 
intellectual property rights and assets for commercial development (Oliver and Liebeskind, 
1997/98, p. 77), it is hard to see how success can be achieved without a degree of 
community working and knowledge sharing between the members of a collaborative team. 
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Although knowledge acquisition may be the corporate objective of alliance formation, 
knowledge sharing is more likely the R&D objective in such collaborations. 
Whilst collaborative research involves the direct interaction between people working on a 
particular project and thus appears to offer the greater chance for such cross-boundary 
knowledge sharing (Becerra-Fernandez and Sabherwal, 2001, Table 3, p. 42), this 
interaction is usually of short duration, so that the knowledge shared may be of limited 
extent. Cross-boundary personal networks, on the other hand, whilst not usually involving 
direct project interaction, can last for many years. The knowledge and understanding built 
up between the people in the network over these years may then go beyond that which may 
be built up from a collaboration of short duration. 
Social strategies for promoting the spread of knowledge between communities have been 
described in terms of `translation', `brokering', and `boundary objects' (Brown and 
Duguid, 1998, p. 103). Organizational translators are individuals who frame the interests of 
one community in terms of another community's perspective. They need to have some 
knowledge and understanding of both communities. They also need to have the trust and 
respect of both communities. Knowledge brokers are those workers who actively 
participate in overlapping communities. Trust is then less of an issue, since knowledge 
brokers, unlike translators, are subject to the consequences of the messages they carry. 
Boundary objects may be physical objects, technologies, or techniques which are of 
interest to each community involved but which are used differently by each of them. 
`Through them, a community can come to understand what is common and what is distinct 
about another community, its practices, and its world view. Boundary objects not only 
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help to clarify the attitudes of other communities, they can also make a community's own 
presuppositions apparent to itself' (ibid, p. 103). 
From experience, knowledge translators for R&D purposes are normally the senior 
technical staff with several years' commercial involvement. However, when the science is 
new, external mediators and consultants may be used. Knowledge brokers for research are 
usually the individual researchers. Knowledge brokers for development may theoretically 
be any member (scientific or commercial) of the development team. Boundary objects 
within R&D are typically the R&D process, the science and technology involved, and the 
organization's mission and strategy statements. 
In adopting matrix management approaches, Western companies appear to be reflecting 
aspects of the Japanese `rugby team' approach whereby the whole team moves forwards 
towards project completion despite the `ball' passing from one `player' to another. 
However, in working in this way, Western organizations do not have the support of Japan's 
accepted `rules of the game' which institutionalize expectations that regular male 
employees can expect to spend many years working together in the same organization. As 
a consequence, they rarely, if ever, develop the close community relationships that emerge 
in Japanese organizations, relationships which can create considerable esprit de corps that 
helps to carry projects seamlessly across functional boundaries (Ray and Little, 2001, 
p. 155). However, although expectations in the US, UK and other Western contexts 
normally afford rather more autonomy to the individual than would be considered 
appropriate in Japan, an emphasis on team production can yield dividends, notably in terms 
of increased flexibility, as the understanding held in common amongst team members 
creates a cushion for absorbing the effects of uncertainty. And, even in western contexts, 
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integrating the R&D function with the other parts of the organization does allow a more 
coordinated approach than was formerly the case - although there are limits: it is doubtful 
whether Western teams will ever share the same level of understanding that exists within 
the Japanese team that `lives, works and dreams together' (Harvey-Jones, 1994, p. 178). 
2.3.3 Project Termination (`Activity 8') 
In one sense, projects never terminate as there are always improvements to be made or 
replacement products to be developed (Jewkes et al, 1958, p. 200). And, even if a project 
fails to meet the desired objectives, it may be possible to use the results obtained at a later 
date or for a different purpose: for example, inventions that `come before their time' may 
need to await further inventions (ibid, p. 122); or a new product or process may be more 
successfully employed elsewhere (ibid, p. 123). What is important is that failure is 
recognized as part of the process. Come what may, knowledge is created and lessons are 
learnt by R&D workers. As pointed out by Leonard-Barton, the problem is that this point 
is still rarely recognized by corporate management: 
'IBM's famous 360 computer drew heavily on knowledge developed in a 
"failed" prior project ... Nevertheless, 
in most organizations, because previous 
projects were "unsuccessful, " they become invisible, and managers delude both 
themselves and others about the debt owed to failures. Only development team 
members know how much they individually gained from previous unsuccessful 
explorations. ' (Leonard-Barton, 1995, p. 120) 
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2.3.4 A Summary of the Knowledge Types and Knowledge Processes used in the 
Practice of R&D 
Table 2.3.1 (below) provides a summary of the main types of knowledge and the 
predominant knowledge processes used during the various stages of the R&D process. 
Context, in the form of the particular activity involved, would appear to affect knowledge 
creation in corporate R&D. 
TABLE 2.3.1: THE R&D PROCESS: KNOWLEDGE TYPES AND KNOWLEDGE PROCESSES 
Activity Knowledge Types Knowledge Processes 
Project Basic scientific and technical Knowledge acquisition, sharing, 
Initiation knowledge. evaluation and integration for idea 
Commercial knowledge, generation. 
particularly user knowledge and Knowledge entrepreneuring for idea 
knowledge of competitors' promotion. 
activities. Knowledge creation through 
knowledge combination, 
experimentation and exploration. 
Project Scientific and technical knowledge, Project related knowledge 
Management particularly related to design and acquisition, sharing and integration, 
manufacturing. largely through team working. 
Commercial knowledge, Knowledge creation mainly through 
particularly marketing, procedural, knowledge application and 
and legislative knowledge. adaptation. 
Project and team skills. 
Project Scientific, technical and Knowledge renewal and 
Termination commercial knowledge, internal consolidation to yield understanding 
and external to the company. and learning. 
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2.4 Conclusion to the Chapter 
This chapter has aimed at deconstructing some of the complexity associated with the 
interrelationship between corporate R&D and the context in which that R&D takes place. 
Each respective R&D generation discussed in Section 2.2 represents a simple explanation 
of what was considered important at the time. As the history of corporate R&D has 
unfolded, different factors have vied for the attention of policy makers. However, R&D is 
a complex process and, as the chapter has sought to show; simplistic explanations only 
form part of the picture - although they can be a very important part of the picture. 
For example, if we adopt the idea that basic science provides the fountain from which new 
ideas flow, which is the essence of first generation R&D, commercial investment in 
invention might be a matter of replicating university-style basic research in a corporate 
setting - perhaps in a setting detached from the cut and thrust of daily business imperatives 
(as suggested by skunkworks). Under such a science-push model, assessing the viability of 
a proposed research agenda relies heavily on the authority of scientific assessments. 
Nevertheless, in a commercial environment there is always scope for economic, political 
and other interests to lobby for their preferred interpretation of what might be possible. 
Indeed, second generation R&D seems to strengthen the power of those from outside the 
technical sphere. And, the idea that necessity is often the mother of invention, inherent in 
the second generation approach, shifts the focus of attention from what might be possible 
to what is `needed'. In this respect, it can be said that corporate strategy seeks to reconcile 
two continually changing forces: science is pushing, whereas needs are pulling. 
Accordingly, third generation R&D might be seen as the fulcrum in the push/pull seesaw - 
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although the fulcrum need not be in the middle and the force needed to gain leverage can 
vary considerably. Nevertheless, no firm is an island. 
The tendency to view the organization as a self-contained entity often lends an 
unwarranted solidity to the concept of organizational boundaries, resulting in the view that 
the organization is a self-contained thing that can be treated as an object in its own right. 
Yet, organizational boundaries can be extremely ambiguous and permeable to the 
movement of people and ideas. The context in which an organization operates enables and 
constrains its practices. Fourth and fifth generation approaches to R&D accept this, and 
recognize that activities beyond the organization can have significant implications for 
internal events. However, whilst fourth generation R&D seeks to `manage' these 
activities, fifth generation R&D appears to seek advantage by facilitating the cross- 
boundary networking activities that are an integral part of how individuals act out their 
everyday lives. 
Organic networks of the type implied by fifth generation R&D involve complex 
interactions. Although it might be possible to map some aspects of network-related 
activities, it is not possible to reduce the influence of networks to cause-and-effect 
connections. Everything is connected to everything else, and changing one thing can have 
non-linear consequences. On occasions, a small event can contribute to considerable 
consequences. Shared experience, among people who come to know each other well, 
shapes the significance that people attach to information that flows in networks: trusted 
connections that link powerful people can mean that small amounts of information 
contribute to big differences. Moreover, as we will see in the next chapter, it is not 
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possible to map what Michael Polanyi called the tacit integration of `clues', which render 
information signals meaningful. 
Clearly, networks facilitate information flows; but information is only part of the picture - 
no message can read itself and access to the right information is not the same as knowing 
what it means. Thus, fifth generation R&D certainly embraces the concept of information 
super-highways, but the extent to which they are useful to innovating organizations is 
shaped by what is happening in the here-and-now of everyday practice. And this concern 
with practice re-anchors our enquiry in the activities and processes of the innovating 
organization. 
Section 2.3 considered organizational activities in terms of the principal stages of the R&D 
process. R&D projects have a beginning, middle and end, but not necessarily in that order 
and not necessarily within the organization. Some projects start elsewhere, while others 
falter in the middle or are finished by competitors. In many cases, what was achieved, 
along with the merits or otherwise of doing things differently, is contested by different 
parties. Any claim of cause and effect per force involves the imposition of rationality on 
experience, but this begs key questions: whose rationality and whose experience? 
Roughly speaking, views about knowledge and knowing have been divided into two 
categories according to whether of not they see the subject as relatively straightforward or 
highly problematic. Arguably, Knowledge Management falls into the former category: 
tacit knowledge can be converted into information (i. e., `explicit knowledge') and 
`managed' (McInerney and LeFevre, ? 000, p. 1). Similarly, the five generations of R&D 
are characterized by a relatively unproblematic approach to knowledge: knowledge only 
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becomes awkward because of its absence. If that absence can be fixed by scientific 
discovery, responding to a need, the integration of business activities, fourth generation 
collaboration, or fifth generation virtual networking, the problem goes away. Thus, to 
achieve `success', corporate strategy merely has to transport the right information to the 
right place and wait for everything to take care of itself - or so the argument might run. 
Alternatively, there is a different view that sees knowledge as highly problematic (Hull, 
2000, p. 64). Knowledge is not a transferable commodity and communication is not a form 
of transport. Instead of being viewed as an abstract entity that is separate from the 
knowing subject and the messiness of power relations associated with a specific context, 
this second view makes knowers - the people who know things - the focal point of 
attention. If we are to begin to consider the issues raised by this second and more 
challenging domain, it is necessary to extend our literature review beyond the simplistic 
view of `knowledge as information'. Accordingly, the next chapter explores these issues 
and reaches into the second domain by considering more complex perspectives on the 
processes by which people know how to do things in practice. 
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3 KNOWLEDGE CREATION: A LITERATURE REVIEW 
3.1 Introduction 
It was noted at the end of Chapter 2 that the R&D Management and much of the 
Knowledge Management literature has a tendency to treat the concept of `knowledge' in a 
rather simplistic way. From this perspective, knowledge is viewed as an object that can be 
acquired, shared, applied and even created via a simple transfer mechanism. That such is 
not the case is perhaps evidenced by the consensus that technology transfers are rarely the 
simple processes they are initially expected to be: the transfer of plant (machinery and 
equipment) and written operating procedures are rarely sufficient to convey the knowledge 
held by the plant operators of the sourcing department, knowledge that is often crucial in 
keeping that plant operating smoothly; neither are they generally sufficient to provide the 
in-depth knowledge needed for the continued development of that plant. Before reviewing 
the literature on knowledge creation, Section 3.3 of this chapter therefore looks at the 
nature of knowledge to see why knowledge may not be the transferable commodity that it 
is often assumed to be, and why, even if knowledge can be transferred, verbal 
communication is not always the form of transport necessary. One of the conclusions of 
this section is that, in a purist sense, it is only information that can exist independently and 
which can thus be directly transferred. Knowledge acquisition or knowledge sharing - 
with no guarantee that the knowledge acquired or shared is the same for all parties - then 
results from the same or similar interpretations of this information, brought about as the 
result of a shared or similar understanding of what is meant by the information undergoing 
transfer. As noted in Chapter 1 (Section 1.4, page 11), references to knowledge 
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acquisition, knowledge sharing, and knowledge transfer in this thesis should be understood 
with this point in mind. 
The importance of creating, sharing, and leveraging knowledge in organizations has been 
observed by a number of authors (see Becerra-Fernandez and Sabherwal, 2001, p. 24). 
However, in an R&D context, the terms creating, sharing, and exploiting knowledge are 
more often used. In general, this thesis chooses to use the terms creating, sharing and 
applying knowledge as it is felt that these more accurately describe the activities under 
consideration. In particular, the term `exploitation' suggests to the present author the 
aggressive promotion of particular items of `knowledge'. In contrast, this study is more 
concerned with the application of knowledge relevant to the task in hand. 
There are also a number of reports in the literature that refer to the need for knowledge 
dispersion or diffusion, and to the fact that dispersed or diffused knowledge is only of use 
if it is first absorbed or integrated (respectively, Tang, 1998, p. 301; Polanyi, 1966, p. 6). 
These processes have, in part, been assumed as fundamental activities in the knowledge 
acquisition, knowledge sharing, and knowledge application processes described in this 
thesis. It should, however, be noted that the use of the terms knowledge dispersion and 
knowledge diffusion also implies the assumptions associated with the more general use of 
the terms knowledge acquisition and knowledge sharing outlined above. Once again, it 
should not be assumed that the knowledge provided by the provider is the same as the 
knowledge received by the receiver. Indeed, different interpretations of the same `piece' 
of knowledge may spark innovative thinking. 
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There are three models of organizational knowledge creation that have been variously 
suggested in the Knowledge Management literature. One of these models looks at the 
context within which knowledge is being created, whilst the remaining two refer to the 
actual knowledge creation process. In addition, whilst many authors refer to the 
contributions made by Michael Polanyi, they fail to acknowledge that Polanyi, himself, 
offers us a model of knowledge creation which is worthy of consideration. Section 3.4 in 
this chapter outlines the main points of these models. 
Specifically, Section 3.4.1 looks at the work of Michael Gibbons, Camille Limoges, Helga 
Nowotny, Simon Schwartzman, Peter Scott, and Martin Trow as described in their book 
The New Production of Knowledge (Gibbons et al, 1994). These authors identified a new 
form of knowledge production (knowledge production in the context of application) that 
they saw as emerging alongside the traditional form (knowledge production in a 
disciplinary context). They termed the new form Mode 2 and the traditional form Mode 1. 
They suggested that Mode 2 knowledge production would have profound effects upon not 
only the way in which knowledge would be produced, but also upon what knowledge 
would be produced. However, as will be shown in Chapter 6, the present thesis suggests 
that these speculations are not necessarily consistent with practice. 
Section 3.4.2 summarizes the model of organizational knowledge creation suggested by 
Ikujiro Nonaka (Nonaka, 1994) which was developed further in his book with Hirotaka 
Takeuchi: The Knowledge-Creating Company: How Japanese Companies Create the 
Dynamics of Innovation (Nonaka and Takeuchi, 1995). This model was particularly 
influential during the latter half of the 1990s because, referring to Michael Polanyi's work, 
it emphasized the importance of tacit knowledge, something that Western companies had 
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previously paid little heed to, assuming instead that all relevant knowledge could be 
expressed explicitly and stored in company databases (Chumer et al, 2000, p. xvii). 
However, a problem with this model is that it relies upon successive conversions between 
tacit knowledge and explicit knowledge, of the individual and group forms, and thus relies 
upon the assumption that knowledge is, in effect, an object that can be separated from 
context. As implied above (page 76), whilst this might apply to information, it is not 
something that can be guaranteed where knowledge is concerned. In addition, by 
separating knowledge into tacit and explicit forms, these authors do not appear to have 
taken on board Polanyi's assertion that all knowledge contains a tacit dimension. 
Section 3.4.3 outlines the model of Scott D. N. Cook and John Seely Brown and described 
in their paper Bridging Epistemologies: The Generative Dance between Organizational 
Knowledge and Organizational Knowing (Cook and Brown, 1999). Cook and Brown 
reject the notion of knowledge conversion proposed by Nonaka and Takeuchi and suggest 
a model based upon a pluralist framework which differentiates between different 
categories of `knowledge tools' that are possessed, which are used in the `active process of 
knowing'. The generation (creation) of new knowledge and new knowing is then seen as a 
possible result of the interplay between knowledge (as a tool of knowing) and knowing (as 
an aspect of our interaction with the social and physical world). In one respect, Cook and 
Brown's approach might be taken to reflect what actually happens in practice: that is, we 
use the knowledge available to us at the time to carry out the task we are given. In 
addition, it does emphasize the importance of knowing. However, by treating the four 
forms of knowledge indicated by the tacit-explicit and individual-group dimensions as 
distinct entities in themselves, Cook and Brown also have not remained true to Polanyi's 
original explanation of knowledge. 
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Section 3.4.4 looks at Michael Polanyi's work as described in his book, The Tacit 
Dimension (Polanyi, 1966). Although Polanyi's arguments adopt the perspective of the 
individual, as will be shown in Chapter 6 of this thesis, they nevertheless may be used to 
develop further insights into the knowledge creation processes within corporate R&D. 
Polanyi describes personal knowledge creation as a process of emergence. He shows us 
that by exercising our tacit powers of knowing we are able to assimilate sets of particulars 
to form an interpretation of the universe which is unique to ourselves, an interpretation 
which changes as we learn and understand more about the world in which we live. 
Polanyi's work outlined in this chapter forms part of his studies into the philosophy of 
science. Whilst an investigation into such a philosophy is not the purpose of this thesis, 
some reference should perhaps be made to the ways in which philosophers have viewed the 
growth of knowledge within the scientific community, since such an exercise may perhaps 
throw some light on the way in which scientists think - or at least on the way in which 
philosophers of science believe they think - and, hence, on scientists' ways of working. 
Section 3.2 attempts to do this, although it perhaps goes without saying that the section can 
offer only a very brief and simplistic sketch of a field of work that is vast and ongoing. 
Section 3.5 summarizes the main points of the Chapter. 
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3.2 The Growth of Scientific Knowledge 
Debate in the twentieth century centred around two differing philosophical standpoints, 
summarized by Lakatos as `science: reason or religion' (Lakatos, 1970, p. 91). Essentially, 
the argument was between the growth of scientific knowledge as a process of conjecture 
and refutation (Popper) and the growth of scientific knowledge as the result of informed 
scientific consensus (Kuhn). Whilst Kuhn has generally been acknowledged to have won 
the debate (Fuller, 2003, p. 4), as noted below, Popper's views perhaps still play some part 
in normal scientific practice. 
For the most part, Popper and Kuhn work from similar premises. For example, they both 
accept that scientists necessarily develop their ideas within a definite theoretical 
framework (Kuhn, 1970b, p. 242; Popper, 1970, p. 51); they both reject the view that 
science progresses only by accretion and emphasize instead the revolutionary process by 
which an older theory is rejected and replaced by an incompatible new one (Kuhn, 1970a, 
p. 1); and they both underscore the role played in this process by the older theory's 
occasional failure to meet challenges posed by logic, experiment, or observation (ibid, p. 2). 
They both also reject a number of classical positivism's most characteristic theses. For 
example, they both emphasize the intimate and inevitable entanglement of scientific 
observation with scientific theory; they are both sceptical of efforts to produce any neutral 
observation language; and they both insist that scientists may properly aim to invent 
theories that explain observed phenomena and that do so in terms of real objects (ibid, p. 2, 
italics in original). Nevertheless, as will be shown below, there is a fundamental difference 
between the ways in which these two philosophers view discovery and the consequent 
advancement of science. 
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Francis Bacons' advice to scientists was to study nature by collecting related observations 
with a view to discerning patterns of occurrence that call for explanation (Sheppard, 1999, 
p. 6). As stated by Russell: 
`In arriving at scientific laws there are three main stages: the first consists of 
observing the significant facts, the second in arriving at a hypothesis which if it 
is true would account for those facts, the third in deducing from this hypothesis 
consequences which can be tested by observation' (Russell, 1931, p. 58). 
Thus, scientific advance is assumed to be a logical process involving observation, 
hypothesis formation by induction, deduction from the formed hypothesis, and the testing 
of that deduction. 
Popper's contribution to this reasoning was to emphasize that no matter how many times 
we make logical deductions from a hypothesis and test them to be positive, we can never 
be sure that there are not some other logical deductions that might prove negative. That is, 
in themselves, new observations which confirm a hypothesis cannot constitute reliable 
verifications of the hypothesis (Popper, 1963. p. 55). Instead, we should look for new 
observations which falsify the hypothesis, since these will require a new theory to be 
devised, and in so doing we take a logical step forward (ibid, p. 69). Thus, scientific 
advance becomes a logical process based upon conjecture and refutation (ibid, 1963, p. 43). 
Popper's advice to scientists is that they should use their imagination to select an 
hypothesis, and should then continually seek to falsify it, since in so doing they may learn 
more from their mistakes. As he states: 
`[Conjectures] can never be positively justified; they can be established neither 
as certainly true nor even as `probable' ... 
Criticism of our conjecture is of 
decisive importance: by bringing out our mistakes it makes us understand the 
difficulties of the problem we are trying to solve. This is how we become better 
acquainted with our problem, and able to propose more mature solutions: the 
very refutation of theory - that is, of any serious tentative solution to our 
problems - is always a step forward that takes us nearer to the truth. ' (Popper, 
1963, p. xi) 
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Whilst accepting that many research problems may proceed via Popper's hypothetico- 
deductive form, Kuhn rejects falsification as the means for advancing scientific theory. He 
suggests that the scientist's object when undertaking `normal research' 9 is to solve a 
'puzzle', and existing theory is required to define that puzzle and to `guarantee' that it can 
be solved (Kuhn, 1970a, p. 5). Since, in a scientific context, no puzzle-solving enterprise 
can exist unless the practitioners of the particular science involved share criteria which, for 
that group and for that time, determine when that puzzle is solved, any `failure' on the part 
of the individual puzzle-solving scientist is, at least in the first instant, simply a failure on 
the part of that scientist, and not a failure of the current theory of that science. 
Kuhn further points out that whilst `falsification' and `refutation' are antonyms of 'proof, 
they are drawn principally from logic and from formal mathematics. When scientific 
theories are being propounded, he suggests that `arguments are seldom so apodictic'. 
`All experiments can be challenged, either as to their relevance or their accuracy. 
All theories can be modified by a variety of ad hoc adjustments without ceasing 
to be, in their main lines, the same theories. ' (Kuhn, 1970a, p. 13) 
Indeed, it is by challenging observations or adjusting theories that scientific knowledge 
grows during the course of normal research (ibid, p. 13). Only when a crisis develops - for 
example, repeated failure by the most brilliant professionals to match theory with the 
natural world - may the failure that had previously been personal come to be viewed as a 
possible failure of the theory being applied (ibid, p. 7). Thus, with or without tests, a 
' According to Kuhn, normal research is the `generally cumulative process by which the accepted 
beliefs of a scientific community are fleshed out, articulated, and extended' (Kuhn, 1970b, p. 250). 
Normal research involves scientists and technologists who are concerned with three classes of 
problems: determination of significant fact; matching of facts with theory; and articulation of theory 
(Kuhn, 1962, p. 34); problems which are propelled by the desire to be useful, the hope of finding 
order, the drive to test established knowledge, or simply the excitement of exploring new territory 
(ibid, p. 37). Whether, or not, normal research differs from any other form of research, the problems 
ascribed by Kuhn to normal research are essentially the problems with which this current thesis is 
concerned. 
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puzzle-solving tradition can prepare the way for its own displacement (Kuhn, 1962, p. 5). 
Kuhn's proposition is then that only when a theory is in crisis, will a period of 
`extraordinary research' be encouraged, invoking a fundamental rethink of the underlying 
scientific principles, and in so doing produce a result that may lead to the rejection of the 
existing theory in favour of another, and even to the rejection of one way of thinking over 
another -a paradigm change or scientific revolution. The criteria with which scientists 
determine the validity of an articulation or an application of an existing theory are then not 
by themselves sufficient to determine the choice between competing theories, since the 
problem of theory choice cannot rely on logical criteria that are applicable in full only 
when a theory can already be presupposed (ibid, p. 19). Instead, Kuhn sees the rejection of 
a previously accepted theory and the decision to accept another as `an act of judgement 
involving the comparison of both theories with nature and with each other' (ibid, p. 77, 
italics in original). Thus, `given examples of what a scientific theory does and being 
bound by shared values to keep doing science, one need not also have criteria in order to 
discover that something has gone wrong or to make choices in case of conflict' (Kuhn, 
1970b, p. 275). 
In practice, this means that a scientific community will rarely embrace a new theory unless 
that theory has solved all, or almost all, of the quantitative, numerical puzzles that had 
already been treated, although not necessarily solved, by its predecessor (Kuhn, 1970a, 
p. 20). And even then, for a period of time, there may remain within that community a 
group of scientists who remain loyal to the old theory, in the hope that further adaptation of 
that theory may account for the anomalies that have accrued: 
`For a man trained as a puzzle-solver will wish to preserve as many as possible 
of the prior puzzle-solutions obtained by his group, and he will also wish to 
maximize the number of puzzles that can be solved. ' (Kuhn, 1970a, p. 21) 
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At the same time, simplicity, precision, and congruence with the theories used in other 
specialties are all of value to the scientist during decision-making. However, these factors 
may not all dictate the same choice, nor will they necessarily be applied in the same way 
between specialties. When this is so, Kuhn suggests that group unanimity is of paramount 
importance (Kuhn, 1970a, p. 21). 
To Lakatos, this statement of group unanimity suggests that theories which inspire 
scientific revolutions or paradigm changes are the result of `mob psychology' (Lakatos, 
1970, p. 178). To the present author, it is more a case of informed consensus based upon 
the respective merits of conflicting paradigms to explain the observations made of nature 
as they exist at the time; not necessarily a strictly logical process, but perhaps a rational 
one, knowing that there is much that is still unknown. This latter view is perhaps the point 
that Kuhn makes in his Reflections on my Critics (Kuhn, 1970b, p. 260). Whilst, on the 
surface, Lakatos' proposals outlined below might suggest a more specifically logical 
approach to discovery and scientific advance than do those of Kuhn, Lakatos is perhaps 
wrong to suggest that `in Kuhn's view there is no logic, but only psychology of discovery' 
(Lakatos, 1970, p. 178). 
Lakatos criticizes Kuhn's arguments against falsification. Whilst he accepts that these 
arguments do apply to `naive falsificationism', adopting Popper's views and building on 
Popper's work, Lakatos asserts that they do not apply to a more sophisticated form of 
falsificationism (ibid, p. 93). Sophisticated falsificationism retains the `code of honour' 
that scientific honesty consists in specifying, in advance, an experiment such that if the 
result contradicts the theory the theory has to be given up (ibid, p. 112). However, it makes 
allowance for the fact that scientists necessarily employ experimental techniques that may 
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be based upon fallible theories, and that they accept these fallible theories in a given 
context as unproblematic background knowledge for the purpose of testing the theory of 
interest (Lakatos, 1970, p. 106). In consequence, if falsification occurs, it allows for the 
fact that this may be due to an error in experimental technique or possibly an error in some 
other background knowledge, which will then need to be investigated further before 
rejection of the theory should be made. It also accepts the fact that one single observation 
may be the stray result of some trivial error rather than an error of the theory, and 
prescribes some safeguards to overcome such a problem; the simplest being to repeat the 
experiment (ibid, p. 107); another being to `fortify' the potential falsifier by a `well- 
corroborated falsifying hypothesis'. By separating rejection from disproof, sophisticated 
falsificationism ensures that theories are not eliminated prematurely (ibid, p. 109). But, by 
doing so, it introduces decision-making into the process (ibid, p. 112). And, decision- 
making incurs risks, so, how then might these risks be minimized? 
In contrast to Popper, who construes `falsification' as the result of a `dual between theory 
and observation, without another better theory necessarily being involved' (ibid, p. 181, 
italics in original), Lakatos suggests that an existing theory is `falsified' if and only if 
another theory has been proposed such that the latter theory (a) predicts novel facts, 
(b) explains all the un-refuted content of the previous theory, and (c) has excess content, 
some of which has been corroborated (ibid, p. 116). Whilst accepting that all theories, even 
those that have corroborated counter-evidence, may be adjusted and made acceptable by 
the addition of auxiliary hypotheses, in line with Popper, Lakatos suggests that `saving a 
theory with the help of auxiliary hypotheses which satisfy certain well-defined conditions 
represents scientific progress, but saving a theory with the help of auxiliary hypotheses 
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which do not, represents degeneration' (Lakatos, 1970, p. 117). The aim, of course, is to 
progress. Thus, Lakatos states: 
`Einstein's theory is not better than Newton's because Newton's theory was 
refuted but Einstein's was not: there are many known `anomalies' to Einsteinian 
theory. Einstein's theory is better than - that is, represents progress compared 
with - Newton's theory anno 1916 ... 
because it explained everything that 
Newton's theory had successfully explained, and it explained also to some extent 
some known anomalies, and, in addition, forbade events like transmission of 
light along straight lines near large masses about which Newton's theory had 
said nothing but which had been permitted by other well-corroborated scientific 
theories of the day; moreover, at least some of the unexpected excess Einsteinian 
content was in fact corroborated (for instance by the eclipse experiments). 
(Lakatos, 1970, p. 124, italics in original) 
Lakatos' proposals mean that any scientific theory has to be appraised with its auxiliary 
hypotheses, its initial conditions, and any `certain conditions', together with its predecessor 
theories, in order that the change brought about by the new theory be assessed (ibid, 
p. 118). And, importantly, the elimination of the predecessor by its antecedent is brought 
about through defined rules which are not those described by naive falsification. As 
Lakatos states, `falsification in the sense of naive falsificationism (corroborated counter- 
evidence) is not a sufficient condition for eliminating a specific theory: in spite of hundreds 
of known anomalies we do not regard [a theory] as falsified (that is eliminated) until we 
have a better one. Nor is `falsification' in the naive sense necessary for falsification in the 
sophisticated sense. Science can grow without any `refutations' leading the way' (ibid, 
p. 121). Thus: 
`We never reject a specific theory simply by fiat. If we have an inconsistency ... 
we do not have to decide which ingredients of the theory we regard as 
problematic and which ones as unproblematic: we regard all ingredients as 
problematic in the light of the conflicting accepted basic statement and try to 
replace all of them. If we succeed in replacing some ingredient in a 
`progressive' way (that is, the replacement has more corroborated empirical 
content than the original), we call it `falsified'. ' (Lakatos, 1970, p. 125, italics in 
original) 
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In a similar way, in deciding between which of two mutually inconsistent theories should 
be eliminated, Lakatos states: 
`One had to try to replace first one, then the other, then possibly both, and opt 
for the new set-up which provides the biggest increase in corroborated content, 
which provides the most progressive problemshift' (Lakatos, 1970, p. 130). 
These views would, at least to the present author, appear to have some similarities with 
Kuhn's views expressed above (page 84); the difference being that for Lakatos the 
acceptance of a new theory is more specifically based upon whether the new theory 
represents a progression by way of defined criteria. 
In pursuing a particular research programme, Lakatos suggests that scientists are then not 
necessarily irrational when they tend to ignore counterexamples. They may be assuming 
that their experimental results are unreliable (Lakatos, 1970, p. 176), or that the 
discrepancies that exist between the experimental results and theory are only apparent and 
will disappear with the advancement of understanding (ibid, p. 177). As he says, `Popper is 
right in stressing that the dogmatic attitude of sticking to a theory as long as possible is of 
considerable significance, [since] without it we could never find out what is in a theory ... 
and in consequence no theory would ever be able to play its role of bringing order into the 
world, of preparing us for future events, of drawing our attention to events we should 
otherwise never observe' (ibid, p. 177). However, as he also points out, this is a view that 
would appear to contradict Popper's comments elsewhere (Lakatos, 1970, p. 177, 
footnote 3; and, for example, page 86 above). 
Polanyi would appear to take a similar attitude to Kuhn as regards `falsification' and might 
therefore, likewise, be criticized by Lakatos. Noting that an apparent falsification can 
never be totally decisive (Polanyi, 1958, p. 3 16), he states that, in practice, scientists do not, 
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and should not, immediately reject a theory because of an apparent anomalous observation, 
provided that the theory is strongly supported on other grounds (Polanyi, 1958, p. 20). So, 
on the practical aspect of theory rejection, Polanyi, Lakatos, and Kuhn would appear to 
agree, although Popper might not. Polanyi, additionally suggests that, in any case, 
scientists do not explicitly attempt to falsify their theories, `for to have found one of 
promise is an achievement in itself which can be enjoyed permanently' (ibid, p. 173). 
Polanyi, like Kuhn, also notes that personal judgement forms an essential part of science 
since `there are always some conceivable scruples which scientists customarily set aside in 
the process of verifying an exact theory' (ibid, p. 20). But, in addition, Polanyi believes 
that discovery is about something more than judgement. It is about a deep personal 
appreciation of the problem to be solved and about the use of intuition in finding the 
solution (ibid, p. 120). As Drusilla Scott points out, `while induction and deduction make a 
tidy logical formula into which philosophers have fitted discovery', Polanyi, as a scientist 
of eminence, `knew that this was not what discovery was like' (Scott, 1985, p. 30). `The 
beginning is not like Russell's first stage; it is a vague sense of a problem, which draws the 
scientist into a personal obsession in searching for the solution. This carries him through 
the patient meticulous work, the setbacks and disappointments, till a sudden flash of 
illumination, an imaginative leap, may show the answer. And the answer is an 
understanding of an aspect of reality, which may not be experimentally testable for years, 
and may have unpredictable consequences. It does not fit the rules at all' (ibid, p. 31). 
In line with Kuhn's view of a scientific paradigm, Polanyi also sees science as being 
pursued and transmitted to succeeding generations `only within an elaborate system of 
traditional beliefs and values' (Polanyi, 1962, p. 70). However, rather than Kuhn's 
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paradigm shifts and scientific revolutions, Polanyi sees this `system of tradition' as, itself. 
a `dynamic entity which is dependent upon constant self-renewal through the originality of 
its followers' (Polanyi, 1962, p. 72). In this respect, Polanyi is perhaps closer to Popper 
and Lakatos, than Kuhn. 
Also like Kuhn, Polanyi recognizes the importance of group unanimity. And he suggests 
the form that this unanimity might take. It is a unanimity based upon the 'free cooperation 
of independent scientists, coordinating their activities through a process of `mutual 
adjustment of independent initiatives' (ibid, p. 54) in relation to criteria laid down by the 
scientific community at large (ibid, p. 57) -'A Republic of Science' (ibid, p. 54). Whilst 
the scientist's choice of problem may be said to have an economic character in that 
decisions are designed to produce the highest possible result by the use of a limited stock 
of intellectual and material resources (Polanyi, 1962, p. 56), the depth of a problem and the 
importance of its prospective solution are primarily assessed by reference to professional 
standards of scientific merit. These are standards which depend upon plausibility in 
relation to current scientific opinion about the nature of things (ibid, p. 57, italics added); 
scientific value based upon perceived accuracy, systematic importance, and intrinsic 
interest of the subject matter; and originality assessed by the degree of surprise which its 
communication should arouse among scientists (ibid, p. 58, italics added). Although 
Lakatos might still see this as a form of `mob psychology' this is not the view held by the 
present author. As Polanyi notes, whilst plausibility and scientific value tend to enforce 
conformity, it is the value attached to originality that encourages dissent (ibid, p. 58). 
Rather than the traditional view of scientists rejecting all authority, it is Polanyi's view that 
scientists are bound by the authority of the scientific community to which they belong 
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(Polanyi, 1962, p. 68). It is the existence of this community authority that fosters, controls 
and protects the pursuit of free scientific enquiry (ibid, p. 67), and any attempt at guiding 
scientific research towards a purpose other than its own is thus an attempt to deflect it from 
the advancement of science (ibid, p. 62). At the same time, whilst the 'freedom' of the 
scientist is rooted in scientific tradition, this tradition is such that it allows subversion (ibid, 
p. 69) and thus cultivates `radical' progression (ibid, p. 72). Nevertheless, in agreement 
with Kuhn, Polanyi acknowledges that well-established or traditional views can lead to an 
initial reluctance to the acceptance of new ideas when these ideas are subversive of the 
basic tenets of the sciences involved. Kuhn's view is that as long as these tenets `retain an 
element of the arbitrary, the very nature of research ensures that novelty shall not be 
suppressed for very long' (Kuhn, 1962, p. 5). Polanyi's more comprehensive view is that 
the open and international nature of science ultimately enables even radical new ideas to 
take root once the supporting evidence is judged to be sound (Polanyi, 1962, p. 72). 
One last point should perhaps be made before moving on to the main subject matter of this 
chapter. However logical some philosophers of science might like the processes of 
discovery and scientific advance to be, as we shall see in the sections and chapters that 
follow, science is not necessarily like that. Intuition is an important part of scientific work, 
even within the realms of `normal science'. Thus, whilst there is undoubtedly some truth 
in each of the views outlined above, it is Polanyi's thoughts that ring true for the present 
author, and which are therefore discussed further in this thesis. 
Chapter 3: Knowledge Creation 91 Section 3.2 
3.3 The Nature of Knowledge 
A problem arises when discussing the nature of knowledge in that there would appear to be 
no unambiguous definition of the term `knowledge'. The most common interpretations are 
therefore outlined and discussed below. Yet, despite their differences, what becomes clear 
when all of these interpretations are looked at in more detail is that they all point towards 
the inherently personal nature of the complex `thing' that is generally referred to as 
knowledge (Polanyi, 1958, p. vii). 
Justified True Belief 
Philosophers commonly refer to knowledge as `justified true belief, a concept that was 
first introduced by Plato in his Meno, Phaedo, and Theaetetus (Nonaka and Takeuchi, 
1995, p. 21). But what does `justified true belief really mean? If the belief is in reality 
true, why does it have to be justified? If, on the other hand, the belief is simply something 
that is truly believed, then it is simply a belief. Justification in this case may prove the 
reality of the belief but then that brings in the question, `Justified by whom and in what 
way or by what rules? ' As will be shown below, what is a justified true belief to one 
person may not necessarily be a justified true belief to another, since the evidence available 
to and the interpretation made by one person is not necessarily the same as the evidence 
available to and the interpretation made by another. 
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That which is Known 
Knowledge is also referred to as `that which is known' (Quintas and Jones, 1999. p. 36). 
Although true in one respect, it might also be added that we `know' information. More 
importantly, this definition begs the question, `Known by whom? ' Since what we know at 
any one time is likely to be influenced by our past knowledge, experiences, values, and 
culture, once again, knowledge is not necessarily a universal truth, but is something that is 
unique to the individual (Brown and Duguid, 1998, p. 95; Daft, 1995, p. 3; Polanyi and 
Prosch, 1975, p. 44). 
Data, Information, Knowledge 
Within the general management literature, knowledge is often associated with data as well 
as information. The story goes: data is a set of unorganized facts or observations; 
information is data arranged and processed into meaningful patterns; and knowledge is 
information put into productive use, made actionable, given meaning (Davenport and 
Prusak, 1998, respectively, pp. 2,3 and 5). This story is often assumed to imply that 
knowledge is an `object' or `commodity' that can be stored, arranged, and otherwise 
worked upon. However, when looked at in more detail it can be shown that, once again, 
knowledge is inherently a personal phenomenon. 
The word `data' has its roots in the Latin for `giving' (dare `to give'; dator 'giver'). Data 
is all around us. It is potentially infinite. It is present, giving out a signal to those who are 
capable of observing it in a meaningful manner. However, we may not necessarily notice 
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that signal, and, even if we do, it may appear irrelevant for our current purposes. As a 
consequence, the data that we observe is likely to be that which either informs us 
(informare `to give shape to') about something or which would appear to have the 
potential to inform us about something. At any one time, we thus make a judgement as to 
what data is important to us. The data we observe is therefore inherently personal and 
context dependent. So what then is information and how does it differ from data? 
Information can perhaps best be thought of as pre-selected data that has been processed to 
provide some meaningful pattern. But can we be sure that the pattern provided is the one 
that we would ourselves have established? Are we aware of the context for which or 
within which the data was selected? Are we in fact interpreting the meaningful pattern in 
the way in which it was intended? Can we even observe the meaningful pattern? What is 
information to one person has often been observed to be merely data to another. Without 
the same `interpretation code' we will not necessarily derive the same meaning from 
information that others might or have derived from it (Itami, 1992, in Ray and Little, 2001, 
p. 162; Cilliers, 2000, p. 10). Information, like data, is thus also inherently personal and 
context dependent. What is required for information to inform in the way in which it was 
intended is that the information producer and the information receiver share a common 
understanding of how the information should be interpreted. So, for information to be 
made actionable in the way in which it was originally intended, and thus be termed 
knowledge, not only does the information need to be remembered, but so also must the 
interpretation code or the common understanding associated with that information. As 
pointed out by Spradley, language is a tool for constructing reality. And, different 
languages create and express different realities. They categorize experience in different 
ways. They provide alternative patterns for customary ways of thinking and perceiving 
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(Spradley, 1979, p. 17). In effect, a common language can be seen as a vehicle for 
constructing a common understanding. Thus existing knowledge is always context 
dependent (Tsoukas, 1996, p. 11; McKinlay, 2000, p. 119) and its effective application is 
dependent upon the sharing of a common language, whether it is expressed in written, 
verbal or non-verbal form. Knowledge can thus be defined as information that is 
remembered in a particular way. Without the common language which conveys the 
understanding behind the information, it is hard to see how people can communicate and 
knowledge can be transferred. The result is that whilst information may flow, knowledge 
will not necessarily do so. In this sense, it is only information that can exist independently 
and thus be directly acquired, shared, or, in general, transferred. 
Within a Western context, `language' is typically associated with the written or verbal 
word, and the knowledge resulting from the sharing of such a language is generally 
referred to as `explicit knowledge'; it is `knowledge that can be codified and clearly 
defined and thus conveyed in written form' (Nonaka and Takeuchi, 1995, p. viii). 
However, even within a Western context it is recognized that there is some knowledge that 
cannot be written down or spoken about verbally. As Polanyi has often been quoted as 
saying: `I shall consider human knowledge from the fact that we can know more than we 
can tell' (Polanyi, 1966, p. 4, italics in original). This is the knowledge of insight and of 
intuition. It is evidenced by the fact that, for example, the driver of a car can initiate an 
emergency stop as much as 0.5 seconds before he/she is conscious of perceiving the reason 
to do so (Ray, 2001, p. 4). It is evidenced by the group's spontaneous laughter that breaks 
out before anyone can say why this should be (Ray, 2005, p. 17). This tacit `knowing' is 
something that is unknowable in any abstract sense; its existence is only implied by the 
ability to 'do things' in the course of purposeful activity (Ray and Carter et al, 2002, p. 20). 
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A frequently quoted example in the Knowledge Management literature is the act of riding 
a bicycle. How can we talk or write about the knowledge of riding a bicycle? The answer 
is that we cannot do so in any meaningful way. We each learn how to ride a bicycle 
through our attempts at trying to ride a bicycle. And, throughout our attempts we 
remember and apply the experience we have gained previously to inform our subsequent 
actions, but we do this without conscious thought of the cognitive processes that make 
these activities possible. In effect, we gain the knowledge of how to ride a bicycle through 
practice. Tacit knowledge (as this knowledge is often referred to) `is preconscious; it 
cannot be consciously turned off but kicks-in automatically to shape practice' (Ray, 2001, 
p. 4). It is thus quite distinct and wholly different from explicit knowledge. 
The practice of R&D involves the sharing of knowledge within and between a number of 
different departments or organizational functions (technical, operations, marketing, sales, 
finance, etc. ) sometimes external to the company. Thus terms such as `group knowledge' 
and `organizational knowledge' would appear to be appropriate within such a context. 
Whilst it would seem clear that the presence of a common language that is understood by 
all members of the `collective' is necessary for both of these forms of knowledge, previous 
literature reports would suggest that this has not always been deemed so. For example, 
Simon saw organizational knowledge as being synonymous with the knowledge of the 
organization's individual members. New organizational knowledge is then created either 
by the learning of these members, or by ingesting new members with knowledge the 
organization did not have previously (Simon, 1991, p. 125). In contrast, other researchers 
have seen organizational knowledge as being something more than simply the sum of the 
organization's individual knowledge. In particular, Nelson and Winter refer to 
organizational knowledge as an attribute of the firm as a whole, as an organized entity' 
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which is `not reducible to what any single individual knows, or even to any simple 
aggregation of the various competencies and capabilities of all the various individuals. 
equipment, and installations of the firm' (Nelson and Winter, 1982, p. 63). Brown and 
Duguid try to make this point more clearly and suggest that when individuals have similar 
backgrounds and experiences - that is they have the same information and speak the same 
language in all senses of the word `language' - they can arrive at a shared understanding of 
what is meant by particular actions or information. This shared understanding is what 
Brown and Duguid term collective or group knowledge (Brown and Duguid, 1998, p. 96). 
Whilst emphasizing that all knowledge is inherently personal, this is the view that will be 
taken in this thesis when reference is made to all forms of group knowledge. 
A Fluid Mixture of Framed Experience, Information, Values and Insight 
To talk about knowledge is perhaps to imply that knowledge (as opposed to knowing) is a 
static phenomenon. In some instances this may be so: knowledge of the car, for example, 
might be thought of as essentially static in the sense that cars have standard features (such 
as an accelerator or drive pedal, brakes, a transmission system and so on) that are arranged 
in relatively standard design configurations. But, as time passes, the knowledge that we 
each individually or as a group hold is constantly changing. What we know and how we 
interpret new information and stimuli is constantly reviewed or revised as we experience 
and learn new things. One definition that indicates the complex and changing nature of 
knowledge and indicates that knowledge might in fact be created in the mind of the 
individual is the one suggested by Davenport and Prusak: 
`Knowledge is a fluid mix of framed experience, values, contextual information, 
and expert insight that provides a framework for evaluating and incorporating 
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new experiences and information. It originates and is applied in the minds of 
knowers. ' (Davenport and Prusak, 1998, p. 5) 
Michael Polanyi's Tacit Knowing 
Although, many contributors to the knowledge debate refer to tacit knowledge and make 
reference to the historic work of Michael Polanyi, it would appear that few have taken the 
time to understand what this author is really trying to say. This is a pity, since Polanyi's 
original ideas offer us a much deeper insight into the nature of knowledge than is presented 
in much of the contemporary Knowledge Management literature. Whilst the following 
paragraphs cannot do justice to the wider implications of Polanyi's philosophical insights, 
they aim at reflecting the logically coherent nature of his propositions. These paragraphs 
outline how, by using the work of Gestalt psychology and viewing knowledge from the 
perspective of the individual, Polanyi illustrates how all human action is based upon tacit 
thought, and, as a consequence, all knowledge, even that which is commonly referred to as 
being explicit, includes a tacit dimension. 
As mentioned above (page 95), Polanyi began his investigation into `The Tacit Dimension' 
by considering human knowledge from the fact that `we can know more than we can tell' 
(Polanyi, 1966, p. 4, italics in original). That is, there is more to knowledge than that which 
can be expressed in explicit terms. He gives, as an example of this fact, the way that 
teaching occurs in the descriptive sciences. He notes that all descriptive sciences study 
physiognomies that `cannot be fully described in words, nor even by pictures. ' However, 
the possibility that these physiognomies can be learnt through practical exercises suggests 
that nevertheless we can tell our knowledge of them'. But, as he points out, we can do 
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this only by `relying on the pupil's intelligent co-operation for catching the meaning of the 
demonstration' (Polanyi, 1966, p. 5). Polanyi refers to this knowledge that cannot be told 
as `tacit knowing'. He notes that Gestalt psychology has demonstrated that we may know 
a physiognomy by integrating our awareness of the particulars of this physiognomy 
without being able to identify these particulars. And he takes the view that the 'shaping 
and integrating' that occurs, is the `great and indispensable tacit power by which all 
knowledge is discovered and, once discovered, is held to be true' (ibid, p6). From this 
background, he develops a structure for tacit knowing and explains how we each exercise 
our tacit powers of knowing. 
In Polanyi's view, the structure of tacit knowing consists of two components (viz. 
Polanyi's `terms'): the proximal and the distal. The former can be associated with the 
particulars of tacit knowing, the latter with the focal target of the act of tacit knowing 
(Polanyi and Prosch, 1975, p. 34). Polanyi adds that it is the proximal component `of 
which we have knowledge that we may not be able to tell' (Polanyi, 1966, p. 10). He 
arrives at this conclusion by referring to the electric shock experiments of McCleary and 
Lazarus (1949) and Eriksen and Kuethe (1956). In McCleary and Lazarus' experiments a 
subject was shocked after being shown certain nonsense syllables, and learnt to expect the 
shock event (McCleary and Lazarus, 1949, p. 178). In Eriksen and Kuethe's experiments, a 
subject learnt to suppress the utterance of certain word associations which would evoke the 
shock (Eriksen and Kuethe, 1956, p. 207). In both cases the shock-producing particulars 
(the proximal component) remained tacit: the subject could not identify them. However, 
the subject did learn to connect the shock-producing particulars with the electric shock (the 
distal component) that subsequently occurred. When this was so, the sight of the shock 
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syllables led to the expectation of a shock, and the utterance of the shock associations was 
suppressed in order to avoid the shock. 
In considering why the connection remained tacit, Polanyi concludes that it was because 
the subject was `riveting his attention on the electric shock' and was `relying on his 
awareness of the shock producing particulars only in their bearing on the electric shock' 
(Polanyi, 1966, p. 9). In general, he suggests that we know the proximal component only 
by relying on our awareness of it for attending to the distal component. In the act of tacit 
knowing, we therefore `attend from something for attending to something else' (ibid, p. 9, 
italics in original). Polanyi calls thisfrom-to relationship the functional relation between 
the two components of tacit knowing. The components together with their relationship 
form the functional structure of tacit knowing (ibid, p. 10). 
Polanyi then adds that although the subjects of the experiments cannot explicitly identify 
the shock-producing particulars, they do become aware of them in terms of the 
apprehension they invoke. Thus, he says, `we are aware of the proximal term of an act of 
tacit knowing in the appearance of its distal form; we are aware of that from which we are 
attending to another thing, in the appearance of that thing. ' He calls this the phenomenal 
structure of tacit knowing (ibid, p. 11, italics in original). 
Furthermore, once the connection is made, the shock-producing particulars can be said to 
signify' the approach of a shock. This is the meaning of the shock-producing particulars to 
the subject. In general, `when the proximal component of an act of tacit knowing arouses 
an apprehension in us, without our being able to identify that component itself, we can say 
that we know this component only in terms of its meaning' (ibid, p. 11). In this sense, 
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meaning can be said to be displaced away from the subject - hence Polanyi's justification 
of the terms proximal and distal. This is the semantic aspect of tacit knowing (Polanyi, 
1966, p. 13). 
Polanyi suggests that there is a fourth aspect of tacit knowing which can be deduced from 
the functional, phenomenal and semantic aspects. His argument is that since tacit knowing 
establishes a meaningful relation between two terms, it can be identified with an 
`understanding of the comprehensive entity which these two terms jointly constitute'. This 
is the ontological aspect, which tells us what tacit knowing is a knowledge of. In Polanyi's 
terminology, `we comprehend the entity by relying on our awareness of its particulars for 
attending their joint meaning' (ibid, p. 13). 
Polanyi then suggests that when we make a thing function as the proximal component of 
tacit knowing we `incorporate it into our body, or extend our body to include it, so that we 
come to dwell in it' (ibid, p. 16). He adds that it is by dwelling in the proximal component, 
whilst focusing on the distal component that we can, for example, understand a work of 
art, understand the mind of another person, and apply a theory within the practice of 
science (ibid, p. 17). As he says, `It is not by looking at things, but by dwelling in them, 
that we understand their joint meaning' (ibid, p. 18). 
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3.4 The Knowledge Creation Models 
3.4.1 Michael Gibbons and Co-workers' Modes of Knowledge Production 
Traditionally, knowledge was produced within a disciplinary context. Schools and 
universities taught knowledge from a disciplinary perspective (physics, chemistry, 
mathematics, social science, etc. ) and industrial organizations separated their activities into 
discipline-based functional departments (chemistry, finance, human resources, etc. ). Thus, 
it was the discipline that determined the cognitive and social norms which had to be 
followed in the production, legitimization and diffusion of knowledge (Gibbons et al, 
1994, p. 1). Forms of practice which adhered to the rules of the discipline were then termed 
`scientific' whilst those that violated them were not `scientific'. Mode 1 knowledge 
production is thus often referred to as `scientific' knowledge production. Gibbons et al 
define it as: 
`The complex of ideas, methods, values and norms that has grown up to control 
the diffusion of the Newtonian model of science to more and more fields of 
enquiry and ensure its compliance with what is considered sound scientific 
practice' (Gibbons et al, 1994, p. 167). 
Mode I knowledge production assumes a linear view of science and innovation: to 
discover new ideas, transfer them, and then exploit them in new products (ibid, p. 60). It 
assumes a separation of producers and consumers of knowledge. It carries a distinction 
between what is fundamental and what is applied (ibid, p. 19). Quality is determined 
mainly through peer review judgements about the contributions made by individuals. And, 
control is maintained by careful selection of those judged competent to act as peers, which 
is in part determined by their previous contributions to their disciplines. It is thus a process 
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in which quality and control mutually reinforce one another. Mode 1 is clearly the primary 
form of knowledge production in first generation (science/technology push) R&D 
(Chapter 2, Section 2.2.1, page 18). 
However, Gibbons et al contend that there is sufficient empirical evidence to indicate that 
a distinct set of cognitive and social practices is emerging which differs from that which 
governs Mode 1 knowledge production. And, these cognitive and social practices are 
emerging from knowledge generation carried out for the purpose of achieving a practical 
goal. They define this new form of knowledge production as: 
`Knowledge production carried out in the context of application and marked by 
its: transdisciplinarity; heterogeneity; organisational heterarchy and transience; 
social accountability and reflexivity; and quality control which emphasises 
context- and use- dependence' (Gibbons et al, 1994, p. 167, italics in original). 
Mode 2 knowledge production is transdisciplinary in that `consensus is conditioned by the 
context of application and evolves with it': the final solution does not arise solely, or even 
mainly, from the application of knowledge that already exists; is normally beyond that of 
any single contributing discipline; cannot necessarily be reduced to disciplinary parts; and 
is developed using its own distinct theoretical structures, research methods and modes of 
practice, which are not necessarily located on the prevailing disciplinary map (Gibbons et 
al, 1994, p. 4). Mode 2 knowledge production is heterogeneous in terms of the skills and 
experience people bring to it, with the composition of the problem solving team changing 
over time as requirements evolve, rather than being planned or coordinated by any central 
body. Mode 2 knowledge production involves organizational heterarchy and transience in 
that people from diverse backgrounds and from different locations or organizations come 
together in temporary work teams and networks, which dissolve when a problem is solved 
or redefined (ibid, p. 6). And, social accountability and reflexivity to the impact of research 
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is built-in to Mode 2 working in that research teams involve social scientists working 
alongside natural scientists, engineers, lawyers and business people (Gibbons et al, 1994, 
p. 7). In consequence, quality is determined by criteria that reflect both the context of the 
application and the standpoints of the participants involved (ibid, p. 8). 
Unlike Mode 1 knowledge production `where results are communicated through 
institutional channels, the results [of Mode 2 working] are communicated to those who 
have participated in the course of that participation'. Subsequent diffusion of the resulting 
knowledge then occurs primarily as the original practitioners move to new problem 
contexts. A particular solution can become the cognitive site from which further advances 
can be made, but it is difficult to predict where this knowledge will be used next and how it 
will develop (ibid, 1994, p. 4). In Mode 2 working, `science and innovation' is therefore no 
longer a linear process: ideas arise throughout the problem solving process; there is no 
distinct separation between producers and consumers; and there is no distinction between 
what is fundamental and what is applied, or between what is theoretical and what is applied 
science. Discovery and application cannot be separated, since the relevant science is 
produced in the course of providing solutions to problems defined in the context of 
application (ibid, p. 33). Hence, Mode 2 knowledge production would appear to be most 
closely related to the third, fourth, and fifth generations of R&D (Chapter 2, Sections 2.2.3, 
2.2.4, and 2.2.5, respectively, pages 23,25, and 29). 
Although Gibbons et al see no need for Mode 2 activities to be institutionalized in a 
particular way, or for participants to move permanently to new institutional locations, they 
do see other implications for all institutions engaged in knowledge production, whether 
they are universities, government research establishments, or corporate laboratories. 
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First, because of its modus operandi, Mode 2 knowledge is both supplied by and 
distributed to individuals and groups across the social spectrum. The degree to which 
knowledge producing institutions become more permeable will not, according to Gibbons 
et al, alter the fact that knowledge production is becoming more widely distributed. 
Hence, institutions unprepared to become permeable may well end up being scientifically 
and technically isolated from some intellectual developments (Gibbons et al, 1994, p. 14). 
Second, since Mode 2 knowledge is context specific, much [one might say all] of the 
transferable knowledge resulting from this mode of knowledge production is tacit 
knowledge embodied in the people participating in the process. This is expected to have a 
fundamental influence on how institutions design and organize their knowledge producing 
activities in the future (ibid, p. 18). One implication that Gibbons et al foresee is that there 
will be closer integration of the process of discovery with that of fabrication (ibid, p. 19). 
Another is that the organization of research will be more open and flexible (ibid, p. 20). 
Third, in Mode 2 knowledge production, preference is given to collaborative rather than 
individual performance, and excellence is judged by the ability of individuals to make a 
sustained contribution in open, flexible types of organization in which they may only work 
temporarily (ibid, p. 30). Since resources are often held in different organizations, 
organizational boundaries become blurred. As a consequence, these resources may be at 
one moment collaborative and at another competitive (ibid, p. 48). 
Fourth, the expansion in the number, nature and range of communicative interactions 
between different sites of knowledge production will lead not only to more knowledge 
being produced but also to more knowledge of different kinds (ibid, p. 35). Gibbons et al 
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note that numerous novel pathways towards solutions can be traced to encounters between 
scientists brought together from different sites, and they suggest that the more mobility a 
science system permits or even encourages, the more potential instances of this kind can be 
expected (Gibbons et al, 1994, p. 36). 
Fifth, they suggest that the transient research clusters of Mode 2 will increasingly produce 
the specialist knowledge that will come to characterize the knowledge industries of the 
future (ibid, p. 69). 
It is perhaps no coincidence that the emergence of Mode 2 (or perhaps more accurately its 
increase) occurred as Western governments (a) reduced their overall funding to universities 
and (b) placed a greater emphasis on the funding of research for economic purposes. 
Rather than continuing to carry out fundamental research, universities were encouraged, if 
not forced, to enter into a range of collaborative ventures with industry and pursue research 
within the context of application. Arguably, there are clear advantages: knowledge is more 
widely distributed, university researchers can widen their horizons, and it is always 
satisfying to see the results of one's efforts being used. But at the same time, one might 
question the loss of interest in the basics of science inherent in Mode 1 working. 
Gibbons et al argue that parallel to the diffusion of Mode 2 knowledge production, 
network firms, R&D alliances, high value-added firms and new interface relations between 
competition and collaboration will emerge. They suggest that firms will take on some of 
the characteristics of a spider's web, whereby each node in the web is a problem-solving 
team possessing a unique combination of skills, which is linked to other nodes by a 
potentially large number of lines of communication (ibid, p. 122), and whereby the nature 
Chapter 3: Knowledge Creation 106 Section 3.4.1 
and viability of nodes is intertwined with changing circumstances. In consequence, flows 
of knowledge, products, people and ideas become more important than structures (Gibbons 
et al, 1994, p. 138). The source of value-added will then lie in the precise form which the 
collaboration of groups and the experience and skills of its members take (ibid, p. 1 12). 
That is, the locus of value-added shifts from the creation of knowledge to its configuration 
(ibid, p. 122). 
Finally, Gibbons et al point out that the interdependence of research and industrial 
innovation implies a degree of vulnerability for those engaged in research and with this in 
mind, they pose three questions: 
`How much stability, predictability and routine is needed to support the more 
exotic, intermittent and transitory unstable patterns of transdisciplinary work? 
How much fungibility1° is possible? How much insecurity can individual 
researchers bear without their creativity suffering? ' (Gibbons et al, 1994, p. 150) 
They suggest that adaptability is the condition for continued success, and that an 
environment is needed which cultivates institutional openness and flexibility and which 
allows room for experimentation and initiative in local arrangements (ibid, p. 150). 
'° Fungibility was not defined, but was said to increase when scientists or engineers are moved to 
new jobs, demanding other skills and a different knowledge profile (Gibbons et al, 1994, p. 150). 
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3.4.2 Organizational Knowledge Creation according to Ikujiro Nonaka and 
Hirotaka Takeuchi 
Nonaka and Takeuchi describe organizational knowledge creation as a spiral process 
(Nonaka and Takeuchi, 1995, p. 57). They assume that knowledge is created within the 
mind of the individual, but is then converted into higher level knowledge (group, 
organizational, inter-organizational) through four knowledge conversion processes: 
socialization, externalization, combination, and internalization (ibid, p. 62). They link these 
knowledge conversion processes with four modes of interaction involving tacit knowledge 
and/or explicit knowledge (ibid, p. 61). " Their overall process is shown diagrammatically 
in Figure 3.3.1 (next page). 
Socialization is the conversion of tacit knowledge to new tacit knowledge. It comes about 
through the sharing of experiences, and is the way in which mental models and skills are 
shared as, for example, when the apprentice learns craftsmanship through observation, 
imitation, and practice (ibid, p. 62). The knowledge created is termed `sympathized' 
knowledge (ibid, p. 71). Externalization is the conversion of tacit knowledge to explicit 
knowledge, which is achieved by the use of metaphors, analogies, concepts, hypotheses, or 
models (ibid, p. 64). The knowledge created is termed `conceptual' knowledge (ibid, p. 71). 
Combination is the conversion of explicit knowledge to yield new explicit knowledge by 
the combination and reconfiguration of different bodies of explicit knowledge, as held in, 
for example, documents, meetings, telephone conversations, or computerized 
communication networks. Prototypes or combined component technologies are given as 
examples (ibid, p. 67). The knowledge created is termed `systemic' knowledge (ibid, p. 71). 
Tacit knowledge and explicit knowledge are here assumed to be as described in Section 3.3, 
page 95. 
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Tacit knowledge 
Tacit 
Knowledge 
From 
Explicit 
Knowledge 
To 
Explicit knowledge 
SOCIALIZATION EXTERNALIZATION 
Sympathized knowledge Conceptual knowledge 
INTERNALIZATIO COMBINATION 
Operational knowledge Systemic knowledge 
EPISTEMOLOGICAL DIMENSION 
Organization 9 
Group "... 
Individual 
FIGURE 3.3.1: THE ORGANIZATIONAL KNOWLEDGE CREATION SPIRAL 
Adapted from Nonaka and Takeuchi, 1995: Figure 3.2, p. 62; Figure 3.3, p. 71; and Figure 3.5, p. 73 
Internalization is the conversion of explicit knowledge to tacit knowledge. It is the process 
of embodying explicit knowledge into the tacit knowledge of the individual, the group, or 
the organization (Nonaka and Takeuchi, 1995, p. 69). The knowledge embodied typically 
includes knowledge about project management, production processes, new product usage, 
and policy implementation. The knowledge created is termed `operational' knowledge 
(ibid, p. 71). 
Based upon their knowledge conversion process, Nonaka and Takeuchi suggest that new 
product development is a five-phase process that involves the sharing of tacit knowledge 
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(socialization), the creation of and justification of concepts (externalization), the building 
of an archetype (combination), and the cross-levelling of knowledge (internalization) 
(Nonaka and Takeuchi, 1995, p. 83). And they identify five enabling conditions: 
organizational intention - the organization's aspiration to its goals (ibid, p. 74); individual 
autonomy - the acceptance that all members of an organization should be allowed to act 
autonomously as far as circumstances permit (ibid, p. 75); fluctuation and creative chaos - 
internally and intentionally generated fluctuation and chaos designed to improve reflection, 
and focus attention on problem definition and resolution of an appropriately generated 
crisis (ibid, p. 79); redundancy of information - the existence of information that goes 
beyond the immediate operational requirements of organizational members (ibid, p. 80); 
and requisite variety - the organization's internal diversity is a match with the variety and 
complexity of the environment in which it operates (ibid, p. 82). 
Nonaka and Takeuchi argue that Japanese companies are successful at innovation because 
they are particularly good at systematic organizational knowledge creation (ibid, p. 17). 
And this, they imply, is largely because, unlike their Western counterparts, they have 
effective group-based processes (ibid, p. 198). 
Nonaka and Takeuchi's work has been the basis for a number of subsequent studies in the 
Knowledge Management literature (Armbrecht et al, 2001, p. 46; Becerra-Fernandez and 
Sabherwal, 2001, p. 25). However, their work has been criticized on several counts. 
First, McAdam and McCreedy suggest that knowledge transfer in organizations is more 
complicated and convoluted than Nonaka and Takeuchi's simple cycle of socialization, 
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externalization, combination and internalization implies (McAdam and McCreedy, 1999, 
p. 91). 
Second, Ray and Carter et al point out, that Nonaka and Takeuchi do not remain entirely 
true to Polanyi's original definition of tacit knowledge. Nonaka and Takeuchi refer to 
`tacit' knowledge as being something that is not easily visible and expressible, and which 
is thus difficult to communicate to or share with others. They separate `tacit' knowledge 
into two dimensions: the first is the `hard-to-pin-down' skills or crafts captured in the term 
`know-how'; the second consists of `ingrained schemata, mental models, beliefs and 
perceptions that reflect our image of reality (what is) and our vision for the future (what 
ought to be) that shape the way we see the world around us' (Nonaka and Takeuchi, 1995, 
p. 8). It is conceivable that with such a definition, some tacit knowledge might well be 
expressible as explicit knowledge. However, importantly, the proposal that `tacit 
knowledge is something that cannot be articulated very easily' conflicts with Polanyi's 
view that tacit knowledge cannot be expressed at all (Ray and Carter et al, 2002, p. 20). 
Third, Ray and Little point out that Nonaka and Takeuchi's spiral process `posits an 
ontological continuum from the individual to the wider community, the implication being 
that different types of knowledge can be converted into a common currency and moved 
from one context to another'. However, this begs the question: `But what about the 
"interpretation code" (Itami, 1992) that renders information comprehensible and 
meaningful in a particular context? ' (Ray and Little, 2001, p. 162, italics in original). 
Fourth, Ray and Little also suggest that Nonaka and Takeuchi's spiral metaphor 'does not 
engage with Japan's wider institutional context': 
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`But Nonaka and Takeuchi's spiral metaphor ... 
[appears] to assume away 
(1) the role that Japan's institutional framework plays in situating knowledge- 
generating practice inside Japan's workplace ba'2, and (2) the possibility that 
(through a complex dialectical process) groups influence the personal knowledge 
created by their members. ' (Ray and Little, 2001, p. 162) 
But what do Nonaka and Takeuchi really mean when they refer to inter-organizational 
processes? Are they perhaps referring to the links between members of a particular 
keiretsu'3 grouping? Are they perhaps arguing the case for greater collaboration, rather 
than saying that this collaboration exists? Certainly by talking about a spiral process 
Nonaka and Takeuchi give the impression that group influence on individual knowledge is 
not important. However, they do also suggest that the various ontological levels `are not 
independent of each other, but interact with each other iteratively and continuously' 
(Nonaka and Takeuchi, 1995, p. 89). Might this not imply that groups do influence the 
personal knowledge created by their members? 
Although the ontological status of groups remains controversial, Cook and Brown (1999) 
have argued that it is a mistake to reduce the knowledge possessed by a group to the sum 
of the knowledge possessed by each individual member. The whole is not only greater 
than the sum of its parts, but also qualitatively different from any given part. Nevertheless, 
as is outlined in the next section, Cook and Brown argue that group-knowledge and 
individual-knowledge mutually enable the active process of knowing how to do things in 
12 Ba: Ray and Little explain: `Although the Chinese character representing `ba' roughly means 
`place', the concept of ba is concerned with the interaction space (which may be real, virtual or a 
mixture of the two) within which purposeful activity is situated' (Ray and Little, 2001, p. 157). 
Ray and Carter et al comment further: `Itami [1992] has conceptualised ba in terms of a bounded 
context, where those with a willingness to co-operate and a common agenda, interact on a regular 
basis. In the process, they evolve a shared `interpretation code' that gives meaning to information 
signals (which might include gestures, tone of voice or indeed the absence of any signals)'. 
(Ray and Carter et al, 2002, p. 16) 
13 Keiretsu: `A bank-based group of companies bound together through cross-shareholdings, 
interlocking directorates, intra-group trade, and periodic meetings of member company presidents. 
(Ray and Carter et al, 2002, p. 10) 
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practice. By combining representations of `knowledge as a thing' with `knowing as a 
process', Cook and Brown thus claim to bridge the divide between abstract knowledge and 
practical knowing. 
3.4.3 Knowledge Generation according to Scott D. N. Cook and 
John Seely Brown 
Cook and Brown propose three shifts that they believe answer some of the criticisms made 
about Nonaka and Takeuchi's work, namely: 
1. It is not possible, under any circumstances, for tacit knowledge to become explicit 
knowledge (or vice versa), but it is possible for one to be a useful tool for generation of 
the other through a process of productive enquiry. 
2. Since explicit knowledge and tacit knowledge are generated and disseminated each in 
their own right, whether either can `be easily leveraged by the organization as a whole' 
depends on the specific needs and resources that an organization has at hand in a given 
situation. 
3. The production of new knowledge does not lie in a continuous interaction between 
tacit knowledge and explicit knowledge but rather lies in the use of knowledge as a 
tool of a productive enquiry as part of a dynamic interaction with the things of the 
social and physical world (Cook and Brown, 1999, p. 397). 
Thus, the four categories of knowledge assumed in Nonaka and Takeuchi's model are now 
seen as distinct and co-equal forms. They constitute `what is known'. They are the 
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knowledge that people or groups possess, and thus provide the appropriate focus for an 
`epistemology of possession' (Cook and Brown, 1999, p. 382). 
Specifically, Cook and Brown argue that knowledge (as possession) is static. One form of 
knowledge cannot be made out of or converted into the other, but each form of knowledge 
may be used as an aid in acquiring the other: 
`If you know how to ride [a bicycle], for example, you might use your tacit 
knowledge to ride around in a way that helps you discover which way you turn 
when you begin to fall. Likewise, if a novice is told how to turn to avoid a fall, 
that explicit knowledge could be used while learning to ride as an aid in getting a 
feel for staying upright. ' (Cook and Brown, 1999, p. 385) 
Similarly: 
`While individual copier technicians have a sense of how a particular copier 
ought to sound when operating properly (groups do not have ears), it is a group 
of technicians that possess "war stories" about what odd noises can mean ... part 
of what is known about a given domain is possessed by individuals, part by 
groups ... The "body of knowledge" of a group is "held in common" by the 
group. We do not expect every individual in a group (discipline, profession, 
craft, etc. ) to possess everything that is in the `body of knowledge' of that 
group. ' (Cook and Brown, 1999, p. 3 86) 
Furthermore, Cook and Brown contend that there is more in what we know `how to do' 
than can be accounted for solely in terms of the knowledge we possess (ibid, p. 382). For 
example, they claim that the act of riding a bicycle does distinct epistemic work of its own. 
And, they hold that this type of epistemic work is an inextricable facet of human action 
itself. They mark this distinction by referring to it as `knowing' rather than knowledge, 
and they introduce an `epistemology of practice' which takes `ways of knowing' as its 
focus (ibid, p. 383). 
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Cook and Brown then make the point that no one form of knowledge can be used by itself 
to acquire the other, but one must also, at the very least, undertake some activity to enable 
this to be so (Cook and Brown, 1999, p. 385). For example: 
`Neither tacit nor explicit knowledge can be used by itself to acquire the other: 
one must also, at the very least, get on a bicycle. ' (Cook and Brown, 1999, 
p. 385) 
In consequence, an understanding of individual and group action requires consideration of 
both `knowledge used in action' and `knowing as part of action'. In particular, it is the 
interplay between knowledge and knowing or the `generative dance' between knowledge 
and knowing that has the potential to create new knowledge and new knowing (ibid, 
p. 381). By bridging the epistemologies of possession and practice, Cook and Brown 
suggest that it is possible to draw upon the four forms of knowledge within the same 
activity. Cook and Brown's Figure 4, presented here in modified form in Figure 3.3.2 
(next page), shows the four forms of `knowledge' with a circle superimposed to represent 
`knowing'. The arrows suggest the `active use of knowledge in our interaction with the 
social and physical world' (ibid, p. 393). 
Cook and Brown's view that one form of knowledge can be used as an aid in acquiring 
another form of knowledge but cannot be converted into another form would appear to be 
profoundly different to that of Nonaka and Takeuchi's proposal that one form of 
knowledge is converted into another form. But is the difference as wide as it might seem? 
Nonaka and Takeuchi talk about knowledge conversion, but what do they really mean by 
the word `conversion'? When applying their model to new product development, might 
not Nonaka and Takeuchi be implying the use of one form of knowledge to acquire another 
form of knowledge, rather than the exact conversion of one form of knowledge into 
another? 
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Individual knowledge 
Explicit 
knowledge 
Tacit 
knowledge 
Group knowledge 
Things an individual can know, 
learn and express explicitly, e. g.: 
concepts, rules, equations 
Things that are expressed explicitly, 
yet are typically used, expressed or 
transferred in a group, e. g.: `war 
stories', use of metaphors or phrases 
that have useful meaning within a 
specified group 
Knowing 
in Action 
Tacit knowledge possessed by 
individuals, e. g.: a skill in making 
use of concepts, rules, equations; 
a `feel' for the proper use of a tool 
or for keeping upright on a 
bicycle 
Tacit knowledge possessed by 
groups, which covers the distinctive 
and useful meanings a given group 
attaches to its various literary, 
physical and social artefacts, and its 
different types of activities (termed 
organizational genre). Meanings 
emerge and undergo constant 
confirmation and/or modification 
through a kind of `negotiation in 
practice' as they are used in the 
context of the group's ongoing work 
FIGURE 3.3.2: A PLURALIST FRAMEWORK OF KNOWLEDGE AND KNOWING 
Source Cook and Brown, 1999, Figure 4: Adding Knowing to Knowledge, p. 391 
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3.4.4 Knowledge Creation according to Michael Polanyi 
In Section 3.3, we saw how Polanyi defined tacit knowing. We also saw that when we 
make a thing function as the proximal component of tacit knowing we 'incorporate it into 
our body' and `dwell in' it, and by indwelling in the proximal component whilst focusing 
on the distal component we arrive at an understanding of their joint meaning. This section 
expands upon Section 3.3 and describes how Polanyi takes his argument further and 
explains how we each create our own personal knowledge. 
Polanyi suggests that the way in which we come to understand (and learn from) each other 
is through the use of two kinds of indwelling. He gives, as an example, the way in which 
one person comes to understand the skilful performance of another. Whilst the performer 
co-ordinates his moves by dwelling in them as part of his body, the watcher tries to 
correlate these moves from outside. By exploratory indwelling, the watcher eventually 
comes to interiorize these moves within his/her body. The performer skilfully uses his/her 
body; the watcher `cleverly' uses his/her mind. Polanyi then suggests that similar 
situations hold when one person tries to understand the mind of another, as chess players 
seek to do by rehearsing the games of the chess master (Polanyi, 1966, p. 30) and, it might 
be added, as scientists seek to do by repeating the work of others. As Polanyi notes, `the 
question of how we can infer the existence of other minds from observing their external 
workings does not arise, for we never do observe these workings in themselves. ' Instead, 
it is a case of `picking out clues with a personal bearing on the presence of something they 
appear to indicate' (ibid, p. 31). By extension, by exploratory indwelling in the particulars 
of the information available to us, we are able to arrive at the meaning of these particulars 
in the context within which we are operating. 
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Polanyi argues that throughout the course of our lives we keep expanding our body into the 
world, by assimilating to it sets of particulars which we integrate into reasonable entities. 
By exercising our tacit powers of knowing, we `form intellectually and practically, an 
interpreted universe populated by entities, the particulars of which we have interiorized for 
the sake of comprehending their meaning' (Polanyi, 1966, p. 29). 
Polanyi believes that the two components of tacit knowing - the proximal which involves 
the particulars and the distal upon which we focus - can be viewed as two levels of reality, 
controlled by distinctly different principles. But, he notes that `between two such levels a 
logical relation exists, which corresponds to the fact that the two levels are the two terms 
[components] of an act of tacit knowing which jointly comprehends them' (ibid, p. 34). 
Polanyi pictures the universe as consisting of strata of realities, joined together 
meaningfully in pairs of higher and lower strata' (ibid, p. 35). 
Because the laws governing the different levels of reality are distinct, one from the other, 
Polanyi suggests that a higher level can come into existence only through a process not 
manifest in the lower level, a process which thus qualifies as emergence (ibid, p. 45). And 
it is through the particular process of emergence that results from the combination of tacit 
comprehension with a set of fixed logical operations that a child first learns to comprehend 
the world and, in later life, the adult learns to deepen his/her understanding. Hence, 
through emergence, new knowledge is formed or created: 
`A child starts off with a scanty repertoire of innate mental connections and 
enriches them rapidly by using his powers of comprehension for establishing 
further fixed relations of experience ... 
Stimulated by the interiorization of 
language, this development eventually produces the adult mind. (Polanyi, 1966, 
p. 45) 
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Polanyi's view of knowledge suggests that tacit thought forms an indispensable part of all 
knowledge. That is, even the knowledge that is often referred to as `explicit' has a tacit 
dimension, since it is formed through our own actions of tacit knowing (Polanyi, 1969, 
p. 195; Polanyi and Prosch, 1975, p. 91). By indwelling in the particulars, we arrive at a 
comprehension of the thing we are trying to understand - an act of tacit knowing. We may 
think that we can make, to some extent, the knowledge so formed explicit, but in so doing 
we will of necessity be imparting our own original tacit assumptions. In addition, the 
transfer of any knowledge to another person, whether or not we can make that knowledge 
explicit, will depend upon the other person's `intelligent co-operation for catching the 
meaning of what we are saying or demonstrating' - another act of tacit knowing. And, 
since it might be expected that we are all of us unique in the strata of realities that we hold, 
it may well be that the understanding so obtained may differ from ours. Thus, again, the 
knowledge that we each hold is inherently personal to ourselves. 
The above points have important implications for the organizational knowledge creation 
models of Nonaka and Takeuchi and Cook and Brown reported above. First, if all 
knowledge includes a tacit dimension, can we really accept the tacit-explicit split 
suggested in these models. Second, if all knowledge is indeed personal can we really 
adopt the concept of group knowledge also advocated within these models? Whilst we 
might be able to accept that there is some knowledge that is personal to the group, can we 
really be sure that such knowledge is held in the same way by all members of the group? 
Or does this really matter? Third, the need for indwelling suggests that organizational 
knowledge creation is neither the simple knowledge conversion process proposed by 
Nonaka and Takeuchi nor the 'generative dance' between knowledge and knowing 
proposed by Cook and Brown. 
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Polanyi's thoughts are additionally important in that they provide greater insight into the 
personal act of discovery. Polanyi points out that `it is commonplace that all research must 
start with a problem'. And so he asks the question, `But how can one see a problem? ' He 
points out that to see a problem is to see something that is hidden; to have an intimation of 
the coherence of hitherto not comprehended particulars (Polanyi, 1966, p. 21). He adds that 
we take this for granted without noticing the clash of self-contradiction entailed. He notes 
that Plato has pointed out this contradiction in the Meno. 
`He [Plato] says that to search for the solution of a problem is an absurdity; for 
either you know what you are looking for, and then there is no problem; or you 
do not know what you are looking for, and then you cannot expect to find 
anything. ' (Polanyi, 1966, p. 22) 
Whilst Plato offers the solution that all discovery is a remembering of past lives (past 
experiences? ), Polanyi concludes that the resolution of the paradox of the Meno lies in the 
tacit knowledge that we each possess (ibid, p. 22); tacit knowledge that yields an intimation 
of something hidden which we may yet discover (ibid, p. 23). In the pursuit of discovery, 
`all the time we are guided by sensing the presence of a hidden reality toward which our 
clues are pointing; and the discovery which terminates and satisfies this pursuit is still 
sustained by the same vision. It claims to have made contact with reality: a reality which, 
being real, may yet reveal itself to future eyes in an indefinite range of unexpected 
manifestations. ' (ibid, p. 24). In essence, the pursuit of discovery is based upon an insight 
into what might be; an insight which is `simply our own meaningful integration of the parts 
of the complex entity' we are trying to understand (Polanyi and Prosch, 1975, p. 54). 
Thus, as Polanyi points out, tacit knowing can account for a valid knowledge of a problem; 
for the scientist's capacity to pursue it, guided by his/her sense of approaching its solution: 
and for a valid anticipation of the yet indeterminate implications of the discovery arrived at 
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(Polanyi, 1966, p. 24). Hence, discovery involves a deep commitment that something is 
there to be discovered that will offer a deeper understanding of reality; that it is personal, 
in the sense that it involves the personality of the scientist so committed; and that it 
involves a personal judgement in relating evidence to an external reality. Polanyi 
concludes, `The anticipation of discovery, like discovery itself, may turn out to be a 
delusion. But it is futile to seek for strictly impersonal criteria for its validity' (ibid, p. 25). 
Thus, we might conclude, even scientific discovery cannot be guaranteed to be an 
`absolute truth' since it is based in all instances on a reality that is inherently personal. 
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3.5 Conclusion to the Chapter 
After undertaking a brief discursion into the philosophical debate concerning the growth of 
scientific knowledge in general, this chapter looked at the more recent models of 
organizational knowledge creation in an attempt to understand how they might apply in the 
practice of corporate R&D. We have seen that, although Nonaka and Takeuchi's work 
suggests a model of knowledge creation that is far too ordered to reflect the actual practice 
of R&D, it does nevertheless hint at the importance of processes such as knowledge 
sharing (socialization), concept generation (externalization), knowledge combination 
(combination), and knowledge acquisition (internalization) to that practice. In addition, 
whilst Cook and Brown's model reflects the intuitive feeling that we use the knowledge, of 
whatever type, that is available to us at the time to create new knowledge, it gives us little 
idea of which forms of knowledge and knowing are involved within any particular context, 
at any particular time, or for any particular purpose. However, more importantly, we have 
seen how Polanyi's thoughts on the nature of knowledge have implications for not only 
how knowledge is created by the individual, but how knowledge might be created in 
organizations. 
A general acceptance of the existence of tacit knowledge and explicit knowledge of the 
individual and group varieties has enabled Nonaka and Takeuchi and Cook and Brown to 
base their models on the idea that it is meaningful and useful to talk about tacit knowledge 
and explicit knowledge as if they were identifiable entities. Indeed, Cook and Brown 
claim that knowledge (whether tacit or explicit) is 'about but not in the tangible world' 
(Cook and Brown, 1999, p. 387, italics in the original). Yet, if Cook and Brown's four 
types of knowledge tools (tacit knowledge and explicit knowledge, each possessed by 
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individuals and groups) are not in the tangible world, we might reasonably ask where these 
four types of knowledge reside? Is it necessary to imagine an intangible world to anchor 
the abstract side of Cook and Brown's epistemological bridge? Polanyi's response to the 
problem of conceptualizing abstract knowledge was to insist that knowledge is in the heads 
of persons: it is personal - all of knowledge is tacit or rooted in the tacit dimension and 
there is no such thing as a strictly independent explicit knowledge. 
We have also seen that by investigating the context within which knowledge is created 
Gibbons and his co-workers have identified a new form of knowledge production - 
knowledge production in the context of application - which bears some similarities with 
the later R&D Generations models outlined in Chapter 2. This work, in particular, points 
to the increasing importance in the West of the social implications associated with the 
advancement and application of science and technology, and hence towards the need for 
knowledge production that is conditioned by and evolves with those needs. This would 
seem to cast doubt on the relevance of corporate research (as opposed to corporate 
development), since knowledge creation in the context of application would appear to 
leave little time for scientific discovery, relying instead on the adaptation or exploitation of 
existing scientific and technical knowledge. One might question whether this will 
eventually be good for society, since from whence will come the new scientific 
breakthroughs that can change the way we advance and explore the world? Will they be 
expected to be the sole province of the universities, many of whom are themselves, 
because of budgetary pressures, being pushed to work within a context of application? 
Chapter 2 has shown us that knowledge creation within Western environments has become 
increasingly dependent upon knowledge held external to the firm. As a consequence, the 
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quest for efficient and effective processes for knowledge acquisition and know ledge 
sharing, and for the subsequent application of that acquired and shared knowledge have 
become important objectives within Western R&D. However, since knowledge acquisition 
and knowledge sharing are not the simple processes that they are often assumed to be, we 
might question such an approach. This and related issues raised in this present chapter ý, ti ill 
be discussed further in Chapter 6. In the meantime, Chapter 4 outlines the methodology 
used in the empirical research conducted for this thesis, and Chapter 5 presents the findings 
of that research. 
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4 METHODOLOGY 
4.1 Introduction 
The primary aim of this thesis was to determine how knowledge is created in successful 
corporate R&D (Chapter 1, Section 1.1, page 4); the underlying assumption being that 
there is a link between the way in which knowledge is created and success in R&D). The 
reason for adopting this particular approach was the view that knowledge creation is the 
primary knowledge process driving corporate as well as academic R&D. 
A further assumption made, and the reason for the focus on the UK pharmaceutical 
industry was that, relative to other industries, this industry would provide adequate 
examples of successful corporate R&D. The validity of this assumption was based on the 
significant consensus that existed at the time within the global scientific community, of 
which the present author was a part, that such was the case. This assumption was thus 
based more upon `expert' opinion than upon comparative performance data. Nevertheless, 
the observation that a number of the larger North American corporations continued to carry 
out pharmaceutical R&D within the United Kingdom, despite the many changes that had 
taken place throughout the industry, was taken as a strong indicator that UK-based 
pharmaceutical R&D activities were effective. In addition, reports in the popular scientific 
press suggested that this assumption was somewhat justified. For example, in writing 
about the investment potential within the UK biotechnology sector, Coghlan noted that 
'The land where penicillin was discovered has long been home to one of the world's most 
flourishing pharmaceutical industries' (Coghlan, 2003. p. 55). 
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The final major assumption of this thesis relates to the way in which companies were 
sampled for participation in the empirical study. As will be explained in Section 4.3 
below, companies were selected on the basis that corporate success is to some extent 
dependent upon success in R&D. Whilst accepting that corporate success may depend 
upon many factors (effective marketing, good sales skills, efficient operational practices, 
suitable strategy, etc. ), the importance of R&D to corporate success was judged 
particularly high in an industry which is increasingly dependent upon the burgeoning 
science and technology associated with the human genome. 
The key consideration for choosing the study of one industry relates to the very real 
practical problem of controlling extraneous variance which might induce error into the 
findings of any research. There are basically two ways to control such variance. The first 
is by the use of multivariate analysis (Sapsford, 1999, p. 209), and the second is by 
homogenous sampling. This study chose homogeneous sampling for three reasons. First, 
it is much simpler conceptually. Second, it is, according to Astley, much less prone to 
error: as extraneous forces are not allowed to vary, they are not subject to any 
measurement error, and therefore cannot confound relationships between key sources of 
variation (Astley, 1978). And, third, homogeneous sampling controls variation which has 
not been identified, which was a particular concern in this present investigation. 
Given the current state of theorizing and research into the impact of knowledge-based 
approaches on firm performance (Coates, 2001, p. 9; Sohn, 2004, p. 6), with the attendant 
difficulty of developing a set of hypotheses which would be tightly enough specified for 
the application of quantitative techniques, Section 4.2 makes the case for employing more 
exploratory techniques to uncover current practices and to try and tease out their 
Chapter 4: Methodology 126 Section 4.1 
effectiveness rather than relate them to some hard performance measures. Section 4.3 then 
describes the method of sampling, and Sections 4.4 and 4.5 outline and discuss, 
respectively, the specific procedures employed in the collection of the data upon which this 
thesis is based, and the subsequent analysis of the data so obtained. Section 4.6 
summarizes and concludes the chapter. 
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4.2 The Choice of Methodology 
The choice of a particular methodology, as opposed to the choice of a method of collecting 
data, is to a large extent driven by the state of the knowledge domain which defines the 
field of enquiry at a particular point in time. This, in turn, has an impact on the kind of 
knowledge it is possible to produce at a given point in the development of the field which, 
in turn, impacts on both the methods and methodology which the researcher can employ. 
Basically, the state of knowledge may mean that is not always possible for a researcher to 
formulate a problem simply, clearly or completely. He/she may often have `only a rather 
general, diffuse, even confused notion of the problem' (Kerlinger, 1969, p. 18). It may thus 
take a great deal of exploratory work before a researcher can precisely formulate the 
questions to which he/she has been seeking answers. The diffuse stage of the knowledge 
in the emergent field of research that might loosely be termed `knowledge management' 
(Beeby and Booth, 2000, p. 75; Gupta et al, 2000, p. 18; Davenport and Grover, 2001, p. 3), 
means that this area of enquiry is in more a `theory generation' than a `theory testing' 
mode. This leads to the proposition that relationships between sources of variation are 
imperfectly understood and are therefore not capable of precise measurement. A 
quantitative data collection method is then inappropriate. 
In rejecting a quantitative approach to data collection the researcher faces a set of choices 
for collecting qualitative data. These are to some extent bound in with the choice of source 
of data. Does the researcher, for example, become actively involved as a participant 
observer or action researcher of ongoing processes with one or more organizations? 
Alternatively, is it, for example, appropriate to use publicly available data in the form of 
narrative cases from either academic or other sources? As R&D work typically involves a 
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range of informal as well as formal approaches and practices, some form of `observational' 
method was required. At the same time, it was the intention that, as far as was possible, 
the causes of and the meanings for what was being observed were established. A method 
involving a degree of adaptability in its application was then also needed. 
For someone with an extensive knowledge base in chemistry it would have been possible 
to have engaged in direct observation and to have had a good understanding of what was 
being undertaken and why it was being undertaken, without running the risk of totally 
alienating the people being observed. However, gaining access to R&D personnel in their 
working environment is difficult. There are health and safety issues in allowing laboratory 
access to external personnel. Obtaining access to people actually doing the job would 
normally require that the participating company gain at least the perception of a 
recognizable benefit from the encounter. This might have proved difficult to justify. 
Observing R&D personnel might also have raised issues of being an insider, one who has a 
direct knowledge of process and practice. How might any previous experiences have 
influenced the way things were viewed? How much more (than with someone else) might 
subjects have been influenced? Also, would companies allow access to another scientist, 
albeit one now studying management processes? Confidentiality might well have been 
seen to be a problem and the situation was perhaps best avoided. 
Since direct observation could have been problematic, some form of indirect observation 
was required. Requests for stories about product innovations might have provided some 
useful insights, but there would be no guarantee that the range of approaches and practices 
employed within corporate R&D would be covered using such an approach. At the same 
time, narratives are open to judicial editing. For example, stories submitted might have 
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been based upon the company's more successful rather than upon their more typical 
activities. They would also be recounted with the benefit of hindsight, which could cloud 
historic and contemporary issues (Sapsford, 1999, p. 83). A technique that enabled the 
observation of current approaches and practices with some degree of control over the scope 
of the data collected was desirable. For this reason a direct interview technique was the 
primary method of choice. 
The decision remaining is whether this technique should be structured or unstructured, the 
choice being rooted in the current state of knowledge in a field and the nature of the 
research questions. These being related to each other suggests that an unstructured 
technique would be effective when the field is seriously under-theorized and emergent and 
the researcher is tasked to use a more grounded approach to theory development (Glaser 
and Strauss, 1967), whilst a structured technique would be more effective when some 
theory already exists and/or the nature of the research question is clear. Unstructured 
interviews might have generated extremely interesting insights and would have perhaps 
had the potential to add something entirely new to the study of knowledge creation within 
corporate R&D. However, the practical constraint of time would have severely restricted 
the scope of any such interview. In addition, something that is appropriate in one setting 
will not necessarily be appropriate elsewhere. Applicability to other settings might have 
been difficult to validate. What was needed was a focus on the approaches and practices 
employed in R&D, but an openness as to what might arise. Semi-structured interviews 
employing open questions accommodate this stance. They also allow additional questions 
to be introduced, arising out of what is said, and according to the interviewee's willingness 
to offer additional insights. This was the approach adopted, and the following sections of 
this chapter describe the way in which this approach was applied. 
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4.3 The Choice of Sample 
The case for choosing UK pharmaceutical companies was outlined earlier in Section 4.1 
(page 125). However this industry is not as homogeneous as the appellation might imply. 
Companies within the UK pharmaceutical industry can be classified as pharmaceutical 
(prescription, and over-the-counter), biopharmaceutical (drugs developed using 
biotechnology techniques such as gene technology), biotechnology (supplying biology- 
based techniques), drug discovery research organizations (DRO), clinical research 
organizations (CRO), and formulation companies (manufacturers of pills and tablets). This 
study is based on data drawn from companies belonging to the first three categories only, 
the major corporate players in drug/therapy R&D, the selection being made as follows. 
The `FAME' (Bureau van Dijk) company directory (http: //fame2. bvdep. com) was searched 
electronically in March 2001 for companies operating within the pharmaceutical sector in 
the United Kingdom. The result was a listing of 653 companies, 56 of which were 
identified as carrying out research and/or development activities. This excluded some 
companies known to the present author to be carrying out such operations, and this was 
despite the fact that these known companies were present in the full `FAME' listing. Over 
a period of two weeks, the complete list of 653 companies was therefore checked for 
accuracy regarding research and development operations using prior knowledge, 
telephone, or website enquiry. Those companies not involved in research or development 
operations or no longer solvent were removed from the list, and merged companies were 
consolidated. This left a total of 64 companies. This updated list was further simplified by 
excluding (a) those companies acting as contract research organizations (DROs and 
CROs), since these are service organizations involved in only part of the drug/therapy 
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R&D process; (b) those companies dealing specifically with animal or veterinary health, in 
order to remove any variance due to, for example, the different regulatory requirements 
that might exist between animal and human healthcare; and (c) those companies dealing 
with diagnostic aids, drug delivery systems, and general medical materials or devices, as 
these activities are peripheral to drug/therapy R&D. The result was a list of 23 companies 
-4 biopharmaceutical, 3 biotechnology, and 16 pharmaceutical - all involved in 
drug/therapy R&D. This list of 23 was augmented by a further 13 companies - 
2 biopharmaceutical and 11 biotechnology - found by searching the scientific and business 
literature. 
Since the main concern of this thesis was with effective knowledge creation in corporate 
R&D, a selection of those companies thought to have the most successful R&D was made 
from the 36 companies identified above. As there would appear to be no one proven or 
generally accepted measure of R&D success, for the purpose of this study, the decision 
was made to base R&D success on, what might loosely be called, the company's pro- 
activity within its industry sector. This was a composite measure based upon the 
company's ranking within its particular sector (pharmaceutical, biopharmaceutical, or 
biotechnology) as regards: (i) its quoted R&D intensity; (ii) the number of scientific papers 
published or presented in recent years, averaged for the number of R&D staff employed; 
and (iii) the degree of dynamism in the company's new jobs market. No scaling was 
applied. The reasons were as follows. 
Quantitative measures such as `number or proportion of products developed within the last 
five years' or `number or proportion of products accounting for 80% of sales' are 
frequently quoted in the general management literature as measures of corporate success. 
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But there is a question as to the extent to which such measures are valid for R&D. Since 
many products can be developed from one initial idea or discovery, these measures might 
well be simply measures of successful development, including successful marketing or 
sales initiatives, rather than successful research and development. 
A measure frequently used within the pharmaceutical industry is `number of products in 
the R&D pipeline'. However, number of products in the pipeline is no guarantee of 
number of products eventually emerging from that pipeline and brought to market: attrition 
in pharmaceutical R&D is high. Also, such a measure is appropriate only for established 
organizations. Newly formed companies, such as those predominating in the 
biotechnology sector, may initially concentrate only on the research and development of 
one product. Yet, this can hardly be taken to mean that they are less successful in their 
R&D. 
The UK government annually quotes figures for `R&D intensity', expressed as R&D 
spending as a percentage of sales, as an indicator of R&D success, since this measure has 
been positively correlated in the medium term (3-5 years) with company performance 
measures such as sales growth, productivity, and market value (www. innovation. gov. uk/ 
projects/rd scoreboard/introfr. html). R&D intensity was therefore one of the measures 
adopted in this present study as an indicator of R&D success, although it should be 
recognized that, in absolute terms, such a measure highly favours the newly initiated 
research-based organizations where spending in R&D may or may not be high but sales are 
minimal or non-existent. In the pharmaceutical industry, R&D intensity is also heavily 
influenced by the costs incurred during the clinical trials stages, which may not necessarily 
be a good indicator of successful R&D: success is dependent upon positive trial results, but 
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many costs may be incurred to show only negative results. Rankings of R&D intensity 
were determined from figures quoted for the year 2000 (Stevenson, 2001, p. 33). 
Within the chemical industry, the number of patents published over a set time period has 
been used as a measure of corporate R&D success, but, as evidenced by the present 
author's experience, this measure suffers from the problem that some companies 
deliberately do not patent their most innovative ideas. The number of papers published or 
presented at conferences is also used as an indication of R&D success as determined by 
peer group judgement, but these papers can vary significantly as regards their content and 
ultimate value to science or technology. Like patents, they may also be suppressed for 
corporate reasons. However, companies within the UK pharmaceutical industry do 
generally record such publications in their annual company reports. This measure, with 
due regard to the type of publication or conference quoted, was therefore assumed to be 
valid for the purposes of sampling. 
The final measure of R&D success - the degree of dynamism in the company's new jobs 
market - was suggested by the number of new R&D positions being created within the 
industry at the time of this study. New R&D positions, as opposed to replacement 
positions, were obtained from advertisements in the scientific and national press, and were 
assumed to be an indicator of a successful and expanding R&D organization, rather than 
one with simply a high staff turnover. Whilst not foolproof - companies do advertise 
replacement positions using new job titles - this measure was particularly useful in 
gauging the commercial potential and ultimate viability of the biotechnology organizations 
under consideration. 
Chapter 4: Methodology 134 Section 4.3 
Upon the above basis, nineteen companies were initially contacted as possible participants: 
2 biopharmaceutical 
5 biotechnology 
12 pharmaceutical. 
The pharmaceutical group included three companies which were classed as being less 
successful according to the above criterion. These were to serve as controls. 
Seven of the selected companies agreed to be formally interviewed. Informal 
conversations and conference presentations provided the answers for three additional 
companies. One participant from a further company agreed to be interviewed but had to 
withdraw because of work pressures. However in this last instance, and rather 
surprisingly, much of the information requested was later published on the company's 
website. These eleven companies provided the information upon which this thesis is 
based. They included six multinational pharmaceutical companies (the majority of the 
well-known companies operating in the UK and a little under half the possible population), 
one national and one international biopharmaceutical company (one third of those 
operating in the UK), and one large and mature and two small and young biotechnology 
companies (less than twenty percent of those operating in the UK). The pharmaceutical 
companies were AHP, AstraZeneca, Bioglan Pharma, Eli Lilly, GSK, and Pfizer. Included 
were the largest and second largest pharmaceutical companies in the world in terms of 
turnover. The biopharmaceutical companies were Antisoma and Celltech. The 
biotechnology companies were Amersham, Astex Technology, and Oxford BioMedica. 
It was believed that these companies were representative of their organizational category. 
Of the remaining eight companies contacted, two declined to participate, one was about to 
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close its UK operations, and five did not respond despite further written and telephoned 
requests. To preserve company confidentiality in the pages that follow, Company-A to 
Company-F designate the pharmaceutical companies, Company-G and Company-H refer 
to the biopharmaceutical companies, and Company-I to Company-K denote the 
biotechnology companies participating in this study. Only one of the `less successful' 
pharmaceutical companies agreed to participate (Company-C). 
During the course of this study, gaining access to biotechnology companies was 
particularly difficult. The business community in this segment was particularly fluid at the 
time and companies were continually being formed, acquired or dissolved. Small start-up 
companies had other priorities, and those involved in merger, acquisition, or dissolution 
were uncertain of their future and felt unable to participate. The larger biotechnology 
company involved in this study was a long established and successful multinational 
organization. The two smaller biotechnology companies interviewed whilst not financially 
sound in the sense that their turnover more than compensated for their expenditure were, 
nevertheless, well funded through venture capital, and appeared relatively stable in that 
they had been in existence in the United Kingdom for more than three years 
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4.4 Data Collection 
Politeness required the first contact with a company's R&D personnel to be the R&D 
Director (or equivalent). However, for this study, R&D managers were the interviewees of 
choice, as these people were likely to have not only the subject specific knowledge and 
experience of interest but also the responsibility for and active involvement with the R&D 
unit. Thus, whilst their responsibilities would enable them to adequately portray the 
overall approach to R&D, their involvement and likely background in practical R&D 
would enable them to also portray the practice of R&D from the perspective of the R&D 
worker. In fact all interviewees did have previous experience working as R&D researchers 
or developers prior to becoming managers (or in one case a director) responsible for R&D. 
A final reason for choosing R&D Managers was that they tend to be more accessible than 
either R&D workers or R&D directors. 
Potential companies were first contacted by telephone to ascertain their likely participation 
and, where possible, to gain a contact name. An interview request letter was then sent to 
prospective participants. This letter briefly outlined the reason for the request, the 
background to the study, the area of research interest, and the limits of confidentiality 
(see Appendix 4.1 for a specimen). Contacts who had agreed to participate were each sent 
a copy of the interview questions approximately one month prior to any interview. This 
was in order to check the viability of the questions in relation to their organization's 
activities, their own organizational roles, and any needs for secrecy or confidentiality. It 
also allowed participants time to undertake any necessary preparatory work prior to the 
actual interview. 
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Face-to-face interviews were carried out wherever possible, as it was felt that these would 
allow for the best possible understanding between interviewer and interviewee: non-verbal 
as well as verbal communication would be possible, feedback would be instant, and 
conversations could be allowed to progress as time and other constraints dictated. In 
practice, non-verbal signals were found to be particularly useful for saying the `unsayable', 
although such signals are, of course, open to interpretation. `R&D' and 'knowledge' mean 
different things to different people. This meant that although the same questions were 
asked in, as far as possible, the same manner, it was necessary on some occasions to adapt 
questions accordingly. There was thus the possibility that answers may sometimes have 
been influenced by the words used, although the uniformity of the answers supplied would 
suggest otherwise. 
Interviews were carried out during the months of August 2001 to December 2001. As 
suggested by Miles and Huberman, time was allowed to assimilate the information 
obtained from one interview to enable emerging ideas to be explored in subsequent 
interviews (Miles and Huberman, 1984, p. 53). Three telephone interviews (one a follow- 
up interview) and seven face-to-face interviews (including three interviews with different 
managers from one company) were conducted. Telephone interviews lasted approximately 
45 minutes. Face-to-face interviews usually lasted between one and two hours. Since 
people's perceptions about particular approaches and practices can vary, the triplicate 
interviews were used to test for any differences between the views expressed by 
interviewees within the same company, and thus the validity of their responses. Although 
different aspects were sometimes emphasized, the responses from the particular company 
involved (Company-A) did turn out to be fairly uniform. It had been hoped that additional 
interviews within the other participant companies would also have been possible, but this 
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was not so. In one instance (Company-E) it was possible to compare the formal interview 
with some ad hoc conversations that occurred during and after a conference presentation. 
although in this case the people involved were from different divisions of the same 
company, one division dealing with prescription, and the other dealing with over-the- 
counter drugs. Personal experience did, however, suggest that the answers to the posed 
questions received from these and other participants did `ring true'. 
In line with the factors thought to be the most influential in determining how knowledge is 
created within R&D, the structured interview questions were separated into three sections: 
(A) R&D approach 
(B) R&D practice 
(C) Knowledge working in R&D. 
The actual interview questions are listed in Appendix 4.2. 
The questions in the first section (R&D approach) were answered wherever possible by 
recourse to published data prior to any interview. This enabled the maximum amount of 
interview time to be spent discussing the meanings behind any observations, rather than 
simply checking the facts or observations themselves. Company annual reports, company 
websites, economic and market websites, and conference proceedings were the major 
publications used. As an example, company mission statements quoted on company 
websites often indicated whether the overall R&D approach was predominantly a 
marketing orientated (second generation R&D) or closer to a business integration 
(third generation R&D) strategy. 
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There were three main questions in the second section (R&D practice): (i) how are projects 
initiated, (ii) how are projects managed, and (iii) how are projects terminated? Combined 
with questions in the third section, these questions were used to determine how knowledge 
is created within an R&D context. Answers were descriptive, with some reasons suggested 
for the approaches taken. 
Questions in the third section (Knowledge working in R&D) were intended to give an idea 
of the extent and purpose of the processes commonly referred to as `knowledge 
acquisition', `knowledge sharing', and `knowledge application'. In particular, the degree 
of formality involved and the possible influence on R&D approaches and practices was of 
interest. Answers were mainly informed guesses, and a degree of subjectivity was perhaps 
to be expected. 
Whilst there have been a number of reports in the literature benchmarking best practice in 
R&D (see, for example, Davidson et al, 1999, p. 13), a final question was posed in an 
attempt to discover what R&D managers in the UK pharmaceutical industry 
contemporaneously believed to be the most important factor in the successful management 
of corporate R&D. 
Semi-structured interviews appeared to work well. They enabled the answers to the 
predetermined questions to be answered within the time acceptable to most R&D 
managers, and they gave these managers the option of adding their own thoughts and 
opinions as they thought appropriate. Thus, the actual practices were described, the 
reasons behind those practices were sometimes given, and the effects caused were 
explored. However, the use of semi-structured interviews is prone to several dangers. 
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First, the questions presented might have directed interviewees towards giving the replies 
that they thought were needed (Sapsford, 1999, p. 104). To counteract this possibility. 
interview questions were kept as open as possible. Second, the perceptions of interviewer 
and interviewee might vary. To reduce this possibility, factual questions were interposed 
as checks to perceptions, and the factual information so obtained was verified whenever 
possible with published information in company reports and accounts, and reports in the 
scientific and business press. Finally, focused interview questions may have meant that 
more important issues were missed. However, doing otherwise may well have extended 
the scope of the exercise to unmanageable proportions. 
The questions highlighted in bold type in Appendix 4.2 were introduced into all interviews. 
The remaining questions were introduced as circumstances suggested. Further 
supplementary questions were asked when clarification was required or when they seemed 
appropriate to direct the flow of the conversation. 
As noted in Section 4.3 above, the data from these formal interviews was augmented by 
data from three informal conversations and one particular website communication. 
Written notes were made during all interviews and conversations. Scheduled interviews 
were recorded on audio-tape when acceptable to the interviewee and when the necessary 
equipment was available (in all but two instances). Informal conversations were not audio- 
recorded. All formal interviews were transcribed within two weeks of the date of the 
interview. 
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4.5 The Method of Analysis 
The final set of transcribed interviews, conversation notes, and website communication 
was analysed as follows. 
First, the interviews/notes/communications were separated into groups according to the 
type of company being interviewed: pharmaceutical, biopharmaceutical or biotechnology. 
This was to enable any differences between these three industry sectors to be more easily 
observed. Differences might have resulted, for example, from the participant selection 
process outlined in Section 4.3 above, or perhaps from the science being applied. Might 
the selection process have resulted in an unfair comparison between young and old, or 
small and large organizations? Would, for example, the greater understanding that could 
be expected from the use of gene therapy result in a more traditional and `managed' 
approach to the practice of R&D? 
Second, for each group of companies, the answers to the individual questions were collated 
(or segmented) into corresponding answer sets. 
Third, for each answer set, the answers were manually compared and contrasted for 
common themes and differences. These themes and differences were summarized in note 
form. These notes are outlined in Appendices 5.1 to 5.9. The interpretation or `sense' 
made of the answers obtained, and the themes and differences so selected are, no doubt, to 
some degree subjective (personal), and for this reason the actual interview transcripts are 
available separately. The overall themes and differences are presented in Chapter 5. They 
provide the substance for the discussion on knowledge creation presented in Chapter 6. 
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4.6 Conclusion to the Chapter 
This chapter began by discussing the assumptions made in the present investigation into 
knowledge creation in corporate R&D. These assumptions were: success in corporate 
R&D is dependent upon the way in which knowledge is created; UK-based corporate 
pharmaceutical R&D provides adequate examples of successful R&D; and corporate 
success within the pharmaceutical industry is dependent upon successful corporate R&D. 
Given the emergent nature of the field of research into knowledge-based approaches on 
firm performance, the chapter then made the case for the use of more explorative 
techniques, and outlined the choices made in arriving at a semi-structured interview 
method for collecting data on the approaches and practices employed within 
pharmaceutical R&D. In choosing to observe through the words of R&D managers, it was 
hoped that any insider bias would be minimized. Whether, or not, this is so is difficult to 
verify. The researcher (the present author) did, however, believe that she went into these 
interviews with an open mind, and, as will be shown later, the major finding of this 
empirical work produced a result that was contrary to her pre-existing belief (Chapter 7, 
page 291). In this respect, it might be claimed that the design of the research was 
sufficient to show `that the researcher's beliefs could be falsified by the evidence' 
(Sapsford, 1999, p. 13). Semi-structured interviews allowed the direction that was needed 
to enable the required observations to be obtained in the time available. At the same time 
they left scope for further observations to be made at the interviewee's discretion. Thus, 
factors additional to those thought important by the present author could be and were 
introduced by managers currently working within R&D. 
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The use of semi-structured interviews provided data that was well-structured and fairly 
tight, and was thus amenable to manual analysis. However, the fact that the data made use 
of observations leaves the possibility that interpretation (on the part of both the interviewee 
and the interviewer) has played a part in the findings reported later in this thesis. Without 
the justification that might have been obtained through a quantitative test of a set of 
hypotheses, it is hard to see how this might be improved. But this then introduces the 
question of prejudice in any questions that might have been asked in such a set. What can 
be said is that, in the main, the interview questions posed were open, the answers obtained 
were fairly uniform, and the observations made `rang true' to the previous experiences of 
the present author. 
Organizations within the UK pharmaceutical industry are far from homogeneous in respect 
of their particular fields of activity. This study has investigated those companies typically 
classified as pharmaceutical, biopharmaceutical, and biotechnology which concentrated on 
human drug/therapy R&D. Companies were not specifically controlled as regards age, 
size, or structure, although pharmaceutical companies tended to be mature, larger and more 
hierarchical, and biopharmaceutical and biotechnology companies were generally younger, 
smaller, and organic. This could have led to extraneous variances which were not 
controlled within this present study. However, the separate analyses of these three groups 
of organizations and the similar findings obtained throughout would suggest that any such 
variances were insignificant for the purposes described herein. 
Participant organizations were, with one exception, believed to be representative of those 
companies that operated successful R&D departments. Since there would appear to be no 
one proven or generally accepted measure of R&D success, this study chose to use a 
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composite measure based upon company rankings as regards quoted R&D intensity, the 
number of recent papers presented for peer review per number of R&D staff, and the 
degree of dynamism in the company's new R&D jobs market. The justification for this 
approach was based largely upon experience. However, it is perhaps interesting that the 
only company classed `less successful in R&D' within this study was the one company 
that has since closed its operations. 
Chapter 3 has shown us that the interpretations that we each make and the realities that we 
each construct are inherently personal to ourselves and are not necessarily the same as 
those made by or constructed by others. Chapter 5 therefore now attempts to outline the 
findings of the empirical research in a manner that is, as far as possible, free from personal 
interpretation. The discussion on knowledge creation within R&D, based upon the present 
author's interpretations of these findings, is reserved for Chapter 6. 
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5 THE FINDINGS OF THE EMPIRICAL RESEARCH 
5.1 Introduction 
The questions asked in the empirical study upon which this thesis is based were separated 
into those dealing with (a) the approach, (b) the practice, and (c) the knowledge processes 
used in R&D (Chapter 4, Section 4.4, page 139). This chapter follows this same order, 
with Section 5.2 describing the influences upon and the corporate approaches adopted in 
UK-based pharmaceutical R&D, Section 5.3 outlining the ways in which R&D is carried 
out, and Section 5.4 looking at the knowledge processes employed. Section 5.5 concludes 
with a summary of the main points of the chapter. 
The companies participating in this study differed significantly in terms of their size, type, 
maturity, and geographic spread (Appendix 5.1, page A5). They varied between some of 
the largest pharmaceutical companies in the world, formed as the result of `mega mergers' 
between large mature multinational companies; to medium and small biopharmaceutical 
companies with few products in the market place; to small start-up biotechnology 
companies turning little or no profit. They varied between those involved in chemical 
drugs; to those involved in biological therapies; to those involved with the technologies 
useful for drug or therapy discovery, analysis, or development. They varied between those 
that could carry out in-house all operational processes from drug discovery to product 
launch; to a semi-virtual company that outsourced most of its activities to others. They 
varied between those with their home base in the USA; to those with their home bases in 
Europe (the UK and Sweden). And they varied between those operating many R&D sites 
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throughout the world; to those operating only one site within the environs of another 
organization. In addition, whilst all companies claimed overall R&D strategies akin to 
business integration (third generation R&D), as intimated by previous reports (Chapter 2, 
Section 2.2.6, page 35), some tended more towards science/technology push (first 
generation R&D) whilst others appeared to be more market pull orientated (second 
generation R&D). At the same time, all companies participated in a range of collaborative 
ventures characteristic of fourth generation R&D. 
Despite the differences that undoubtedly existed, distinct similarities could, however, be 
observed in the way in which all companies practiced their R&D and in the knowledge 
processes and techniques that they all employed. This chapter highlights these common 
themes, whilst noting some of the differences. 
In presenting the findings of this empirical work, the view has been taken that research is 
not the same as development, and the later sections in this chapter have been segmented 
accordingly. This is despite the fact that with the present management fashion for `cross- 
functional teams' and `rugby scrum' approaches to new product development, we might 
perhaps be forgiven for assuming the contrary. Indeed, with few exceptions (see, for 
example, the work of Kumpe and Bolwijn, 1994; and Becerra-Fernandez and Sabherwal, 
2001), the more recent literature in this field refers to R&D as if it is a single entity, or 
talks about the R&D process as if it is a single process (albeit involving several stages). 
The justification for separating the findings for research from those for development is that 
companies that work in the pharmaceutical arena do in fact clearly separate research from 
development. They do this because research serves a very different agenda to 
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development: research is about the search for something new - the exploration for new 
knowledge; development is about the improvement of something that already exists - the 
exploitation of existing knowledge. These different agenda have important implications 
for the approaches and practices adopted in research and development. Sections 5.2 and 
5.3 indicate that research retains the approaches and practices of first generation R&D, 
whilst development employs many of the approaches and practices associated with third 
and fourth generation R&D. Section 5.4 then shows that, as a consequence of these 
differences, the knowledge necessary for and created in research differs from the 
knowledge necessary for and created in development. And, whilst the processes 
commonly referred to as knowledge acquisition, knowledge sharing, and knowledge 
application play important roles in creating knowledge within both research and 
development, the techniques associated with these processes differ between these two 
activities. 
All interviewees viewed their R&D operations as being important to the continuing success 
of their organizations -a perhaps far from surprising finding from R&D managers. 
Nevertheless, pharmaceutical R&D is important, not least of all because it is expensive: 
R&D costs were, typically, 15 to 17 percent of annual sales revenue in the larger mature 
companies and substantially higher in percentage terms in the smaller younger companies. 
Thus, although R&D cost structures vary across the sector, the costs incurred are 
substantially higher than those usual for most other UK industry sectors (2 per cent or 
lower). 
Research is fundamental to the pharmaceutical industry for sustaining the momentum 
associated with competitive innovation, and it is difficult to blend the inherently uncertain 
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process of what we shall later see is best described as transdisciplinary Mode 1 type 
discovery as if it were a subset of the comparative certainty associated with the evolution 
of market-rational user-needs. As an aside, it is interesting to note that the one company in 
the present sample classed as `less successful' emphasized development over research, 
adopted a stronger leaning towards a market-pull approach, and had a seemingly reduced 
tendency towards the formation of collaborative ventures and the allowance of individual 
networking. These factors are not discussed further within this chapter, but they have, 
nevertheless, been influential in considering the management of R&D discussed later in 
Chapter 6. 
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5.2 Corporate Approaches in UK-Based Pharmaceutical R&D 
5.2.1 The Most Important Factors Influencing Corporate R&D 
From a strategic perspective, commercial viability was the factor most frequently 
mentioned as becoming increasingly important in justifying research as well as 
development expenditures (Appendix 5.9, page A35). Government pressures to reduce 
prices, combined with the threat of generic competition, even before products come off- 
patent, have meant that, moral issues notwithstanding, companies now tend to channel 
most of their R&D efforts into only the most profitable treatment areas: 
`The increasing pressure from outside on commercial viability ... 
is probably the 
most important thing, because all the other stuff we'll focus on anyway. 
Everybody likes doing science here and all the other things, but if you don't 
focus on the commercial stuff you're not going to be in business very long. ' 
Company-A-4, p. 12 
From a management perspective, a clear focus, a flexible approach, and a culture of 
experimentation were the factors most frequently mentioned as being important in research 
(Appendix 5.9, page A34; Kanter (1983) and Leonard-Barton (1995) Chapter 2, 
Section 2.3, page 38). A clear focus is important so that everyone knows what the research 
is trying to achieve and what their particular role is in helping to reach that achievement: 
`I think it's focus, it's knowing what you are trying to achieve, and for everyone 
in the organization to know their part in that, their role in that. All the other 
things [come] to nothing if they're not all on the same side, if they are not all 
heading in the same direction. ' Company-B, p. 27 
But, at the same time, a flexible approach is needed to manage the balance between 
shaping research and allowing the experimentation that is needed to make it happen: 
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`You can't manage [research] as tightly as you can manage development 
activities or production activities or whatever. You have to accept that there are 
going to be blind alleys and there are going to be backtrackings and sudden 
breakthroughs 
... 
You have to allow enough flexibility. So I think it's managing 
the balance between trying to monitor and shape what's going on in research and 
giving people the creative flexibility they need. ' Company-G, p. 27 
Teams of people (Appendix 5.9, page A34; Chapter 2, Section 2.3.2, page 64) and a clear 
project plan that everyone had `bought into' (Appendix 5.9, page A35; Burton et al, 
Chapter 2, Section 2.3.2, page 66) were the factors thought to be most important in 
development. Since pharmaceutical development is now very much a multidisciplinary 
and multifunctional activity (see Section 5.3.2, page 168), or more accurately a 
transdisciplinary and transfunctional activity (Chapter 6, Section 6.3, page 219), it is 
perhaps no surprise that teams of people working together were thought to be particularly 
important during this stage: 
`The whole business revolves around teams of people. The task is far too big for 
any one individual or any one group now. ' Company-A-4, p. 13 
`I just see the whole process as a team knowing what they are going to do, and 
they've all got the same colour shirt on and they know who is defending and 
who is attacking and so on. ' Company-B, p. 27 
And, because of the need to remain commercially alert, a clear project plan is needed to 
clarify what needs to be achieved, how the work is to be attempted, and what the outcome 
is likely to be after a particular time interval. At the same time it was emphasized that all 
participants to the process should be involved in the production of this plan, and should 
crucially be able to `buy-in' to it: 
'A clear project plan which everyone is working within, a plan that everyone has 
bought-into, so, this is what we're going to do, this is why we're going to do it, 
this is how we're going to do it, and this will be the outcome at this time. And if 
that level of clarity is there, it makes it much easier to manage the entire 
situation. ' Company-C, p. 10 
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The importance of communication (Appendix 5.9, page A34) is perhaps an indicator of the 
importance of knowledge processes to R&D. Effective communication at all levels with 
people inside and outside the company was perhaps the most often quoted factor for the 
successful management of R&D (and beyond). Imparting a clear focus, combined with the 
need for flexibility in research and working in teams in development requires effective 
communication between all participants to the R&D process and at all times: 
`Communication is probably key. Our chief executive ... says, `We're not 
selling drugs, we're selling knowledge'. And, I think on every step of the way 
communication is the big thing. ' Company-H, p. 18 
5.2.2 Approaches to Research and Development 
The increasing importance of commercial viability noted in Section 5.2.1 above (page 150) 
is clearly evidenced by changes in companies' mission statements. These invariably used 
to make reference to `meeting unmet medical needs': essentially a science/technology led 
or first generation R&D approach. For example: 
`Our global quest is to improve the quality of human life by enabling people to 
do more, feel better and live longer. ' (Company-D, Half Year Report, 2001, 
page before p. 01) 
Since disease and illness is a global affair, these mission statements translated into a global 
approach towards research. The large pharmaceutical companies in their annual reports 
outlined global research strategies in line with their overall corporate strategies, and 
biopharmaceutical and biotechnology companies pursued their research expertise on the 
world stage with global partners. However, at the same time there was and is no universal 
procedure for the acceptance of safety and efficacy in drug usage. Whilst information may 
be universal, the knowledge associated with that information and incorporated into local 
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healthcare requirements is not necessarily so. The result is that companies need to meet 
the healthcare rules and regulations of each of their target markets before candidate drugs 
can be tested, authorized, and sold to human beings within those markets. Whilst research 
strategies were on the whole global, development strategies also needed to take a more 
local perspective (Appendix 5.2, page A9). 
The costs of drug R&D are high (typically of the order of US $500 million plus), and 
ongoing since drugs are continually regulated throughout their lifetime. Prices were high 
in order to recoup costs. But, the increased pressures on companies to reduce these prices 
led first to company mergers and acquisitions to yield economies of scale and scope, and 
second to rationalization of R&D activities to further reduce costs. Whilst still making 
reference to improving life for others, more recent mission statements have consequently 
changed to reflect a business integration or third generation R&D approach. For example: 
`We will become the world's most valued company to patients, customers, 
colleagues, investors, business partners, and the communities where we work 
and live. ' www. company-a. com/are/mn_about_mission. htm1, January 20,2003 
Whilst development strategies are now highly influenced by commercial considerations, 
research strategies do, however, retain a high degree of science/technology push. This 
difference was attributed, in part, to the fact that the greatest proportion of the cost of 
`R&D' is in development: the cost breakdown normally quoted is 10 percent for research 
and 90 percent for development. And, importantly, it is recognized that channelling 
research efforts too early can restrict the options available for later stage developments: 
`Discovery, by the nature of things, you know, being a chemist, you can't 
channel people too much at the beginning. There is a certain amount of 
serendipity, and inspiration is very important. So things are a little bit diffuse in 
research. But gradually as [projects] get through - and there are decision 
making bodies such as the research management team, the development 
management team and then the group commercial development management 
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team - all the time decisions are taken [at the various levels], and they will look 
at the portfolio and decide what should carry on. ' Company-H, p. 5 
At the same time, because most of the biological processes in the human body have more 
than one impact, work at the research stage may yield knowledge that can prove useful 
across a wide range of therapeutic areas. At the very least it will increase the 
understanding of how the human body works. Science and technology is of fundamental 
importance to corporate pharmaceutical research: 
`What we are looking at is understanding biological processes at the molecular 
level 
... so you can understand how a disease progresses. If you understand that, 
you can look at ways in that metabolic process or that biochemical pathway that 
you can influence. And there are always loads of ways in which you can do 
[that]. For instance 
... 
if you look at the cascade of events that leads to the 
control of blood pressure there's loads of feedback mechanisms.... So if you try 
to interact at a certain point it could stop everything that goes on afterwards, or it 
could change it to another process, or it could affect one thing without another, 
because most of the biological processes in the human body have more than one 
impact. ' Company-B, p. 10 
Nevertheless, commercial pressures have meant that, in recent years, even research 
strategies have tended to concentrate more on meeting the more lucrative age-related 
medical needs of Western markets (heart disease, diabetes, etc. ) where prices can be levied 
so that profits are high and costs can be more than recouped. Research and development 
into cures for predominantly third world diseases have been limited and have usually been 
at the instigation of the World Health Organization and similar entities (Hayman, 2002, 
p. 12; Rappuoli, 2002, p. 25; The Economist, 2003, February 1, p. 60 and December 6, p. 12). 
This has raised the issue of the moral right of developing countries to access the medicines 
they need, at prices they can afford, to support the lives of their citizens. There have been 
some moves by the larger Western organizations to take this issue on board, and some drug 
prices have been reduced to certain areas of the world. But this has been largely because 
of the threat of, or the actual loss of, sales to generics companies who are able and willing 
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to manufacture substitute product at marginal cost and often before patent expiry. These 
companies can, of course, do this because they incur none of the costs and none of the risks 
associated with drug R&D. 
R&D rationalization has resulted in the larger companies operating semi-autonomous 
research units. These units generally have autonomy within a particular therapeutic area 
with global objectives for that area (Appendix 5.2, page A 10). Thus, there has been a 
change from an approach of trying to do everything and anything on any one site, to 
accepting that one site cannot do everything, and what it does do should fit with corporate 
strategy. Thus, there has also been a change from allowing or even encouraging internal 
competition between units to a more collaborative approach between units, a decidedly 
more efficient approach to using the resources available: 
`We are talking about 6 years ago ... There was a period of three or 
four years 
when there ... was a competitive autonomous set of R&D sites. If you think 
about it, it's a pretty stupid thing to do, to have competition within your own 
organization. I think challenging each other's site to be good and be better, 
that's one thing. That's like having fifteen players and choosing the best eleven. 
And I think that's fine. But [the individual sites] saw the other sites as their 
competitors. They didn't see [other companies] as their competitor[s], they saw 
the other parts of the organization, which I think was pretty pathetic ... 
So that's 
the old model. The new model is this autonomy, certainly autonomy where you 
have an allocated area within which you can work. ' Company-B, p. 7 
Development units on the other hand tend to be more general and cover a range of issues 
and therapies of relevance to the local region (Appendix 5.2, page A 10). 
In one respect the research units of the larger pharmaceutical companies are now similar to 
the units of the smaller and younger biopharmaceutical and biotechnology companies: they 
have a clear knowledge area (or areas) on which to concentrate and for which they are held 
entirely responsible. In other respects they differ from the units of these smaller 
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companies: they have formal links to a number of in-house units working in a variety of 
different areas; and they are supported by units providing specialist technical and analytical 
services (Appendix 5.2, page A7). The extent to which the in-house services are an 
advantage over external providers is perhaps reflected in the esteem in which they are held: 
in most cases this appeared to be high. In turn, this is perhaps a reflection of the greater 
understanding that can be achieved within the same organization that `speaks the same 
language' than can be achieved between organizations that hold different views, take 
different perspectives, and have different priorities. 
The need for formal processes of coordination tended to be higher in the larger, more 
mature companies where it is simply not possible for everyone to know what everyone else 
is doing. Coordination in smaller and younger companies is loose and relies to a large 
extent on personal contact: 
`It's relatively easy when the company's small because if there's only ten or 
twenty of you then you're always bumping into each other, and you can say the 
mean free path between persons is sufficiently small that you tend to interact and 
you know what's going on. So communication and networking around the 
organization is dead easy. It's only when the company starts to get bigger and 
... you get to the point where you see [someone] and you think, "Well who's he? " Well we're just going through this process ... 
So we're already grappling 
with the problems of expansion and how you make sure the things you were able 
to capture and manage at the small stage you don't lose as you get bigger. And 
it's not rocket science, but it's a lesson that so many people have been through 
and everyone still gets wrong. ' Company-I, p. 2 
Although the type of work undertaken has affected the choice of R&D location, the actual 
choices made would appear to depend upon more than the simple trade-off between 
supporting either market demand or technology supply as suggested in the previous 
literature (see Chapter 2, Section 2.2.3, page 24). For example, R&D in the 
pharmaceutical companies was historically located with or close to pharmaceutical 
production, and production sites tended to be where there were tax breaks. This is also one 
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reason why there are now a number of pharmaceutical manufacturing and R&D facilities 
in Ireland. In turn, production sites were traditionally located at the mouth of a river 
estuary, where waste and effluent regulations were generally less severe (Company-A-4. 
p. 1). R&D locations may also be determined by closeness to external support facilities 
(specialist equipment, animal house facilities, hospital clinical facilities, etc. ). The 
clustering in the Thames Valley and Cambridge regions in the United Kingdom was said to 
be, mainly, for this reason. Location decisions may also be influenced by other factors 
such as the perceived need to be near the organization's financial backers (Company-G, 
p. 7). 
Nevertheless, the capacity of researchers to participate in the act of discovery is shaped by 
what they know. Where they are, in a geographical sense, can shape how they learn what 
they know, and all companies emphasized that the existing knowledge and expertise at a 
location would be a contributing factor in determining the choice of site and the type of 
work (research and/or development) carried out at that location (Appendix 5.2, page A 10). 
With the introduction of research specialization, the larger companies have therefore 
tended to locate their more recently established research sites close to relevant external 
`centres of excellence', ostensibly to facilitate easy recruitment of knowledgeable and 
experienced personnel. In this respect, the UK is still seen as an important location by 
some companies because of its excellence in pharmaceutical and related research and the 
availability of a highly skilled workforce (Loftus, 2001, p. 88). However, it is possible that 
this will change. The continental European countries are now spending relatively more on 
healthcare R&D than is the UK. As evidenced by the number of job advertisements in the 
scientific press, continental European companies would also appear to be poaching 
research personnel based in the UK. In addition, the relative ease of merger and 
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downsizing has resulted in there being now only one major UK `owned' pharmaceutical 
player, whereas six years ago there were five. And, there has been a decrease in the world 
educational ranking of UK schools (The Economist, 1997, March 29, p. 25; 2001, 
September 22, p. 34; and 2003, April 19, p. 25). All of these factors may be expected to 
have an effect on the ability of UK institutions to continue to carry out world class 
pharmaceutical R&D, even though government edicts continue to suggest that this sector 
of research remains a priority. Indeed, the fact that many external `centres of excellence' 
are now located in the USA is perhaps one reason for the recent trend by companies to 
relocate their R&D headquarters there (Appendix 5.1, page A5). Other reasons may 
include the wish to (a) improve their profile in the largest drugs market in the world and/or 
(b) distance themselves from the `animal rights' activists who have become particularly 
vocal and disruptive in the UK in recent years (Chemistry in Britain, 2001, March, p. 5; 
and 2003, June, p. 5). 
UK Biotechnology spin-outs have tended to locate close to their original sources of 
inception, but more than one interviewee felt that this might become less important as the 
spin-out companies establish themselves as `centres of excellence' in their own right 
(Appendix 5.2, page A8). Being close to a centre of excellence in a particular knowledge 
area is then not as relevant as the ability to use and expand upon existing knowledge and 
create new knowledge in order to produce something new. Thus, neither established nor 
newly formed organizations believed that geographic proximity between internal and 
external workers was a particular requirement for successful research. The view expressed 
was that, since scientists regularly attend conferences and `talk' over the Internet 
(Appendix 5.7, pages A23 and A29, respectively), technology spillovers (Chapter 2, 
Section 2.2.3, page 24) occur, come what may. However, distance is relative, and, 
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compared to some countries in the world, anywhere within the United Kingdom could 
perhaps be thought of as `close'. At the same time, increased global interconnectedness 
can decrease any effects that distance might cause. 
In contrast to the literature reports (Jewkes et al (1958), Gibbons and Johnston (1974), 
Chapter 2, Section 2.3.1, page 43), interviewees felt that government initiatives had little 
influence on research activities at a particular location, except possibly in a negative way: 
`It won't be that you'll start to do some work in a particular area because 
someone said it's trendy, or it's good, or whatever, or here's some ideas. But 
what you would do would be to not start work in a particular area if it was felt 
that it was going to be controlled in a way that would stop you making a profit 
for instance. And genetic modification would be an example where you might 
say, `Actually we don't want to be in this field'. I am thinking not particularly 
of our industry, but an industry like agrochemicals, where if you can't do the 
trials, if the government's not amenable to doing the trials, how on earth are you 
going to prove that you've got something worth selling. ' Company-B, p. 14 
For development purposes, proximity to the relevant regulatory authorities (Chapter 2, 
Section 2.3.2, page 64) was, however, thought to be important in aiding `drug approval' 
since it increased the scope for face-to-face trust building and understanding: 
`The regulators are heavily involved ... 
They know what we're doing and we 
can get input from them on whether we're going in the right direction to actually 
get something approved. That's obviously, in terms of the whole lifecycle, quite 
late on in the process. We don't go to them in discovery and say we're thinking 
of discovering some drugs ... but certainly when we get 
into development, this 
is straight across the world now, we go and look at the major regulatory agencies 
and involve them in what we're doing. ' (Company-A-4, p. 6) 
Where it had occurred, the internationalization of R&D was seen as an advantage: it allows 
companies to recruit the most knowledgeable and most experienced scientists available for 
research (Company-B, p. 4), and at the same time allows local development activities to 
concentrate on national or regional health priorities and regulatory requirements 
(Company-B, p. 5). In effect, it enables a much greater use of global knowledge, and at the 
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same time brings diversity and the full range of talent into R&D. Where R&D 
internationalization had occurred by merger, knowledge acquisition was seen as an 
advantage gained (Company-H, p. 11). The interviewees from those companies that had 
not yet internationalized their R&D operations foresaw similar advantages to those given 
above. However, they also suggested that the disadvantage would be the loss of a `family' 
atmosphere and approach (Appendix 5.2, page A9). 
The R&D sites of the larger companies carrying out both research and development can 
perhaps be seen as a compromise between the needs of research and the needs of 
development, with the needs of the former taking precedence in recent years. 
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5.3 R&D Practices in UK-Based Pharmaceutical R&D 
Drug R&D is by necessity a staged process, ultimately involving several phases of 
increasingly expensive clinical trials, each of which must be completed before the next is 
allowed, and before product can be released for human consumption. However, in all of 
the companies interviewed, it was emphasized that there was a clear distinction between 
the work classified as `research' and that classified as `development', to the extent that 
research units are functionally separate from development units. Although they may be 
located in the same building or complex of buildings, with contact occurring between the 
two sets of workers, research units were also said to have completely different 
management structures and approaches to those of development units (Appendix 5.3, 
page A 13). The stages typically involved in drug research and drug development are 
outlined in Figure 5.3.1 (below). 
Drug Discovery: First Patent - Lead optimization 4 Clinical trial - Concept 
testing -i 
Drug Development: Product licence - Clinical Development (Phase 1, Phase 2, 
Phase 3 Toxicology and Pharmacokinetic studies) - Pharmaceutical and Analytical 
development - Process Chemistry and Manufacturing -* Registration and Regulatory 
affairs - Sales and Marketing (preparation, promotion, advertising and selling) 
- Product life cycle support. 
FIGURE 5.3.1: TYPICAL STAGES IN THE DRUG DEVELOPMENT PROCESS 
Adapted from the AstraZeneca Annual Report, 2000, p. 17 
The present findings thus suggest that research and development each generates its own 
distinctive work culture. One interviewee remarked that he believed these cultural 
differences were, in part, a consequence of the huge sums of money needed for drug 
development, as opposed to drug research: 
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`It took me many years to understand the difference ... there's a very big 
difference in the way they think, the way they work ... In 
discovery 
... people 
can say this is the case, and they'll argue until they are blue in the face, and 
they'll try to do the experiments to prove one way or the other. But in 
development they are much more keen to avoid being seen as the person who 
brings a product down, or who's fault it is that a product fails ... 
[So] you can 
bring forward development into research and you can keep on doing research in 
development, but there is a point where major investment kicks in, so there's a 
different culture kicks in at that point. ' Company-B, p. 1 
But perhaps these different cultures exist as much because of the different skills and 
requirements involved: 
`You have research which is really coming up with the new chemicals and 
getting them to proof of concept, and then you have development which is 
charged with actually getting them approved onto the market place 
(Company-A-1, p. 2)... rounding up all the resources to produce the data the 
regulatory authorities need to know. ' Company-A-1, p. 7 
The pharmaceutical industry is understandably a highly regulated industry. The disciplines 
needed to take a candidate drug through extensive clinical trials to ensure safety to humans 
or animals are different to those needed to discover candidate products in the first place. 
It is perhaps hardly surprising that companies separate creative discovery from regulated 
development. 
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5.3.1 Project Initiation 
Research 
Whilst agreeing with the view that ideas for research projects might come from anywhere 
(Leonard-Barton, Chapter 2, Section 2.3.1, page 43), all interviewees stated that the move 
into product development is ultimately dependent upon there being a fit with corporate 
strategy and a balance between technical feasibility and commercial viability (Appendix 
5.3, page A 11). The extent to which each of these factors influence research activities in 
the early stages is, however, hard to quantify. Certainly, most companies initially appear 
to adopt a high degree of science/technology push (first generation R&D) rather than a 
market-pull (second generation R&D) or business integration (third generation R&D) 
approach: 
`We used to do anything, but now there are strategic areas that we will look at ... 
We rely on our clever guys in discovery to look at areas of relevance to the 
company. ' Company-A-4, p. 2 
`Projects come from wherever you think there is a chance to make a difference. 
Likely sources nowadays are biological innovations. [Products come from] 
understanding biological processes at the molecular level ... 
[we are] looking at 
ways in which we can modify [disease-associated proteins] to affect the progress 
of a disease. ' Company-B, p. 10 
`Ideas can come from anywhere. And good ideas can be tested informally as to 
their feasibility. However, in order for an idea to become a project it needs to fit 
with our corporate strategy. ' Company-C, p. 3 
`The new company with a range of experience in emerging technologies will 
possess significantly enhanced scale and scope to discover, develop and deliver 
new and better medicines in a faster and more efficient way. ' 
Company-D, Annual Report, 1999, Note on the `Merged Company'. 
`Everything ... 
begins with the unmet medical needs of people. ' 
www. company-f. co. uk/internationaUindex. html 5 `}' April 2001 
'We've got people who ... trawl round 
for interesting molecules ... and 
licence 
those in. ' Company-G, p. 1. The focus is on oncology. ' Company-G, p. 3 
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`Before the merger, [Company-H] ... tended to 
discover drugs in any indication, 
take them through to `proof of principle', and then would get a partner who was 
a large pharma... [Now] rather than research going into any area where there is 
an opportunity, we would try and focus into the particular disease areas which 
we could then take through development and then take on to our group to sell. ' 
Company-H, p. 4 
`There is a creative tension between what is seen to be a research opportunity 
and between what is seen as a market opportunity or a business opportunity ... Projects may be research driven (the scientist reads a paper and has an idea) or 
business driven (the business people see a big opportunity), but ultimately there 
needs to be a balance between technical feasibility and commercial viability. ' 
Company-I, p. 1 
Work is focused on the `visualization' of therapeutically significant protein 
families with a view to finding primary binding domains, and hence target drug 
candidates. Company-K, p. 2 
It is interesting and perhaps a little surprising that those companies that are more vocal in 
advocating science/technology push are those that are currently favoured by the UK 
financial houses. There will, of course, be many reasons for a company's stock market 
valuation, but one of the deciding factors for mature companies working in the UK 
pharmaceutical sector would appear to be the number of products that the company has 
under current development (that is, in its pipeline). And, a science/technology push 
approach would appear to increase this number. Rightly or wrongly, Company-D's low 
London stock market valuation in 2002 (relative to other companies in the pharmaceutical 
industry) was attributed to the absence of sufficient products in the company's pipeline. " 
Such a valuation is not of course possible for a newly forming company. In this case, 
valuations reflect the company's business plan, its management team, and the potential of 
its patented technology (Company-I, p. 18). 
14 It may be remembered from Chapter 4 (Section 4.3, page 133) that the number of products in the 
pipeline is no guarantee of the number of products eventually emerging from that pipeline. 
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Science and Technology Advisory committees consisting of eminent scientists and medical 
clinicians from the leading institutions around the world form part of the management 
structure in most of the companies studied. The role of these committees is generally 
strategic in nature. For example: 
`A Science and Technology committee reviews and makes recommendations 
regarding the company's strategic research goals and objectives, and reviews 
new developments, technologies, and trends in pharmaceutical research and 
development. ' Company-F, Annual Meeting of Shareholders' Proxy Statement, 
2001, p. 12 
`A Science Advisory Board advise the executive management on science policy 
and strategy. ' www. company-j-l. co. uk/about/index. html 16th November, 2001 
`Ultimately, the decision on the company's strategy progression is decided by 
the board of directors [Company-I, p. 9] ... A 
Scientific Advisory Board 
contributes scientific knowledge and expertise, generally on a one-to-one basis. ' 
Company-I, p. 30 
Full project initiation in research is largely the province of in-house technical and 
commercial teams: 
At the `idea' stage this could be an individual or team effort. When an idea 
becomes a project, then that is run by the Director of Research and his various 
deputies. Projects are then a team approach. Team members include people 
from the research, development, safety, and regulatory sections. ' 
Company-C, p. 3 
But: 
`More and more, people are being influenced by what is commercially viable. 
So whereas a few years ago it might have been, `This is a great idea and we can 
make the drug, ' it's become, `Can we sell the drug at the end of the day? ' 
Company-H, p. 6 
The main drivers for the research undertaken in the large mature pharmaceutical 
companies are the outcomes of external research by universities, research institutes, and 
biotechnology companies (Jewkes et al, (1958), Gibbons and Johnston (1974), Chapter 2, 
Section 2.3.1, page 43). The needs of patients and general practitioners may also influence 
project initiation, as can organizations such as the World Health Organization. Suppliers 
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can, rarely, influence project initiation. The large mature biotechnology company noted 
similar influencers. In contrast, the larger biopharmaceutical company felt that although it 
was unusual to get an idea from a university or research institute, these institutions do very 
much help in the early development stages. Partner companies who are the bank rollers are 
the strong influencers for the work undertaken by the smaller biopharmaceutical and 
biotechnology companies (Appendix 5.3, page A 11). Although clearly there are regulatory 
issues that need to be considered and grants that may be available, all companies 
interviewed felt that governments had little influence on specific project initiation 
(Appendix 5.3, page A 12). In addition, the ability of any `lead user' (Chapter 2, Section 
2.3.1, page 48) to conduct its own work (and thus influence R&D activities) is severely 
limited by legal and ethical restrictions. It was also noted that it is not uncommon for 
previously failed products to later find commercial success. However, in this case, patent 
life considerations play a significant role in project re-initiation (Company-A-4, p. 7). 
Development 
Drug development follows initial clinical trials and concept testing. Projects may arise 
from either in-house or external research. An actual or anticipated business advantage is 
crucial for this extremely expensive stage of the process, as is also a clearly defined route 
to commercialization: 
`Successful [development] projects have a good business case, a defined scope, a 
delivery strategy, and controlled delivery. ' Company-D, p. 3 
A formal project proposal will normally be submitted for board or management 
approval before the commencement of any work. This proposal will then be vetted 
for its development worthiness by a team consisting of research, development and 
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commercial directors, managers, or staff (cf. third generation R&D). Unless a science or 
technology can be shown to be of significant importance to the future of the company, 
commercial factors will normally take priority over technical interests. 
5.3.2 Project Management 
Research 
All interviewees remarked on the need for a flexible, non-bureaucratic management 
approach in the early stages of research (Burns and Stalker, Chapter 2, Section 2.3, 
page 38), with feasibility studies being the province of research staff, whether individually 
or as a small team; such staff often being responsible for both the strategic and operational 
elements of the work that they undertake (Appendix 5.3, page A 14): 
`You don't want to make it too rigid. You don't want to make it too 
bureaucratic so that if [someone] has an idea then they're allowed to make the 
idea, they're not criticized as if they're wrong. And, you haven't got ten 
committees to go through before somebody says, `Yes that's a good idea'. 
[Company-I, p. 2] ... `These people are clever people, they know what's needed, 
so they learn, they adapt. ' [Company-I, p. 5] 
The process in the early stages is often unclear or fuzzy: 
`I don't think there is necessarily an absolute set of `rightness' just a 
consciousness that we're here, we're aiming to get over there, and we're trying 
to get there via the most direct route. It doesn't mean to say that there is one fine 
way of doing it, there's going to be a number of ways of doing it. ' Company-I, 
p. 11 
Management's role is more one of facilitation and coaching: 
[During feasibility studies] we encourage people to say what it is they are trying 
to do, and they will then get the nod. ' Company-B, p. 1 l 
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Once an approach has been validated, or when specific drug compounds are being made or 
a technology needs extensive evaluation, projects were said to become a multidisciplinary 
team effort managed by a project leader, overseen by a research director, and ultimately 
controlled by a research management committee (Appendix 5.3, page A 14). In the larger 
companies, this committee usually consists of the managers or directors of the various 
technical departments such as biology, biochemistry, chemistry, etc. In the smaller 
companies, the corporate management team or, rarely, a science advisory committee acts 
as the research management committee. Projects are then reviewed on a regular basis to 
determine continued viability (Appendix 5.3, page A 14). In the early stages, continuance 
is based mainly upon expert technical judgement rather than on strict milestone 
commitments. In later stages, continuance depends upon the ability of the research to meet 
initial clinical trials. 
Development 
Drug development involves product licensing, followed by three phases of toxicology and 
pharmacokinetic studies, pharmaceutical and analytical development, process chemistry 
and manufacturing, registration and regulatory affairs, the production of information for 
marketing promotion, and life cycle support of the resulting product (Figure 5.3.1, 
page 161, above). Although the process is essentially linear, development is very much a 
team effort with people from the different scientific disciplines working together with 
production, regulatory, and marketing personnel (Chapter 2, Section 2.3.2, page 64) to 
bring product to market in the shortest possible time. As noted in Section 5.2.2 (page 156, 
above), in the larger pharmaceutical companies, specialist technical units (bioinformatics, 
high throughput screening, structural chemistry, etc. ) may support the work undertaken. 
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Teams are thus multidisciplinary and multifunctional, and in the larger companies can be 
multi-site. Teams may also include members who are external to the company, as some or 
all of the work may be outsourced or carried out in partnership with others (Chapter 2, 
Section 2.3.1, page 52). Outsourced activities typically include product formulation; 
product manufacture and packaging; and studies of stability, pre-clinical safety, and 
toxicity. Collaborative partnerships are outlined in Section 5.4.2 (pages 200-202, below). 
In line with Mode 2 working (Chapter 3, Section 3.4.1, page 103), the development team 
make-up may change with time, with research staff giving way to commercial staff as the 
project progresses to completion. Alternatively, there may be two teams, one involving a 
partnership with commercial colleagues and focusing on strategic elements, and the other 
focusing on the operational side and responsible for delivery of all the data needed for 
regulatory approval (Company-A-1, p. 9). 
Matrix management is employed in the larger companies, and project control predominates 
over technical or marketing control (Appendix 5.3, page A 13; Henderson, Chapter 2, 
Section 2.3.2, page 65). Email, electronic conferencing, teleconferencing, and travel are 
used to aid, what is, in essence, a transdisciplinary approach (Chapter 3, Section 3.4.1, 
page 103). Cost and time estimates are deduced from the scope of the project and the 
resources available. Critical issues are highlighted. The objectives, common or shared 
targets, goal posts (which markets, actives, doses), risks, and assumptions are provided to 
all involved (Company-E-2, p. 3). 
Project managers usually hold the budgets and are empowered and are held accountable for 
project decisions: 
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`The project managers, who are the group I control, hold the budgets. So they 
are really given the authority to make the decisions. They are empowered and 
they are also accountable ... 
If there is any conflict between projects then they 
would go up to the Development Management team meeting. It would be 
discussed there ... where the priorities should 
be. ' Company-H, p. 4 
However, as pointed out by several interviewees, it is the functional line managers who are 
usually responsible for allocating staff to the development teams. These managers 
consequently have a strong influence over project `time lines' and ultimate success rates: 
`It's more that you've got to bring people together based on their technical 
expertise. You've therefore got to rely on the lines to actually formulate who is 
on your team. ' Company-A-1, p. 10 
With only a finite number of staff to be spread across a range of projects, the luxury of 
forming teams from staff having the most appropriate personality characteristics (see, for 
example, the work of Belbin, 1981; Roberts and Fusfeld, 1981; and Hurst et al, 1989) in 
addition to the necessary practical skills is non-existent. Instead, what at least one 
company does attempt to do is to bring the latest `best practice' to newly forming teams by 
pursuing cross-team participation (see Section 5.4.2, page 191, below). 
Despite basing team membership on technical ability (and, when conditions allow, perhaps 
an assessment as to who will work well with whom), the most common problem observed 
with this type of team working was linked to the fact that people on multiple teams can 
have conflicting work commitments: 
`It's not ideal in that you get people that are on multiple teams across different 
areas and therefore have conflicting agendas. ' Company-A-1, p. 9 
The advantages include the diversity of different viewpoints as new members join, and 
continuity when people bring their experience into play in different teams: 
You have some people that are on both of those teams in full development. 
which can be helpful because obviously you have got that extra level of 
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continuity, but equally you are then lacking bringing extra perspective to the 
table. ' Company-A-1, p. 9 
Matrix management also allows for `easy' exchange of resources between sites: 
`Even within the specialties we often need resource from the other site for one 
reason or another, and so with matrix management it's quite easy to chop and 
change between sites. The fact that they're geographically adrift doesn't 
necessarily matter. ' Company-H, p. 4 
In the larger companies, the continuation of a development project is subject to the 
approval of a Development Management Committee (possibly with sub-committees for 
specific areas or activities). In smaller companies, this may be left to the technical director 
or technical manager, the science advisory team, or more usually the general management 
team. Although it is not possible to predict the exact outcome of clinical trials, at this 
stage the route is fairly well defined and progress can be evaluated against target 
milestones. 
Moving from research to development thus increases considerably the ability to control the 
work undertaken. Development projects can be managed in the traditional sense: they can 
be defined, designed, scheduled, implemented, monitored, reviewed and controlled 
(Company-E-2, p. 4). Project management tools, such as Microsoft Project®, are often 
used as aids in managing this process (Chapter 2, Section 2.3.2, page 69), and have been 
said to increase intra- and inter-departmental awareness of what is being done, why it is 
being done, and how much it is likely to cost: 
`I think that it has improved the way we do R&D because everything's become 
more transparent. It's not suddenly a black hole [that] money goes into and 
there doesn't seem to be any return at all until the commercial side has got hold 
of the product. It's now much more transparent, where you know what R&D are 
working on, where the money is going, etc. Certainly pieces of software like 
Microsoft Project® have made it much easier to plan out projects. And you can 
actually produce a visual image of what the project looks like, which I think 
helps people to see what it is that's being done. ' Company-C, p. 10 
Chapter 5: The Research Findings 171 Section 5.3.2 
In some cases, subject to management approval, the project teams themselves set project 
milestones and deadlines. This was said to encourage the setting of more realistic time 
lines and improved resource allocation decisions. It was also thought to have increased 
team commitment (Company-E-2, p. 6). Thus, rather than being simply a method of 
control, the use of this software had enhanced coordination and participation (McKinlay, 
2000, p. 109). Rather than being simply a monitoring device it was being used to share 
thoughts on what should best be done next (ibid, p. 111). It had, in fact, extended and 
empowered the links between the various communities of practice - research, 
development, operations, and management - working within the organization (ibid, p. 113). 
In this respect, it might be said to disprove Focault's prognosis that `knowledge' always 
empowers the already powerful (Focault, in McKinlay, 2000, p. 107). 
In the effort to reduce costs, most companies have sought to reduce the time from 
discovery to launch. One way in which this can be achieved is by adopting `rugby team' 
approaches, whereby the various development activities are run in parallel (Ray and Little, 
Chapter 2, Section 2.3.2, page 69). Whilst not always feasible in pharmaceutical 
development, in the case of Company-D, this means designing the manufacturing facility 
in parallel with the clinical trial. Referred to as `Fast Tracking' drug development, this 
process ensures that manufacturing processing problems are solved during clinical trial 
production, rather than at the later stage during the facility start-up. It also ensures the 
equivalence of the drug at the clinical and final supply stages by removing any differences 
in product quality that might be caused by manufacturing scale-up. Since marketed drugs 
in the UK have to be materially the same as and manufactured in the same way that clinical 
trial material is produced, this parallel development reduces the time delays that might 
occur if manufacturing scale-up is initiated after clinical approval and then incurs 
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unforeseen problems. It does, however, mean that the costs of process design and 
engineering are introduced before final product approval, thus introducing additional risks 
into the process. The solution according to Company-D is to manage those risks 
(Company-D, p. 9). Fast tracking is not just about speed; it is also about recognizing what 
can be done differently. In addition, it is about time-based risk review and planning in all 
project areas, and about all functions working together as one team. Overall, it is about the 
`benefits of having a more robust process and greater product experience within the project 
supply chain' (Company-D, p. 12). 
5.3.3 Project Termination 
Projects may be terminated at any stage throughout the research and development 
processes. In research, termination may occur because the project has been handed over to 
development - the research stage of the project is `complete' - although research staff 
usually retain some association with the project, for example, by acting as `consultants' to 
the development team. Termination in research may also occur as the result of the science 
or technology not fulfilling its promise within a reasonable time scale and, therefore, 
within its cost limit. Termination in development may be for either scientific or 
commercial reasons: either the science/technology does not fulfil its early promise (for 
example, clinical trials show irreparable adverse effects); or the developing product/ 
process is no longer commercially viable for reasons of cost, projected completion date, 
competitor actions, etc. 
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In general, companies use their regular project review meetings (team, management, or 
board) to re-evaluate projects for continued commercial and technical viability and 
strategic fit (Appendix 5.3, page A 14). Decisions in research are based more upon 
experience and general progress, whilst decisions in development are based upon progress 
against formal targets (Company-A-4, p. 6). Decisions are ideally by team consensus but 
with the ultimate decision being taken at the executive management or board level: 
`[Project termination is] ideally by consensus, but ultimately a decision [is 
made] at executive management / board level, after a careful review of existing 
data, information, knowledge. ' Company-I, p. 10 
`Project teams report through a formal structure to an executive team to monitor 
milestones and resources, to obtain approval to commence projects and to 
recommend ending a project if it is not meeting our objectives. ' 
www. company-j-2. com/rd_zone/ 29th November, 2001 
Several companies admitted that they had not been particularly good at terminating 
projects. Projects could often drift on or remain in limbo until a use could be found: 
`We're not very good at it, because if you look at most of our really big sellers, 
all of them at some stage have come to the point of, `Well this doesn't work for 
what we thought it would and we're going to kill it. ' ... There are two 
key 
considerations: technical and commercial. It's a very fine line to draw. On the 
one hand, if you keep plugging away at it ... you've got more chance of actually discovering something ... equally, early attrition ... 
[of] things that aren't going 
to become drugs [saves] wasting money. It's a mixture of formal reviews and 
formal milestones between the team and the governance of experienced senior 
managers, [plus] serendipity and [available] capacity. ' Company-A-4, p. 7 
`Well ... 
in the business school we did a case on Amgen who, you know, are 
supposed to be the most successful biotech company in the world. And there's a 
quote in there from somebody saying they never really get terminated, they sort 
of drift on at a low level. ' Company-G, p. 6 
Others ensure that projects are terminated: 
in the past they would be with great reluctance terminated ... 
In the present 
climate it's very hard-nosed ... 
The data is reviewed. The validity of the 
approach is checked. Is it working/ going to work? Will it be a marketable 
product? It's much more objective [now]. ' Company-B, p. 12 
`It's a very transparent system. If people start spending money out of a budget 
on something which is not an active project, it will not get signed off. So there's 
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no opportunity for people to carry on doing a little bit on the side ... And people 
accept it very well. They know that it's actually a positive thing to kill a project 
before you spend too much money on it. ' Company-H, p. 8 
It was recognized that termination decisions can be especially painful for the research staff 
who originate a particular avenue of enquiry. To the extent that development staff are less 
concerned with the creation of the original idea these staff may find it easier to make a 
detached assessment of the project's worth in the light of prevailing technical and 
commercial evaluations. 
`Particularly in the research side people become very protective of their projects. 
In development, because there is a high attrition rate in the pharmaceutical 
industry 
... 
because it's not our baby and we haven't invented it, we tend to treat 
them a little bit more objectively. And certainly if something needs to die, we'll 
just kill it 
... 
And people are generally supportive. It's hard if they've worked 
on something for four years and suddenly it goes down, but they generally 
accept it. ' Company-H, p. 7 
`Scientists don't like having their favourite project canned ... It's a process you 
have to manage. And I think in a small company it is not that difficult to do ... 
It's not as though there isn't something else that is equally exciting and 
interesting that they can then latch onto. There's no shortage of ideas to 
progress. ' Company-I, p. 16 
`When teams fold ... there are celebrations of what the team achieved. 
If you 
think about it, most of our candidates don't get to market, so if we only learnt 
from our successes, we'd be nowhere. ' Company-A-1, p. 20 
As the above quotations also indicate, termination is embedded within a wider process. 
It is intertwined with the provision of a supportive environment, providing alternative 
opportunities, and `learning from failure' (Leonard-Barton, Chapter 2, Section 2.3.3, 
page 70). Failure is not necessarily the same as a `mistake' and, if appropriate lessons are 
learned, it might provide a stepping-stone to subsequent success. 
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5.4 Knowledge Processes in UK-Based Pharmaceutical R&D 
5.4.1 Research 
Knowledge Creation 
As indicated in Section 5.3 above, the aim of corporate research is to create something that 
is different to what has gone before: as Polanyi would say, the search for a `hidden reality' 
which we may yet discover (Polanyi, Chapter 3, Section 3.4.4, page 120). Consequently, 
knowledge creation in research is as much about widening scientific horizons as it is about 
creating knowledge that may ultimately give the organization an advantage over its 
competitors, although those horizons will, to a large extent, be guided by the objectives of 
that organization. At the same time, the knowledge created in pharmaceutical research has 
the potential to provide benefits to the whole of mankind. So, added to the scientific 
propensity to share knowledge, there is the moral issue that knowledge should not be kept 
from others if it may do some good. Consequently, much scientific and technical 
knowledge is available to and is the subject of extensive debate across a wide community 
of researchers. The difficulty in research is in knowing, at the beginning of the process, 
which existing knowledge is important and in what way that existing knowledge will 
ultimately be used (Scott, Chapter 3, Section 3.2, page 89). Researchers may hypothesize 
about what will happen, but the actual outcomes of research depend as much upon new 
experimental results as upon existing scientific theory. Indeed the results may well 
question existing theory. Knowledge creation in research is therefore essentially a 
knowledge exploration process. And, the techniques employed in research to acquire, 
share and apply knowledge reflect this knowledge exploration process. 
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Table 5.4.1 (below) summarizes these techniques and the following paragraphs describe 
the application, the acquisition, and the sharing of knowledge within corporate 
pharmaceutical research. 
TABLE 5.4.1: KNOWLEDGE PROCESSES AND TECHNIQUES EMPLOYED IN 
PHARMACEUTICAL RESEARCH 
Knowledge Process Technique Major Use 
Knowledge Creation Exploration Idea generation, problem solution 
Knowledge Application Intuition Idea generation, problem 
evaluation, experimental design 
Experience Idea selection, problem 
evaluation, and experimental 
design 
Knowledge Acquisition Peer reviewed literature Idea generation and problem 
searches solution 
Patent searches Project selection and design 
Database searches Project design and problem 
solution 
Buying or hiring-in Establishing new technical 
expertise ventures 
Knowledge Sharing Personal networking Idea generation, problem solution, 
and the advancement of science 
and technology 
Multi-science-based Project design, and problem 
project teams solution 
Knowledge Application 
Knowledge application in research relies upon individual intuition as well as upon prior 
experience. What work is undertaken may also be to some extent the result of `trial and 
error' - let us try something and evaluate and understand the outcome - although even in 
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this case it might be argued that intuition will determine what is first undertaken: certainly 
in a corporate context there is simply not the time to try anything and everything. 
Importantly, what might be useful in one research context will not necessarily be useful in 
another (Hull, 2000, p. 62). In research, it is not possible to write down a procedure or 
learn a skill that can then necessarily be applied in the same way at a later date. What can 
be learnt from research stems from the outcome of that research: to what extent does the 
research project fulfil expectations and do those expectations indicate that a viable product 
might follow? These are obviously crucial issues from a commercial perspective, but they 
are not necessarily useful for determining how the next research project should be 
undertaken. Although projected research outcomes and faith in their commercial value 
might filter the fruits of creativity, they do not tell the individual researcher how to be 
creative (Section 5.3.2, page 167). And the personal judgement that suggests, to the 
researcher, the way to proceed in any one instance will differ from one individual to the 
next and from one project to the next. It will also change as the project progresses, since it 
changes as new knowledge is created within the organization and within the wider 
community. As pointed out by one interviewee, this does sometimes mean that when 
innovation is the object, as in research, the knowledge and lessons of the past are not 
always thought to be important even when they may be so: 
`I think there is a ridiculous amount of freedom in the way [research] approaches 
things ... Perhaps that's required 
because you are expecting people to be 
essentially creative. But it certainly is another potential barrier to knowledge 
transfer and so on ... 
Perhaps it would be a lot better for all concerned if we 
spent a little bit of time looking at what we were going to be doing and what 
other people have done, rather than just say we're going to change the world and 
do this again. That's what we historically probably have not been doing, 
consciously pulling that off. ' Company-A-2, p. 11 
This should not, however, be taken as an argument for or against the `path dependency' of 
knowledge (Chapter 2, Section 2.2.4, page 27), since path-dependency was not generally 
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thought to be a problem in pharmaceutical research (or development). Although most 
interviewees recognized that existing ways of working might conceivably blind them to 
new ways of working, they felt that the scientific training of their research (and 
development) staff was such that existing knowledge was not a hindrance to knowledge 
interpretation or application, since the factual evaluation of data would overcome too much 
reliance on existing assumptions: 
`The whole process of drug discovery is one which requires the assessment of 
experiments that have gone before as well as those that are new ... 
Sometimes 
current opinion will suggest that a particular outcome will result or something 
cannot be done, but as long as that is an opinion then it is nothing more than an 
opinion. If you can say that you can't do that and here is the objective 
information, then it is not an opinion, it becomes factual. You may have 
overlooked something but it's not an opinion any longer. So in that respect, I 
think factual evaluation of data gets around the old data being used wrongly. In 
that respect I don't think it's a hindrance. ' Adapted from Company-B, p. 20 
`I think people will come to particular problems with their own baggage ... They 
will be experienced research scientists and will know what Fred Bloggs did in 
1992 
... and so there is a knowledge set that they rely on ... [Yet], we have had 
examples where guys have said, "I want to try this, " but existing knowledge 
would suggest it wouldn't work. ... And we've said, "That won't work" ... And [they have gone] away and sometimes it does work. That's the nature of the 
business we're in ... They 
have a training that does try and make them think 
sideways and be creative. ' Company-I, p. 27 
At the same time, most interviewees felt that bringing in new knowledge from external 
sources - in the form of informal knowledge networking, formal collaborations, and 
hiring-in expertise - could add a new dimension or a new way of thinking (Liyanage et al, 
Chapter 2, Section 2.2.4, page 29) that could lead to revolutionary products or processes 
that might otherwise not have been thought of (Company-C, p. 7). 
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Knowledge Acquisition 
Even assuming that the researcher has a clear idea of how he/she is to initiate a project, 
with the diverse and complex nature of the scientific and technical knowledge that exists in 
the pharmaceutical field it is unlikely that he/she will know everything that is needed to 
proceed with that project (Chapter 2, Section 2.2.4, page 26). Neither will he/she have the 
time to learn from scratch what is needed. If knowledge is available elsewhere, then why 
not use it? `Not invented here' was not thought to be a problem in pharmaceutical 
research, and knowledge acquisition was said to be of significant importance to all 
researchers, whether they are pharmaceutical, biopharmaceutical, or biotechnology based. 
Indeed, it is part of `due diligence feasibility in both research and development in order to 
understand what is possible and what might be possible (Appendix 5.5, page A20). Since 
the knowledge that is deemed relevant at any one time may come from any quarter 
(Appendix 5.3, page A 11), a flexible approach to knowledge acquisition is needed. It is 
important to have access to a range of knowledge sources and to keep a range of 
knowledge channels open. 
Access to the latest scientific papers is particularly important for increasing the 
understanding to the individual of the disciplinary status quo (Mansfield, Chapter 2, 
Section 2.3.1, page 51). This, in turn, may lead to new ideas or solutions for existing 
problems. Abstracting services for such sources are increasingly available over the 
Internet, although, as pointed out by one interviewee, it is not always possible to determine 
whether a scientific paper is or is not relevant to one's own work until it has been read. If 
payment for the service is high, this can restrict the knowledge accessed by the company 
(Company-G, p. 12). 
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Patents and patent applications also provide some scientific information, although this may 
mean that a preferred research approach may no longer be commercially viable. They also 
provide commercial information regarding a competitor's existing and possible future 
activities (Company-I, p. 26). Most of the larger companies have library support services 
that assist their research (and development) staff in making literature and patent searches 
(Appendix 5.5, page A20). 
Scientific databases can be useful aids in problem solving. For example, compound 
databases provide information on chemical structures and properties, and hence suggest, to 
the knowledgeable user, the likely reactivity of a particular material under specific 
experimental conditions, and, in turn, the likely effect of a final drug product on the living 
system. Such databases are often company-based, but are frequently open to and accessed 
by researchers outside the organization. Simulation software goes one step beyond these 
information databases to actually simulate the chemical reaction or the effect on the body, 
and might therefore be thought of as knowledge databases (Appendix 5.7, page A29). 
These tools cannot (yet) replace actual experimentation, since the `knowledge' they 
contain is far from complete, but they can give an indication of which chemical route 
might offer the best approach for the synthesis of a particular drug. 
One way that companies can acquire knowledge directly is by hiring-in knowledgeable 
employees (Allen, Chapter 2, Section 2.3.1, page 59). Companies tend to do this when 
they are moving into new areas of research. They will employ an expert in the new field 
and then grow their own people around that expert (Appendix 5.5, page A20). 
We would positively recruit to get that expertise, because you can grow it in- 
house, but if someone already has the experience you've got a flying start ... 
We 
would ... recruit someone with 
the knowledge and experience that we need to 
set up a group and then we would grow the group. ' Company-B, p. 17 
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When the amount and type of work varies, companies may use contract research 
organizations for similar purposes. Relationships with contractors can be long term, 
especially when the contractor has expertise in an area of particular interest, and in this 
event a considerable understanding may develop between the internal and external staff 
involved about the knowledge they each hold and their various ways of working 
(Company-H, p. 10). 
Knowledge may also be acquired as each individual networks with others, both within and 
external to the organization. However, since such activities are more normally thought of 
as ways of sharing knowledge they are described in the following subsection. 
Knowledge Sharing 
In the initial stages of research, knowledge sharing is overwhelmingly a result of the 
informal knowledge networking activities that occur between industrial and academic 
scientists, essentially on an individual rather than a company basis (Appendix 5.7, 
page A23). These networks would appear to resemble the social circles recognized by 
Crane (Chapter 2, Section 2.3.1, page 54): 
`Informal knowledge networking in the scientific disciplines is widespread and 
vital and crosses organizational boundaries. Networking is part of the scientific 
process, part of the quest for the scientific truth. ' (Company-B, p. 22) 
`There is a culture of collaboration and sharing; ideas, information and 
knowledge are exchanged, as is traditional in the wider scientific community. ' 
(Company-A-1, p. 19) 
Most interviewees suggested that their researchers tend to keep certain 'community of 
practice' networks active, whatever the work they are doing, in order to keep abreast of 
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new developments within their principal discipline (Company-G, p. 21; Company-B, p. 22; 
Company-H, p. 14; Company-I, p. 31). However, they will also form new networks as and 
when the work requires them to do so (Company-G, p. 16; Company-H, p. 12). 
Most companies do recognize the need for their R&D staff to share basic scientific and 
technical information, and the knowledge behind that information, outside their 
organizational boundaries, and they do encourage, or at least accept, these informal 
knowledge networking practices. They recognize that to progress their work further 
researchers need to bounce their ideas off each other. They also recognize that in many 
instances the people with the experience and knowledge to appreciate and expand upon 
those ideas are external to the organization (Company-H, p. 15). Several interviewees also 
referred to `serendipity' and the importance of being in the right place to gain the right 
knowledge at the right time (Company-I, p. 28; Company-H, p. 5; Company-A-2, p. 9). 
Attendance at conferences (and the informal meetings that invariably occur before and 
after conference sessions) is therefore generally encouraged to enable network building. 
Most (but not all) companies also encourage their staff to give presentations or publicize 
non-sensitive material: it is part of the reward system. They recognize that even industrial 
scientists are motivated to some extent by the need to be revered by their scientific peer 
group: 
`To some extent scientists are differently motivated from other people ... There 
goal in life is not necessarily to promote the company's activities, it is more to 
be seen as important by their own peer group. So going to conferences and 
getting publications and that kind of networking, they see that as their 
community rather than the company. ' Company-G, p. 21 
`Scientists do like to have recognition and they do like to talk about their work at 
conferences and so forth ... 
People who work in this industry want to be 
recognized as experts, and the way to do that is through publications, through 
presentations and so forth. ' Company-A-4, p. 3 
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And, not only can such activities build the reputation of the researcher, they can also build 
the reputation of the company in turn (Company-G, p. 23). 
Accepting that reciprocity is part of the knowledge sharing process (Brown and Duguid. 
Chapter 2, Section 2.3.1, page 54), companies trust their staff to, or at least hope that their 
staff will, consider the commercial implications of the knowledge being shared. Some also 
take a pragmatic view, recognizing that, come what may, knowledge sharing will occur; 
that knowledge may be gained as much as, if not more than, is lost; and that in a rapidly 
changing environment the value of the knowledge exchanged is in any case reduced to zero 
within a very short time: 
`So it is a fine balance between sending people off to conferences so they can 
learn about what everyone else is doing and [everyone else] finding out what 
we're doing at the same time. ' Company-A-4, p. 4 
`There is a tension between the commercial needs for secrecy and the academic 
world in which information is supposed to be freely available. So when they go 
to conferences ... they ... 
have to tread quite a fine line ... I always think, 
if 
there's one of your scientists and there's a hundred other people does that mean 
you're going to learn a hundred times more stuff than you actually give out? 
Maybe! ' Company-G, p. 21 
`I think ... most of the 
information people are going to tell each other has 
probably, as a currency, lost its value within six months. ' Company-I, p. 33 
Several interviewees suggested that informal knowledge networks can influence the 
research that companies undertake, since not only are they a source of ideas that may be 
novel to the company (Company-B, p. 24; Company-C, p. 9), but they may also influence 
the knowledge acquired by the individual worker (Company-B, p. 25) and thus the work 
carried out by that worker. 
Informal research (and development) networks can also provide routes to commercial 
networks: 
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`Often you can perceive that you've got a particular product/ opportunity that 
would be ideal [for another company], but you ... 
haven't established a proper 
network into that organization to know who is the right person to target. But 
often you suddenly discover that you know a young research scientist ... and his 
mate ... 
has just joined the company you're interested in ... And often that route 
opens the door to get you into who you should talk to, and that's been successful 
on more than one occasion. ' Company-I, p. 32 
In general, interviewees felt that the new communications technologies had enabled faster 
and more time friendly internal and external networking in both research and development 
(Rothwell (1992), Ahmed (1998), Chapter 2, Section 2.2.5, page 32), but had not 
significantly altered the networking patterns between the various groups. Staff were said 
to now email each other rather than talk to one another, even when they work in adjacent 
offices (Company-H, p. 17). However, the new technologies may have increased 
networking throughout the company as a whole. For example, in at least one company, 
staff now copy emails to their managers where telephone conversations would not, 
formerly, have been recorded or reported. The manager is now part of the network and, 
thus, has a better idea of what is actually happening (Company-H, p. 18). Although not 
specifically questioned, the impression given was that, in general, these actions were not 
political manoeuvrings on the part of the researchers to curry favour with their bosses 
(Hayes and Walsham, 2000, p. 79), but were genuine attempts to diffuse the knowledge 
thought necessary to all concerned for future decision making. Perhaps, in this instance, 
the manager was included in what was deemed to be a `safe enclave': a shared social space 
where researchers' underlying views could be expressed freely, allowing for discussion 
and reflection on the different ways of working (ibid, p. 83). A more cynical view, 
although not the one taken by the present author, might be that researchers were merely 
covering themselves against future problems. While perceptions about the significance of 
networks vary, Table 5.4.2 (next page) summarizes interviewees' assessments of the 
relative importance of the more frequently used research networks. 
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TABLE 5.4.2: NETWORKS SUPPORTING PHARMACEUTICAL RESEARCH 
Network type Relative Importance 
Internal Variable. Increasing as the research progresses. 
Community of High. Important for idea generation, building and consolidation, 
Practice and generally for scientific and technical knowledge sharing, 
building and advancement. 
Customer High. The aim is to meet the unmet medical needs of the patient. 
Supplier Low. 
University/ Research High. They are a major source of ideas for innovative projects and 
Institute of compounds for drug development. They also support PhD 
studentships. 
Companies in related High. The research in pharmaceutical companies is very highly 
fields influenced by what is happening in the biotechnology fields and 
vice versa. 
Government Generally low, although National Health Organizations may 
influence some research activities. 
Other The World Health Organization and Opinion Leaders can influence 
the work undertaken. Competitors' actions are also important. 
Although knowledge creation in pharmaceutical research is initially an individual activity, 
in the larger companies it soon becomes a disciplinary and later a multidisciplinary, if not 
transdisciplinary, activity as scientists in one discipline begin to work with scientists in a 
range of other disciplines (Section 5.3.2, page 168): 
`The purpose of those [multidisciplinary] project teams is to head towards more 
specific biological activity, which means ... understanding 
how the chemistry 
interacts with the biology ... 
So the chemist might say, "Here's my chemical 
route to make that compound. " And the biologist may say, "And here's the 
biochemical pathway that applies. " But they have to come together, because if 
they don't there is no point in trying to rationally design the next compound, to 
know why this worked or the reason it didn't. ' Company-B, p. 28 
Knowledge sharing through the auspices of team working therefore plays a part in the later 
stages of research, with review meetings serving as the forum for the introduction of and 
discussion about the more general scientific and technical advances of interest. 
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External collaborations do occur at the research stage but these generally take the form of 
`blue skies' research undertaken by research institutes or biotechnology companies, in both 
instances usually for pharmaceutical companies. They are for work that cannot be carried 
out within the pharmaceutical company due to either commercial pressures or perhaps due 
to insufficient in-house specialist knowledge, and, as such, they are essentially knowledge 
`acquisitions' by the pharmaceutical company for payment of a `fee'. Some knowledge 
sharing may occur between company and academic researchers during these 
collaborations, but in most cases contact usually only becomes important at the 
development stage. 
Principal Knowledge Types, Processes, and Techniques used in Research 
With reference to Chapter 2, Section 2.2.6, Table 2.2.1 (page 34), the types of knowledge 
used during research activities can be summarized as basic scientific and technical 
knowledge with some design and manufacturing knowledge. The major knowledge 
processes may be summarized as scientific and technical knowledge creation through 
exploration and experimentation, based mainly upon knowledge acquisition and sharing 
through literature searching and informal community of practice networking. That is, the 
knowledge and knowledge processes mainly associated with first generation R&D and 
Mode 1 working. However, in order to produce a `prototype' product some 
transdisciplinary knowledge application is also necessary. 
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5.4.2 Pharmaceutical Development 
Knowledge Creation 
Section 5.3 has shown us that development is about applying the results of research (either 
internal or external to the organization) in order to produce a new product or process that 
can be used or sold for financial gain (Jewkes et al, Chapter 2, Section 2.3.2, page 64). It 
is about exploiting existing knowledge to produce new knowledge. And, it is about 
knowledge production in the context of application (Gibbons et al, Chapter 3, 
Section 3.4.1, page 103). Developers are trained in the same scientific and technical 
disciplines as researchers and they bring this knowledge to bear on the work they 
undertake. They do, however, use this knowledge in a more applied sense, looking to 
mould the research product or process into something that will meet the stringent 
requirements needed for regulatory approval. To some extent, the work of development is 
therefore determined by reference to standard procedures (Jewkes et al, Chapter 2, Section 
2.3.2, page 64), although it is also about modifying these procedures when they are no 
longer appropriate. It is also about producing a product that can be manufactured 
efficiently and effectively and to strictly controlled quality requirements. Development 
thus also relies on the knowledge associated with product and process design. In addition, 
development is about matching the properties of the product or process to the needs of the 
business, and about achieving this match within commercially sensitive cost and time 
scales (Jewkes et al, Chapter 2, Section 2.3.2, page 64). Commercial knowledge is an 
integral factor in deciding development activities; in research it is used more for guidance. 
These requirements mean that the acquisition, sharing and subsequent application of 
existing knowledge are also important knowledge processes in pharmaceutical 
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development, but they also mean that the techniques employed in development differ 
significantly from those used in research (Table 5.4.3, below). 
TABLE 5.4.3: KNOWLEDGE PROCESSES AND TECHNIQUES EMPLOYED IN 
PHARMACEUTICAL DEVELOPMENT 
Knowledge Process Technique Major Use 
Knowledge Creation Exploitation Idea generation, problem solution 
Knowledge Application Project team working with Project selection, design, 
due regard to standard implementation, and evaluation 
procedures and regulations 
Knowledge Acquisition Individual networking Accessing procedural knowledge 
for regulatory approval 
Licensing Product and process acquisition, 
developing product expertise, 
gaining financial resources, 
reducing development time 
Knowledge Sharing Team working Project implementation 
Knowledge networking Idea generation, problem solving, 
and the advancement of science 
and technology 
Formal collaboration Resource (financial, scientific, 
and technical, and human) 
acquisition, idea generation 
(technical and commercial) 
Company reporting To review and focus activities 
Knowledge Application 
The need for continued scientific, technical, and commercial input means that knowledge 
application in development is invariably a multifunctional team-based activity 
(Section 5.3.2, page 168), with team membership typically including staff from regulatory, 
manufacturing, and marketing departments, in addition to the various scientific and 
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technical units. When formed as the result of collaborative ventures, teams will also 
contain members from outside the organization. In all instances, team selection is based 
upon the capabilities and competencies needed for the task in hand (Kanter (1983), Best 
(1990), Leonard-Barton (1995), Chapter 2, Section 2.3.2, page 64). 
Since the development process follows a fairly structured and regulated route, what is 
required in one instance is often the same as what is required in another instance. Projects 
can therefore be defined, designed, scheduled, implemented, monitored, and controlled. 
Consequently, they are amenable to the standard practices associated with traditional 
management approaches (Section 5.3.2, page 171). 
The procedures employed may be discipline, task, or project-related. Scientific and 
technical databases may contain information regarding discipline-based practices which 
may help in project implementation. Internal company or local authority reports are often 
available outlining the steps for obtaining regulatory approval. Development updates and 
end-of-project review meetings are used for consolidating or improving existing practices. 
Such meetings allow for two-way communication, and hence cater for discussions 
regarding the applicability of using an existing approach in a new context: the judgement 
call is informed. They may also highlight problems encountered, and enable solutions to 
be suggested. Incident reports, case reports and `lessons learnt' databases pinpoint project 
problems encountered and overcome in a particular context, but their applicability in 
another context may be unknown: the judgement call is perhaps less informed. 
Several interviewees felt that their companies had not always been particularly effective in 
using much of the experience that they had available to them: 
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[The company] hires people, like myself, who've got very relevant experience in 
the industry or in similar industries ... and we're saying, `Well from my 
experience in my past company you do this, this, and the other. ' And that is 
possibly not acted upon as often as it ought to be. ' Company-G, p. 15 
One company was tackling this problem by promoting `action-based learning' techniques. 
An example given was that of cross-team participation: the team that has recently 
completed a project, actively shares its knowledge and ways of working by participating 
with a new team that is in the early stages of a project (Company-A-1, p. 14). It was noted 
that although the members of the old team were happy to share their thoughts and ideas 
with the new team, there was a degree of reluctance on the part of the new team, 
particularly the scientific members, to learn from the old. This was attributed, in part, to 
the need to see the relevance of what had been done before, and then to apply the lessons 
learnt: 
`It's not so much a problem getting people who have just completed to share 
their knowledge, they are usually very happy to share it. It's more a problem 
editing it ... and making sure that 
it's relevant ... The 
biggest problem I find is 
getting people to reflect on that data, turn it into information that they can use 
and then behave differently as a result of it ... 
Sometimes it's because they have 
a real belief that their team or their compound is so different to this other one 
that it couldn't possibly apply to them. Sometimes it's difficult because they 
don't have time to apply it; they're so swept along by the whole process. So that 
to me is where the crunch is, of actually getting people to apply what other 
people have learnt. ' Company-A-3, p. I 
It was also thought to be due to the early scientific training of these workers, which 
emphasized individual questioning and learning by experimentation rather than learning 
from others: 
`I think ... we employ people 
[scientists] who are not inclined to learn from 
other people, they're inclined to learn from their own experience... I think it is 
absolutely to do with their training. They're taught to not take anything at face 
value, `Test it out for myself. ' Company-A-3, p. 2 
But, additionally, it was thought to be due to a degree of scientific arrogance: 
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`But it is also about, `Well why should I learn from you? I'm different. ' 
Company-A-3, p. 2 
Once such a process was seen to be useful, it was said to work well (Company-A-1, 
p. 8). However, a problem was voiced about how to get the project team `learning' back to 
the technical lines in general. This was thought to be important, first so that others could 
learn the same lessons, and second so that team members could be recognized and justly 
rewarded for what they had achieved: 
`So 
... we can see compound teams learning but we don't necessarily [see] individuals back in the line learning ... What I'm not clear about at the moment is whether there is a drive to do `learnings' back in the line, if you like in the 
professional line. I think that's very important, and until we start doing that you 
don't get managers absorbing `learnings', therefore you don't get people being 
rewarded for having learnt and put things into practice. ' Company-A-3, p. 3 
Knowledge Acquisition 
As implied in the previous subsection, the success of a development project is dependent 
upon the effective synthesis of commercial and technical information. For example, raw 
material, product, and manufacturing costs; health and safety and material handling 
requirements; regulatory issues; as well as market needs will need to be known (and met). 
Knowledge of competitor clinical trials may also indicate whether a particular 
development approach is justified or should be abandoned for either technical or 
commercial reasons. 
Individual knowledge networking was particularly important in helping staff to develop an 
understanding of what would be expected for future regulatory acceptance: 
'I did some interviews ... with some people who were going to 
leave the 
company for retirement ... 
Something that a couple of people who had been here 
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a long time were very concerned about was the relationships that they'd built up 
with people in government positions, in hospitals, in wherever, [that meant that] 
... there was a general understanding of what [was] required to do a clinical draft or whatever, so that they could very quickly ... get those sorts of things done 
... those sorts of relationships were 
[going to be] lost, and would take 
another fifteen years to get back. ' Company-A-4, p. 4 
In-licensing agreements are used extensively to gain access to both technology and 
products (Appendix 5.5, page A20; Chapter 2, Section 2.3.1, page 52). Pharmaceutical 
companies in-license technology from the newer biotechnology companies to increase their 
knowledge about the latest analytical methods and techniques, and they in-license drugs 
from biopharmaceutical and other pharmaceutical companies in order to gain competitor 
knowledge and fill or augment their product pipelines. Biotechnology companies in- 
license technology from academic research centres and other biotechnology companies to 
gain additional technical knowledge, and they in-license drug product from pharmaceutical 
companies in order to test their own technologies. Biopharmaceutical companies in- 
license drugs and technology from research institutes and other companies to build their 
strengths in drug discovery and rapid product development. Indeed one of the companies 
in this sector undertakes all of its development work using in-licensed products (Appendix 
5.5, page A20). In contrast to Dickson and Hadjimanolis' findings (Chapter 2, Section 
2.3.1, page 52), the exclusive use of licensors does not appear to have had a negative affect 
on the wider learning and accumulation of expertise in this particular organization. The 
difference, perhaps, is that knowledge (as well as information) is being acquired. In 
agreement with the findings of Quintas and Brauner on outsourcing activities (Chapter 2, 
Section 2.3.1, page 52), this particular company has perhaps retained the capability to 
understand and assimilate the external knowledge and combine it with its internal 
resources and capabilities. This is something that is perhaps easier to achieve when 
scientific knowledge is involved, as in this instance. Whether this particular approach 
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would continue to be viable was, however, questioned on the grounds that it is now much 
easier for academics to obtain venture capital to set up their own companies and develop 
promising candidate drugs themselves (Company-G, p. 14). 
One company's in-licensing agreement is another company's out-licensing agreement. 
And, whilst in-licensing may bring a dependency upon others for new knowledge, out- 
licensing offers a company the chance to use its knowledge on a wider basis and in 
different ways, often for direct financial gain. What is interesting in the pharmaceutical 
industry is that many companies participate in both activities to roughly equal degrees. 
So, like in-licensing, out-licensing is also a major activity for all of the companies in this 
study (respectively, Appendix 5.5, page A20, Appendix 5.6, page A22). The use of in- 
licensing and out-licensing together means that, at the development stage, rather than the 
possibility of one company becoming dependent upon others for new knowledge 
acquisition, or one company exploiting its knowledge to others for financial gain, all 
companies within the pharmaceutical industry are to a degree dependent upon each other 
for knowledge acquisition and its subsequent application. 
The larger pharmaceutical companies usually have a central function looking into in- 
licensing and out-licensing opportunities. They usually (although not always) out-license 
non-core products and technology. Out-licensing provides additional revenues for internal 
research and development, and, in the case of smaller companies, may provide sales access 
to new geographic markets. Cross-licensing of products between major pharmaceutical 
companies also occurs so that they can each effectively avoid monopoly situations and 
subsequent government interference in their operations. 
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Out-licensing is particularly important for the smaller biopharmaceutical companies. 
These companies, at least in the early years, do not have the financial resources to pay for 
the huge costs of drug development and neither do they have the marketing and sales 
forces needed for final product launch. They therefore rely on out-licensing their 
intermediate stage product (researched to `proof of concept') to large pharmaceutical 
companies to gain financial resources for further in-house R&D. Payment to the 
biopharmaceutical company is typically in the form of either (a) an annual licence payment 
plus a percentage on final sales, or (b) total payment for the continued development of the 
product to launch. Option (b) is often chosen initially, although access to venture capital 
can negate the need for this approach and consequently favour option (a). As the 
biopharmaceutical company becomes `cash' rich it tends to opt increasingly for option (a), 
until eventually it has sufficient resources to develop products entirely in-house. In so 
doing, the company removes the risks associated with R&D from the eventual buyer and 
can thus ask for a higher premium on sales. A number of US biopharmaceutical 
companies have pursued this strategy very effectively and now have the resources to 
compete with the traditional pharmaceutical companies that have often paid for their early 
development. 
Out-licensing is also a necessity for most biotechnology companies. These companies 
have a (new) technology that is an aid to drug research and development, but their 
knowledge of particular drug treatments and drug effects is often minimal. Neither do they 
necessarily see drug development as part of their business remit, at least when they are 
initially founded. They need both the finances and the knowledge of the pharmaceutical 
companies to fully exploit their technology. At the same time, pharmaceutical companies 
are always looking for ways in which they can reduce the time and costs of drug R&D. 
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A technology that offers such advantages is obviously worthy of consideration. These 
alliances between biotechnology companies and pharmaceutical companies are said to be 
extensive and usually successful. Perhaps the major reason for their success is that it is in 
the interests of both parties that the technologies are developed as far as may be possible. 
However, in time, biotechnology companies may themselves decide to move into drug 
development. There will then be a move from a model of `mutual collaboration' to one of 
`competition'. Who will be the winners and who the losers, or can all companies remain 
winners? The pharmaceutical companies have an edge in that they have the resources and 
abilities to access a whole range of technologies. The biotechnology companies have an 
edge in that they can concentrate on developing one or perhaps several technologies to gain 
further advantages. The question is, `For how long will those technologies remain the 
technologies of choice? ' 
Knowledge Sharing 
In development, the sharing of project-related knowledge is through the auspices of team 
working, whether or not these teams are formed as the result of a formal collaborative 
venture (Appendix 5.8, page A30; and page 189 above). In the larger companies, manuals 
may also exist for training new starters in business awareness, and verbal briefings may 
provide updates on company-wide issues. Company intranets are common to all 
organizations, but their usage can vary - perhaps in relation to the particular `politics' of 
the situation (Hayes and Walsham, 2000, p. 83; Newell et al, 2000, p. 90). Key business 
priorities are, however, generally cascaded throughout organizations to ensure a unified 
focus and purpose to the work being undertaken (Appendix 5.7, page A26). 
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Working in multidisciplinary and multifunctional project teams was said to enhance 
knowledge continuity between research, development and the commercial activities, and 
increase the common understanding of what is required from all workers (Kanter (1983), 
Best (1990), Leonard-Barton (1995), Chapter 2, Section 2.3.2, page 64). Task-related 
difficulties, possible solutions, and the likely business implications are shared within the 
team as they arise and do not have to await the advent of the next review meeting. Delays 
in operational decisions are thus minimized (Appendix 5.7, page A26). 
Working together in multifunctional teams also offers opportunities for team members to 
begin to understand and appreciate the workings of other departments. However, since 
development teams in the UK pharmaceutical industry consist of people who bring their 
own particular skills (functional and discipline-based) to the process, the extent to which 
these team members share the same `language' is likely to be severely restricted compared 
to their multi-skilled Japanese counterparts (Ray and Little, Chapter 2, Section 2.3.2, 
page 69). In addition, the fact that development teams are usually relatively short-lived 
(although some in the pharmaceutical industry may last for 8-10 years) further reduces the 
likelihood of any in-depth shared understanding. On the other hand, the fact that teams are 
dissolved and new teams are formed with different members means that the diversity of 
knowledge that is brought into the process increases and with this may come the chance of 
some unique solutions. 
Knowledge networking does occur in development but not to the same degree as in 
research. Knowledge networks are important for individual development scientists and for 
much the same reasons as for research scientists - to expand their scientific and technical 
knowledge - but the 'rules of engagement' differ. Owing to the commercially sensitive 
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nature of development, external knowledge networking in development is, in line with 
Myers and Marquis' (1969) and Oliver and Liebeskind's (1997/98) findings (Chapter 2, 
Section 2.3.2, page 67), restricted to matters that are more general: 
`As things progress ... 
into development, people become much more secretive 
... 
I'll go along to a meeting and I'll talk to my opposite number and be very 
friendly, but we wouldn't dream of giving each other anything that could be 
construed as proprietary information. ' Company-H, p. 14 
The relative importance of the networks used to support development is suggested in 
Table 5.4.4 (below). As mentioned in the preceding subsection (page 192), networks with 
the regulatory authorities are very useful in gaining an understanding of what is currently 
required for product licensing. And, long-term networks between company employees and 
the regulators, built upon mutual trust and shared understanding, can aid in the acceptance 
TABLE 5.4.4: NETWORKS SUPPORTING PHARMACEUTICAL DEVELOPMENT 
Network type Relative Importance 
Internal High within project teams. Moderate across project teams. 
Community of High. Important for problem solving and for idea generation, 
Practice building and consolidation. Fairly important for scientific and 
technical knowledge acquisition and sharing. 
Customer High. Drug trials are dependent upon volunteer patients. 
Supplier Low, although they can act as advisors to projects. 
University/ Research Generally high. Support is both formal through agreed contracts 
Institute and informal through old pals' networks. 
Companies in related High between pharmaceutical and biotechnology organizations, and 
fields between these organizations and clinical research organizations. 
Government High from a regulatory perspective. Limited as regards the 
provision of grants. 
Other Trade Associations help build industry consensus. Business 
Associations may also promote scientific and technical 
development initiatives. Partner organizations can profoundly 
affect development progress by providing knowledge, resources, 
funds, etc. 
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of new procedures (by either the organization or the regulatory authority) when these are 
necessary. On the other hand, networks within Trade Associations help to harmonize 
industry views about what should be required in the future (Appendix 5.7, page A25). 
And, Trade Association lobbying enables a more coordinated approach to be taken when 
existing regulations are seen to be inappropriate by industry members. Knowledge 
networks in development are therefore closer to those of the technologists described by 
Allen (Chapter 2, Section 2.3.1, page 58); although the role of technological gatekeeper 
would appear to have diffused down to the individual scientists (Chapter 2, Section 2.3.1, 
page 60). 
Participation in government initiatives to encourage informal knowledge sharing between 
organizations is limited. Several interviewees felt that many of the technical areas dealt 
with in pharmaceutical development do not have direct equivalents in other industries. 
The opportunities for cross-industry learning were therefore minimal. On the commercial 
side, the pharmaceutical industry in the UK is also different to most other industries in that 
direct sales and advertising to the consumer is not allowed. Management techniques were 
thought to be the exception to the rule whereby cross-industry networking might prove 
helpful (Company-A-4, p. 14; Appendix 5.7, page A27). In reality, only one of the 
companies studied was involved in such a government initiative. Called `London First', 
this was described as a `government quango' which promotes industry and infrastructure in 
the London area. Mixing chief executives, business managers, academics, industrial 
scientists, intellectual property advisors, venture capitalists, etc., it was formed to 
encourage closer collaboration between industry and the London Research Hospitals, to 
everyone's mutual benefit (Appendix 5.7. page A27). Whilst having no clearly defined 
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benefits to report, London First was said to be well supported and did provide a degree of 
scientific cross-fertilization. 
Whilst strategic scientific and technical knowledge is rarely shared through external 
informal knowledge networks during development, it is shared through formal 
collaborative ventures. Collaborations usually occur between pharmaceutical, 
biopharmaceutical, or biotechnology development units and universities or other research 
institutes; and between the development units of pharmaceutical companies and those of 
either biotechnology or biopharmaceutical companies. Collaborations may also occur 
between biotechnology companies, who are increasingly combining their technologies to 
develop new ways of doing things (Appendix 5.8, page A31). 
In line with the literature reports (Chapter 2, Section 2.2.4, page 26), the main reasons 
given for such partnerships were to gain resources, share costs, or generate ideas. They 
provide the financial and commercial resources needed by younger and smaller companies 
to enable them to develop their products or processes further. They provide the scientific 
and technical expertise that is not available in-house (Company-G, p. 17). They suggest 
ideas for novel products that would not have been thought of or made possible by in-house 
development alone (Company-B, p. 21). And, they give older companies access to the 
latest patented knowledge, which might not necessarily be available to them through any 
other arrangement (Company-I, p. 29). An additional reason mentioned for collaborations 
with the universities and research institutes was that companies have a vested interest in 
fostering relations with these institutions, since they ultimately provide the new 
generations of company scientists and technologists upon which their R&D departments 
depend (Company-B. p. 15 ). 
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Collaborations of all types were viewed as bringing benefits to all parties involved, 
although it was recognized that this was sometimes at the cost of increased complexity of 
working, some lack of overall control of the process, shared ownership of the outcome, and 
the possible need for conflict resolution (Appendix 5.8, page A33). Collaborations 
between academia and industry were said to be particularly prone to conflicts of interest 
because of the different perspectives employed by the participants. The academic pursuit 
of scientific excellence is not always necessary for the effective development of a 
commercial product or process. 
Collaborations in the pharmaceutical industry are always formal in nature, that is, they are 
always agreed by contract. This is because patent rights and technology know-how may 
ultimately provide the huge sums of money required for continued commercial viability. 
However, in line with Ray's findings (Chapter 2, Section 2.3.2, page 67), most 
interviewees felt that once a collaboration was established it was important that all parties 
to the collaboration should share their knowledge and work as one team without the 
restriction of bureaucratic controls or the hindrance of `red-tape' (Appendix 5.8, 
page A31). 
Existing collaborations often suggest ideas for further work. This may result in the 
existing collaboration being extended or a new collaboration being formed 
(Company-C, p. 8). Successful collaborations may lead to further joint working between 
the same partner(s), because the expectation is that the new collaboration will also be 
productive. Alternatively, they may lead to new collaborations with new partners, because 
eventually the particular expertise brought into the organization by the original partner(s) 
will become part of the organization's own knowledge base. At that stage, new partners 
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are sought with different expertise to increase further the pool of in-house knowledge 
(Company-B, p. 23). 
The apparent success of collaborations in the pharmaceutical industry would suggest that 
the companies involved have perhaps struck the right balance between `renewal and 
stability' (Kumpe and Bolwijn, Chapter 2, Section 2.2.4, page 28). 
As noted in Section 5.3.2 (page 171), project management tools are increasingly being 
used to share project-related information. By informing others, it is hoped that the relevant 
knowledge held throughout the organization can be brought to bear at each and every stage 
of the project (Appendix 5.7, page A29). That is, project management is also viewed as a 
tool for knowledge sharing, and not simply as a method for control (Burton et al, 
Chapter 2, Section 2.3.2, page 66). By acting as a `boundary object' (Chapter 2, 
Section 2.3.2, page 68), project management tools have perhaps replaced any need for 
dedicated knowledge translators and brokers within the development process. 
A number of companies are looking into the use of electronic laboratory notebooks for the 
sharing of detailed technical information. A current `sticking point' is that verifiable data 
entry (a requirement for claiming patents in the USA) is not yet a possibility 
(Appendix 5.7, page A28). Experts' databases are used to point individual workers to the 
expertise and skills available within and sometimes external to the organization. Several 
companies also store project information in the form of `stories' databases: what was done, 
why it had been done, what were the lessons learnt, etc. Companies initially attempted to 
make the ' lessons learnt' sections of these databases context independent. Most now 
accept that this is difficult, if not impossible, to do, and rely on their trained and 
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experienced staff to make sense of the lessons of the past and, where appropriate, relate 
these lessons to the problems of the present. There was a consensus, however, that 
databases can become unwieldy and considerable resources are needed to keep them up-to- 
date. There is also the dissatisfaction that in any case databases cannot contain the 
knowledge, and neither do they usually contain all of the relevant information that is 
available within the company or that is necessary in order for people to carry out their 
work activities. And, even when databases do contain valuable lessons, people rarely have 
the time to make the necessary searches. As a result, some of the larger companies are 
now attempting to incorporate the latest knowledge and thinking into their day-to-day 
working practices rather than simply trying to provide `knowledge' in a database 
(Company-A-1, p. 15). The importance of such an approach is suggested by the fact that 
some companies are employing teams of people to make this happen: 
`Project management do have this big database of lessons ... 
The challenge is in 
getting it to the people to whom it matters, because these folk are extremely 
busy. ' [Company-A-1, p. 15] ... `The remit 
for ourselves is ... to try to mobilize 
this internal knowledge, primarily working between departments as the glue or 
the jelly if you like that holds things together. ' [Company-A-1, p. 1] ... 
`Do you 
start by capturing it all, building this big database and let people use it as they 
see fit? Or do you ... 
[ingrain] it in the day-to-day working practices? ... 
I 
think, the key thing is action-based learning, action-based knowledge; work with 
the people who are actually going to make a difference. ' Company-A-1, p. 6 
The process of cross-team participation outlined in the previous subsection on 
knowledge application (page 191) is an example of such an approach. 
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Principal Knowledge Types, Processes and Techniques used in Pharmaceutical 
Development 
With reference to Chapter 2, Section 2.2.6, Table 2.2.1 (page 34), the types of knowledge 
used during development activities can be summarized as basic scientific and technical 
knowledge, product and process knowledge, design and manufacturing knowledge, 
commercial knowledge (particularly marketing and legislative knowledge), and team 
working and project management skills. The major knowledge processes can be 
summarized as knowledge creation through exploitation and adaptation, based upon 
knowledge application and sharing mainly through team and collaborative working. That 
is, the knowledge and knowledge processes associated with third and fourth generation 
R&D and Mode 2 working. 
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5.5 Conclusion to the Chapter 
This chapter has described the approaches, the practices, and the knowledge processes 
employed within UK-based pharmaceutical R&D, which form the building blocks for the 
discussion presented in Chapter 6. In so doing, it has, to a degree, confirmed some of the 
findings of previous researchers. However, it has also demonstrated that overly simple 
models may do violence to the complex processes of pharmaceutical research and 
pharmaceutical development. Although the chapter has confirmed the importance of 
business integration (third generation R&D) and external collaboration (fourth generation 
R&D) as corporate R&D approaches, it has noted that such approaches occur during 
pharmaceutical development. In contrast, pharmaceutical research continues to reflect a 
science/technology pushed (first generation R&D) approach. Thus, what would seem to be 
reality at the corporate level is not necessarily so at the task level, a result that is perhaps 
not unexpected when we consider the different natures of research and development: 
research is about the exploration for something new, whereas development is about the 
modification or adaptation of something that already exists. 
Perhaps, most importantly, this chapter has detailed the way in which the practices of 
research differ from the practices of development. In research, project initiation is 
dependent upon the thoughts and ideas that originate from in-house technical or 
commercial teams, often influenced by leading-edge university research, and which may or 
may not fit with existing corporate strategy. Project management is flexible and non- 
bureaucratic, often discipline-based, and individualistic in nature. Project termination is by 
consensus based upon expert opinion. In contrast, in development, project initiation results 
from either in-house or external work that has passed the requirements of initial clinical 
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trials, and which is deemed both commercially and technically viable. Project 
management is traditional in the sense that projects are defined, designed, scheduled, 
monitored, reviewed and controlled to ensure costs and timescales remain within 
predetermined limits. Project teams are multidisciplinary, multifunctional, and often 
multi-site and multi organizational, but an essentially transdisciplinary approach is 
encouraged by giving control of the matrix of workers to specific project managers, rather 
than allowing control to be determined by either the technical or marketing functions. 
Project termination is affected by commercial and technical requirements. Again, these 
different processes can be related to the different natures of research and development. 
Whilst pharmaceutical R&D is dependent upon the acquisition, sharing and application of 
knowledge held throughout and external to the organization, the types of knowledge and 
the techniques employed to acquire, share and apply that knowledge differ significantly 
between research and development. Whilst research relies predominantly on scientific and 
technical knowledge, development requires a synthesis of mainly commercial and 
technical knowledge. Whilst flexible techniques such as personal networking are used in 
research for the acquisition and sharing of extra-organizational knowledge, more 
coordinated methods such as formal collaborative ventures predominate in development. 
And, whilst knowledge application in research is largely the remit of the individual, 
knowledge application in development is through the auspices of team working. The 
knowledge creation process in research is thus fundamentally different to the knowledge 
creation process in development, and this again can be attributed to the fundamental 
differences between research and development: research is about the exploration for new 
knowledge, whereas development is about the exploitation of existing knowledge. 
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Although knowledge creation in research shows many similarities with Gibbon's et al 's 
Mode I form of knowledge production - it is discipline based, it is individualistic, it does 
assume a linear view of science - it was noted that some transdisciplinary knowledge 
working is also necessary for a research product to reach `proof of concept' or `prototype' 
stage. At the same time, although knowledge creation in development has many 
similarities with these authors' Mode 2 form of knowledge production - it is carried out in 
the context of application, it is team-based, it is transdisciplinary - team formation and 
dissolution is ultimately governed by a management body and not through self-evolution. 
The Modes of knowledge production along with the knowledge creation models suggested 
by Nonaka and Takeuchi, Cook and Brown, and Polanyi are discussed further in Chapter 6, 
which, in addition, elaborates upon the reasons already suggested as to why things are as 
they are in pharmaceutical research and pharmaceutical development. 
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6 DISCUSSION 
6.1 Introduction 
This chapter takes another look at the literature outlined in Chapters 2 and 3 in the light of 
the findings of the empirical research presented in Chapter 5. 
First, Section 6.2 revisits the R&D generations approaches described in Chapter 2, 
Sections 2.2.1 to 2.2.6, to assess the extent to which UK-based pharmaceutical R&D has 
evolved, and might be expected to evolve towards the virtual learning systems 
characteristic of fifth generation R&D. The suggestion is that whilst pharmaceutical 
development may be expected to retain the business integration and collaborative 
approaches associated with third and fourth generation R&D, pharmaceutical research 
should continue to adopt the science/technology push approach of first generation R&D. 
The move from first to fifth generation R&D is far from being a certainty. And, as noted 
earlier in Chapter 2 (Section 2.1, page 15), the advent of a new R&D generation does not 
necessarily replace or negate the existence of former R&D generations. 
Second, Section 6.3 discusses the extent to which UK pharmaceutical R&D reflects 
Gibbons et al's modes of knowledge production outlined in Chapter 3, Section 3.3.1. The 
suggestion is that whilst pharmaceutical development might be described as a `Coordinated 
Mode 2 type' activity, pharmaceutical research may be more appropriately termed a 
`Transdisciplinary Mode 1 type' activity. Thus, whilst there might appear to be a move 
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away from the scientific discipline-based Mode 1 approach to the application-based 
Mode 2 approach, this is not the entire picture. 
Third, the chapter revisits the knowledge creation models outlined in Chapter 3, 
Sections 3.4.2 to 3.4.4, to establish the extent to which these models might be useful in 
explaining how knowledge is created in UK pharmaceutical R&D. By considering the 
various activities involved in the research and development processes, Section 6.4 suggests 
that, whilst the uncritical acceptance of Nonaka and Takeuchi's model of tacit-explicit 
knowledge conversion raises problems, their model does highlight the importance of 
knowledge sharing, concept generation, knowledge combination, and knowledge 
acquisition in contemporary corporate R&D. And, whilst the definition of different types 
of knowledge in Cook and Brown's `generative dance' between knowledge and knowing is 
perhaps questionable, their framework nevertheless does point to the fact that we use the 
knowledge available to us at the time to undertake the task in hand. Moreover, whilst 
Polanyi's model does not talk about organizational knowledge creation as such, it does 
nevertheless point us towards a better understanding of how individual knowledge is 
created, how individuals learn from others, and thus how knowledge might be created in an 
organizational setting. 
Fourth, Section 6.5 links context with practice to look at the reasons for why things are as 
they are, and concludes that it is the needs of research that influence the management of 
research, the knowledge needs of research, and knowledge creation in research, but it is the 
needs of the organization that influence the management of development, the knowledge 
needs of development, and ultimately how knowledge is created in development. The 
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suggestion is that research should be to some extent the master of the organization, 
whereas the organization should definitely be the master of development. 
Fifth, Section 6.6 discusses the implications of the various factors identified by the 
empirical research as being those most important in managing R&D in the pharmaceutical 
industry. In so doing, the section highlights the emphasis on commercial viability in 
development, whilst suggesting the need for a degree of exploration in research, factors 
which can explain the separation between the activities of research and development, but 
not of the people involved. 
Finally, Section 6.7 poses some questions and draws some conclusions. 
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6.2 The R&D Generations and Pharmaceutical R&D 
In recent years, collaboration in the pharmaceutical industry has been used as an exemplar 
of fourth generation R&D (see, for example, the work of Liyanage and co-workers, 1999). 
And, as confirmed by the findings in this study, collaborations do abound in this industry. 
Collaborations are formed between many players: mature multinational pharmaceutical 
giants; medium-sized biopharmaceutical companies; medium and small biotechnology 
companies; universities and other research institutes. And they are formed for the usually 
quoted reasons: to gain access to the latest scientific and technical knowledge; to gain 
access to business resources such as financial assistance, marketing knowledge and sales 
facilities; and to share costs (Chapter 5, Section 5.4.2, page 200). In essence, organizations 
collaborate to overcome their weaknesses and build upon their strengths. However, this 
study has also found that collaborations normally occur at the development stage. 
Although some research may be outsourced to universities or other research organizations, 
the finding was that corporate research is mostly carried out in-house. It is the outcome of 
that research (pharmaceutical, biopharmaceutical or biotechnology) that is then developed 
further through scientific and technical collaboration. It is perhaps therefore more accurate 
to say that pharmaceutical development is the example of fourth generation `R&D'. At the 
same time, and in line with third generation R&D, it is clear that both commercial and 
technical considerations hold the key to development, since projects will not be undertaken 
without a clearly defined business advantage and route to commercialization (Chapter 5, 
Section 5.3.1, page 166). 
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Despite the fact that pharmaceutical research is still very much built upon the 
science/technology push philosophy of first generation R&D (Chapter 5, Section 5.3.1, 
page 163), there are indications that this is increasingly being replaced with a 'business 
integration' (third generation R&D) approach. Expending money on speculative work that 
may or may not eventually yield vast returns is possible when companies are able to 
adequately recoup these costs. It becomes difficult when companies are increasingly 
called to reduce prices to meet government edicts, or to answer concerns about access to 
medicines and health care for the most vulnerable members of society (Chapter 5, 
respectively, Section 5.2.1, page 150; Section 5.2.2, page154). Whether or not a more 
business oriented approach is a good thing remains to be seen. Competitive innovation, 
driven by the quest for monopoly profits arising from being first-to-market, is particularly 
important in the pharmaceutical industry. Promises of such profits are fundamental to the 
financing of the expensive clinical trials needed for further drug development. In the past, 
the UK pharmaceutical industry has itself carried out a significant amount of basic 
scientific research in order to produce more advanced products and thus secure such 
profits. With the increasing pressure to achieve rapid commercial returns from an 
increasingly global market, companies might find it more difficult to create `space' for 
truly basic research. Although universities and medical research centres might be able to 
take up the shortfall, transforming promising ideas into prototype pharmaceutical products 
typically requires significant investment; investment that, politically, may not always be 
available. 
Regulatory harmonization within the European Union adds a further dimension to the costs 
of developing novel products and the benefits that might accompany their success. Given 
such high stakes it would seem important that the leading pharmaceutical companies make 
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every effort to coordinate their assessments of the viability or otherwise of promising R&D 
programmes. On this account, dealing with sources of invention outside the firm may 
offer substantial cost savings, but they can also accentuate concerns about trust: the 
apparent efficiency of collaborating with strangers can be overshadowed if these strangers 
fail to deliver what was agreed, or if they misuse sensitive information. 
If fourth generation R&D is a reality in pharmaceutical R&D (or at least in pharmaceutical 
development), is fifth generation R&D also a reality or could it become so? Viewed from 
an organizational perspective, there is reason for caution. Although some R&D projects 
may result from the `opportunistic alliances' formed during ad hoc meetings at 
conferences, during existing collaborative ventures, or simply during the normal course of 
research or development work (Chapter 2, Section 2.2.5, page 29), many more projects are 
the result of the purposeful search for and managed solutions to specific business 
objectives (Chapter 5, Section 5.3.1, page 163). If, however, we consider the informal 
networking activities between individual R&D workers, particularly at the research stage, 
then fifth generation R&D would appear to have existed for many years, since these 
activities do depend upon the mutual respect among R&D personnel distributed among a 
number of distinct operating entities, and, within these networks, there is the need and 
willingness to continuously learn from each other to create new knowledge as a way of 
adding value to the entire system (Chapter 5, Section 5.4.1, page 183). Repeat transactions 
in these informal networks can mean that participants, who come to know each other well, 
are able to trust each other's judgement, and make effective use of ideas that arise from 
elsewhere (thereby circumventing the negative implications associated with the `not 
invented here' syndrome). 
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In line with Rogers' fifth generation R&D (Chapter 2, Section 2.2.5, page 30), 
pharmaceutical management practices would appear to be fluid and flexible, especially in 
research, and management systems would appear to be collaborative (Chapter 5, Section 
5.3.2, page 167), with R&D now being just one part of a networked innovation system 
(Chapter 5, Section 5.4.2, page 202). However, whether R&D managers really think about 
their work in terms of `knowledge working' to include the `optimization and monitoring of 
knowledge flows' is perhaps questionable. Certainly, knowledge sharing is deemed 
extremely important and is actively encouraged, but knowledge optimization and 
monitoring implies a degree of control that might owe more to `industrial age' factory 
work than twenty-first century `knowledge work'. In addition, the assessment of 
performance in terms of intellectual assets is perhaps counter-productive in a team-based 
environment. Performance assessment in terms of the ability to create and apply new ideas 
in the market place is perhaps also inappropriate when failure rates are as high as they are 
in the pharmaceutical industry. In fact, all companies in this study recognized the need to 
support genuine failure, that is, failure that has resulted because of the unexpected need for 
further knowledge, or because of the unforeseen outcomes of the experimental search for 
new knowledge. Certainly the major shifts that Rogers notes (Chapter 2, Section 2.2.5, 
page 30) are happening in practice, but whether these will ultimately result in the 
collaborative learning networks exactly as envisaged in her conception of fifth generation 
R&D is doubtful. 
Pharmaceutical R&D practices also illustrate many of Ahmed's suggested fifth generation 
`success factors' (Chapter 2, Section 2.2.5, page 32). For example, the importance that 
Ahmed attaches to innovation and discovery continues to be a distinguishing feature of 
leading innovators in the pharmaceutical sector. Similarly, his idea that fifth generation 
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R&D should encourage the internal sharing and processing of ideas has become 
increasingly important. However, Ahmed's vision of a culture of `equals' raises questions 
about what is meant by equal. Innovation turns on the capacity of individuals to imagine a 
difference, and the extent to which the organization is able to `make a difference'; an 
undue focus on equality can distract attention from the relationship between diversity and 
the power to innovate. Also, Ahmed's suggestion that fifth generation R&D will result 
naturally from the increased utilization of the new telecommunications technologies 
(Chapter 2, Section 2.2.5, page 32) is not born out by this present study. The findings 
herein suggest that although these technologies have aided communications between R&D 
workers and others, they have not substantially increased or altered the communication 
linkages or the way in which collaborative ventures develop (Chapter 5, Section 5.4.1, 
page 185). There is a fundamental difference between advances in electronic 
communication, as a tool for communicating, and the incentive to use that tool. In 
addition, in line with Rothwell's approach (Chapter 2, Section 2.2.5, page 30), formal 
collaborations are very much dependent upon a `managed' approach towards meeting the 
organization's objectives. R&D strategies are now more planned than emergent, and in an 
industry that is increasingly under pressure to reduce costs it is hard to see that this will 
change. For the near future, fifth generation R&D practices, at least in the UK 
pharmaceutical industry, are likely to be limited to the informal workings between 
individual R&D employees rather than between different organizational entities. 
Another reason why virtual R&D laboratories may not be appropriate to an organization's 
need for flexibility and economy stems from the shared understanding that is inherent 
among organizational insiders: where members of a single organization share a history of 
working closely together, it is often relatively easy to understand the context in which an 
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idea is to be used or a problem is to be solved, and the constraints on what can be 
undertaken and the limitations to what can be achieved. When the work to be undertaken 
involves participants from different organizations, the background to the problem may be 
understood in different ways, the constraints imposed may differ, and the expected 
outcomes may vary significantly. In consequence, there is a `time cost' in building the 
required shared understandings needed for effective collaborative ventures, which may 
outweigh any of the advantages gained. This was noted to be particularly the case in 
industry-university collaborations (Chapter 5, Section 5.4.2, page 201). 
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6.3 The Modes of Knowledge Production in Pharmaceutical R&D 
Research 
In Chapter 5, it was suggested that knowledge creation in pharmaceutical research is 
essentially Mode 1 in nature: it is often carried out by a lone individual working from the 
basis of a particular scientific discipline; it does involve the production of new `scientific' 
knowledge; and it does assume a linear view of science and innovation to the extent that 
new ideas are transferred to development teams for exploitation. Hence, there would 
appear to be a separation between the producers and consumers of knowledge. But it was 
also implied that it was not that simple (Chapter 5, Section 5.4.1, page 187). 
As pointed out by several interviewees, the early stages of research are often hazy. 
Somebody has an idea that something may be important, but cannot necessarily explain 
that idea and is certainly not clear about any consequences of exploiting that idea. He/she 
may simply have a feeling that something about the status quo is not quite right, or that a 
current practice is inefficient or even wrong. Time is needed to investigate or experiment 
with the idea in order to come up with something more concrete that can then be shared 
and worked on with others. An individual approach is thus often the only way to proceed 
in the initial stages. However, this does not necessarily mean that a single disciplined 
approach is taken. As people experiment, and observe, and talk about their results with 
other people throughout the company and elsewhere, a multidisciplinary approach may 
emerge. This is particularly so in pharmaceutical research which, of necessity, involves 
the merging of ideas from biology, biochemistry, genetics, chemistry, pharmacology, and 
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many more disciplines, in order to understand the full implications of what is being carried 
out. In addition, although separate working areas are usually provided in the larger 
pharmaceutical companies, this does not mean that the disciplines are, in fact, totally 
separate from each other. Separate working areas are needed because certain activities 
require specific tools or environments that would be too expensive and unnecessary to 
provide on an `across the board' basis. This does not mean that the producers of research 
knowledge are completely separated from the consumers of that knowledge. Indeed, most 
of these companies also provide dedicated cross-functional meeting areas. 
Although new `scientific' knowledge is one product of pharmaceutical research, the usual 
objective of that research is to provide a prototype -a candidate drug or therapy - for 
further development. It is hard to see how such an outcome can be achieved if there is no 
input at all from the development or business functions of the organization. In fact, as 
reported above (Section 6.2, page 212), these functions are increasingly involved early on 
in the research stages. Yet, knowledge production in research is clearly not truly Mode 2 
in nature. Pharmaceutical researchers and the companies they work for are interested in 
promoting the fundamental science behind their activities, to the extent that companies 
mostly encourage their researchers to publish or otherwise share such results (Chapter 5, 
Section 5.4.1, page 183). In addition, understanding failure is also particularly important 
in research (Chapter 5, Section 5.3.3, page 175). The practice of pharmaceutical research, 
thus, echoes some of the collegial traditions associated with basic research conducted in an 
academic context, but the research agenda - what to tackle - is guided by commercial 
considerations. The findings presented in this thesis would suggest that perhaps the best 
description for knowledge production in pharmaceutical research is `Transdisciplinary 
Mode 1, carried out with due regard to the commercial needs of the organization'. 
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Development 
Pharmaceutical development is carried out more specifically for the distinct purpose of 
achieving a practical goal: the launch of a new drug or therapy. It is dependent upon there 
being a perceived business advantage (Chapter 5, Section 5.3.1, page 166). It is 
knowledge production carried out in the context of application (Chapter 3, Section 3.4.1, 
page 103). 
Although interviewees generally referred to development teams as being multidisciplinary 
and multifunctional, according to the Mode 2 model, they are perhaps more appropriately 
described as transdisciplinary. While such teams are formed from a heterogeneous set of 
participants, their expertise evolves from the mix of disciplines and functions involved: it 
transcends the expertise of individual participants and cannot be reduced to the sum of its 
parts. Teams might embrace members from a diversity of fields, spanning, for example, 
the different areas of science, the business functions, organizations engaged in related 
activities, the regulatory authorities, various healthcare workers, patients and 
environmentalists, but the expertise that emerges from interacting together as a team is 
qualitatively different from the expertise possessed by any given participant. Clearly, 
teams are subject to constraints associated with the extent to which participants are able to 
commit to collective activity and to broader contextual factors in the form of regulatory 
requirements. However, they embody a considerable degree of autonomy: the work of the 
team is largely determined by the team itself and the results achieved. And, whilst project 
leaders might facilitate and coordinate the work of the team, they are simultaneously `part 
of the team' and constrained by team expectations about what counts as acceptable. 
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Although the achievements of development teams may echo the contributions of leading 
participants, they also surpass the simple summation of individual contributions. 
In line with Mode 2 working, development teams are temporary in that they exist for the 
duration of a project and team members do generally join and leave in accordance with the 
need for their particular skills. However, in contrast to Mode 2 working, team initiation 
and team changes are usually coordinated by a management body (Chapter 5, 
Section 5.3.2, page 170). Managers were said to have the breadth of knowledge to make 
decisions on project priorities and on relevant team membership. In addition, because of 
the length of a development project (typically 8-12 years) managers may proactively plan 
membership changes in order to overcome stagnation. Over a period of time, developers 
may also be promoted to other positions or move on to other companies. The proposition 
that Mode 2 teams form and dissolve in line with the evolving needs of the problem to be 
solved without being planned or coordinated by a central body (Chapter 3, Section 3.4.1, 
page 103) is one which has not therefore been attained in pharmaceutical development to- 
date. 
Gibbons et al's view that firms will take on some of the characteristics of a spiders web 
would appear to be born out by the way in which companies in the pharmaceutical industry 
do collaborate and network with each other. Flows of information, knowledge, products, 
people and ideas have become important. But, at least in development, structure (in the 
form of the firm or the extended firm) also remains sacrosanct, since the flows of 
information, knowledge and ideas are tempered by commercial awareness. Thus, although 
collaborative working does involve the sharing of project specific knowledge, informal 
knowledge networking is observed to be of a general rather than a specific nature in 
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development. In development, what is not acceptable in an informal networking 
arrangement is legitimate in a structured and agreed arrangement. Formal collaborations 
thus define the rules of engagement within which people can freely work together. And, 
because of this, knowledge production in pharmaceutical development is perhaps better 
described as a `Coordinated Mode 2' type activity. 
In some ways, Mode 2 working might be thought to have similarities with the virtual 
learning systems of fifth generation R&D (Chapter 2, Section 2.2.5, page 29) since both 
approaches rely on the transient collaborative arrangements that exist between people 
within different organizations. However, fifth generation R&D implies the self- 
government of opportunistic alliances formed across distinct corporate entities (something 
that the companies studied herein would not appear to formally condone, alliance 
formation being a strategic rather than an ad hoc decision process). Mode 2 knowledge 
production on the other hand appears to advocate the self-governance of 
multiorganizational transdisciplinary teams working to solve a particular problem 
(something that companies do appear to condone implicitly if not explicitly). 
The Implications of Mode 2 Working 
Gibbons et al suggested several implications for Mode 2 working that organizations should 
pay heed to (Chapter 3, Section 3.4.1, page 105). The findings of this present study would 
suggest that most of these implications are evident in the UK pharmaceutical industry. For 
example, in line with Gibbons et al's first implication, most companies do recognize the 
permeability of knowledge across organizational boundaries - through formal 
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collaborations and via knowledge networking - and rather than seeking to build non- 
permeable knowledge walls they use the knowledge available to them to expand their 
knowledge bases. Isolation is highly undesirable in a rapidly changing scientific and 
technical environment. What is critical is not the movement of knowledge per se, but 
rather the ability to use and expand upon that knowledge. 
In agreement with Gibbons et al's third implication, companies do recognize the need for 
collaborative rather than individual performance at the development stage, and they use 
matrix coordination to aid the reconfiguration of resources to meet the requirements of the 
problem in hand. However, one outcome of this way of team working is that much of the 
knowledge shared and created within one project team is not easily transferred to other 
project teams. End of project reviews can help, and some knowledge diffusion occurs as 
individuals move between teams, but in agreement with Gibbons et al's second 
implication, much of the team knowledge is lost to the organization. As noted in Chapter 5 
(Section 5.4.2, page 191), one company is attempting to go some way towards stemming 
this loss by promoting cross-team participation. The assumption is that some of the 
existing knowledge will be applicable or may be adaptable for use in the new team context. 
In line with Gibbons et al's fourth implication, all of the interviewees in this study did 
recognize that the scientific community does display many of the features of a global 
village. However, they rely on both their research and development staff to share only that 
knowledge that is appropriate. 
As we saw in Chapter 5 (Section 5.4.1, Table 5.4.1, page 177; and Section 5.4.2, 
Table 5.4.3, page 189), R&D networks and alliances are used extensively in the 
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pharmaceutical industry, and universities and other research institutes are often part of 
these systems (Section 5.4.1, Table 5.4.2, page 186; and Section 5.4.2, Table 5.4.4, 
page 198). However, in contrast to Gibbons et al 's fifth implication, many interviewees 
did not necessarily agree that the transient clusters of Mode 2 working would increasingly 
produce the specialist knowledge that will characterize the knowledge industries of the 
future. The Mode 1 approach that the various research organizations are traditionally 
known for is highly valued. Basic research is (still) expected to provide many of the 
scientific breakthroughs of the future, in much the same way that the biotechnology 
breakthroughs previously came about. '5 
No specific attempts were made in this present study to answer the three questions posed 
by Gibbons et al regarding stability, fungibility and insecurity (Chapter 3, Section 3.4.1, 
page 107). However, the findings herein might suggest the following. 
First, pharmaceutical researchers do not necessarily look for stability, predictability or 
routine. In fact it is by observing the unexpected that new understanding and knowledge is 
created. What researchers do require is a supportive environment that accepts the failure 
that may result from instability, unpredictability and experimentation. In contrast, 
pharmaceutical developers are required to use a range of routine processes to adapt the 
work of others. The fact that some stability, predictability and routine is present may then 
perhaps atone for the intermittent and transitory unstable patterns of transdiciplinary 
working. 
's It should, perhaps, be pointed out here that, in a later report, Gibbons stated that it was not being 
argued that Mode I would eventually succumb to Mode 2, but that the terms of their co-existence 
would `depend as much on the response of the institutes that are currently supporting Mode I as on 
the social diffusion of Mode 2. ' (Gibbons, 2001, p. 43) 
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Second, R&D is a continuous learning process. Change is expected. Moving scientists to 
new jobs which demand new skills and different knowledge profiles (that is, increasing 
fungibility) within the capabilities of these scientists is not recognized as a problem. 
However, time and support is needed for the acquisition of those new skills and knowledge 
profiles. 
Third, the amount of insecurity that any one person can bear is subjective. Yet, the need 
for a supportive environment in R&D would perhaps suggest that insecurity should be kept 
at a minimum to increase creativity. 
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6.4 The Knowledge Creation Models and their relevance to 
Pharmaceutical R&D 
6.4.1 Knowledge Creation after Nonaka and Takeuchi 
In Chapter 3, there were essentially two major criticisms that were levelled at the 
knowledge creation model proposed by Nonaka and Takeuchi: first, it makes the 
assumption that four distinctly different forms of knowledge (explicit and tacit, of the 
individual and the group) can be converted into each other (Chapter 3, Section 3.2, 
page 79), something that would seem from their normal definitions to be impossibly 
difficult; and, second, it assumes, at least on the surface, a systematic flow of knowledge 
from the individual to the group to the organization and then beyond, which might be one 
way in which knowledge may flow, but is not necessarily the only way (Chapter 3, 
Section 3.4.2, page 110). The assumption of a knowledge conversion process is perhaps 
one reason why Nonaka and Takeuchi `redefined' tacit knowledge to be that knowledge 
that is `not easily visible and expressible, and which is thus difficult to communicate to or 
share with others' (Nonaka and Takeuchi, Chapter 3, Section 3.4.2, page 111, italics in 
original). And, it should perhaps be pointed out again that even Nonaka and Takeuchi do 
not necessarily see knowledge creation as the simple cyclic process they describe (Nonaka 
and Takeuchi, Chapter 3, Section 3.4.2, page 112). However, a third and more important 
criticism of Nonaka and Takeuchi's model stems from the simple observation that, because 
Polanyi shows us that all knowledge contains a tacit dimension, it seems unreasonable to 
accept the very existence of tacit knowledge and explicit knowledge as two distinct 
knowledge forms (Chapter 3, Section 3.4.4, page 119). In essence, Polanyi argued that 
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there was no such thing as explicit knowledge. Accordingly, Nonaka and Takeuchi's use 
of the term `explicit knowledge', as if it could be attributed to Polanyi, involves an 
epistemological somersault. 
One way to make Nonaka and Takeuchi's model `work' might lie in redefining their terms. 
It is perhaps tempting to equate tacit knowledge with Polanyi's concept of personal 
knowledge, and explicit knowledge with information, since we have seen that, first, all 
knowledge is inherently personal (Chapter 3, Section 3.3, page 92), and, second, it is only 
information that can really be said to exist independently and thus be presented in explicit 
form (Chapter 3, Section 3.3, page 95). However, simply replacing tacit knowledge with 
personal knowledge and explicit knowledge with information in Nonaka and Takeuchi's 
model does not appear to reflect what these authors are trying to say. Yet, without a 
working definition that reflects the spirit of what Nonaka and Takeuchi might mean by 
tacit knowledge and explicit knowledge, it is difficult to relate their model to the findings 
presented in Chapter 5. 
In the discussions that follow, tacit knowledge is treated as knowledge that is personal to 
the individual, or specific to the group, the organization and so on, but which cannot be 
commodified and transferred as if it were an object, whereas explicit knowledge is 
assumed to be a transferable commodity expressed in verbal or written language. These 
definitions rule out the possibility of any conversion between tacit knowledge and explicit 
knowledge, but they do not rule out the possibility that each form may be used to create 
new knowledge of either type, as so assumed by Cook and Brown (Chapter 3, 
Section 3.4.3, page 113). So, accepting the existence of explicit knowledge and tacit 
knowledge as defined, and accepting the use of one form of knowledge to produce new 
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knowledge, to what extent can Nonaka and Takeuchi's model now be used to describe 
knowledge creation in pharmaceutical R&D? The following paragraphs address this 
question, first for knowledge creation in research, and second for knowledge creation in 
development. 16 But, before proceeding, it should be emphasized that the discussions 
presented in this subsection are conducted at the macro-level, that is, at the level of the 
particular activity involved. Yet, knowledge is created at the micro-level, that is, at the 
level of the mind of the individual or individuals involved. Comments regarding this latter 
more elemental level are therefore made towards the end of each separate discussion on 
research and on development. 
Research 
Using the findings of Chapter 5, Figure 6.4.1 (next page) outlines the activities thought to 
be most important in pharmaceutical research. Although not drawn upon in this analysis, 
the numbered activities can be related to those suggested by Tang and presented in 
Chapter 2, Section 2.3, page 40. 
Idea Generation: Pharmaceutical research begins with the generation of an idea that may 
either hint at the solution to an existing problem or suggest an improvement to the status 
quo. Although idea generation may be treated as a personal activity based upon the 
individual's existing explicit knowledge and tacit knowledge, within an industrial context 
it may be expected to be influenced explicitly or implicitly by organizational objectives 
16 In the following pages, normal type font should be associated with the knowledge processes as 
described by Nonaka and Takeuchi, whereas italic type font should be associated with processes 
described by the `use of knowledge to form new knowledge' 
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EXISTING KNOWLEDGE 
1,2. 
3. 
4. 
Idea Evaluation 
l 
Experimental Implementation 
Knowledge Acquisition (technological advances, 
customer needs, organizational objectives) 
Knowledge Sharing (organizational and 
community of practice) 
SOCIALIZATION 4 Sympathized knowledge 
Knowledge Sharing (mainly through knowledge 
networking) and Knowledge Combination 
EXTERNALIZATION -i Conceptual knowledge 
Knowledge Acquisition and Combination 
I Experimental Design COMBINATION - Systemic knowledge 
Experimental Evaluation 
NEW KNOWLEDGE 
(Mode 1) 
Secondary Idea Generation 
Individual Knowledge Application 
Observation and data collection 
Comparison, COMBINATION and/or Deduction 
Knowledge Application 
Formal and Informal Knowledge Sharing 
INTERNALIZATION - Operational knowledge 
FIGURE 6.4.1: KNOWLEDGE CREATION IN PHARMACEUTICAL RESEARCH 
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(Chapter 5, Section 5.3.1, page 163). That is, the sharing of explicit knowledge, in the 
form of mission statements and strategic goals and the implications behind them, guides or 
defines the idea generation stage. Since research is largely a discipline-based activity, idea 
generation may also be influenced by the explicit knowledge and tacit knowledge held 
within the individual's relevant community of practice (for example, the knowledge held 
by the society of biologists, etc. ). In Nonaka and Takeuchi's terminology, socialization 
within an organization or within a community of practice provides sympathized knowledge 
that enables the generation of relevant ideas. However, again, it should be emphasized that 
this should not be taken to imply the conversion of tacit knowledge to tacit knowledge, but 
rather the individual's use of explicit knowledge and tacit knowledge to yield new 
knowledge. 
Idea Evaluation: Once an idea or problem has been identified there may be some 
`vagueness' about how to proceed (Chapter 5, Section 5.3.2, page 167). Pharmaceutical 
research is perhaps unusual in that it regularly requires the combined knowledge and 
understanding of a number of scientific disciplines in order that the `whole picture' can be 
seen and understood. What effect will the chemistry have on the biology? What effect 
will the method of infusion have on the rate of absorption of a drug and how will that 
affect biological reactions and activities? And so on. The initial approach taken in 
pharmaceutical research consequently requires a transdisciplinary evaluation of the idea to 
be used (Chapter 5, Section 5.4.1, page 186). In Nonaka and Takeuchi's terminology, 
externalization of the idea produces the conceptual knowledge needed to fully evaluate the 
usefulness of the idea. But, rather than the conversion of tacit knowledge to explicit 
knowledge, it is the use of the individual's existing tacit knowledge and explicit 
knowledge that enables an explicit representation to be made. Once this has been carried 
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out, and depending upon the predicted needs, the approach taken may be single-discipline 
based, multidiscipline based or transdisciplinary. 
Experimental Design: When the overall approach has been decided, experimental design 
becomes important. What is actually required to validate the idea? To what extent can 
traditional tools and routines be used or combined in the process? What additional tools 
are needed? Can these tools be acquired or can they be built? Is a multidisciplinary 
approach or a transdisciplinary approach expected to be more effective? In contrast to 
what is commonly assumed to be a `trial and error' process, considerable thought may be 
involved before any practical work commences. However, rather than a purely logical 
process, it would seem that researchers also use their intuition in deciding how to proceed. 
In fact, in some instances intuition may well be more important than logic. For example, 
two interviewees (Company-A-4, p. 7 and Company-I, p. 27) noted that some of their most 
successful research had its origins in activities that had run counter to conventional 
wisdom. So, rather than simply the combination of explicit knowledge to produce systemic 
knowledge (Nonaka and Takeuchi, Chapter 3, Section 3.4.2, page 108), it would seem that 
tacit knowledge may also be used at this stage of the process. 
Experimental implementation: Experimental implementation is largely in the hands of the 
individual researchers (Chapter 5, Section 5.3.1, page 167). However, to the extent that 
everyone comes to the job with his/her own particular (scientific) baggage (Chapter 5, 
Section 5.4.1, page 179), `community of practice' knowledge may also be expected to 
influence this stage of the process. Experimental implementation serves no purpose unless 
detailed and accurate observations of the results of any experiment are recorded for future 
reference. The observation and collection of data will be, in part, dependent upon the 
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tools, methods and procedures used. However, it will also depend upon the researcher 
being `open' to the unexpected. Exactly how this `openness' comes about is beyond the 
scope of this present study, but it seems reasonable to assume that it will be shaped by a 
fusion of the researcher's (tacit and explicit) experience and his/her capacity to construct 
coherent interpretations of here-and-now sense perceptions. Certainly what is unexpected 
to one person might go unnoticed by another, and, as a consequence, may not be recorded. 
Thus, we might say that the use of both explicit knowledge and tacit knowledge would also 
seem to be important at this stage. 
Experimental Evaluation: The experimental data is then assessed for meaning and 
relevance. The determination of relevance may involve comparisons with previous results 
to either confirm or question existing findings. If the findings are confirmed, any new 
knowledge that results may then be combined with existing knowledge to produce 
additional knowledge. If the findings are questioned, additional experimental validation 
may be necessary to confirm the accuracy of the new and/or old data and their associated 
meanings. Alternatively, meaning may be deduced directly. Arguably, deduction may 
produce a meaning that is more subjective than is arrived at by the comparison method, 
since it relies only on the experimenter's interpretation of what has occurred, and this 
interpretation may be expected to be dependent upon the experimenter's previous tacit and 
explicit knowledge and skills set, particularly those due to his/her community of practice 
boundaries. Thus, what is meaningful to one person may not necessarily be so to another. 
Consequently, the knowledge created by one person may not necessarily be the same as 
that created by another. 
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Secondary Idea Generation: New knowledge might generate new ideas and generate new 
perceptions about what should be done next. The context of knowledge creation shapes 
these generative processes and, with regard to the present findings, formal project review 
meetings (Chapter 5, Section 5.4.1, page 186) and informal knowledge networking 
activities (Chapter 5, Section 5.4.1, page 182) were shown to be particularly important in 
shaping these ideas and perceptions. Additional ideas may then be incorporated into the 
design scheme, and the research process repeats until the desired result has been achieved 
- the idea concept has been proven or the problem has been solved - or the work is 
abandoned. In either instance, valuable new tacit and explicit operational knowledge will 
have been created and internalized for future use. 
The way in which knowledge is created within pharmaceutical research thus illustrates the 
importance of activities that appear similar to Nonaka and Takeuchi's processes of 
socialization, externalization, combination, and internalization. However, pharmaceutical 
research also indicates that knowledge creation in research is more complicated than 
Nonaka and Takeuchi's model proposes (McAdam and McCreedy, Chapter 3, 
Section 3.4.2, page 110). First, it shows that the various ontological dimensions 
(individual, group, organization, etc. ) may be involved within any one knowledge creation 
cycle. Second, it shows that both tacit knowledge and explicit knowledge are used at the 
same time during that cycle. Furthermore, at the micro-level of the individual, all sense 
making is a matter of observers - people - rendering their perceptions comprehensible. 
That is to say, meaning is constructed in the mind of persons: it is a continuous process of 
ordering and re-ordering sense perceptions and there is no logical reason why 
internalization should come after combination and before socialization. People make 
sense of the world - and interiorize their conclusions - on a continuous basis. As new 
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ways of acting and thinking become assimilated into the subconscious, they become a 'free 
resource' that can be re-used without incurring the time and effort to re-learn what is 
involved. 
These findings do not, however, negate many of Nonaka and Takeuchi's other suggestions. 
For example, Nonaka and Takeuchi's five enabling conditions for new product 
development would appear to be mostly valid in pharmaceutical research. First, 
`organizational intention' does guide pharmaceutical research, although the vision about 
what kind of knowledge should be developed and operationalized is perhaps more in the 
hands of the individual researcher than in the hands of research management. Second, 
`individual autonomy' is clearly respected. Third, `redundancy of information' is 
encouraged to promote understanding and learning between disciplines and within 
communities of practice across organizations. It is also deemed important for generating 
novel ideas. Fourth, research units do tend to have flat and flexible structures, and 
researchers are inter-linked with their organization's information network. They also have 
recourse to their own individual knowledge networks. So, in this sense, `requisite variety' 
is probably present. However, whether the remaining enabling condition, `fluctuation and 
creative chaos', needs application is perhaps questionable. UK pharmaceutical researchers 
would appear to be both reflective and focused in their approaches without the need for 
additional `fluctuation and creative chaos. ' Possibly, the fluctuation and creative chaos 
that have to be stimulated within a Japanese company-as-family workplace organization 
are, within UK pharmaceutical research, a natural consequence of the perturbations 
associated with British attitudes to personal ambition, liberal individualism and labour 
mobility. 
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Nonaka and Takeuchi's suggestion that the process of socialization would not appear to be 
as well developed in the West as it is in Japan would also appear to be confirmed by the 
present study, and there are perhaps three reasons why this may be so. First, research is 
often an individual activity. Second, when teams are formed they are usually dissolved 
with relative frequency. Third, it is possible that, within the UK, more formal management 
procedures - such as regular project review meetings - define prescribed activities that are 
carried out informally during the Japanese process of `living and working together' 
(Harvey-Jones, 1993, p. 178). 
Development 
Using the findings of Chapter 5, Figure 6.4.2 (next page) outlines the activities involved in 
pharmaceutical development. Again, the numbered activities can be related to those 
suggested by Tang (Chapter 2, Section 2.3, page 40). 
Project Proposition: Given the high costs involved, pharmaceutical development begins in 
almost all instances with the submission of a written project proposal. This proposal may 
be based upon the results of internal or external research or upon suggestions for the 
further development of existing products, processes or procedures. In each case the idea to 
be used will have been proven in principle, or will be evident from the previous work 
undertaken. Proposals for development work are usually group-based, may arise from 
either technical or commercial considerations, and must take both technical and 
commercial factors into account. There is typically a defined route to commercialization 
and proposals will normally include an initial evaluation against set criteria such as cost 
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and time estimates (Chapter 5, Section 5.3.2, page 169). However, such an evaluation is 
far from exact, and whether or not a proposal is actually put forward for consideration is 
perhaps based as much upon intuition as upon fact. Thus, the sympathized knowledge held 
within the organization may be expected to take both tacit and explicit forms and may be 
expected to influence project proposition in much the same way that it influences the 
generation of ideas in research. 
Proposal Evaluation: Development proposals are then critically assessed for their 
commercial viability and commercial and technical advantage. Assessments are usually 
carried out by a team consisting of the relevant research, development and commercial 
managers working in an essentially transdisciplinary manner. In some companies the 
assessment team may also include the `scientific advisory team'. Assessments are 
therefore based upon the team's combined knowledge. The assessments undertaken at this 
stage are arguably more objective than the initial evaluations made by the proposer(s), but 
they are, of necessity, still based upon a significant amount of guesswork. The tools 
required to do the job may be largely known, the costs of the expected tests and clinical 
trials may be known, the staff to be allocated to the process may be known, but the number 
(and therefore the costs) of the modifications needed to complete the work is largely 
estimated. Whilst this explicit knowledge is vitally important, the assessment may also 
include an interview with the proposer(s), the purpose being to obtain a better 
understanding of the thinking and reasoning behind the proposition. What, was the reason 
for the submission of the proposal? What are the outstanding points to be considered and 
what really are the expected outcomes? By trying to externalize some of the tacit 
reasoning behind the proposal, it is perhaps hoped that a better decision can be made on 
whether or not the proposal should be advanced. 
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Project Design: Accepted proposals are usually allocated a project manager and the 
detailed project design and implementation stages commence (Chapter 5, Section 5.3.2, 
page 169). Project design in development is transdisciplinary in that the various 
disciplines design the work together with one end in mind: regulatory acceptance of a new 
and valuable product into the health care market, a product that has financial value to the 
company, and which is also valuable to consumer health (Chapter 5, Section 5.3.2, 
page 168). However, many of the components of the overall design will be based upon 
routine scientific techniques and standard processes. For example, clinical trials and tests 
for safety and efficacy will require adherence to predetermined procedures. It is not 
impossible, but it is not easy, to change regulatory requirements. It is certainly expensive. 
Project design is also transfunctional: financial, manufacturing and marketing possibilities 
and needs are designed in from the beginning, as well as being considered throughout the 
implementation process. Regulatory and ethical requirements are designed in likewise. In 
fact, moral issues concerning drug and therapy testing, availability and supply are 
increasingly affecting what work is undertaken and how it is carried out. Project design 
may also be transorganizational. As noted above, although collaborations are invariably 
agreed by formal contract, it is generally accepted that the collaborating participants work 
(and therefore design) together as one team (Chapter 5, Section 5.4.2, page 201). Project 
design in development thus involves the sharing and combination of knowledge across a 
number of ontological dimensions (community of practice, organizational and inter- 
organizational) at the same time, rather than sequentially as suggested by Nonaka and 
Takeuchi's model. In addition, although much of the knowledge involved is explicit, 
intuition (tacit knowledge) may also play a part in the design process in much the same 
way as it does during `experimental design' in research (page 230 above). 
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Project Implementation: Project implementation is a team process, involving members 
from the various disciplines, functions, and organizations working together to get the job 
done. Although the different types of work undertaken (product development, 
formulation, manufacture, clinical testing, stability studies, etc. ) may be carried out at 
different locations, a coordinated Mode 2 type approach is used (Section 6.3, page 221). 
Project implementation (like experimental implementation in research) is also dependent 
upon the detailed and accurate recording of experimental observations. And, again, 
different observers may `see' the same `reality' in different ways, so that what is actually 
observed may depend to some extent upon the observer's existing tacit knowledge and 
explicit knowledge in much the same way as for experimental implementation in research 
(page 230 above). Working in an essentially Mode 2 manner thus involves to some extent 
the sharing, combination, and application or use of knowledge from across both the 
epistemological and ontological dimensions. 
Project Evaluation: A Mode 2 type implementation might be assumed to ensure a Mode 2 
type evaluation of the experimental findings. Certainly, the recorded data will be 
interpreted and much meaning will arise from the context of application. However, it may 
perhaps also be expected that new disciplinary meaning will also arise from the actual 
scientific experiments carried out. Hence, Mode 1 disciplinary knowledge may be 
produced within the minds of the individual team members, whilst context-specific Mode 2 
knowledge may result from the transdisciplinary, transfunctional, transorganizational team 
activities undertaken together. In either case, meaning may, again, be expected to be based 
upon the individual's or the group's existing tacit and explicit knowledge and skills set. 
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Secondary Idea Generation: To the extent that new meaning may be assumed to generate 
additional ideas to be used or problems to be solved, the secondary ideas generated may 
also be expected to take both `Mode 1' and `Mode 2' forms. The operational tacit and 
explicit knowledge generated and internalized by the team members during pharmaceutical 
development may therefore be expected to be both discipline-based and project-based. 
Whilst the new internalized project-based knowledge will take precedence throughout the 
course of the existing development, its relevance to future activities is perhaps 
questionable: its usefulness will depend upon the ability of its `holders' to understand its 
meaning within the new context of application. The new internalized discipline-based 
knowledge, on the other hand, will form part of each individual's enhanced `tool kit' and 
may well prove useful in future contexts. 
The way in which knowledge is created within pharmaceutical development thus also 
illustrates the importance of activities that appear similar to Nonaka and Takeuchi's 
processes of socialization, externalization, combination, and internalization. However, 
again, knowledge creation is more complicated than Nonaka and Takeuchi's model might 
suggest. Again, it would appear that the various ontological dimensions (individual, 
group, organization, etc. ) may be involved within any one knowledge creation cycle. And, 
again, both tacit knowledge and explicit knowledge would appear to be used at the same 
time. Furthermore, at the micro-level of the individual (within the group, organization, and 
so on), meaning is, again, a continuous process of ordering and re-ordering sense 
perceptions and interiorizing the personal conclusions so formed (see page 232, above). 
Moreover, where close community relationships among team members enable these 
members to make sense of the world in an aligned way, it is possible to communicate a 
great deal with a minimum of information: shared experience helps participants to `see' the 
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same `reality' in an aligned way. The group can re-use its shared experience as a tool or 
`free resource' for `getting things done'. In Nonaka and Takeuchi's vocabulary, the effect 
is similar to socialization but the shared experience that enables insiders to see the same 
reality in a similar way is reflexively automatic. It is not possible to `unlearn' or `suspend' 
the tacit knowing that underpins sense making. For example, by talking to our best friend 
as if he or she were a stranger, we do not necessarily revise our estimates about friendship. 
As a corollary, creating knowledge about friendship need not necessarily involve 
externalization. 
Some of Nonaka and Takeuchi's five enabling conditions for new product development 
would also appear to be valid in pharmaceutical development. First, `organizational 
intention' does guide and even determines pharmaceutical development. Second, 
development units do tend to have flat and fairly flexible structures, and developers are 
inter-linked with their organization's information network. They also have recourse to 
their own individual knowledge networks. So, `redundancy of information' is accepted (if 
not necessarily encouraged) and `requisite variety' is probably also present. However, 
whether `individual autonomy' within a team environment is respected is unclear, and 
whilst some `fluctuation' is present in the sense that teams form, disband, and reform, 
`creative chaos' would not appear to be the intention. 
Again, Nonaka and Takeuchi's suggestion that the process of socialization is not as well 
developed in the West as it is in Japan, is perhaps also confirmed in pharmaceutical 
development. The type of close community relationships among colleagues who spend 
their career working, learning and innovating together, which are taken for granted inside 
Japanese organizations, are rare amid British expectations about liberal individualism and 
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labour mobility. Even though development is a team activity, UK teams are still formed 
and dissolved with relative frequency. The possibility of working together, on a long-term 
basis, in the manner of a Japanese team is difficult to imagine without the Japanese 
institutions that lend legitimacy to this style of working. 
Despite the confirmation of much of what Nonaka and Takeuchi observe, the findings of 
this present study would suggest that, even when modified in the way described within this 
subsection, the knowledge creation model that they propose does not appear to adequately 
reflect what happens in either a research or development environment. The next 
subsection therefore moves on to investigate the modifications made by Cook and Brown. 
6.4.2 Knowledge Creation after Cook and Brown 
Cook and Brown retain the assumption that explicit knowledge and tacit knowledge, of the 
individual and the group, exist as four distinct forms. Their model might therefore be 
rejected for this reason alone. But, let us, for the time being, adopt the stance taken in 
Section 6.4.1 above, and assume that tacit knowledge is personal to the individual, or 
specific to the group, the organization and so on, whereas explicit knowledge is assumed to 
be a transferable commodity expressed in verbal or written language (Section 6.4.1, 
page 226). Cook and Brown's proposition that one form of knowledge can be used as a 
useful tool in the generation of the other then neatly overcomes the problems associated 
with the existence of a conversion process between these two different forms of 
knowledge. It also accommodates the observations of this present study that the differing 
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forms of knowledge can be used at the same time during the activities associated with 
research and development. That is, it probably is reasonable to say that the production of 
new knowledge does lie in the `use of knowledge as a tool of productive inquiry as part of 
our dynamic interaction with the things of the social and physical world' (Cook and 
Brown, 1999, p. 397). Cook and Brown's framework thus does appear to offer a more 
appropriate representation of the organizational knowledge creation processes in 
pharmaceutical research and development. Yet, we might question whether the 
`productive inquiries' involved are the result of a `generative dance' between knowledge 
and knowing, since might they not, alternatively, be the result of an act of `tacit knowing' 
(Polanyi, Chapter 3, Section 3.4.4)? For the present, this section will adopt Cook and 
Brown's view in order to investigate further how their model might be used to explain 
knowledge creation in research and development. 
Research 
Applying Cook and Brown's model to the research activities outlined in Section 6.4.1 
above (pages 227-232), suggests the following framework for knowledge creation in 
pharmaceutical research (Figure 6.4.3, next page). 
Idea Generation (page 227): The individualistic and intuitive nature of `idea generation' in 
research would suggest that the predominant forms of knowledge involved in this activity 
are individual explicit knowledge and tacit knowledge. However, the fact that much of the 
individual's personal knowledge will be influenced by his/her community of practice 
knowledge, combined with the fact that ultimately ideas will need to fit with the 
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organization's objectives suggests that group explicit knowledge and tacit knowledge may 
also play a part (Figure 6.4.3. a). 
Idea Evaluation (page 229): The need for a transdisciplinary evaluation of the idea that is 
proposed would suggest that group knowledge predominates during the `idea evaluation' 
activity. Whilst business knowledge is input, it is not necessarily the deciding factor in 
determining whether the evaluation is positive or negative. What is more important in 
research is whether or not the idea is technically feasible, and this will be based largely 
upon the explicit and implicit use of community of practice knowledge; that is, explicit 
knowledge is used overtly, but tacit knowledge may also influence evaluation decisions 
(Figure 6.4.3. b). 
Experimental Design (paw): Whilst `experimental design' may be based, at least 
initially, upon the standard techniques and practices of the relevant community of practice 
knowledge, this group knowledge may be expected to be significantly influenced by the 
thoughts and ideas of the individual researcher, that is, by his/her individual explicit 
knowledge and tacit knowledge (Figure 6.4.3. c). 
Experimental Implementation (paw): The fact that `experimental implementation' in 
research is largely an individual activity, means that individual knowledge predominates at 
this stage of the process. And, as outlined in Section 6.4.1 above, the need for 
experimental cognition would suggest that both explicit knowledge and tacit knowledge 
are important. However, since researchers are mainly employed for their scientific 
knowledge and skills, once again it may be expected that community of practice 
knowledge will influence this activity (Figure 6.4.3. d). 
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Experimental Evaluation (page 231): Similarly, `experimental evaluation' is predominantly 
an individual activity, but, one which, once again, may be expected to be highly influenced 
by the individual's community of practice knowledge. And, since the meaning associated 
with the evaluation of data results from an interpretive act, we might again expect that both 
explicit knowledge and tacit knowledge are involved (Figure 6.4.3. e). 
Secondary Idea Generation (page 232): Since the knowledge created in research is shared 
mainly within the scientific community, `secondary idea generation' might be expected to 
involve the use of individual explicit knowledge and tacit knowledge, influenced by 
`community of practice' explicit knowledge and tacit knowledge, in much the same way in 
which the original `idea generation' made use of those same knowledge forms (Figure 
6.4.3.0. 
Although Figure 6.4.3 suggests that knowledge creation in research is mainly an individual 
and discipline-based activity, to propose that it is simply Mode 1 knowledge production is 
clearly a simplification too far. 
Development 
Applying Cook and Brown's model to the development activities outlined in 
Section 6.4.1 above (pages 234-239), suggests the following framework for knowledge 
creation in pharmaceutical development (Figure 6.4.4, next page). 
Project Proposition (page 234): The need for a formal written proposal prepared with due 
regard to the commercial and technical implications of the work to be undertaken, implies 
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that `project proposition' is mainly a group (organizational) activity based upon explicit 
knowledge. However, as outlined in Section 6.4.1 above, whilst there might be a defined 
route to commercialization and whilst initial cost and time estimates will have been given, 
this route and these estimates will be based as much upon intuition as upon theoretical and 
arithmetic calculation. Tacit knowledge is therefore also important in this activity 
(Figure 6.4.4. a). 
Proposal Evaluation (page 236): The critical and essentially transdisciplinary assessment 
of project proposals implies that organizational knowledge is also involved during the 
`project evaluation' stage. And, whilst these assessments are undertaken in order to check 
upon the detail of the proposal and determine more accurately the resources required, the 
financial costs involved, and the importance of the final product to the company, the 
evaluation does nevertheless still involve a degree of `expert opinion'. Whilst explicit 
knowledge predominates, it might be expected that actual decisions will be influenced by 
group tacit knowledge (Figure 6.4.4. b). 
Project Design (page 237): The `project design' stage in development is essentially a 
transdisciplinary activity, based upon the use of standard techniques and practices, and 
thus upon group (community of practice, organizational, and possibly external) explicit 
knowledge. However, the incorporation and appropriateness of these techniques will be, in 
part, based upon the judgement of those involved, and thus upon their group tacit 
knowledge (Figure 6.4.4. c). 
Project Implementation (page 238): The team-based approach to `project implementation' 
suggests the use of group (project team) knowledge during this stage of the development 
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process. Whilst the procedures outlined and the experimental work conducted might be 
assumed to involve predominantly explicit knowledge and data collection, the tacit 
understandings behind these procedures and the interpretations made as to which data 
should be collected imply the use of tacit knowledge. Also, since particular aspects of the 
work undertaken may involve the work of the lone developer (not everyone in the team 
will perform a particular clinical procedure, for example), it is conceivable that this group 
knowledge may be influenced by the explicit knowledge and tacit knowledge of the 
individuals employed (Figure 6.4.4. d). 
Project Evaluation (page 238): Whilst Mode 2 type knowledge is the desired outcome of 
development, as outlined in Section 6.4.1 (page 238), Mode I type knowledge may also 
result from the experimental work carried out by the individual developers. `Project 
evaluation' may then be expected to yield new meanings that may be both (A) individual 
and (B) group (project team) based. And, these new meanings may, again, be expected to 
be dependent upon both the explicit knowledge and tacit knowledge of the individual or 
the group (project team) (Figure 6.4.4. e). 
Secondary Idea Generation (page 239): Similarly, the action of `secondary idea generation' 
will predominantly be based upon group (project team) explicit knowledge and tacit 
knowledge, although individual ideas may be generated and used elsewhere 
(Figure 6.4.4.0. 
Figure 6.4.4 suggests that although knowledge creation in development is mainly a group- 
based activity carried out in the context of application, to propose that it is simply Mode 2 
knowledge production is also a simplification too far. 
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Coupling Cook and Brown's framework with the basic activities involved in 
pharmaceutical research and pharmaceutical development has graphically shown us some 
of the intricacies of and the differences between the knowledge creation processes in these 
two environments. In particular, it has highlighted the fact that knowledge creation in each 
of these activities is more complicated than the links to respectively, the Mode I and 
Mode 2 approaches suggested by Gibbons and his co-workers: organizational knowledge is 
integral to research activities, and disciplinary knowledge may result from the team 
working employed in development. It has also highlighted the fact that both explicit 
knowledge and tacit knowledge (as defined within this section) appear to be employed at 
the same time in all of the activities assumed important for knowledge creation in research 
and development. So, again, we might question whether such a split is valid. An 
additional concern, and one which is perhaps more a question of terminology than actual 
intention, is that Cook and Brown's assumption of a `generative dance' between 
knowledge and knowing suggests to the present author a degree of randomness that is not 
necessarily present in the way in which we each approach the things that we do. For 
example, when we attempt to generate an idea, at least within a corporate setting, is there 
not some purpose to our thoughts? When we attempt to solve a problem do we really 
employ a random `dance' between two entities called knowledge and knowing? Even if 
we cannot always say what it is that we are trying to find or trying to do, do we not, 
instead, think our thoughts and pursue our actions in the light of what we are trying to find 
or trying to do, or upon which our innermost thoughts and actions are focusing? So, can 
perhaps the application of Polanyi's work add more to the discussion than has so far been 
possible? The next section investigates this possibility. 
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6.4.3 Knowledge Creation after Michael Polanyi 
Polanyi has shown us that by exploratory indwelling in the particulars of the `clues' 
available to us, we arrive at a meaning of these particulars in the context within which we 
are operating (Polanyi, Chapter 3, Section 3.4.4, page 117). Furthermore, Polanyi has 
suggested that, in participating in this act of tacit knowing we are guided by sensing the 
presence of a hidden reality toward which these clues are pointing (Polanyi, Chapter 3, 
Section 3.4.4, page 120). So, adopting Polanyi's perspective, we view each of the 
activities within the research and development processes as acts of tacit knowing. In so 
doing, we do not, of necessity, assume the existence of explicit knowledge and tacit 
knowledge as distinct forms. Neither do we assume the knowledge conversion process 
proposed by Nonaka and Takeuchi, nor the generative dance between knowledge and 
knowing suggested by Cook and Brown. Rather, the creation of new knowledge occurs as 
we focus on the object of the act of tacit knowing, whilst dwelling in the particulars of that 
act of tacit knowing. Knowledge creation in pharmaceutical research and development 
might then be described as follows. 
Research 
Table 6.4.1 (next page) lists the acts of tacit knowing assumed in pharmaceutical research. 
Idea Generation: Ideas for new products or for solutions to existing problems may arise 
from anywhere: from the science or technology involved; from business opportunities or 
threats; from the emergence of new strains of bacteria, etc. Nevertheless, in order for the 
idea to be worthy of further investigation, it increasingly has to be seen to have value to the 
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TABLE 6.4.1: THE ACTS OF TACIT KNOWING IN RESEARCH 
Act of Tacit Knowing Focus Particulars 
(distal component) (proximal component) 
Idea Generation Unmet medical needs of society Organizational objectives, 
skills, interests and available 
knowledge 
Idea Evaluation The chosen idea or problem Potential and technicalities of 
solution the idea 
Experimental Design Desired project outcome Science involved and skills 
available 
Experimental Practical execution of the Technology involved 
Implementation experimental design 
Experimental Experimental data Science and technology 
Evaluation involved 
organization (Chapter 5, Section 5.3.1, page 163). In the pharmaceutical industry this will 
normally mean that the idea will be related to meeting the unmet medical needs of a 
particular `society' of interest. At the same time, the insight behind the idea will be 
influenced by the individual researcher's skills, interests, aspirations, and any limiting 
issues such as lack of confidence in a particular area of expertise, etc. So, we might say 
that by focusing on the unmet medical needs of the society of interest, whilst dwelling in 
the objectives, skills, interests and knowledge of the organization, the individual researcher 
may be said to participate in an act of tacit knowing which may suggest a way forward: an 
idea for a new product is born, or a suggestion as to how a particular problem may be 
solved is arrived at. 
Idea Evaluation: Initially ideas are `fuzzy' and difficult to describe. There may be no clear 
way to proceed and there may be some doubt as to whether any attempt should actually be 
made to proceed. We have seen that, in the early stages of research, the evaluation of ideas 
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lies largely in the hands of the individual researcher, and will therefore, to some extent, be 
dependent upon that researcher's existing skills set. However, by communicating with 
others within and without the organization, the researcher is able to canvas opinion as to 
whether or not the idea is valid, what solutions may already exist, and what problems may 
in due course arise. By evaluating these factors in the light of the commercial potential to 
the organization, the individual researcher will then decide whether or not the idea is 
worthy of further examination (Section 6.4.1, page 227). We might say that by focusing 
on the idea, whilst dwelling in the potential and the technicalities associated with that idea, 
the researcher participates in an act of tacit knowing that provides the personal justification 
needed for the idea to be worked upon. 
Experimental Design: Once justified, experimental design then becomes important. What 
is the best route to success? Can we use standard techniques to reach the desired outcome, 
or do we need new ways of doing things? What are the criteria necessary for verifying 
success? Who needs to be involved? As we have seen above (Section 6.4.1, page 230), 
whilst the design will be influenced by the existing knowledge and skills available to the 
organization, intuition is also thought to play a part in the process. So, we might perhaps 
say that by focusing on the desired outcome of the experiment, whilst dwelling in the 
particulars of the science involved and the skills available, the researcher participates in an 
act of tacit knowing which suggests the initial approach to be taken. 
Experimental Implementation: Whether or not experimental procedures are designed 
jointly with others, experimental implementation is largely an individual activity, although 
one which is nevertheless influenced by the available tools and the researcher's practical 
competence. And, whilst the practical work may be explicitly described, the data collected 
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may be dependent not only upon the researcher's observational skills, but also upon his/her 
interpretation of what should or should not be recorded. Despite the expectations of 
objectivity, we cannot be sure that experimental implementation is necessarily free from 
personal interpretation (Section 6.4.1, page 23 1). Hence, we might suggest that by 
focusing on the execution of the experiment, whilst dwelling in the practicalities of the 
technology involved, the researcher participates in an act of tacit knowing which results in 
the production of data, which may or may not be free from subjective influence. 
Experimental Evaluation: The result of an experiment may or may not confirm the viability 
of the chosen route to project completion, but the collection of data will, nevertheless, offer 
the researcher clues as to why success was achieved or failure occurred. By interpreting 
these clues and understanding the logic behind these clues, the researcher can start to 
increase his/her understanding of the science and technology involved, and thus improve 
upon the previous work undertaken. We might say that by focusing on the clues that the 
data provide, whilst dwelling in the science and technology involved, the researcher 
increases his/her understanding and brings new meaning to that data. And, by sharing this 
understanding and meaning with others, the researcher adds to the body of scientific and 
technical knowledge, which, in turn, may suggest new ideas or hint at new problems to be 
solved. 
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Development 
In one sense, knowledge creation in development is less complicated than knowledge 
creation in research because the `clues' to progress are more clearly defined: the research 
product or technique to be developed needs to meet the standard regulatory requirements 
for drug approval. In another sense, knowledge creation in development is more 
complicated than knowledge creation in research because it depends upon a group of 
individuals working together towards one goal that is understood and shared by all. 
However, since distinct activities are carried out by different individuals, we might ask the 
question: how does individual knowledge creation interact with or affect team knowledge 
creation and vice versa? The results in Chapter 5 have shown us that development teams 
within the organizations studied consist of people who bring their own particular skills to 
the team process. It would therefore seem plausible that individual knowledge creation 
adopts a functional or disciplinary perspective, whilst team knowledge creation adopts a 
strategic perspective. However, in order that an effective strategy be developed, it is 
important that the individual team members understand each other and the implications of 
the knowledge they bring to the process. Polanyi has shown us how, by exploratory 
indwelling in the thoughts and actions of others, we learn from each other (Chapter 3, 
Section 3.4.4, page 117). This is the assumption that has been made in the following 
paragraphs as regards the creation of team knowledge in development. 
Table 6.4.2 (next page) lists the acts of tacit knowing assumed in pharmaceutical 
development. 
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TABLE 6.4.2: THE ACTS OF TACIT KNOWING IN DEVELOPMENT 
Act of Tacit Knowing Focus Particulars 
(distal component) (proximal component) 
Project Proposition Desired project outcome Technical and commercial 
issues of relevance 
Proposal Evaluation Projected outcome Commercial and technical 
details of the project 
proposition 
Project Design Proposed route to development Technicalities involved 
Project Practical execution of the Technicalities involved 
Implementation development plan 
Project Evaluation Experimental data Functional and disciplinary 
knowledge involved 
Project Proposition: Project proposals in development are based upon existing assumptions 
(Section 6.4.1, page 234). Although these assumptions will have some justification in fact 
-a prototype product or process will have already been synthesized - these assumptions 
may yet prove false in the light of the additional knowledge obtained during detailed 
clinical trials, production scale-up, etc. Nevertheless, in proposing the project, the view 
will have been taken that the project is worthwhile, and this worthiness will have been 
based upon the knowledge and experiences held within both the commercial and technical 
departments. We might say that by focusing on the expected outcome, whilst dwelling in 
the anticipated technical and commercial issues involved, the proposers participate jointly 
in an act of tacit knowing that results in a written statement of the envisaged route to 
commercialization. 
Proposal Evaluation: The evaluation of the project proposal also requires input from the 
commercial and technical departments. It involves an investigation into the project's 
importance in relation to the organization's existing priorities, a more detailed evaluation 
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of resource and time estimates, and, where possible, the clarification of uncertainties 
(Section 6.4.1, page 236). Yet, whilst an overall budget for the project may be estimated 
with some certainty, the final outcome of the project cannot be guaranteed. We might 
therefore say that by focusing on the projected outcome, whilst dwelling in the commercial 
and technical details of the project proposition, the assessors jointly participate in an act of 
tacit knowing that results in an acceptance or rejection of the submitted proposal. 
Project Design: Whilst many of the components of the project design will be based upon 
the standard procedures and practices of the separate functional departments, the overall 
design is a team-based activity (Section 6.4.1, page 237) with the various members from 
the separate functions working together to produce a detailed plan of the work that needs to 
be done, when that work needs to be done, and within what cost that work should be done. 
Thus, we might say that by focusing on the proposed route to development, whilst dwelling 
in the technicalities involved, the team jointly participates in an act of tacit knowing that 
results in a detailed plan of the way ahead. 
Project implementation: Project implementation is essentially a transdisciplinary process 
with the various team members - pharmacists, toxicologists, chemical engineers, 
marketers, regulators, etc. - working together and adapting practices and procedures in 
complex and changing ways (Section 6.4.1, page 238). For example, what will be the 
effect on product yield of using a different grade of raw material? Will the use of a 
cheaper raw material adequately compensate for any increased purification costs? And so 
on. Yet, much of the work is actually carried out on an individual basis. For example, 
toxicologists will check product toxicology in the standard way, chemical engineers will 
apply their skills to the scale-up of production, buyers will use their negotiating skills to 
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source raw material, and so on. Yet, whilst the data collected during project 
implementation will depend upon the use of the relevant standard tools and techniques, the 
results obtained will not necessarily be free from personal interpretation. So, we might 
suggest that by focusing on the execution of the development plan, whilst dwelling in the 
technicalities involved, team members separately and jointly participate in acts of tacit 
knowing that produce the data upon which further progress may be determined. 
Project Evaluation: Within the organizations participating in this present study it is clear 
that both disciplinary and transdisciplinary working occurs in development (Chapter 5, 
Section 5.3.2, page 169). Whilst disciplinary working has the potential to add to the 
knowledge of that discipline in much the same way as occurs during experimental 
evaluation in research (page 253, above), the main purpose of disciplinary working in 
development is to provide the data needed for a transdisciplinary assessment of what 
should be done next. We might therefore say, that by focusing on the clues that the data 
provide, whilst dwelling in the functional and disciplinary knowledge involved, developers 
jointly participate in acts of tacit knowing that provide the meaning behind that data in the 
context of the application and hence bring new ideas and suggestions for the way forward. 
Viewing knowledge creation from Polanyi's perspective thus provides alternative 
descriptions of the knowledge creation processes in research and development, 
descriptions which appear to confirm Polanyi's original statement that tacit knowing can 
account for a valid knowledge of a problem [idea] and for the scientist's capacity to pursue 
it (Polanyi, Chapter 3, Section 3.4.4, page 120). 
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6.5 Knowledge Creation in Research and Development: 
Why things are as they are 
Research 
Many of the seeds of knowledge creation in pharmaceutical research emerge from ideas 
that are associated with established scientific disciplines. On this account, they might owe 
more to the relatively stable tradition of scientific research than the vicissitudes of 
management fashion. To be sure, direction may be given to the research process - for 
example, the company's overall strategies and goals can be made clear through corporate 
mission statements, company briefings, project review meetings, and internal networking 
activities - but this direction is in the form of guidance rather than strictly laid down rules 
of engagement. It has to be so: research is speculative. 
Research is also viewed very much an individual activity, and individual researchers are 
given a great deal of freedom and flexibility in the work that they undertake and the way in 
which they undertake it. Research projects are monitored and evaluated, but the monitors 
and evaluators are, at least in the early days, the researchers themselves. Researchers are 
the experts within their disciplines who are best informed to decide whether or not a 
particular technical path should be progressed (Jewkes et al, 1958, p. 136). 
The application of knowledge is important in research to the extent that researchers use the 
knowledge and skills available to them in the activities that they undertake. Since much of 
the knowledge important to research lies in the scientific community at large, access to the 
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scientific literature and to community of practice activities is crucial for success in 
research. Such access enables researchers to keep abreast of the latest developments in 
their fields of experience and expertise, and avoids the time and resources that may 
otherwise be wasted on duplication. Networking activities fit with the flexibility needed 
by researchers to access the knowledge that they require when they know that they require 
it, and also to access knowledge that they may not know that they require until they have 
acquired it. These facts were recognized by all of the interviewees in this study, and rather 
than attempting to control the access to such knowledge sources, they allow and in most 
cases encourage their researchers to use these sources accordingly. In general, these 
companies also encourage their staff to add to the knowledge within these sources by 
presenting and otherwise publishing their work, albeit with due regard to intellectual 
property considerations. Sharing scientific and technical knowledge within their peer 
groups also enables researchers to gain support for work that may be highly speculative 
and risky. It can lead to suggestions concerning problems that may be encountered, and 
ways in which these anticipated problems may possibly be overcome. And, `bouncing' 
ideas off other people can suggest additional ideas for further research. 
Knowledge networking is dependent upon a degree of understanding between the 
individuals involved. Words may be exchanged, but unless the meaning behind those 
words is understood it is unlikely that any knowledge will be exchanged or shared. 
Knowledge networking is also said to be dependent upon a degree of reciprocity. 
However, many scientists will freely share their basic knowledge in the hope of furthering 
the general understanding of the science and technology involved. What is hoped for is 
constructive and knowledgeable feedback rather than reciprocity (I will give you this 
knowledge if you give me some in return) per se. 
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Several interviewees noted that their companies had acquired specific scientific and 
technical knowledge through company acquisition or merger. This was particularly so 
when companies moved into new fields of activity. Companies may also hire-in specific 
expertise or employ people with particular experience for the same purpose (Chapter 5, 
Section 5.4.1, page 181). At the strategic level, the knowledge available to the company 
can in this way be directed and controlled. The direction or control of this knowledge at 
the practical level will however remain in the hands of the individual researchers. 
The paragraphs above suggest that although some direction can be applied to knowledge 
creation within research as noted by Jewkes and co-workers, very little control can be 
exerted over this process (Jewkes et al, 1958, p. 137). Indeed, it would appear that it is the 
basic needs of research that largely determine how corporate research is managed, what 
types of knowledge are needed for research, and ultimately how knowledge is created in 
research. Figure 6.5.1 (next page) shows this diagrammatically. The figure outlines the 
practice of pharmaceutical research from the view of (a) the basic needs of research, 
(b) the management of research, (c) the knowledge needs of research, and (d) knowledge 
creation within research. The arrows depict the proposed influences. Rather than research 
management influencing knowledge creation, or knowledge creation influencing research 
management, it is suggested that both are determined by the basic needs of research. That 
is, research is to some extent the master of the organization. 
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The Needs of Research 
Research is about creating something entirely new. It is about trying out ideas, about 
experimentation, and about questioning the givens. It involves skills of enquiry and 
creativity (Chapter 5, Section 5.3, page 162). It is risky with many false starts so that time 
lines' cannot be gauged and projects cannot be priced. Specific ends may be desired, but 
the means to achieve them are not necessarily known. Specific means may be known but 
the outcomes that they may yield will not always be clear (Jewkes et al, 1958, p. 151). The 
final result will often depend upon the outcomes of a number of intermediate stages, and 
failure is part of a learning process (Chapter 5, Section 5.3.1, page 166; Section 5.3.3, page 
175). Most importantly, research involves inspiration (Jewkes et al, 1958, p. 223) and a 
vision of what might be possible rather than what is already possible. It is more `future' 
driven (Leonard-Barton, 1995, p. 33). People in research enjoy doing something new and 
solving future problems. Work may be hard, but it is also exciting. In these respects, 
research is similar to radical innovation (Morita et al, 1986, p. 78). 
The Management of Research 
The needs of research mean that managing research is more about facilitation than about 
any particular process implementation. It is more about encouragement than about seeking 
strict accountability for the work pursued. It is more about matching strategic objectives 
and technological expertise. The management structure is flat and loose, and a great deal 
of flexibility is allowed, the expectation being that scientists will follow their own hunches 
(Chapter 5, Section 5.3.2, page 167). In effect, research units are steered (Burton et al, 
1988, p. 1 13) rather than controlled, since the path to completion is not known beforehand 
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(Jewkes et al, 1958, p. 116). Strategy is seen as a `guiding light' rather than an absolute 
target. Motivation is by providing challenging opportunities and creating an environment 
that encourages and supports experimentation (Chapter 5, Section 5.2.1, page 150). 
The Knowledge Needs of Research 
The needs of research necessarily determine the knowledge needs of research. Research is 
more a search for future knowledge than a search for the most efficient use of present 
knowledge. It is more about expanding knowledge boundaries than retaining knowledge 
within existing boundaries. It is essentially science and technology driven, and the 
knowledge used is predominantly of the `Mode 1' type. Researchers undoubtedly use the 
knowledge that is available or accessible to them, but they do so in ways that are unique to 
the work that they are undertaking at the time (Chapter 5, Section 5.4.1, page 178). Since 
it is not possible to know before the work has begun exactly what knowledge will be 
needed or from whence that knowledge will come, researchers need access to a wide range 
of knowledge sources and in all possible ways. 
Knowledge Creation in Research 
Knowledge creation in research is about the exploration for new knowledge. It is science 
and technology led and is essentially a `Mode 1' process. 
Knowledge acquisition is important in research to the extent that it is neither practicable 
nor possible to do everything from scratch. Knowledge is acquired from the 'managed' 
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information in patents and scientific databases, but importantly the latest knowledge is 
`acquired' by networking with other scientists and technicians. As mentioned above 
(page 260), occasionally knowledge acquisition may occur through hiring-in new 
expertise. Knowledge networking and hiring-in expertise arguably facilitates learning as 
well as information transfer. And, sharing early thoughts with others may not only help to 
consolidate those thoughts but may also add other perspectives and ideas (Chapter 5, 
Section 5.4.1, page 183). 
Since it is only as a project progresses and new knowledge is created that the researcher 
becomes aware of what knowledge is needed next, rather than seeking to define an 
absolute set of knowledge processes necessary for research, it would seem that managers 
in research need to know how to promote and encourage flexible knowledge practices in 
general. 
Although not a part of the knowledge creation process, knowledge exploitation through 
further development and technology out-licensing is an important way of acknowledging 
or rewarding staff for work done well. 
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Development 
Knowledge creation in pharmaceutical development is knowledge creation carried out in 
the context of application. It is a transdisciplinary and transfunctional team process. 
Teams are managed by a project leader and they are required to meet preset targets as the 
development progresses. Knowledge creation in development is thus both directed 
towards a specific goal, and controlled to the extent that the inability to meet specific 
targets may seriously jeopardize project continuation. Control is possible within 
development because the processes and procedures used are largely fixed by regulatory 
requirements. Furthermore, knowledge creation in development is essentially about the 
application of existing knowledge rather than the creation of new knowledge by 
experimentation, so that, compared to research, there is a greater understanding of the 
science and technology involved. Project targets can therefore be set with a degree of 
(but not absolute) certainty (Jewkes et al, Chapter 2, Section 2.3.2, p. 41). 
Knowledge application in development is essentially through the auspices of team-working 
and is thus dependent upon the various members of the team working together and 
understanding each other's needs. This is not something that can be controlled, but is 
something that can perhaps be facilitated. Several interviewees stated that they do not 
have the luxury of being able to include specific role types within the teams that they form 
(Chapter 5, Section 5.3.2, page 170). We might question whether they have actually tried 
to do this. However, using one team to aid another was shown to facilitate team learning 
(Chapter 5, Section 5.4.2, page 191). This may be because there is an increased chance 
that the necessary role types are present in the combined teams, although it is perhaps more 
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likely that people will learn more readily from their peers if they know that they have 
already been through the process that they are about to enter. 
Knowledge acquisition in development is both directed and controlled by the needs of the 
project, and usually occurs through technology and compound in-licensing agreements, 
and, particularly in the case of regulatory issues, though knowledge networking. 
Knowledge is shared as part of the team process, whether or not the team consists entirely 
of internal personnel or involves members from collaborating partners. To a large extent, 
the knowledge shared is then directed and controlled by the needs of the project. 
Knowledge may also be shared within the wider organizational community through the 
publication of project reviews, case reports, incident reports, and via company briefings. 
The idea is that others will learn the lessons of the past and build upon them, rather than 
repeat the same mistakes again. These latter forms of knowledge sharing are usually 
directed towards particular issues such as health and safety requirements, or process time 
or cost reduction possibilities. In many instances, the extent to which these lessons can be 
applied at a later date will depend upon either the ability to capture lessons devoid of 
context - something that would seem to be extremely difficult if not impossible to achieve 
- or the ability of individuals to recognize the relevance of past concepts in new contexts. 
Figure 6.5.2 (next page) outlines, in a similar fashion to Figure 6.5.1, the practices of 
pharmaceutical development. In this case, and as indicated by the arrows, it is suggested 
that it is the organizational or management needs that largely determine the needs of 
development, the knowledge needs of development, and how knowledge is created within 
development. In short, development management directs knowledge creation within 
development. That is, the organization is the master of development. 
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The Management of Development 
The management of development is about modifying research discoveries to meet business 
needs, about adapting discoveries as the environment changes, about team working and, 
especially in the pharmaceutical industry, about managing attrition. Since development is 
often carried out in collaboration with others, the management of development is also 
about the management of collaborations and alliances, and most specifically about uniting 
the whole workforce (internal and external) behind the active project. Matrix management 
enables people from the various functions to be brought together in project teams 
(Chapter 5, Section 5.3.2, page 169) and project management tools are employed to track 
progress against milestone commitments, to flag problems as they occur, to undertake 
remedial action at the earliest possible time, and, importantly, to share thoughts and ideas 
throughout the organization (Chapter 5, Section 5.3.2, page 172). A managed approach is 
possible because development is more certain than research in that the desired `ends' and 
`means' are usually known (Chapter 5, Section 5.3.2, page 169). 
People in development are motivated by the satisfaction of bringing a product to market. 
They are also interested in ensuring product integrity (safety and efficacy) and in solving 
current problems (Chapter 5, Section 5.4.2, page 188). They accept that work needs to be 
ordered, but, at the same time, it has to be seen to be worthwhile. Because attrition rates 
are high, reward systems need not only to be based upon final results but also upon what 
has been learnt in the process and whether that learning has been shared with others 
(Chapter 5, Section 5.3.3, page 175). 
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The Needs of Development 
Development is about using the results of research to develop a commercially viable 
product or process (Chapter 5, Section 5.4.2, page 188). It requires a transdisciplinary, 
a trans functional, and sometimes a transorganizational team view (Section 6.3, page 219). 
But, importantly, it is about adopting a `managed' approach in order to gain regulatory 
approval (Chapter 5, Section 5.3.2, page 168). It is thus more present and past driven. 
Nevertheless there are still uncertainties concerning drug efficacy and side effects in 
humans that mean that skills of analysis and an eye for detail are requirements that are 
crucial in order to understand the lessons that may be important for the future. 
Development is thus similar to incremental innovation (Lorenz, 1990, p. 119). 
The Knowledge Needs of Development 
Pharmaceutical development requires strict adherence to regulatory issues. In addition, the 
product and process data generated during development will need to be readily available in 
a format suitable for regulatory approval. Past and present project knowledge, and present 
and possible future regulatory knowledge, and the lessons that may be learnt from that 
knowledge are consequently crucial knowledge requirements in development (Chapter 5, 
Section 5.4.2, page 188). Databases are useful for storing, collating and combining 
existing scientific and technical, information (and to the knowledgeable user, the 
knowledge behind that information). `Experimental results' databases and electronic 
notebooks are useful for storing information (and the knowledge behind that information) 
for regulatory purposes. `Expert resources' databases allow contact to be made with 
knowledgeable individuals. `Stories' and 'lessons learnt' databases can prove useful in 
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helping workers understand the lessons of the past. And, project management tools and 
techniques provide transparency and focus for knowledge creation activities (Chapter 5, 
Section 5.4.2, page 202). 
Knowledge Creation in Development 
Knowledge creation in development is a structured, team-based process that seeks to 
exploit the existing knowledge of research with the development experiences of the past, in 
order to achieve the regulatory and commercial needs of the present and near future 
(Chapter 5, Section 5.4.2, page 188). It is knowledge creation in the context of application 
and is essentially a `Mode 2' process. 
External knowledge acquisition is typically via in-licensing agreements, although 
networking with the regulatory authorities does provide the information needed for specific 
approval issues. Formal collaborations are particularly important for gaining, sharing, and 
exploiting project-related knowledge that might otherwise be deemed secret to outsiders 
(Chapter 5, Section 5.4.2, page 200). Personal knowledge networking is important for 
sharing and expanding upon general rather than project related knowledge (Chapter 5, 
Section 5.4.2, page 198). 
Team working is by necessity transdisciplinary and transfunctional and may be 
transorganizational. And working in this way enables the knowledge of all the 
collaborating partners to be applied to the problem in hand (Chapter 5, Section 5.4.2, 
page 197). 
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6.6 The Most Important Factors in Managing R&D 
Commercial Viability (Chapter 5, Section 5.2.1, page 150) 
Commercial viability is ultimately essential for the continuation of any business enterprise. 
However, until recently, pharmaceutical research was to a significant extent divorced from 
the commercial end of the organization. Commercial viability was the province of 
pharmaceutical development, not pharmaceutical research. The aim of research was to 
discover the new compounds, materials and technologies that had the potential to cure 
disease. There was an implicit need on the researcher's part to understand how these 
materials and technologies functioned and how they might be useful in meeting the future 
needs of the organization, but there was little need to understand the day-to-day operations 
of the existing needs of the business. Research costs may have been significant, 
development costs may have been high, but profits were huge. When questions were asked 
about these profits, the pharmaceutical companies pointed to the high costs of R&D. 
These costs were undoubtedly true, but what was perhaps more important was that it was 
not possible to understand whether or not they were always necessary. There was much 
that was unknown about the science and technology involved. 
Although complete understanding is not yet available today, the advent of biotechnology 
and particularly gene technology has led to a much greater understanding of how living 
systems succumb to disease and consequently how disease might be cured. This leads to 
the possibility of more focused research and more accountability in research. Research, 
like development, can then be more easily adjusted to the commercial needs of the 
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business, and questions about profits can be justified by the specific work carried out. 
Research becomes more business orientated, and commercial viability is important from 
the beginning of the process. The problem with this change is that there is still much that 
is unknown about the science involved. When commercial viability is the requirement, it 
is the safer and largely understood options that are usually adopted and progressed. The 
less understood and therefore more risky options are largely ignored. The tragedy is that 
these more risky options may ultimately yield a far better result for both the company and 
the customer (patient) than might initially be thought to be the case. Whilst there are 
undoubtedly arguments for commercial viability in development, like Pearson remarked, 
`It would be a pity if companies no longer undertook any exploratory research at all' 
(Pearson, 1991, p. 21). Most of the interviewees in this study would probably agree with 
this statement; they do, after all, have a scientific background. 
When research and development activities are separated there is perhaps the implication 
that, to a degree, exploration and educated risk taking is implied or is allowed, at least in 
research. Whether this will remain so if commercial viability is allowed to dominate 
research as well as development is perhaps questionable. Where will the radically new 
ideas come from if research and development is always carried out in the context of 
commercial viability? What about the increased understanding that comes about from a 
consideration of the previously unexplored? Should this be the sole province of the 
universities and other research institutes? Can these research organizations themselves 
continue to advance scientific understanding in this way when their financial resources are 
limited (Chapter 3, Section 3.5, page 123) and they are continually required to account for 
their work in the context of a nation's current rather than its possible future needs? 
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A Clear Focus, a Flexible Approach and a Culture of Experimentation in Research 
(Chapter 5, Section 5.2.1, page 150) 
When management is by guidance rather than by controlled direction it is important that 
the overall purpose is clear. Experimentation can yield a number of alternative paths that 
may be taken, a clear focus guides the researcher towards the path that should be taken. 
A clear focus provides the `control' for what work is to be carried out, how it is to be 
carried out, and why it is being carried out. A clear focus thus encourages efficiency in the 
research process. A clear focus will also help to determine when a particular research 
route needs to be abandoned. 
Working within a multidisciplinary or transdisciplinary environment means that the results 
that one researcher obtains may affect the work of other researchers in other disciplines, or, 
alternatively, the findings of research may mean that the existing commercial requirements 
can no longer be met. A flexible approach is then required to accommodate these possible 
conflicting requirements. 
When intermediate outcomes are inherently uncertain it may perhaps be assumed that 
flexibility is a `given'. However, when a particular approach is passionately believed 
(rather than known) to be the right approach, the determination to succeed with that 
approach can sometimes be seen as inflexibility. What is interesting is that belief and 
determination can sometimes succeed where existing knowledge would suggest that it 
should not. Flexibility is then needed on the part of management to allow researchers to 
pursue their beliefs. To varying degrees, this is something that does appear to happen in 
UK pharmaceutical research. 
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Experimentation is risky since the outcome is uncertain. If it were not, there would be no 
point in carrying out the experiment in the first place. Risk implies the chance of failure. 
Although researchers may inherently be risk takers, companies are rarely so. It takes 
confidence to go against the normal rules. Failure can erode that confidence, especially 
when it is success alone that is rewarded. All of the interviewees in this study recognized 
the importance of supporting their staff through the failures that would inevitably occur 
when experimentation was part of the process. What was important was not that failure 
had occurred, but that failure brought learning and understanding and new knowledge. 
Teams of People, a Clear Project Plan, and Buy-in in Development 
(Chapter 5, Section 5.2.1, page 151) 
Pharmaceutical development is about team working. It is about the various disciplines and 
functions working together to progress and produce a product or process suitable for its 
context of use. Teams are typically put together on the basis of technical (scientific, 
technological or commercial) ability and staff availability. It was simply not possible to 
also put teams together with the most appropriate personality characteristics. Instead, what 
appears to be encouraged in most of the companies in this study is an environment of 
cooperation and facilitation throughout the organization as a whole. Encouraging the 
whole organization to support development activities is one way that arguably overcomes 
any personality deficits within the actual development teams themselves. 
The more certain `ends' and `means' in development support the provision of a clear 
project plan. The provision of such a plan encourages discussion both within and across 
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the various departments involved, and, by making explicit some of the underlying 
functional assumptions, contributes to organizational understanding. It focuses attention 
on the likely financial and resource costs of the project, and the projected time 
requirements of the various activities involved. It gives transparency to the process and 
assists in subsequent accountability and decision making. Notwithstanding the existence 
of a project manager, the process relies on a high degree of self-management, it clarifies, to 
all, what needs to be done, when it needs to be done, and by whom it should be done. 
However, a clear project plan is only useful if it is feasible. The incorporation of 
unrealistic targets and time scales can lead to de-motivation rather than the super-human 
efforts predicted by `stretch'. As pointed out by several of the participants in this present 
study, it is the professional developers who have the greater understanding of what can be 
done, not the managers. Their participation in the drawing up of the plan is therefore 
crucial, and goes a long way to ensuring their `buy-in' to the decisions made 
(Chapter 5, Section 5.3.2, page 172). 
Communication 
(Chapter 5, Section 5.2.1 page 152) 
Because effective communication is dependent upon there being the need for some shared 
understanding between the communicating parties, it is not infrequently assumed that 
communication can be a problem between the different functional groups that make up the 
organization or extended organization. Each group may have its own `language' and may 
adopt a different perspective on what is required and how it should be achieved. Although 
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different views undoubtedly do occur, it is through further communication that these views 
can be declared and shared. What is perhaps forgotten is that despite our variety we are all 
human beings, and thus have some understanding in common. 
It is interesting that both researchers involved in transdisciplinary Mode 1 type working 
(who often work separately from the other functions of the firm) and developers involved 
in coordinated Mode 2 type working (where the functions work together) emphasized that 
communication was important. In research, communication is necessary to give direction 
to the activities undertaken, to obtain and learn from the knowledge available elsewhere, 
and to promote the results of research to others. In development, communication is more 
about the sharing of knowledge within the project team in order to arrive at a unified 
approach to the task in hand. 
When the shared understanding that develops between life-time colleagues is not a 
possibility, it is perhaps hardly surprising that communication is thought to be important. 
How else can knowledge be acquired, shared and used? The problem is that, as shown in 
Chapter 3, Section 3.3, there is more that needs to be acquired, shared and used than the 
explicit knowledge that is normally associated with the spoken word. 
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6.7 Conclusion to the Chapter 
The complexity of pharmaceutical R&D militates against the efficacy of models based on 
overly simplistic assumptions. Indeed, the problems associated with such assumptions can 
generate more questions than answers. As this chapter has demonstrated, challenging 
questions arise from propositions about successive generations of R&D, Mode 1 and 
Mode 2 knowledge production, Nonaka and Takeuchi's notion of tacit-explicit knowledge 
conversion, and Cook and Brown's case for `bridging epistemologies'. However, 
Polanyi's original concept of tacit knowing has stood the test of time: half a century after 
he developed his concept of `tacit knowing', the arguments remain fresh and relevant. 
By comparing the basic needs, the management processes, the knowledge needs, and the 
knowledge creation processes in pharmaceutical research and pharmaceutical 
development, Section 6.5 concluded that it is the basic needs of research that largely 
determine what knowledge is needed, how knowledge is created, and the management 
practices in research, whereas it is the business or management practices that largely 
determine the needs of development, the knowledge needs of development, and how 
knowledge is created in development. Thus, whilst an organization may wish to pursue 
strategies that foster business integration (third generation R&D) and collaborative 
working (fourth generation R&D), is it wise that it do so throughout the entire range of its 
activities? Certainly, successful companies operating in the UK pharmaceutical industry 
continue to adopt research (as opposed to development) strategies akin to a science/ 
technology push approach (first generation R&D). Might it not be wise for other 
companies wishing to carry out research (as opposed to development) to do likewise? 
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Similarly, whilst Mode 2 working within the context of application might be the best way 
to bring the various functions and departments together during development, is this the best 
approach to adopt in research? To the extent that research is largely science-based and 
inherently individualistic, it would be imprudent to ignore the potential contribution of 
Mode 1 knowledge production to competitive innovation in the pharmaceutical and 
similarly research-intensive industries. Indeed, many of the interviewees who contributed 
to this study viewed such working as important for sourcing new ideas and seeding new 
R&D trajectories. They did not appear to agree that the transient clusters of Mode 2 
working would `increasingly produce the specialist knowledge that will characterize the 
knowledge industries of the future' (Gibbons et al, Chapter 3, Section 3.4.1, page 106). In 
fact, the reverse would seem to be implied. Yet, the increasing need for proven 
commercial viability even in corporate research may alter the balance of power in favour 
of Mode 2 knowledge production. From the point of view of applying managerial 
techniques to discovery, this might be seen as progress: it avoids mistakes. But, as 
Einstein is often purported to have said: `A person who never made a mistake, never tried 
anything new'. Ultimately, innovation involves the exploitation of novelty. 
The different perspectives of research and development are reflected in the factors thought 
by the participants of the empirical research to be those most important in managing R&D 
(Section 6.6). For example, most notably, it was thought that not only should 
organizations be commercially aware (cf development) but they should also participate in 
the process of exploration (cf. research). However, whilst considering the differing 
requirements of research and of development, there is also the need to ensure that both of 
these activities are seen as part of the wider organizational process to which they each 
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contribute. Hence, communication, in the widest sense of the word, becomes a key 
requirement for success. 
Clearly, the answer to any question is dependent upon the assumptions made and the 
perspectives adopted. Whilst it is difficult to reconcile the knowledge conversion processes 
suggested by Nonaka and Takeuchi with the fieldwork reported in this thesis, some of their 
concepts reflect relevant issues associated with communicating, learning and innovating. 
Specifically, knowledge sharing through socialization and externalization, and knowledge 
acquisition through combination and internalization are processes that can be envisaged in 
R&D. The proviso is that such processes do not involve the conversion of one form of 
knowledge into a different form of knowledge. 
Although Cook and Brown's focus on `knowing as part of action' circumvents some of the 
difficulties associated with Nonaka and Takeuchi's concept of tacit-explicit knowledge 
conversion, it is not easy to relate actual practice to their claim that tacit knowledge and 
explicit knowledge possessed by individuals and groups represent unambiguously distinct 
categories of knowledge. Nevertheless, the application of Cook and Brown's model to the 
various activities that make up the R&D process graphically highlights the intricacies and 
differences between knowledge creation in research and knowledge creation in 
development. In so doing, it adds to the debate about how these two organizational 
activities might best be managed. For example, where individual knowledge is the 
predominant need of the process or activity of interest, there would appear to be little point 
in promoting team working. Where group knowledge is an essential requirement of the 
activity or process of interest, the promotion of individualism would appear to be 
counterproductive. 
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Finally, the chapter has demonstrated ways in which Polanyi's concept of tacit knowing 
remains both credible and useful. Polanyi points to a coherent interpretation of the 
complex and inherently personal nature of what is commonly referred to as `knowledge'. 
He argues that the quest for knowing implies a personal commitment to seeking a deeper 
understanding of an underlying `reality'. And, his proposition of personal acts of tacit 
knowing that account for the actions that we each take and the way in which we each learn 
from others and come to understand the world around us, would appear to offer a distinct 
advantage over those models that advocate the commodification of `tacit knowledge' and 
`explicit knowledge'. Specifically, the commodification of knowledge implies that 
knowledge is a `thing' that is separate from the knowing subject - hence, the people who 
know how to `do things' in practice are effectively written out of the picture. Instead, 
Polanyi's concept of `personal knowledge' affords a centre-of-stage role to the people who 
know how to think and act in any given context. Although the idea that people (persons) 
know things might sound like a statement of the obvious, traditional expectations about 
scientific objectivity, along with related perspectives based on the `commodification' of 
tacit knowledge and explicit knowledge `objects', effectively exclude the role of people. 
Ultimately, better understanding the organizational capacity to translate pharmaceutical 
R&D into competitive gains and losses depends on better understanding the people who 
know how to make the differences that translate into competitive gains and losses. In a 
world with no people, nobody would know anything. 
In drawing this thesis to a close, the next chapter, Chapter 7, now summarizes and 
discusses the conclusions of this present study, the major contributions to knowledge, and 
the major limitations of and some possible extensions to the work reported herein. 
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7 CONCLUSION 
7.1 The Major Conclusions 
This thesis set out to look at knowledge creation in corporate R&D, the assumption being 
that, in the present knowledge-based economy, effective knowledge creation would be the 
primary driver for successful corporate as well as academic R&D. However, in pursuing 
this objective, it was found necessary to look into the general practices of R&D 
departments and consider relevant aspects of the context of knowledge creation, rather than 
concentrate on knowledge creation per se. This was because, typically, R&D workers and 
managers - the primary sources of the information upon which this thesis is based - do not 
perceive themselves to be driven by the pursuit of `knowledge creation' as an end in itself. 
Hence, in employing knowledge creation as a conceptual vehicle for making sense of a 
wide diversity of R&D practices associated with competitive innovation, the findings and 
the conclusions in this thesis have, of necessity, been grounded in the approaches, the 
practices, and the general knowledge processes employed in corporate R&D. 
Approaching the study of knowledge creation in this way, led to four specific aims of the 
research: 
1. To identify the general approaches and practices employed within corporate R&D and 
the possible influences these approaches and practices might have upon the knowledge 
creation process. 
2. To determine the extent to which Gibbons and co-workers' (1994) modes of 
knowledge production might be important to making sense of contemporary R&D. 
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3. To examine the extent to which the existing models of organizational knowledge 
creation might be useful in interpreting knowledge creation within an R&D context. 
4. To look at the way in which knowledge is created within UK-based pharmaceutical 
R&D as a basis for identifying more general insights into the practice of corporate 
R&D. 
In respect of the first aim of the research, Chapter 2 identified five strategic approaches to 
corporate R&D, the R&D Generations, and outlined conceptual interpretations of the 
practice of R&D that had been reported in the earlier literature. At the same time, the 
chapter suggested the types of knowledge and the knowledge processes employed in each 
instance. In attempting to deconstruct some of the complexity associated with the inter- 
relationship between the practice of corporate R&D and the context within which that 
R&D takes place, it became apparent that the higher level generalizations about R&D 
Generations masked the complexities of micro-level R&D processes: complex 
organizations create knowledge in a variety of ways, and many different nested and 
overlapping interest groups may exert their respective influences over the way in which 
R&D is practiced. While the concept of R&D Generations may help to explain some of 
the observed variations in corporate R&D strategy, attention to micro-level practices 
revealed a more complicated picture. 
The nature of micro-level processes was indicated by the findings of Chapter 6, 
Section 6.2. Specifically, what was deemed appropriate in terms of strategy varied 
according to whether the focal activity was research or development. On the one hand, 
research remained largely free from corporate interference: creativity was aligned with the 
autonomy of researchers in a manner that reflected the `traditional' first generation 
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science/technology-led approach. On the other hand, development was sensitive to the 
edicts of corporate strategy: it typically reflected themes embodied in third generation 
`business integration' and fourth generation `external collaboration' models. Whereas 
research relied heavily on the power of fluid and flexible practices mediated by the 
individual experimental scientist or technologist, development adopted the more managed 
practices required by the business-focused transfunctional project team. In other words, 
research strategies were shaped by the community of researchers, while the interests of the 
organizational managers tended to have a more direct influence on development strategies. 
In relation to the second aim of the research, Chapter 3, Section 3.4.1, outlined the 
principal propositions of Michael Gibbons and his co-workers, and Chapter 6, Section 6.3, 
discussed this work in relation to the findings of this present study. In particular, it was 
shown that neither pharmaceutical research nor pharmaceutical development corresponded 
exactly with either Mode 1 knowledge production or Mode 2 knowledge production as 
proposed by Gibbons and his colleagues. In addition, although the distinction between 
Mode 1 and Mode 2 sounds simple enough in the abstract, research practice in the 
pharmaceutical industry highlights the difference between the production of knowledge 
and labels that relate to knowledge outputs. Although this might sound like an unduly 
subtle point, it has significant implications. 
Both the production of Mode 1 knowledge and the outputs that it produces are commonly 
referred to as `science'. That is to say, the process of conducting basic scientific research, 
according to the scientific method, is assumed to produce scientific outputs, which equate 
to objective knowledge. However, the tendency to equate the process of knowledge 
production with knowledge outputs can contribute to confusion. Although Mode 1 
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knowledge outputs might be objective and value-free, the processes that produce those 
outputs are subject to political, economic and social influences that variously enable and 
constrain the research agenda. Rather than being a purely science/technology-led process. 
pharmaceutical research ultimately relies upon a commercial evaluation of any candidate 
drug or therapy that might be discovered. Accordingly, pharmaceutical research might 
better be termed a transdisciplinary Mode 1 type activity: basic research that is shaped by 
interaction between the scientific disciplines and influenced by `supply-side' factors 
associated with the `context of knowledge production'. 
In contrast, Mode 2 knowledge production does not produce a homogeneous body of 
knowledge (in the sense that science could be described as a homogenous body of 
knowledge). On the contrary, the outputs of Mode 2 knowledge production are 
heterogeneous: different people learn different things as a result of their participation in the 
production of knowledge. Hence, although it might be helpful to talk about the process of 
Mode 2 knowledge production (for example, in terms of the joint efforts of different 
practitioners who contribute to a specific area of problem-solving activity), each 
participant constructs his or her personal interpretation of the learning experience. Mode 2 
knowledge production does not produce disembodied Mode 2 `knowledge outputs' that 
mirror the objective status of Mode 1 scientific outputs: the outputs of Mode 2 knowledge 
production are context-specific and personal. From a managerial point of view, the 
challenge is to recognize and coordinate appropriate aspects of the Mode 2 knowledge- 
producing process. On this account, pharmaceutical development might be classed as a 
coordinated Mode 2 type activity. Managers have to coordinate different aspects of 
personal knowledge possessed by participants who collectively comprise what Gibbons 
and his colleagues refer to as `the context of application'. 
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Corporate pharmaceutical R&D relies on research and development working in tandem: to 
the extent that each needs the other, it is difficult to sustain the idea that one is more 
important than the other. While there are significant differences between the two 
activities, they are bound together in a complementary relationship. Thus, the proposal by 
Gibbons and his co-workers that Mode 2 working would come to predominate over 
Mode I working (Chapter 3, Section 3.4.1) has not been confirmed here. Although many 
areas of economic activity, including research-intensive sectors such as the pharmaceutical 
industry, are indeed becoming more concerned with addressing `user needs' associated 
with the `context of application', significant breakthroughs in basic research can reveal 
new avenues of commercial possibilities. In the case of the pharmaceutical industry, major 
breakthroughs can reshape the commercial landscape and thereby focus more attention on 
transdisciplinary Mode 1 knowledge production. 
In attempting to answer the third aim of the research, Chapter 3, Sections 3.4.2 to 3.4.4, 
described the main points of the knowledge creation models proposed by Nonaka and 
Takeuchi (1995), Cook and Brown (1999), and Polanyi (1966); and Chapter 6, 
Sections 6.4.1 to 6.4.3 outlined the relevance of these models as they applied to corporate 
pharmaceutical R&D. In particular, Chapter 6, Section 6.4.1, outlined how Nonaka and 
Takeuchi's (1995) model suffers on several counts. First, it relies on four processes which 
define conversions between four unique forms of knowledge (tacit and explicit, possessed 
by individuals and groups), forms of knowledge which by their very definition defy the 
possibility of conversion. Second, although making sense of Nonaka and Takeuchi's 
model is made easier if we avoid their use of the verb `to convert' as a way of describing 
the process in which one unique form of knowledge is ostensibly `converted' into an 
entirely different form of knowledge, their remaining implication that knowledge is 
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somehow diminished in the `conversion' process fails to accommodate the idea that 
knowledge is not diminished by its use. For, if one person tells another something useful, 
the second person's knowledge may be increased but the first person's knowledge is 
neither diminished nor converted into something else: it was merely used to support a 
knowledge creating `conversation'. Third, the findings of this present study would suggest 
that the knowledge used within R&D would not seem to be easily separable into the four 
forms of knowledge suggested by Nonaka and Takeuchi. For example, experimental 
design in research and project design in development rely upon what some might refer to 
as the `tacit' knowledge of intuition as well as the `explicit' knowledge of established 
wisdom. Although the abstract concept of a distinction between tacit knowledge and 
explicit knowledge, possessed by individuals and groups, might sound straightforward, 
practical examples suggest that it can be difficult to see where one category of knowledge 
stops and another starts. Fourth, in line with McAdam and McCreedy's comments noted 
in Chapter 3, Section 3.4.2, it would indeed seem that knowledge creation in research and 
in development is not the systematic and cyclic process proposed by Nonaka and 
Takeuchi, since, at least within the companies of this present study, much knowledge is 
created by direct interaction at the same ontological level, and more than one form of 
knowledge may be used at the same time to create new knowledge. In parallel with, what 
might be seen as Nonaka and Takeuchi's `Jacob's ladder' or vertical approach, which 
ascends from individual knowledge to universal knowledge, there are horizontal influences 
on the processes by which the `spiral' of knowledge creation ascends to higher ontological 
levels. 
Nevertheless, the findings of this present study would suggest that processes similar to 
socialization, externalization, combination and internalization do play a part in corporate 
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R&D. The proviso is that these processes do not involve the conversion (or even the use) 
of any one specific form of knowledge to produce another specific form of knowledge. 
Thus, the socialization that occurs through the use of personal knowledge in networking 
and organizational team working is crucial to the acquisition and sharing of the knowledge 
necessary for the activities of both research and development. The externalization of 
knowledge that results through the use of formal organizational statements and formal and 
informal project review meetings is crucial in clarifying objectives and signalling 
problems. The combination of knowledge from the various functional departments that 
make up the organization is critical to ensure the commercial viability necessary for 
development and the guidance needed in research. And, with the internalization of new 
knowledge comes the possibility of a deeper understanding of the reality with which we 
are each confronted in our everyday lives and, thus, the possibility of new ideas and 
solutions. 
By accepting Nonaka and Takeuchi's use of tacit knowledge and explicit knowledge, of 
the individual and group varieties, Cook and Brown's Pluralist Framework also suffers on 
the count that the knowledge used within R&D would not seem to be easily separable into 
these four unique forms of knowledge. Nevertheless, their framework does give one 
explanation of how new knowledge might come about. It comes about through the use of 
knowledge as a tool of productive enquiry as part of our dynamic interaction with the 
things of the social and physical world (Cook and Brown, Chapter 3, Section 3.4.3, page 
113). That is, new knowledge comes about because of the actions we take (physical or 
mental) and the interpretations we make, not because of the conversion of one form of 
knowledge into another. 
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However, the framework in itself gives little idea of which forms of knowledge and 
knowing are involved within any particular context, at any particular time, or for any 
particular purpose. What is needed is a coupling of the framework with the basic activities 
involved in the particular context of interest. The couplings for the pharmaceutical 
research and pharmaceutical development processes, as indicated by the findings of this 
present study, were shown in Chapter 6, Section 6.4.2 (respectively, Figure 6.4.3, 
page 243, and Figure 6.4.4, page 246). These couplings graphically display the differences 
between knowledge creation in research and knowledge creation in development - 
research is clearly seen to be largely, but not wholly, an individual process, whilst 
development is clearly seen to be largely, but not wholly, a group process - but they also 
emphasize the fact that, overall, both processes employ all four forms of knowledge 
represented by the explicit-tacit and individual-collective dimensions. That is, intuition 
(individual tacit knowledge) and shared ways of working (group tacit knowledge) are as 
important as individual explicit knowledge and group explicit knowledge in both research 
and development, although the extent to which these different knowledge forms are used 
and the purposes for which they are used vary depending upon which basic activity is 
being pursued and whether research or development is the process. 
In providing a graphical description of the knowledge creation process in a particular 
context, the coupled model has the potential to improve the understanding of why 
particular processes need to be managed or practiced in a particular way. For example, 
when individual knowledge is the predominant need of the activity concerned, there would 
appear to be little point in promoting team working. When there is the need for efficient 
and effective use of `collective' knowledge, the promotion of individualism would seem to 
be counter-productive. Whilst many companies will inherently pursue their activities in 
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ways that appear (and in many cases are) appropriate for success, the coupled model offers 
an additional way of evaluating the efficiencies and practicalities of the approaches and 
practices being adopted. 
Nevertheless, by adopting Polanyi's view that all knowledge is inherently personal and 
relies upon a tacit dimension, it becomes easier to relate conceptual views of knowing to 
observed practices. Thus, Chapter 6, Section 6.4.3, suggested how Polanyi's approach can 
be used to show us how knowledge creation is the result of the particular personal and 
purposeful acts of tacit knowing of the people involved in the pursuit of a particular 
objective - acts of tacit knowing which rely on the assumptions made and the perspectives 
adopted, and which account for the lessons learnt and the way in which these individuals 
work with each other. 
In deciding between the various models of knowledge creation described above, it should 
perhaps be added that any theoretical model is only as useful as the predictions it is able to 
make (Kerlinger, 1969, p. 12). All models are simplifications, but some models are useful. 
In this respect, it is perhaps Polanyi's approach that offers us more than the models of 
either Nonaka and Takeuchi or Cook and Brown. For example, Nonaka and Takeuchi's 
presumption that knowledge creation is a vertical process, which ascends from the 
individual to higher ontological levels, is inappropriate to Western R&D environments that 
rely heavily on horizontal networking. And, whilst Cook and Brown's model coupled with 
the activities of the process involved might provide a greater understanding of what is 
already known, its predictive potential would appear low. In addition, its sheer 
complexity, which relies on the view that knowledge comes in no less than four distinct 
objectifiable forms (tacit and explicit, possessed by individuals and groups) associated 
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with the category (epistemology) `knowledge as possession', along with a separate 
category (epistemology) associated with `knowing as action', together with the concept of 
bridging epistemologies, militates against its easy application to actual practices. 
If, however, we accept Polanyi's comparatively simple premise that new knowledge is 
created from the existing knowledge base as the result of personal acts of tacit knowing, 
then, in order for new organizational knowledge to be created within any environment, the 
best approach to take is to actively involve the people with the relevant existing knowledge 
in that knowledge creation process. Thus, we might predict that research may be left to the 
scientists and technicians, whilst development should be a joint operation involving staff 
from the research, development, and commercial functions. That is, rather than trying to 
transfer knowledge between departments, the best approach is, as observed in this current 
study, to accommodate transdisciplinary Mode 1 type working in research and 
transfunctional Mode 2 type working in development. In addition, the creation of 
knowledge through personal acts of tacit knowing implies that, even in the scientific field 
of research and development, knowledge creation may not necessarily be the purely 
objective activity it is often assumed to be. As evidence of this, the interviewees 
participating in this present investigation recognized that intuition plays an important part 
in R&D to the extent that significant discoveries are often made by individuals working 
counter to what logic and current theory would dictate. As Polanyi originally stated, 
The pursuit of discovery is based upon a vision of what might be, a vision which is simply 
our meaningful integration of the parts of the complex entity we are trying to understand' 
(Polanyi and Prosch, 1975, p. 54). And, `The discovery which satisfies this pursuit is still 
sustained by the same vision. It claims to have made contact with reality: a reality, which 
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being real, may yet reveal itself to future eyes in an indefinite range of unexpected 
manifestations' (Polanyi, 1966, p. 24). 
In attempting to understand why things are as they are, and thus identify some general 
insights into the practice of R&D - the fourth aim of the research - Chapter 6, Section 6.5, 
advanced the suggestion that it is the needs of research that necessarily determine what 
knowledge is needed, how knowledge is created, and the management practices in 
research; whereas it is the needs of the organization that necessarily determine the needs of 
development, the knowledge needs of development, and how knowledge is created in 
development. The explanation for the differences between research and development was 
based on the observation that research is about the search for something new - exploration 
in pursuit of new knowledge - whilst development is about the adaptation of something 
that already exists - exploitation of existing knowledge. The implication is that, as 
observed within this present study, the activities of research should be separated from 
those of development. 
Whether or not research should be separated from development has been an argument that 
has existed for many years - certainly it was an ongoing discussion during the time that the 
present author was herself involved in such activities. On balance, this present author's 
feelings were that such activities should not be separated, on the grounds that this might 
encourage elitism, and result in the formation of isolated collectives or cliques within the 
organization which would be counter-productive to R&D success. However, the fact that 
the two activities of research and development are grounded on the use of substantially 
different knowledge creation processes suggests a conceptual division: the two activities 
imply different types of practices. Yet, the relationship between these practices is 
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complementary, and paying undue attention to one dimension of a complementary 
relationship can undermine awareness of the way in which the two dimensions work 
together as a pair. 
Certainly, it is clear that separating the work of research from that of development should 
not mean separating researchers from developers. Indeed, researchers ultimately need 
knowledge of the market place to ensure that the work that they are undertaking is directed 
accordingly, and that the results of their research can be focused towards any needs that 
arise. And, developers need to understand the newly found knowledge of the researchers 
in order to apply this knowledge in the most effective way towards the specific ends 
required. Effective connections between research, development and the evolution of user 
needs rely on the intelligent cooperation of colleagues, supported by mutual understanding 
among practitioners concerned with each of the respective processes. The success 
attributed to pharmaceutical R&D in the United Kingdom might perhaps, in part, be 
attributed to the fact that the sharing of information, the knowledge behind that 
information, and the understanding that results is widespread throughout the majority of 
organizations studied, and indeed throughout the industry as a whole. It occurs through 
informal personal networking, through formal research and project review meetings and 
presentations, and through collaborative `team working' in the widest sense. 
The different requirements of research and development are reflected in the factors 
identified by the participants of the empirical study upon which this thesis is based as 
being those most important in managing contemporary corporate R&D. Thus, Chapter 6, 
Section 6.6, showed us that whilst commercial viability is strategically important in 
business driven development, a degree of exploration is fundamental to science/technology 
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led research. And, from a management perspective, whilst teams of people, a clear project 
plan, and buy-in to that plan are specific requirements of development; a clear focus, a 
flexible approach, and a culture of experimentation are needed in research. At the same 
time, given the `natural' separation of the two activities of research and development, 
communication throughout the organization and extended organization is a key 
requirement. 
Based upon the conclusions outlined above, the next section of this chapter, Section 7.2, 
turns to the specific contributions to knowledge claimed by this thesis. 
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7.2 Contributions to Knowledge 
A knowledge perspective was initially adopted for this present work because it seemed to 
offer a useful way of addressing the processes by which people in pharmaceutical 
companies know how to `do things' associated with research, development and the pursuit 
of competitive success. However, a consequence of this way of working is that this thesis 
has been able to offer a contribution to existing knowledge that represents a marriage of 
ideas from the fields of R&D Management, Knowledge Management, and Innovation 
Management. In particular, the thesis has shown the similarities between Knowledge 
Management's Mode 1 working and R&D Management's first generation R&D; and 
between Knowledge Management's Mode 2 working and R&D Management's later R&D 
generations. It has also shown the similarities between the practice of research and 
Innovation Management's radical innovation, and the practice of development and 
Innovation Management's incremental innovation. 
Furthermore, by evaluating Knowledge Management's knowledge creation models in the 
light of research and development practices, the thesis has perhaps provided a deeper 
understanding of these models and the possibilities of their application. It has evaluated 
and upheld the faults associated with Nonaka and Takeuchi's widely quoted knowledge 
creation and conversion cycle: namely, that knowledge creation is a more complicated and 
convoluted process than that proposed (McAdam and McCreedy, 1999); that knowledge 
cannot be converted into a common currency and moved from one context to the other; 
and, hence, that knowledge creation cannot be a knowledge conversion process (Ray and 
Little, 2001). It has questioned Cook and Brown's hypotheses that, first, explicit 
knowledge and tacit knowledge of the individual and group are four unique forms of 
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knowledge, and, second, that knowledge creation is a generative dance between 
`knowledge used in action' and `knowing as part of action'. Yet, the coupling of Cook and 
Brown's basic framework with the specific activities involved in a particular 
organizational process, nevertheless, does yield a graphical representation of that process 
that shows clearly the implications for how that process might be managed. However, 
importantly, it is by applying Polanyi's philosophical arguments to the practice of research 
and development that this thesis perhaps offers a more significant contribution. For, if we 
accept that all knowledge is created from the existing knowledge base as the result of 
personal acts of tacit knowing, then, in addition to the needs of the business, it is to the 
needs of the people involved that we must turn our attention. 
Finally, by adopting a knowledge perspective and concentrating on practices at the task 
level, this thesis has perhaps more clearly than hitherto demonstrated the fundamental 
differences between research and development, and in so doing has given a more 
comprehensive explanation for why these two activities should be carried out separately 
but not separate from each other. In so far as the pharmaceutical industry is concerned, the 
needs of the activity being pursued would appear to be as important if not more important 
than any particular strategy that might be advocated. 
An emphasis on `knowledge' may, however, have overshadowed some of the other issues 
surrounding the management and practice of corporate R&D. At the same time, this thesis 
is based upon the findings from only one industry within the United Kingdom. The same 
findings may not be applicable elsewhere. The final section of this chapter, and of this 
thesis, briefly discusses these limitations of the present study and suggests some possible 
extensions to the work reported herein. 
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7.3 The Major Limitations of and some Extensions to the Research 
The conclusions drawn within this thesis have been based upon the findings from one 
particular industry. This does not necessarily mean that the same conclusions will hold for 
other industries. For example, this thesis has emphasized the importance of science/ 
technology leadership in research and business integration in development. The 
pharmaceutical industry is an industry in which both science and technology are important: 
it is the increased understanding of the underlying science that drives the improvements in 
appropriateness and effectiveness of modern therapies; and it is the advances in technology 
that enable the increased efficiencies required for continued commercial viability in an 
increasingly competitive business sector. Although a reliance on basic research 
distinguishes the pharmaceutical industry from competitive innovation in low-technology 
sectors, the knowledge-based approach developed here, nevertheless, embodies scope for 
application elsewhere. Few industries are immune from the changing pattern of constraints 
and opportunities associated with technological change and global interconnectedness. 
Competitive blacksmiths, for example, might come to regard the Internet as a valuable way 
of coupling their services to customers seeking decorative ironwork. Forging a path 
towards the successful development of high-tech drugs and low-tech ironwork both rely on 
effective positioning within an increasingly interconnected world. In both cases, knowing 
how to make a difference that meets evolving user expectations is the key to effective 
entrepreneurship; but further research is needed to explore the way in which the challenges 
differ. Whilst not appropriate for the UK pharmaceutical industry as described herein, 
Gibbons and co-workers' comments concerning the move towards Mode 2 working may 
well be key for those industries that are less reliant on basic research. 
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In adopting a knowledge perspective, this thesis has assumed that corporate R&D can be 
adequately explained as a form of knowledge working. In research, new knowledge is 
sought and created by experimentation to yield prototype products or processes. In 
development, existing knowledge is applied to adapt these prototype products or processes 
to meet the needs of the organization. But corporate R&D is more than knowledge 
working. It is about believing that the impossible can be made possible, that the problem 
can be solved. It is about the persistence to see a project through to completion. It is about 
championing as well as entrepreneuring (Roberts and Fusfeld, 1981, p. 22) in order that 
new products or processes are accepted. It is about the use of imagination (Hurst et al, 
1989, p. 89) to explore and arrive at a new reality to which the hidden clues are pointing 
(Polanyi, 1966, p. 24). It is above all a quest for the `truth', albeit a scientific or 
technological `truth' (Russell, 1931, p. 103). As a consequence, the management of 
research and development is about envisioning the future, about inspiring the hearts and 
minds of the people who are engaged in the pursuit of that future, about intuition and 
experimentation to test the feasibility of that future, about observation and understanding 
to direct or redirect the results of further research or development, about encouragement 
when experiments fail, about flexibility of outcomes, and about flexibility in processes to 
achieve those outcomes. The management of both research and development is thus in 
conflict with `traditional management' in a number of ways. In particular: 
  Persistence to completion is not always economically viable for the company. 
  Failure is part of experimentation, but is not to be encouraged in business. 
  Company outcomes are normally pre-ordained, but the outcomes of research and 
development are not necessarily so. 
  The quest for scientific `truth' is not the prime directive, although it could lead to new 
opportunities. 
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In general, the findings of this study would, additionally, suggest that the `more successful' 
pharmaceutical, biopharmaceutical and biotechnology companies reported upon herein do 
appear to have achieved a successful compromise between these conflicting requirements. 
They do seem to be able to channel the natural persistence of their research and 
development workers into the directions most appropriate for the company. They do try to 
learn from the failures that inevitably occur. Within the remit of their corporate objectives, 
they do work with their research and development staff to develop, wherever possible, the 
unexpected outcomes of experimentation. And, by collaborating and networking with 
others, they do keep abreast of the latest scientific and commercial `truths' that may affect 
their activities. Above all, they do appear to encourage an environment of cooperation and 
facilitation throughout the organization and the extended organization and throughout the 
industry as a whole. As Alan McKinlay reports, `It's all about going beyond teams - way 
beyond teams - it's all about creating communities' (McKinlay, 2000, p. 114) 
Finally, the focus of this thesis has been on the activities associated with the corporate 
R&D functions of organizations operating in the United Kingdom. However, knowledge- 
based approaches to competitive innovation might be developed in other institutional 
settings. Better understanding the process of knowing how to `do things' - associated with 
creativity and the power to `make a difference' - is important to making sense of practice, 
in any context. Moreover, comparisons between practices that are enabled and constrained 
in different institutional contexts promise new insights into the interaction between 
organizations and their operating environments. 
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Secondary Sources 
Sources used for searching the literature 
Literature searches were conducted using the Open Universities' Voyager system. This 
allowed access to a number of databases. The following proved most useful and were 
accessed periodically throughout the course of the study: 
ABI/INFORM Global (Bell & Howell ProQuest Direct) @ www. umi. com 
Anbar (International Management Library) @ www. anbar. com 
BIDS (Bath Information and Data Dervices) @ www. bids. ac. uk 
EBSCO (Academic Search Elite / Business Source Premier) @ www. global. ebscohost. com 
Emerald (MCB University Press) @ www. emerald-library. com 
Sources used to support and confirm the empirical data 
Company reports and accounts: 
American Home Products Corporation, Annual Report 2000 
Amersham plc, Annual Report 2000 
Amersham plc, Interim Results 7 August 2001 
Antisoma plc, Annual Report and Accounts 2000 
AstraZeneca plc, Annual Report & Form 20-F 2000 
Bioglan Pharma plc, Annual Report & Accounts to 31 January 2000 
Celltech Group plc, Interim Report for 6 Months ended 30th June 2000 
Eli Lilly and Company, Annual Report 2001 
Eli Lilly and Company, 2001 Annual Meeting of Shareholders Proxy Statement 
GlaxoSmithKline, Half-Year Review 2001 
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GlaxoSmithKline, Half-Year Report 2001 
Glaxo Wellcome p1c, Annual Report & Accounts and Form 20-F 1999 
Nycomed Amersham plc, Annual Report and Accounts 1999 
Oxford BioMedica plc, Report & Accounts 2000 
Oxford BioMedica p1c, May 2000 Presentation 
Pfizer Inc., 2000 Annual Report 
SmithKline Beecham plc, Annual Report and Form 20-F 1999 
Company websites 
The following websites were accessed at approximately three monthly intervals throughout 
the period January 2001 and December 2003. 
www. ahp. com 
www. amersham. co. uk 
www. amersham. com 
www. amershambiosciences. com 
www. amershamhealth. com 
www. antisoma. com 
www. apbiotech. com 
www. astex-technolo_gy. com 
www. astrazeneca. com 
www. bioglan. com 
www. charnwood. astrazeneca. com 
www. elililly. com 
www. sýk"com 
www. lill . cy o. uk 
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www. medeva. co. uk 
www. oxfordbiomedica. co. uk 
www. pfizer. com 
www. sb. com 
www. whitehall-robins. com 
www. wsi. com 
www. wyeth. com 
General company and business information 
Drug Discovery Technology: Europe 2001, Where Science meets Business, 23-26 April 
2001, Messe Stuttgart International, Stuttgart, Germany, @ www. drugdisc. com - 
accessed 14 June 2001 
The Economist: A Survey of the Pharmaceutical Industry, 21 February 1998 
The Economist, Economist Newspaper Ltd, London, UK - between January 2000 and 
December 2002 
Euromonitor: Global Market Information Database, World strategies: Global 
pharmaceutical manufacturers, December 2000, @ www. euromonitor. com - 
accessed 16 January 2002 
Harvard Business Review, Harvard Business School Publication Corp., Watertown, 
Massachusetts, USA - between January 2000 and December 2002 
Pharmaceutical Pricing and Reimbursement in Europe: Scrip Reports, @ 
www. pjbpubs. co. uk - accessed 14 June 2001 
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Sources used in determining corporate R&D success 
Bureau van Dijk (FAME) company directory @ http: //fame2. bvdep. com - between 
January 2000 and February 2002 
Euromonitor: Global Market Information Database, @ www. euromonitor. com - between 
January 2000 and February 2002 
Nature, Nature Publishing Group, Macmillan Publishing Ltd., London, UK - between 
January 2000 and June 2001 
New Scientist, Reed Business Information Ltd., London, UK - between January 2000 and 
June 2001 
Reed Information Services @ www. kompass. com - between January 2000 and February 
2002 
The Value Added Scoreboard 2000, DTI Publications, @ www. innovation. oý vuk 
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Appendix 4.1: Specimen Interview Request Letter 
The Open University Business School 
Walton Hall, Milton Keynes, MK7 6AA 
24`h July, 2001 
To the R&D Director/ Manager 
Company A 
Address B 
Dear Sir/ Madam, 
Managing R&D 
I wonder if you can help me. I am a 2nd year full-time PhD student with The Open 
University Business School researching the management of R&D. I am interested in the 
pharmaceutical and biotechnology industries because they are industries that seem to be 
doing something right in R&D, and could perhaps offer some `best practice' guidelines for 
other UK industries. I have been able to obtain some information from your company's 
Annual Report and website, but I have specific questions regarding R&D approaches, 
R&D practices, and knowledge working in R&D that I would like answered. I would 
therefore very much appreciate it if the appropriate person within your organisation could 
spare me a little time to talk about these issues. 
For information, I previously worked for 18 years as a chemist in the construction 
chemicals industry, and during that time completed a part-time MBA with The Open 
University. My interests now are concerned purely with the management of R&D. I 
would not need any specific information on your R&D projects, and any other information 
given me would of course be treated in confidence. I do not intend to undertake any `case 
studies' as such, but would hope to use the information gained to look for general trends in 
R&D management. Specific information about your company need not be revealed, 
although your company would of course be acknowledged for its support. 
Thank you for taking the time to read this letter. 
Yours sincerely, 
Christina R. Folkes, MBA 
Direct Line: 01908 654660 
Email: c. r. folkes a, open. ac. uk 
Appendix 4.1: Specimen Interview Letter A1 
Appendix 4.2 The Interview Questions 
SECTION A: Questions related to R&D Strategies and Structures 
1. Would you describe your work as mainly research (discovery), mainly 
development, mainly technical support, or a mixture of these? 
2. Are your R&D operations carried out on an international basis? Would you 
describe your R&D sites as `Centres of Excellence'? Are they located close to external 
centres of excellence? To what extent is geographic proximity between R&D workers 
important in industrial R&D? To what extent have government regulations and 
initiatives influenced (a) the R&D location and/or (b) the type of work carried out? 
What do you think are the advantages/ disadvantages of R&D internationalisation to 
your company/ your R&D workers? 
3. Are your R&D sites autonomous, semi-autonomous, or totally integrated with 
each other? How is the work of different R&D units controlled, steered, coordinated? 
4. To what extent has the type of work carried out affected the choice of R&D 
location? 
5. To what extent has the location determined the type of work carried out? 
SECTION B: Questions related to Knowledge Processes in R&D 
Knowledge Creation (the R&D process) 
6. How are projects initiated? What are the drivers? Who are the influencers? Is it 
possible to relate the influencer with the type of R&D work undertaken? Has the 
`Technology Foresight' programme influenced the R&D that your company now 
undertakes in the UK? Will such programmes influence the R&D that your company 
plans to undertake in the future? 
7. How are projects managed? Are the research, development, technical support 
functions carried out separately or are they unified within a single department? Are 
projects an individual, team or networked affair? To what extent is R&D integrated 
with other departments? Is it possible to say to what extent external bodies - e. g. 
suppliers/ customers/ universities/ government bodies - are actively involved in the 
process? 
8. How are projects terminated? 
9. Has the practice of R&D changed in recent years? 
Appendix 4.2: The Interview Questions A2 
Knowledge Application 
10. In your view, to what extent is existing knowledge a help or a hindrance in (a) 
adapting existing products or processes, (b) creating entirely new products or 
processes? 
11. Do you have any processes within your company that assist R&D workers to 
learn from past events? To what extent have these been successful in exploiting your 
company's existing knowledge? 
Knowledge Acquisition 
12. Accessing information from externally published sources is important in R&D? 
Do you have any support facilities for such processes? 
13. To what extent does your company acquire knowledge by in-licensing technology 
from external sources? 
14. To what extent is it important to your company that you develop your R&D workers 
internally as opposed to employing-in workers with knowledge in the field of interest? 
15. To what extent do you outsource your R&D work to others? With whom would 
this work normally be outsourced? 
16. Do you have any other ways of acquiring knowledge? 
Knowledge Exploitation 
17. How important is technology out-licensing as opposed to in-house exploitation of 
your own intellectual property? 
Knowledge Sharing - Knowledge Networking 
18. Informal (non-company promoted) R&D networks have received some attention 
in the literature. What do you believe is the extent of such informal knowledge 
networking within your industry? To what extent is such informal knowledge 
networking recognised and/or accepted by your company? 
19. Is it possible to say to what extent informal R&D networks (a) influence and/or 
(b) support the R&D work that your company undertakes? In general, do existing 
knowledge networks determine the type of R&D undertaken, or are they the result of 
the way that R&D is practiced? 
Appendix 4.2: The Interview Questions A3 
SECTION B: Questions related to Knowledge Processes in R&D - Continued 
Knowledge Sharing - Knowledge Networking - Continued 
20. To what extent does your company promote/encourage knowledge networking 
(a) between R&D workers, both internally and externally, and/or (b) throughout 
the company as a whole? Have company promoted networking initiatives 
changed the practice of R&D in any way? 
21. Has your company been involved in any Government initiatives to encourage 
external networldng in R&D (e. g. cross-industry visits)? Which companies were 
involved? To what extent have these initiatives benefited your own R&D activities? 
How important do you believe such initiatives will be to your company/ your R&D 
workers in the future? 
22. To what extent has your company embraced the `electronic age'? Do your R&D 
workers have access to email, company databases, computer conferencing, telephone 
conferencing, video conferencing, The Internet, etc? To what extent have the new 
communication technologies changed (a) the networking activities of R&D 
personnel, (b) the management/ practice of R&D? 
Knowledge Sharing - Collaborative Ventures 
23. To what extent are collaborative research ventures important to your company? 
With whom would you normally collaborate? Are these collaborations mainly formal 
(ie agreed by contract) or informal in nature? Do you have any informal arrangements 
with other parties? Has your company been involved in any Government promoted 
joint research collaborations? Did these initiatives bring benefits to your own R&D 
activities? How important do you believe such initiatives will be to your company and 
your R&D workers in the future? Have you ever collaborated / would you ever 
collaborate with a competitor? 
24. What advantages/ disadvantages have you found with such collaborative 
approaches? 
25. In your experience, does one collaborative venture lead to another? 
SECTION C: A Final Question related to R&D in General 
26. What do you believe is the single most important factor to be considered in the 
successful management of industrial R&D? 
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